Medical Radiology Radiation Oncology Series Editors L.W. Brady, Philadelphia H.-P. Heilmann, Hamburg M. Molls, Munich C. Nieder, Bodø
For further volumes: http://www.springer.com/series/4353
Jiade J. Lu · Luther W. Brady (Eds.)
Decision Making in Radiation Oncology Volume 2
Foreword by L.W. Brady, H.-P. Heilmann, M. Molls, and C. Nieder
Jiade J. Lu, MD, MBA Department of Radiation Oncology National University Cancer Institute National University Health Syetem National University of Singapore 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Republic of Singapore Email:
[email protected] Luther W. Brady, MD Department of Radiation Oncology Drexel University, College of Medicine Broad and Vine Streets Mail Stop 200 Philadelphia, PA 19102-1192, USA
Email:
[email protected]
ISSN: 0942-5373 ISBN: 978-3-642-16332-6
e-ISBN: 978-3-642-16333-3
DOI: 10.1007/978-3-642-16333-3 Springer-Verlag Heidelberg Dordrecht London New York Library of Congress Control Number: 2010937231 © Springer-Verlag Berlin Heidelberg 2011 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Cover design: eStudio Calamar, Figueres, Berlin Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Foreword Foreword
With the development of the patterns of care study chaired by Dr. Simon Kramer, the decision tree concept was initiated for a number of tumor sites including the carcinomas of the larynx, base of the tongue, the anterior two-thirds of the tongue, prostate, bladder, etc. This led to the gathering of significant information in terms of clinical presentations, clinical work-up, and decisionmaking with regard to management during pretreatment, treatment, and post-treatment phases. This concept has been widely accepted in the community of oncologists and it has been the purpose of this book to strengthen that concept and to add the supporting data that make it a very useful clinical tool. The authors have done a superb job in presenting the information that allows for innovative approaches to management and outcome analysis not only in clinical practice but in properly designed clinical trials, and for careful assessment of current practice based on solid and credible clinical research using the concept of the patterns of care but also the concepts of evidence-based outcome studies in oncology. It is very important to have these kinds of information available in the clinical assessment of the patient in order to make the appropriate, proper decision relative to management. It is important for oncologists to have a clear understanding of how the clinical and work-up information can be used to make the appropriate, proper decision relative to management. The present volume is specifically aimed at identifying these resources and how they can be used along with evidence-based medicine not only in terms of outcome from radiation therapy treatment but also in terms of the appropriate, proper work-up that allows for appropriate decisions to be made. The book represents a significant and
VI
Foreword
important standard by which all oncologists can design their treatment management. Philadelphia - Luther W. Brady, M.D. Hamburg – Hans Peter Heilman, M.D. Munich – Michael Molls, M.D. Bodø – Carsten Neider, M.D.
Volume 1 Section I Section II Section III Section IV Section V
Palliative Treatment Head and Neck Cancers Breast Cancer Tumors of the Thorax Cancers of the Gastrointestinal Tract
Volume 2 Section VI Section VII Section VIII Section IX Section X Section XI
Tumors of the Genitalurinary System Gynecological Cancers Lymphomas Tumors of the Central Nervous System Skin Cancers and Soft Tissue Sarcoma Pediatric Tumors
Contents of Volume 1
Section I Palliative Treatment 1A Radiation Therapy for Brain Metastasis . . . . . . . . . . Ugur Selek, Simon S. Lo and Eric L. Chang 1B
3
Palliative Radiotherapy for Bone Metastases . . . . . . 25 Alysa Fairchild and Stephen Lutz
Section II Head and Neck Cancers 2 Nasopharyngeal Carcinoma . . . . . . . . . . . . . . . . . . . . . 45 Jiade J. Lu, Lin Kong and Nancy Lee 3
Cancer of the Oral Cavity and Oropharynx . . . . . . . . 75 Kenneth S. Hu and Louis B. Harrison
4 Cancer of the Major Salivary Glands . . . . . . . . . . . . . . 105 Hiram Gay and Surjeet Pohar 5
Cancer of Larynx and Hypopharynx . . . . . . . . . . . . . . 133 Jay S. Cooper
6 Squamous Cell Carcinoma of Unknown Head and Neck Primary. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 Ivan W.K. Tham 7 Thyroid Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 Roger Ove and Almond Drake III Section III Breast Cancer 8 Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Manjeet Chadha Section IV Tumors of the Thorax 9 Lung Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 261 Steven H. Lin and Joe Y. Chang
X
Contents of Volume 1
10
Thymic Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309 Jiade J. Lu, Ivan W.K. Tham and Feng-Ming (Spring) Kong
11
Esophageal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 Steven H. Lin and Zhongxing Liao
Section V Cancers of the Gastrointestinal Tract 12 Gastric Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 361 Jeremy Tey and Zhen Zhang 13 Pancreatic Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389 Jiade J. Lu and Vivek K. Mehta 14
Hepatocellular Carcinoma . . . . . . . . . . . . . . . . . . . . . . 419 Sarah E. Hoffe
15A Cholangiocarcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . 447 Ravi Shridhar 15B Gallbladder Carcinoma . . . . . . . . . . . . . . . . . . . . . . . . 469 Steven E. Finkelstein and Sarah E. Hoffe 16
Rectal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487 Edward Kim and Luther W. Brady
17
Anal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 511 Qing Zhang, Shen Fu and Luther W. Brady
Index of Volumes 1 and 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
I1
Contents of Volume 2
Section VI Tumors of the Genitalurinary System 18 Bladder Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 James S. Butler 19 Prostate Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567 Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler 20
Testicular Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 Ugur Selek
Section VII Gynecological Cancers 21 Endometrial Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . 641 Keyur J. Mehta, Nitika Thawani and Subhakar Mutyala 22
Cervical Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661 Nina A. Mayr, William Small Jr., and David K. Gaffney
23
Vulva Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 Kevin Albuquerque
24
Vaginal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725 Nitika Thawani, Subhakar Mutyala and Aaron H. Wolfson
Section VIII Lymphomas 25 Non-Hodgkin’s Lymphoma . . . . . . . . . . . . . . . . . . . . . 747 Joanne W. Jang and Andrea K. Ng 26
Hodgkin’s Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . 771 Maryse Bernard and Richard W. Tsang
XII
Contents of Volume 2
27
Multiple Myeloma and Plasmacytoma . . . . . . . . . . 811 Wee Joo Chng and Ivan W.K. Tham
28
Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . . . . . 833 Ivan W.K. Tham
29 Primary Central Nervous System Lymphoma . . . . 853 Marnee M. Spierer and Evan M. Landau Section IX Tumors of the Central Nervous System 30 Meningioma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 873 Allison M. Quick, Eric L. Chang and Simon S. Lo 31
Adult Gliomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 895 Bernadine Donahue
32
Pituitary Tumors . . . . . . . . . . . . . . . . . . . . . . . . . . . . 923 Keith H. C. Lim and Simon S. Lo
Section X Skin Cancers and Soft Tissue Sarcoma 33 Soft Tissue Sarcoma . . . . . . . . . . . . . . . . . . . . . . . . . . 943 Heather McCarty, Colleen Dickie and Brian O’Sullivan 34
Cutaneous Malignant Melanoma . . . . . . . . . . . . . . . 977 José A. Peñagarícano and Vaneerat Ratanatharathorn
35
Basal and Squamous Cell Carcinoma of the Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 995 José A. Peñagarícano and Vaneerat Ratanatharathorn
Section XI Pediatric Tumors 36 Pediatric Brain Tumors . . . . . . . . . . . . . . . . . . . . . . . .1011 Arnold C. Paulino 37
Retinoblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1037 David B. Mansur
Contents of Volume 2
XIII
38
Neuroblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1053 Natia Esiashvili
39
Ewing Sarcoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1073 Daniel Indelicato and Robert B. Marcus Jr.
40
Wilms’ Tumor and Other Childhood Renal Tumors . . . . . . . . . . . . . . . . . . . . . . 1089 Arnold C. Paulino
Index of Volumes 1 and 2 . . . . . . . . . . . . . . . . . . . . . . . . . . 1105
Contributors
Kevin Albuquerque, MD, MS, FRCS Associate Professor, Radiation Oncology Department of Radiation and Oncology Loyola University Chicago Stritch School of Medicine McGuire Building, Room 2944 2160 South 1st Avenue Maywood, IL 60153, USA Email:
[email protected] Maryse Bernard, MD Département de Radio-Oncologie Hôpital Maisonneuve-Rosemont, Centre affilié à l’Université de Montréal 5415, boulevard de l’Assomption Montréal (Québec) H1T2M4, Canada Email:
[email protected] Angel I. Blanco, MD Assistant Professor Department of Radiation Oncology The Methodist Hospital Weill Cornell Medical College 6565 Fannin Street, DB1-077 Houston, TX 77030, USA Email:
[email protected] E. Brian Butler, MD Professor and Chairman Department of Radiation Oncology The Methodist Hospital The Methodist Hospital Research Institute Weill Cornell Medical College 6565 Fannin Street, DB1-077 Houston, TX 77030, USA Email:
[email protected]
XVI
Contributors
James S. Butler, MD Department of Radiation Oncology Maimonides Cancer Center 6300 Eighth Avenue Brooklyn, NY 11220, USA Email:
[email protected] Eric L. Chang, MD Professor of Radiation Oncology Department of Radiation Oncology UT MD Anderson Cancer Center, Unit 97 1515 Holcombe Blvd. Houston, TX 77030, USA Email:
[email protected] Wee Joo Chng, MD Associate Professor and Senior Consultant Department of Hematology and Oncology National University Cancer Institute National University Health System National University of Singapore 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Republic of Singapore Email:
[email protected] Colleen Dickie, MSc, MRT(T)(MR) Sarcoma Research Radiation Therapist Radiation Medicine Department Princess Margaret Hospital 610 University Ave. Toronto, Ontario M5G2M9, Canada Email:
[email protected] Bernadine R. Donahue, MD Clinical Director, Department of Radiation Oncology Maimonides Cancer Center 6300 Eighth Avenue Brooklyn, NY 11220, USA Email:
[email protected]
Contributors
Natia Esiashvili, MD Assistant Professor Department of Radiation Oncology The Emory Clinic 1365 Clifton Road NE, Room A1301 Atlanta, GA 30322, USA Email:
[email protected] David K. Gaffney, MD, PhD Professor and Vice Chair Department of Radiation Oncology Huntsman Cancer Hospital University of Utah 1950 Circle of Hope Dr., Ste 1570 Salt Lake City, UT 84112, USA Email:
[email protected] Daniel J. Indelicato, MD Assistant Professor University of Florida Department of Radiation Oncology University of Florida Proton Therapy Institute 2015 N. Jefferson St. Jacksonville, FL 32206, USA Email:
[email protected] Joanne W. Jang, MD, PhD Brigham and Women’s Hospital Department of Radiation Oncology 75 Francis Street, ASB1, L2 Boston, MA 02115, USA Email address :
[email protected] Evan M. Landau, MD Montefiore Medical Center Radiation Oncology 111 East 210th Street Bronx, NY 10463, USA Email:
[email protected]
XVII
XVIII Contributors
Keith H. C. Lim, MD, MBBS, FRANZCR Consultant Department of Radiation Oncology National University Cancer Institute National University Health System National University of Singapore 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Republic of Singapore Email:
[email protected] Simon S. Lo, MD Visiting Associate Professor of Radiation Oncology Director of Neurologic Radiation Oncology and Radiosurgery Medical Director of Gamma Knife Center Department of Radiation Oncology Case Western Reserve University UH Case Medical Center Cleveland Cleveland, OH 44106, USA Email:
[email protected] David B. Mansur, MD Associate Professor of Radiation Oncology Department of Radiation Oncology Siteman Cancer Center Center for Advanced Medicine Washington University 4921 Parkview Place, Lower Level St. Louis, MO 63110, USA Email:
[email protected] Robert B. Marcus Jr., MD Professor, University of Florida Department of Radiation Oncology University of Florida Proton Therapy Institute 2015 North Jefferson Street Jacksonville, FL 32206, USA Email:
[email protected]
Contributors
Nina A. Mayr, MD Professor of Radiation Oncology Department of Radiation Oncology Arthur G. James Cancer Hospital and Solove Research Institute The Ohio State University Medical Center 300 West 10th Avenue, Suite 080B Columbus, OH 43210, USA Email:
[email protected] Heather McCarty, MD Consultant Clinical Oncologist Northern Ireland Cancer Centre Lisburn Road Belfast, BT9 7AB, UK Email:
[email protected] Keyur J. Mehta, MD Assistant Professor Director of Brachytherapy Department of Radiation Oncology Montefiore Medical Center Albert Einstein College of Medicine 1625 Poplar St, Suite 101 Bronx, NY 10461, USA email:
[email protected] Subhakar Mutyala, MD Chairman and Associate Professor Department of Radiation Oncology Scott and White Healthcare System Texas A&M Health Science Center College of Medicine 2401 South 31st Street Temple, TX 76508, USA Email:
[email protected] Andrea K. Ng, MD, MPH Professor of Radiation Oncology Department of Radiation Oncology Brigham and Women’s Hospital and Dana-Farber Cancer Institute Boston, MA 02115, USA Email:
[email protected]
XIX
XX
Contributors
Brian O’Sullivan MD, FRCPI, FRCPC, FFRRCSI (Hon) Bartley-Smith / Wharton Chair in Radiation Oncology Professor, Department of Radiation Oncology University of Toronto, Associate Director Radiation Medicine Program Leader, Head and Neck Oncology Site Program Radiation Oncology Sarcoma Site Program Leader Princess Margaret Hospital 610 University Avenue, Toronto, ON M5G2M9, Canada Email:
[email protected] Arnold C. Paulino, MD Professor of Radiation Oncology Vice-Chair for Education Department of Radiation Oncology The Methodist Hospital Weill Cornell Medical College 6565 Fannin Street, DB1-077 Houston, TX 77030, USA Email:
[email protected] José A. Peñagarícano, MD Associate Professor of Radiation Oncology Department of Radiation Oncology University of Arkansas for Medical Science 4301 W. Markham #771 Little Rock, AR 72205, USA Email:
[email protected] Allison M. Quick, MD Clinical Instructor of Radiation Oncology Department of Radiation Oncology Arthur G. James Cancer Hospital Ohio State University Medical Center 300 West 10th Avenue Columbus, OH 43210, USA Email:
[email protected] Vaneerat Ratanatharathorn, MD Professor and Chairman Department of Radiation Oncology University of Arkansas for Medical Science 4301 W. Markham #771 Little Rock, AR 72205, USA Email:
[email protected]
Contributors
Ugur Selek, MD Department Chief of Radiation Oncology American Hospital Güzelbahçe Sokak, No. 20 Tesvikiye, 34365 Istanbul, Turkey and Adjunct Associate Professor of Radiation Oncology University of Texas M.D. Anderson Cancer Center 1515 Holcombe Boulevard Houston, TX 77030, USA Email:
[email protected] William Small, Jr., MD, FACR, FACRO Professor and Vice Chairman Department of Radiation Oncology Associate Medical Director Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School of Medicine NMH/Arkes Family Pavilion Suite 1820 676 N Saint Clair Chicago, IL 60611 USA Email:
[email protected] Marnee M. Spierer, MD The Farber Center for Radiation Oncology 21 West Broadway New York, NY 10007, USA Email
[email protected] Ivan W.K. Tham, MD Consultant Department of Radiation Oncology National University Cancer Institute National University Health System National University of Singapore 1E Kent Ridge Road NUHS Tower Block, Level 7 Singapore 119228 Republic of Singapore Email:
[email protected]
XXI
XXII Contributors
Nitika Thawani, MD Assistant Professor Department of Radiation Oncology Scott and White Healthcare System Texas A&M Health Science Center College of Medicine 2401 South 31st Street Temple, TX 76508, USA Email:
[email protected] Bin S. Teh, MD Professor and Vice Chair Department of Radiation Oncology The Methodist Hospital The Methodist Hospital Research Institute Weill Cornell Medical College 6565 Fannin Street, DB1-077 Houston, TX 77030, USA Email:
[email protected] Richard W. Tsang, MD Professor of Radiation Oncology Department of Radiation Oncology University of Toronto Princess Margaret Hospital 610 University Avenue Toronto, Ontario M5G 2M9, Canada Email:
[email protected] Aaron H. Wolfson, MD Professor and Vice Chair Department of Radiation Oncology University of Miami Miller School of Medicine 1475 N.W. 12th Avenue Miami, FL 33136, USA Email:
[email protected]
Section VI Tumors of the Genitalurinary System
VI
18 Bladder Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 533 James S. Butler 19
Prostate Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 567 Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
20
Testicular Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . 611 Ugur Selek
18
Bladder Cancer James S. Butler1
Key Points Bladder cancer is the second most common cancer of the genitourinary tract, and is the second most common cause of deaths among genitourinary tract cancers. Most patients present with hematuria (75%). A quarter of patients present with irritative and/or obstructive symptoms. Patients with advanced disease can present with decreased appetite, weight loss, bone pain, and/or pelvic pain. Clinical diagnosis starts with history and physical examination, laboratory studies with urine cytology, then cystoscopy with pyelography (to rule upper tract tumors). If invasive disease is found, then imaging with chest X-ray and abdominal/pelvic computed tomography (CT), and a bone scan is performed. Stage at diagnosis is the most important prognostic factor. Superficial disease is not immediately life threatening, as only invasive disease metastasizes. Invasive disease can be divided into four prognostic groups: organ confined, extravesicular extension, metastasis to the pelvic nodes, and metastasis to distant sites. Prognostic factors that favor successful bladder preservation therapy include complete transurethral resection of bladder tumor (TURBT), complete regression of disease after chemoradiation therapy, solitary tumor, organ confined versus extravesicular extension, and no hydronephrosis. Treatment is determined by the prognostic factors. If a patient has superficial disease then he/she is treated with TURBT, with or without intravesicular chemotherapy, and closely observed for development of other bladder cancers. If invasive disease is localized, then a patient will be treated with cystectomy or chemoradiation therapy if he/she also has the correct prognostic factors conducive to bladder preservation. If invasive disease is metastatic, then the patient is treated with chemotherapy: gemcitabine/cisplatin or methotrexate, vinblastine, doxorubicin and cisplatin (MVAC).
1
James S. Butler, MD Email:
[email protected] J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_1, © Springer-Verlag Berlin Heidelberg 2011
534
James S. Butler
Epidemiology and Etiology The incidence of bladder cancer is 9.9/100,000 in men and 2.3/100,000 in women in the USA. There were 70,530 cases diagnosed in the U.S. in 2010, with 13,060 deaths. In 1999, there were 263,000 cases worldwide, representing 4% of all cancers. However, incidence varies throughout the world. In North Africa, it is estimated that more that 30% of cancers are bladder cancer. The incidence is twice as high in white Americans as in black or AsianAmericans, with the lowest incidence found in China. A number of risk factors have been identified for bladder cancer (Table 18.1). Table 18.1 Risk factors for bladder cancer Risk factor
Description Age and gender: most patients are diagnosed with bladder cancer when they are 60–70 years old. The male:female ratio is 4:1 Race: twice as common in white Americans than in nonCaucasians Lifestyle: cigarette smoking is felt to be responsible for approximately 50% of bladder cancers in the USA
Patient related
Past medical history: pelvic radiation, chemotherapy such as Cytoxan, bladder lithiasis, chronic catheterization, multiple urinary infections, exposure to schistosomiasis, transplant recipient Genetic predisposition: no genes have been identified as causing bladder cancer; however, multiple genes have been found to be associated with a poorer prognosis and higher chance of progression include human epidermal growth factor receptor (EGFR) 2, p53, ras oncogenes, RB, P21, P27, and P16, Ki-67, S100A2, S100A4, fragile histidine triad gene, and cyclin D1
Environmental
Industrial chemicals: exposure to industrial chemicals such as aniline dyes, naphthylamines, benzidines, biphenyls, coal soot, phenacetin, and arsenic
Chapter 18 Bladder Cancer
535
Anatomy The bladder is a hollow, muscular organ located in the pelvis superiorly and posteriorly to the pubic bone (Figure 18.1). When full, the bladder holds about 500 ml of urine, extends superiorly into the abdomen to a level superior to the umbilicus, and has an ovoid shape. When empty, the bladder collapses into a tetrahedral shape.
Subperitoneal fatty-areolar tissue Obliterated umbilical art. Inf. epigastric vesseis Urachus Peritoneum Fascia iliaca Fascia nerve Psoas & Iliacus Ext. iliac art. & vein Ureter Rectus Vessels to urogenital organs
Sciatic nerve
Bladder Prostate (enlarged)
Ductus deferens Seminal vesicle Tendinous arch, Retropubic space Int. pudental art. & pudental nerve Ischiorectal fossa Artery to bulb, piercing perineal membrane
Bulbo-urethral glands in deep perineal pouch Perineal brs. of posterior Bulbo-spongiosus covering cutaneous nerve of tigh the bulb, and its nerve
Figure 18.1 Relation of bladder to urachus, peritoneum, ureters, and prostate (Reprint permission courtesy of Williams and Wilkins. Original figure appeared in Grants’ Atlas of Anatomy 7th edition.)
536
James S. Butler
The apex (anterior superior part of bladder) extends superiorly to taper at its attachment to the urachus, which attaches to the umbilicus. The superior surface is the only part of the bladder covered by peritoneum. The base is the posterior wall where the ureters enter. The base and inferior lateral walls then taper inferiorly to form the neck of the bladder, which then becomes the urethra (Figures 18.2 and 18.3). Bladder Rectovesical pouch Pubic symphysis Prostate Corpus cavernosum
Rectum
Urethera
Urogenital diaphragm
Corpus spongiosum
Corpus spongiosum
Glans penis
Figure 18.2 Relation of bladder to rectum, prostate, seminal vescicles, penis, urethra, and scrotal contents. (Source: OOZ © Fotolia)
Ovary Uterus Bladder Urethera Vagina
Rectum
Figure 18.3 Relation of the bladder, rectum, uterus, ovary, vagina, and urethra (Source: OOZ © Fotolia)
Chapter 18 Bladder Cancer
537
Pathology See Table 18.2 regarding various pathologies. Table 18.2 Pathologic subtypes Type
Description
Transitional cell carcinoma
Accounts for >90% of bladder cancer cases in the USA ~70% are superficial carcinomas Arise from normal urothelium and are associated with smoking and carcinogen exposure
Squamous cell carcinomas
Caused by chronic irritation from urinary calculi, long-term indwelling catheters, chronic urinary infections, infections by schistosomiasis, or bladder diverticula. These irritants cause the transitional epithelium to develop squamous changes, from which these cancers can then arise The incidence varies widely in different parts of the world. It accounts for only 1% of bladder cancers in England, 3–7% in the USA, about 50% in Egypt
Adenocarcinoma
<2% of primary bladder cancers Includes three groups: primary, urachal, and metastatic to bladder Can occur in intestinal urinary conduits
Small-cell carcinoma
<1% of all bladder cancers Behaves similarly to small cell carcinoma found elsewhere in the body
Mixed histology
Transitional cell with adenocarcinoma or squamous >25% of cases Treated in the same fashion as transitional cell carcinomas with the same results
538
James S. Butler
Routes of Spread/Recurrence Field effect leading to second primary, local extension, and regional (lymphatic) and distant (hematogenous) metastases are the three major routes of spread/recurrence in bladder cancer (Table 18.3). Table 18.3 Routes of spread/recurrence in bladder cancer Routes
Description
Field effect
Superficial bladder cancer does not invade the bladder; therefore, it does not have access to blood or lymphatic vessels and cannot metastasize. However, it has a field effect wherein there can be multiple recurrences/formation of new urothelial cancers elsewhere in the bladder or in the urothelial lining of the ureters or kidney Over time, superficial bladder cancers can dedifferentiate and gain the ability to become invasive Invasive bladder cancers successfully treated with bladder conservation require surveillance as these tumors also have a field effect wherein there can be multiple recurrences/formation of new urothelial cancers elsewhere in the bladder or in the urothelial lining of the ureters or kidney Invasive bladder cancers successfully treated with cystectomy can also have a field effect wherein there can be multiple recurrences/formation of new urothelial cancers in the urothelial lining of the ureters or kidney
Local extension
Invasive bladder cancer grows directly into the wall of the bladder, then into extravesicular fat, and finally into adjacent organs In cystectomy series, ~ 55% of patient have organ-confined disease, and ~ 20% have extravesicular extension Bladder cancer can grow along the wall of the bladder as either a continuous sheet of tumor or it can be multifocal Bladder cancer can grow along the wall of the bladder into the urethra or ureter(s)
Regional lymph node metastasis
Lymph node metastases are seen in approximately 25% of patients who undergo cystectomy Lymph nodes commonly involved include internal iliac, obturator, external iliac, and common iliac nodes
Chapter 18 Bladder Cancer
539
Table 18.3 (continued) Routes
Description
Distant metastasis
Approximately a third of patients with invasive disease develop metastatic disease Sites of metastatic disease often initially include lymphatic spread into para-aortic lymph nodes, and hematogenous spread to bone and lung. Multiple other organs then can become involved Patients at the highest risk for development of metastatic disease include those with extravesicular extension, invasion into adjacent organs such as the prostate, and pelvic lymph node metastases
Lymph Node Metastasis Patterns of lymphatic spread is depicted in Figure 18.4. Figure 18.4 Lymph node groups commonly involved include internal iliac, obturator, external iliac, and common iliac Source: Roth B et al (2009) A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol. DOI:10.1016/j.eururo.2009.10.026
Figure 18.5 delineates the pattern of bladder lymphatic drainage by injection of technetium nanocolloid into bladder wall sites before extended pelvic lymph node dissection. This demonstrates that standard pelvic lymph node dissection limited to the anterior portions of the external iliac vessels, and the obturator fossa would remove only approximately 50% of all radioactive nodes, whereas extended pelvic lymph node dissection along and around all the major pelvic vessels distal to the crossing of the ureter and iliac vessels removes about 90%.
540
James S. Butler
Figure 18.5 Boundaries of pelvic lymph node dissection subdivided into different regions and distribution of corresponding TC99m-positive lymph nodes; external iliac (Ia), distal and (Ib) proximal, obturator fossa (IIa) distal and (IIb) proximal, internal iliac (IIIa) distal and (IIIb) proximal, common iliac (Iva) distal and (IVb) proximal, (V) para-aortic/caval Source: Roth B et al (2009) A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol. DOI:10.1016/j.eururo.2009.10.026
Diagnosis, Staging, and Prognosis Clinical Presentation Signs and symptoms of bladder cancer are outlined below in Table 18.4. Table 18.4 Commonly observed signs and symptoms in bladder cancer Signs/Symptoms ematuria is the most common presenting symptom in patients H with bladder cancer (75%) Irritative/obstructive symptoms occur in a quarter of patients with bladder cancer elvic pain can occur in patients who have locally advanced disease invading P into adjacent organs Bone pain occurs in patients who have metastatic disease ecreased appetite and weight loss occur in patients D who have large tumor burdens
Chapter 18 Bladder Cancer
541
Diagnosis and Staging Figure 18.6 illustrates the diagnostic procedures for bladder cancer, including suggested examination and tests.
Hematuria or irritative urinary symptoms (Bladder cancer suspected)
Complete history and physical, Urine cytology, blood work, and CXR
Cystoscopy with pyelography
Invasive
Superficial (Muscularis must be present without tumor invasion)
Abdominal/Pelvic CT and Bone Scan
History includes noting symptoms as outlined in Table 18.4 Thorough physical includes bimanual exam to evaluate for pelvic mass and abdominal exam to asses for such signs as organomegaly and also boney palpation Urine cytology has sensitivity of 20 –50%, with 80–100% specificity. Cytology is a very useful noninvasive test that can establish presence or persistence of bladder cancer Blood work includes CBC, serum chemistry, and liver function tests Pyelography is necessary to rule out the coexistence of other primary urothelial cancers in the upper genitourinary tract. This can be accomplished at the time of cystoscopy with a retrograde pyelography or later with IV or CT pyelography Ultrasound, PET/CT, and MRI are optional tests
Figure 18.6 A proposed algorithm for diagnosis and staging of bladder cancer
Tumor, Node, and Metastasis Staging The tumor, node, and metastasis (TNM), and stage grouping systems as determined by the American Joint Committee on Cancer (AJCC) are outlined in Tables 18.5 and 18.6.
542
James S. Butler
Table 18.5 AJCC TNM classification of bladder cancer Stage
Description
Primary tumor (T) TX
Primary tumor cannot be assessed
T0
No evidence of primary tumor
Ta
Noninvasive papillary tumor
Tis
Carcinoma in situ, “flat tumor”
T1
Tumor invades subepithelial connective tissue
T2
Tumor invades muscularis propria
T2a
Tumor invades superficial muscularis propria (inner half)
T2b
Tumor invades deep muscularis propria (outer half)
T3
Tumor invades perivesical tissue
T3a
Microscopically
T3b
Macroscopically (extravesicle mass)
T4
Tumor invades any of the following: prostatic stroma, seminal vesicles, uterus, vagina, pelvic wall, abdominal wall
T4a
Tumor invades prostatic stroma, uterus, vagina
T4b
Tumor invades pelvic wall, abdominal wall
Regional lymph nodes (N) include primary and secondary drainage regions. All nodes above the aortic bifurcation are considered distant metastases NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)
N2
Multiple regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac, or presacral lymph node)
N3
Lymph node metastases to the common iliac lymph nodes
Distant metastasis (M) MX
Distant metastasis cannot be assessed
M0
No distant metastasis
M1
Distant metastasis
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Berlin Heidelberg New York, Springer
Chapter 18 Bladder Cancer
543
Table 18.6 Stage grouping of bladder cancer Stage Grouping T1
T2
T3
T4a
T4b
N0
I
II
III
III
IV
N1–3
IV
IV
IV
IV
IV
M1
IV
IV
IV
IV
IV
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Berlin Heidelberg New York, Springer
Prognosis Stage is the most important determinant of survival. The 5-year overall survival (OS) rates after cystectomy, according to stage, are detailed in Table 18.7. Some prognostic factors are listed in Tables 18.8 and 18.9. Table 18.7 5 year overall survival (OS) after cystectomy Type
Description
Stage
Superficial T0Pa; N0
Organ confined P2; N0
Extravesicle P3-4; N0
Node positive
5-Year survival
85%
T2a, 77% T2b, 64%
47%
31% 40% (1–4+) 25% (>4+)
P: Primary tumor category Source: Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675
Table 18.8 Prognostic factors for bladder preservation Factor
Favorable
Adverse
TURBT
Complete
Incomplete
Response to chemoradiation
Complete regression
Residual disease
Extent of tumor
Solitary
Diffuse or multiple
Disease invasion
Organ confined
Regional extension
Hydronephrosis
Absent
Present
544
James S. Butler
Table 18.9 Prognostic factors for recurrence-free survival in superficial bladder cancer Characteristic
Low risk
High risk
Total
Definitions
Low grade; papillary configuration
High grade; CIS; multifocal/rapid recurrence
Recurrences
50%
70%
70%
Progression to invasive disease
<5% (if solitary, 0%)
30%
15%
CIS: carcinoma in situ
Treatment Principle and Practice Treatment for bladder cancer is multimodal and determined by the patient’s prognostic factors: Superficial bladder cancer is managed primarily by transurethral resection with or without intravesicular chemotherapy. Localized invasive bladder cancer traditionally has been managed by cystectomy. If the patient has prognostic factors predictive for bladder preservation, the patient can be treated with chemoradiation therapy. Metastatic disease is primarily managed by chemotherapy, with palliative radiation therapy or surgery for symptomatic control.
Chapter 18 Bladder Cancer
545
Treatment of Superficial Bladder Cancer See the proposed algorithm for treatment presented in Figure 18.7 and Table 18.10 for treatment of superficial bladder cancer.
Superficial Bladder Cancer
TURBT
Low Risk (low grade, papillary)
Superficial bladder cancer recurrence
High Risk (high grade, CIS, papillary)
Intravesicular chemotherapy
Cytoscopic surveillance (every 3 months ×2 years, then every 6 months × 2 years, then yearly
Invasive recurrence
Progressive high-risk disease not controlled
Bladder preservation therapy
Cystectomy
Figure 18.7 A proposed algorithm for treatment of superficial bladder cancer
546
James S. Butler
Table 18.10 Clinical evidence for the use of intravesicular chemotherapy after TURBT for superficial bladder cancer
a
Trial
Description
Pawlinski et al (Medical Research Council [MRC]/ EORTC metaanalysis)a
Meta-analysis of MRC and EORTC prospective studies 2,535 patients entered in EORTC or MRC trials and randomized to no treatment or intravesicular chemotherapy with thiotepa, VM-26, doxorubicin, Epodyl, Epirubicin, or mitomycin C Intravesicular chemotherapy reduced recurrence of bladder cancer by 20% at a median follow-up of 4.6 years Unfortunately, intravesicular chemotherapy did not change chances of development of invasive disease, time to development of invasive disease, or survival
Sylvester et al (Meta-analysis)b
Meta-analysis of randomized trials that compared intravesicle Bacillus Calmette-Guérin (BCG) vaccine to intravesicle chemotherapy 700 patients with CIS entered into 9 randomized trials, who received either BCG versus mitomycin C, epirubicin, adriamycin, or BCG versus sequential mitomycin C/adriamycin 70% of patients treated with BCG had complete regression of disease versus 50% on chemotherapy 34% of complete responders who were treated with BCG and 50% of those treated with chemotherapy recurred At a median follow-up of 3.6 years, 47% of patients treated with BCG and 26% with chemotherapy were disease free It is important to note that BCG cannot be given right after TURBT because it will be systemically absorbed
Source: Pawlinski A, Sylvester R, Kurth KH et al (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156:1934–1940 b Source: Sylvester RJ, van der Meijden AP, Witjes JA et al (2004) Bacillus CalmetteGuérin versus chemotherapy for the intravesicle treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174:86–91
Chapter 18 Bladder Cancer
547
Treatment of Invasive Bladder Cancer See the proposed algorithm in Figure 18.8 for treatment of invasive bladder cancer.
Invasive Bladder Cancer
CT and bone scan No metastatic disease
Partial cystectomy if candidate
Unifocal, no hydronephrosis, no extravesicular disease
Yes
No
Locally advanced disease (T3/T4; N+)
Yes TURBT No Chemotherapy (preoperative RT controversial)
Chemoradiation
Complete regression of disease
No
Cystectomy
Yes Consolidative chemoradiation
Locally advanced disease (T3/T4; N+)
Chemotherapy
Figure 18.8 A proposed algorithm for treatment of invasive bladder cancer
548
James S. Butler
Definitive Surgical Intervention Radical Cystectomy Radical cystectomy involves removal of the bladder, prostate (cystoprostatectomy), and pelvic lymph node dissection in males. In a female, an anterior exenteration (removal of the bladder, urethra, anterior vaginal wall, and uterus) and pelvic lymph node dissection is performed. Standard pelvic lymphadenectomy begins medially to the genitofemoral nerve and involves dissecting the external iliac artery and vein up to the bifurcation of the common iliac artery. Inferiorly this dissection is carried to the endopelvic fascia. The lymphatic package is then dissected free of the iliac vessels and extends medially into the obturator fossa up to the bladder. Finally, the nodes are dissected from the hypogastric artery and vein. Extended lymphadenectomy yields more pathological information and may improve local control and survival. The superior limit of dissection extendeds up to the aortic bifurcation and takes the presacral nodes. After radical cystectomy (Table 18.11), urinary diversion is performed with a segment of bowel. The most common is the noncontinent ileal conduit. A continent diversion can be an orthotopic neobladder or an abdominal pouch. Continence in the abdominal pouch utilizes a catheterizable stoma. The orthotopic neobladder utilizes the patient’s urethral sphincter. Table 18.11 Efficacy of radical cystectomy for invasive urothelial bladder cancer Extent
Confined
Extravesicle
Node+
Total (no. of patients)
Hautmann et ala Local failure
4%
16%
20%
9% (788) 10 years
Distant metastases
9.5%
19%
45%
18%
T3a/b, 52%; T4, 35%
15%, 10 years
45%
Recurrence-free survival
T2a/b, 70%, 10 years
Madersbacher et alb Local failure
3%
11%
15%
8% (507)
Distant metastases
25%
37%
51%
Recurrence-free survival
73%, 5 years
56%, 5 years
33%, 5 years
62%
Survival
62%, 5 years
49%, 5 years
26%, 5 years
59%
Chapter 18 Bladder Cancer
549
Table 18.11 (continued) Extent
Confined
Extravesicle
Node+
Total (no. of patients)
Local failure
6%
13%
13%
7% (1054), 5 years
Recurrence-free survival
85%, 5 years
58%
35%
68%
Survival
78%, 5 years
47%, 5 years
31%, 5 years
60%
81%,10 years
44%
33%
48% (248)
Stein et alc
Boström et al Survival
d
a
Source: Hautmann RE, Gschwend JE, de Petriconi RC et al (2006) Cystectomy for transitional cell carcinoma or the bladder: results of surgery only series in the neobladder era. J Urol 176:486–492 b Source: Madersbacher S, Hochreiter W, Burkhard F et al (2003) Radical cystectomy for bladder cancer today – a homogenous series without neoadjuvant therapy. J Clin Oncol 21:690–696 c Source: Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675 d Source: Boström PJ, Mirtti T, Kössi J et al (2009) Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. Scand J Urol Nephrol 43:357–364
Pre- or Postoperative Chemotherapy There is a modest improvement in survival for use of chemotherapy in patients who are known to have locally advanced bladder cancer prior to cystectomy (Table 18.12). There is also a possible improvement in survival for patients receiving chemotherapy after cystectomy, if they are found to have locally advanced bladder cancer (Table 18.13).
550
James S. Butler
Table 18.12 Evidence-documented efficacy of neoadjuvant chemotherapy Study
a
Chemotherapy regimen
Chemotherapy
No therapy
Benefit
MRC/ EORTCa
Methotrexate, vinblastine, cisplatin (MVC)
3-year survival: 55%
3-year survival: NS 50%
Nordic Ib
Cisplatin and doxorubicin
59% 5-year survival
51% 5-year survival
NS
Nordic IIc
Cisplatinmethotrexate
53% 5-year survival
46% 5-year survival
NS
SWOGd
MVAC
77-month median survival
46-month median survival
p = 0.06
ABC metaanalysise
Trials utilizing platinum-based chemotherapy
50% 5-year survival
45% 5-year survival
p = 0.02
Sources: [No authors listed.] (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540; Hall R et al (2002) On behalf of the International Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, updated results of a randomized controlled trial of neoadjuvant cisplatinum, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer. Proc Am Soc Clin Oncol 21[Abstract]:178 b Source: Malmstrom PU, Rintala E, Wahlqvist R et al (1996) Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 155:1903– 190 c Source: Sherif A, Rintala E, Mestad O et al (2002) Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand J Urol Nephrol 36:419–425 d Source: Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866 e Advanced Bladder Cancer Meta-analysis Collaboration (2008) Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. DOI: 10.1002/14651858.CD005246
Chapter 18 Bladder Cancer
551
Table 18.13 Efficacy of adjuvant chemotherapy Study
Chemotherapy Chemoregimen therapy
No chemotherapy
USC–Skinner, 1991a
Cyclophosphamide, adriamycin, and platinum (CAP)
4.3-year median survival 47 patients
2.4-year median survival 44 patients
p = 0.006
German–Stockle, 1992b
Methotrexate, vinblastine, adriamycin/ epirubicin, and cisplatin (MV[A/E]C)
10-year OS: 26.9% 26 patients
10-year OS: 17.4% 23 patients
p = 0.069
Swiss–Studer, 1994c
Cisplatin
5-year OS: 57% 40 patients
5-year OS; 54% 37 patients
p = 0.65
Stanford–Freiha, 199d
5-year disease-free surCisplatin, vival (DFS): methotrexate, 50% and vinblastine 5-year OS: (CMV) 54% 25 patients
5-year DFS: 22% 5-year OS: 34% 25 patients
p = 0.01 p = 0.32
ABC metaanalysise
Adjuvant cisplatin based
50% 3-year survival: 245 patients
p = 0.19
59% 3-year survival 246 patients
Benefit
These studies are all small; therefore, adjuvant chemotherapy is not currently considered standard. The EORTC 30994 trial is currently investigating adjuvant chemotherapy a Source: Skinner DG, Daniels JR, Russell CA et al (1991) The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 145:459–464 b Source: Stockle M, Meyenburg W, Wellek S et al (1995) Adjuvant polychemotherapy of non–organ-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153:47–52 c Source: Studer UE, Bacchi M, Biedermann C et al (1994) Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152:81–84 d Source: Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155:495–499 e Source: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2006) Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev. 9:CD006018
552
James S. Butler
Bladder Preservation Partial cystectomy (Table 18.14) can be performed in about 5% of patients. The cancer needs to be unifocal and in a place in the bladder that would allow resection with 2-cm margins. If these criteria are met, survival is equivalent to radical cystectomy. Patients need to be followed with serial cystoscopy as are patients treated with chemoradiation therapy. Table 18.14 Efficacy of partial cystectomy in the treatment of bladder cancer Trial
Description
SEER database
7,243 patients treated with partial cystectomy (1,573) or cystectomy (5,670) When patients were matched for age, race, pT stage, pN stage, number of lymph nodes, tumor grade, and year of surgery, the 5-year survival was 57% for partial cystectomy patients and 55% for cystectomy patients
Source: Capitanio U, Isbarn H, Shariat SF et al (2009) Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis. Urology 74:858–865
Radiation Therapy Radiation therapy alone (Table 18.15) was used extensively from the 1950s to the 1980s. Local control is inferior to cystectomy. Multiple studies have documented local control rates of 30–40% only. Table 18.15 Efficacy of radiation alone Trial
Description
Shelley et al (Meta-analysis)
Meta-analysis compared surgery versus radiation therapy Three randomized trials comparing preoperative radiotherapy, followed by radical cystectomy (surgery) versus radical radiotherapy 439 patients, 221 randomized to surgery and 218 to radical radiotherapy 36% 5-year survival for surgery versus 20% 5-year survival for radiation
Source: Shelley M, Barber J, Wilt T et al (2008) Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev. CD002079
Chapter 18 Bladder Cancer
553
However, there is a subgroup of patients who are an exception: clinical T2 disease, no ureteric obstruction, complete transurethral resection of bladder tumor (TURBT), solitary tumor, and complete resolution of disease after radiation therapy (Table 18.16). Table 18.16 Evidence-documented efficacy of radiation therapy alone
a
Trial
Description
Shipley et al (Massachusetts General Hospital)a
55 patients with invasive bladder cancer treated with full-dose radiation therapy 45% survival of cT2 versus 9% for T4 Papillary tumor had 63% survival versus 20% for flat tumor 54% survival for complete TURBT versus 17% without 47% without ureteric obstruction versus 14% without
Prince of Wales Hospitalb
342 patients, radiation only, with a mean follow-up time of 7.9 years Multiple tumors and obstructed ureter, 91% local failure Single tumor and obstructed ureter, 69% local failure Multiple tumors and ureter non-obstructed, 68% local failure Single tumor T4, 50–55% local failure Single tumor T3, 40–45% local failure Single tumor T1/2, 34–37% local failure
Source: Shipley WU, Rose MA, Perrone TL et al (1985) Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 134:679–683 b Source: Mameghan H, Fisher R, Mameghan J et al (1995) Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31:247–254
554
James S. Butler
Brachytherapy Brachytherapy has been studied and practiced in Holland, but it is not commonly practiced in North America (Table 18.17). Table 18.17 Evidence-documented efficacy of brachytherapy
a
Trial
Description
University of Utrechta
111 patients with 6.2-year median follow-up T1G3–T2 bladder tumors <5 cm External beam radiotherapy (28 Gy, 12 fractions), followed by iridium-192 (40 Gy) 67% disease-free survival 70% 5-year survival; 50% 15-year survival 82% disease-specific survival at 5 years and 73% at 15 years Local recurrence in 27% patients Bladder function preserved in 89%
University of Amsterdamb
122 patients with solitary bladder tumor <5 cm and a median follow-up of 5 years Patients received either 3× 3.5-Gy or 20× 2-Gy EBRT, followed by surgery 10 days later (37 patients received partial cystectomy), then 20–70 Gy via low dose rate or via pulsed dose rate (PDR) in 23 patients 76% 5-year local relapse-free survival 83% 5-year distant relapse-free survival 5- and 10 -year relapse-free survival rates were 69 and 66% 5- and 10-year survival rates were 73 and 49%
Source: van Onna IE, Oddens JR, Kok ET et al (2009) External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 56:113–121 b Source: Blank, LE, Koedooder K, van Os R et al (2007) Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1–T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol 69:454–458
Chapter 18 Bladder Cancer
555
Chemoradiation Therapy Figure 18.9 presents an algorithm based on the results of a Canadian National Cancer Institute study of radiation therapy versus radiation/chemotherapy for the treatment of bladder cancer.
T2–T4 Bladder Cancer
Locally advanced disease (T3/T4; N+)
40 Gy per 20 fractions (48 patients)
40 Gy per 20 fractions, CDDP 100 mg/m2 every 2 weeks ×3 (51 patients)
20 Gy per 10 fractions or cystectomy
20 Gy per 10 fractions or cystectomy
59% 5-year pelvic relapse
40 % 5-year pelvic relapse
36% bladder preservation
Figure 18.9 Canadian National Cancer Institute study
70% bladder preservation
556
James S. Butler
Concomitant cisplatin and radiation therapy is the standard therapy (Table 18.18). Table 18.18 Evidence-documented efficacy of concurrent cisplatin and radiation therapy Trial
Description
National Bladder Cancer Groupa
62 patients with cT2–cT4 bladder cancer not fit for surgery 45 Gy per 25 fractions to pelvis, with bladder boost of 19.8 Gy per 11 fractions Cisplatinum 70 mg/m2 every 3 weeks × 8 77% complete tumor regression; 73% of these patients maintained local control in bladder 64% 4-year survival for T2; 24% 4-year survival for T3/4 40% had diarrhea, with 16% needing to interrupt therapy; 23% had urinary frequency and dysuria, which caused 13% to interrupt treatment 3 patients had gastrointestinal (GI) complications requiring hospitalization, 1 had surgery, 1 had cystectomy for hematuria, 1 had hip replacement 1 patient developed renal failure, 3 developed sepsis, 80% developed nausea and vomiting – in 32%, the nausea and vomiting were severe enough for the patient to not be able to/refuse further cisplatinum
RTOG 8512b
42 evaluable patients with cT2–cT4 bladder cancer 40 Gy per 20 fractions to pelvis; 2-week rest, then cystoscopy if negative, then bladder boost to 24 Gy per 12 fractions Cisplatinum 100 mg/m2 every day 1 and 22, and with the bladder boost 66% complete tumor regression; 73% of these patients maintained their bladders 64% 3-year survival 1 patient developed grade 3 acute GI toxicity, 4 developed grades 3 or 4 nausea and vomiting, 4 experienced reversible grade 3 or 4 hematologic toxicity 1 late–grade 4 (bladder) and 1 grade 3 (small bowel) toxicity reported; 1 cystectomy for radiation injury
Chapter 18 Bladder Cancer
557
Table 18.18 (continued)
a
Trial
Description
University Erlangenc
415 patients with high-risk cT1 and cT2–cT4 bladder cancer Median 45 Gy at 1.8–2 Gy per fraction to pelvis; median cumulative dose to bladder, 54 Gy 126 patients receiving radiation therapy (RT) alone; 145, cisplatinum 25 mg/m2/day × 5 days, 1st and 5th weeks; 95, carboplatin, 65 mg/m2/day × 5 days, 1st and 5th weeks; 49, cisplatin 20 mg/m2/day × 5 days, 1st and 5th week, with fluorouracil (5-FU), 600 mg/m2/day, 120-h continuous infusion 72% complete tumor regression. Of these patients, 65% have been free of disease in their bladders. 2% required cystectomy for RT damage although all these patients had multiple TURs 51% 5-year overall survival: 40% RT alone, 45% RT/ carboplatinum (CBBP), 62% RT/ cis-cisplatinum (II) (CDDP), 65% RT/CDDP and 5FU
RTOG 8903d
123 patients with cT2–cT4 bladder CA 39.6 Gy per 22 fractions with cisplatinum 100 mg/m2 × 2 every 3 weeks. Then, 4 weeks later, cystoscopy. If negative, 25.2 Gy per 14 fractions with cisplatinum, 100 mg/m2 Patients were randomized to receive 2 cycles of MCV before RT/chemotherapy or not 49% overall 5-year survival, with no difference between arms 59% complete recovery at cystoscopy; 72% of these patients have maintained their bladders 20% of patients in the MCV arm experienced >grade 3 hematologic toxicity and nausea and vomiting; 3 of these patients died. Another patient subsequently died of a GI bleed after concomitant platinum/RT 6% of patients in the non-MCV arm experienced >grade 3 hematologic toxicity. 1 patient in the cisplatinum/RT alone arm died of a duodenal perforation
Source: Shipley WU, Prout GR, Einstein AB et al (1987) Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258:931–935 b Source: Tester W, Porter A, Asbell S et al (1993) Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 8512. Int J Radiat Oncol 25:783–790 c Source: Rodel C, Grabenbauer GG, Kuhn R et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061–3071 d Source: Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16:3576–3583
558
James S. Butler
A proposed algorithm for bladder preservation with chemoradiation therapy is presented in Figure 18.10.
Bladder cancer eligible for organ preservation
Maximal TURBT
40–45 Gy to pelvis with CDDP (70–100 mg/m2 every 3 weeks). Can use lower, divided doses, as in Erlangen study
Cystoscopy 2–4 weeks after chemotherapy/ RT
Residual disease
Complete disease regression RT to bladder, cumulative mean dose of 64.8 Gy, with 1 more cycle of CDDP
Cytoscopic surveillance (every 3 months ×2 years, then every 6 months ×2 years, then yearly
Cystectomy
Recurrent invasive bladder cancer
Superficial tumor recurrence (see Fig. 18.6)
Figure 18.10 Proposed algorithm for bladder preservation with chemoradiation therapy
Chapter 18 Bladder Cancer
559
Unfortunately, not all patients are able to tolerate cisplatin-based chemotherapy. Table 18.19 lists clinical trials utilized non-cisplatin-based chemotherapy used concurrently with radiation therapy. Table 18.19 Evidence-documented efficacy of concomitant non-cisplatin chemotherapy and radiation therapy
a
Trial
Description
SWOG 8733a
81 patients with multiple comorbidities primary or recurrent muscle-invasive bladder cancer 20 Gy per 10 fractions with 5-FU, 1,000 mg/m2 × 4 days every 3 weeks Operable patients who received 2 cycles underwent cystoscopy; if negative, they continued to a third cycle; 28% of evaluable patients had complete remission (CR). There was a 22% 5-year survival Inoperable patients received 3 cycles; 49% of evaluable patients achieved CR. There was a 30% 5-year survival for this group 22 of 61 evaluable patients died of bladder cancers This regimen was very tolerable, with 92% completing the regimen in the surgery group, and 100% in the inoperable group, with only 45% experiencing >grade 3 toxicity
University of Michiganb
24 patients with cT2–3 Phase I study: 60 Gy per 30 fractions to bladder with gemcitabine biweekly; 10, 20, 30, and 33 mg/m2 during RT, then TURBT 4 weeks later 76% 5-year survival 62% of patients has bladder-intact survival MTD of gemcitabine was calculated to be 27 mg/m2
University of Hallec
42 patients with primary or recurrent bladder cancer 45–60 Gy with paclitaxel, 25–35 mg/m2 twice weekly 28 patients underwent restaging TURBT 6 weeks after therapy; 24 patients had CR 13 patients died; 7 of tumor 2-year follow-up This regimen was very tolerable, with 16 patients experiencing >grade 3 toxicity
Source: Higano CS, Tangen CM, Sakr WA et al (2008) Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin report of Southwest Oncology Group Trial 8733. Cancer 112:2181–2187 b Source: Oh KS, Soto DE, Smith DC et al (2009) Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial. Int J Radiat Oncol 74:511–517 c Source: Müller AC, Diestelhorst A, Kuhnt T et al (2007) Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. Strahlenther Onkol 183:177–83
560
James S. Butler
Current areas of investigation include hyperfractionated radiation with polychemotherapy. Patients in these studies have been reported to have higher rates of complete regression of their bladder tumor, as well as possibly higher rates of bladder preservation. However, there are no prospective randomized studies that compare these approaches to standard daily radiation therapy with cisplatin.
Treatment of Metastatic Bladder Cancer Bladder cancer is responsive to chemotherapy, and chemotherapy improves overall survival. The two most active regimens used for metastatic bladder include methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), and gemcitabine/cisplatin ([GC] the current standard) (Table 18.20). A number of regimens elicit responses are used as second- and even third-line therapy. Table 18.20 Efficacy of chemotherapy Trial
Description
MSKCCa
133 patients with advanced bladder cancer treated with MVAC CR and partial response (PR) rates were 36 and 36%, respectively Median survival times were 38, 11, and 8 months for patients with CR, PR, or no response, respectively
International trialb
405 patients with stage IV bladder cancer: GC versus MVAC Response rates were 49 versus 46% response rate for GC versus MVAC; median survival times were 13.8 versus 14.8 months for GC versus MVAC (p = NS) 1 versus 3% toxic death rate. Patients receiving GC also had a better quality of life GC regimen is considered the current standard
MSKCC: Memorial Sloan-Kettering Comprehensive Cancer Center a Source: Sternberg CN, Yagoda A, Scher H et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium efficacy and patterns of response and relapse. Cancer 64:2448–2458 b Source: von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 17:3068–3077
Chapter 18 Bladder Cancer
561
Treatment of Non-urothelial Bladder Cancer Treatment of Small Cell Carcinoma Small cell carcinoma accounts for <1% of all bladder cancers in the USA. It is responsive to chemotherapy, and patients treated with chemotherapy have better survival that those who are not. Currently, there is no standard local therapy. Outcomes of two series of small cell bladder carcinoma studies are presented in Table 18.21. Table 18.21 Small cell bladder carcinoma studies Trial
Patients (n)
Chemotherapy
No chemotherapy
East Anglian Cancer Networka
20
33-month median survival
3-month median survival
46
77% 5-year cause-specific survival (chemotherapy before cystectomy)
36% 5-year cause-specific survival (chemotherapy after cystectomy)
MDACCb
MDACC: MD Anderson Comprehensive Cancer Center a Source: Mukesh M, Cook N, Hollingdale AE et al. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 2008; 103:747–752 b Source: Siefker-Radtke AO, Dinney CP, Abrahams N et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J Urol 2004; 172:481–484)
562
James S. Butler
Treatment of Squamous Cell Carcinoma Squamous cell carcinoma is managed primarily by surgery. Preoperative radiation can be considered for locally advanced disease, as suggested by evidence presented in Table 18.22. Table 18.22 Treatment of squamous cell carcinoma studies RT cystectomy
Cystectomy
U Mansouraa 92
10/30 P3-4, N +/-, 5-year survival
6/30 P3-4,N +/-, 5-year survival
MDACCb
10 patients downstaged had local control and survival
7/15 patients not downstaged had local failure and died
Trial
Patients
25
P: primary tumor category a Source: Ghoneim MA, Ashamallah AK, Awaad HK et al (1985) Randomized trial of cystectomy with or without preoperative radiotherapy for carcinoma of the bilharzial bladder. J Urol 134:266–268 b Source: Swanson DA, Liles A, Zagars G et al (1989) Preoperative irradiation and radical cystectomy for stages T2 and T3 squamous cell carcinoma of the bladder. J Urol 143:37–40
Treatment of Adenocarcinoma Adenocarcinoma is primarily managed by cystectomy, and adjuvant radiation therapy may be considered (Table 18.23). Table 18.23 Potential role for adjuvant RT Description
Results
NCI Egypt
192 patients with advanced bladder adenocarcinoma 69 patients who received postoperative RT for a 61% 5-year DFS and a local control of 92% 123 patients had cystectomy alone and had a 37% 5-year DFS and a 53% local control
Source: Zaghloul MS, Nouh A, Nazmy M et al (2006) Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 24:13–20
Chapter 18 Bladder Cancer
563
Radiation Therapy Techniques Simulation and Field Arrangements Radiation fields should encompass tumor bed plus regional lymph nodal areas for locoregional control. Patients are simulated and treated with an empty bladder. Field setup using a four-field technique (anterior/posterior[AP], PA, and opposed lateral fields) is illustrated in Figure 18.11a,b and detailed in Table 18.24.
Figure 18.11 a, b Four-field pelvis covering the internal/external iliacs (at least 2-cm rim of pelvis), the empty bladder, a prostate (if male), and b proximal urethra (if female)
Table 18.24 Pelvic fields for bladder cancer conservation therapy (Figure 18.11a,b) Field(s)
Borders
AP/PA
Superior: top of sacrum Inferior: below the bladder to at least the bottom of the obturator foramen Lateral: include 2 cm of the pelvic rim
Lateral
Superior/inferior: as AP/PA fields Anterior: at least 2 cm anterior to the bladder Posterior: at least 2 cm posterior to the bladder Block small bowel superiorly/anteriorly
All fields should be irradiated on daily basis Some institutions’ protocols treat bladders with margin, only without pelvic nodes
564
James S. Butler
Dose and Treatment Delivery Conventional fractionation to a total dose of 40–45Gy is recommended to the pelvic fields. After cystoscopy confirmation of complete response, an additional 24 Gy (1.8–2 Gy per fraction) is delivered to the partial bladder to a total of 64–64.8 Gy, if the original tumor can be localized (Figure 18.12a,b). Otherwise, the entire bladder is treated (Figure 18.13a,b). It is important to respect the normal tissue tolerance of the neighboring bowel, which sometimes means that the cumulative dose must be lowered.
Figure 18.12 a, b Fields for partial bladder boost to the anterior bladder of a male patient. The patient had fiducial markers and dose verification system sewn onto the outside of the bladder overlying the tumor bed via laparoscopy. a His bladder was catheterized daily with 100 ml sterile water instilled, b then, he had localization with on-board imaging (OBI) and the dose verification system
Figure 18.13 a, b Cone-down field to irradiate the entire empty bladder (patient voiding daily just before going on the table)
Chapter 18 Bladder Cancer
565
Follow-Up Follow-up after definitive therapy for bladder cancer is necessary, and the examinations recommended in each follow-up depend on the extent of disease and treatment modality utilized in definitive settings. Schedule of posttreatment surveillance as well as diagnostic interventions during follow-up are detailed in Figures 18.7 and 18.12, and Table 18.25. Table 18.25 Follow-up schedule and examinations Schedule
Frequency
First follow-up
2 weeks after radiation therapy
Years 0–1
Every 3 months
Years 2–5
Every 6 months
Years 5+
Annually
Examination History and physical
Laboratory tests
Imaging studies
Complete history and physical examination Cystoscopy for superficial bladder cancer or after bladder conservation for invasive disease during each followup session
Urine cytology at each follow-up Complete blood counts (CBC) and serum chemistry Liver and renal function tests Lab tests are optional for superficial bladder cancer but recommended for invasive disease every 6 months
Chest X-ray every 6 months for invasive disease Imaging for collection system every 3–6 months for invasive disease
Adapted from: National Comprehensive Cancer Network [NCCN]. Clinical practice guidelines in oncology: bladder cancer v.1. 2010. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp. Cited 2009
566
James S. Butler
Sequelae of radical cystectomy include hyperchloremic metabolic acidosis and other electrolyte abnormalities, renal calculi, bacteriuria, sepsis, malabsorption of vitamin B12, fat-soluble vitamins and bile salts, short-bowel syndrome, urine incontinence, ureteral obstruction, renal deterioration, and bowel obstruction. Metabolic complications are more likely to occur in continent diversions than in noncontinent urinary diversions. A vitamin B12 shot annually is recommended if a patient had a continent orthotopic diversion. Acute side effects of chemoradiation therapy include frequency, urgency, dysuria, nausea, vomiting, and diarrhea. These side effects usually resolve. Late effects after chemoradiation therapy include hematuria, chronic frequency, contracted bladder that can sometimes necessitate cystectomy (<5%). Most of the patients who maintain their bladders have normal to nearnormal function, and they have reported higher quality of life than that can be achieved with cystectomy. Quality of life after bladder conversation seems to be better than after cystectomy (Table 18.26). Table 18.26 Quality of life after chemoradiation therapy Trial
Results
Karolinska
Questionnaires mailed to patients treated with RT, cystectomy, and some patients selected randomly from the population 58 irradiated patients, 251 cystectomy patients, and 310 population controls returned the forms 75% of irradiated patients reported little or no urinary symptoms 38% of irradiated patients had intercourse in the prior month, and 57% reported that they had ejaculated versus 13 and 0% of the cystectomy patients, respectively However, 32% of irradiated patients reported worse GI symptoms versus 24% of cystectomy patients versus 9% of controls
Source: Henningsohn L, Wijkstrom H, Dickman PW et al (2002) Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol 62:215–225
19
Prostate Cancer Bin S. Teh1, Angel I. Blanco2, Arnold C. Paulino3 and E. Brian Butler 4
Key Points Prostate cancer is the most commonly diagnosed malignancy in US men. The majority of diagnoses relate to the use of screening prostate-specific antigen (PSA), which remains controversial. A combination of PSA level at diagnosis, clinical stage, and Gleason score is used to stratify patients into prognostic groups, with risk-adapted treatment assignment. Expectant management is a valid alternative for patients with very low-risk (T1a, Gleason ≤6, PSA <10 ng/ml, less than three positive biopsy cores and <50% cancer per core, and PSA density <0.15 ng/ml) disease. Because of screening PSA, most patients present with curative disease and, according to population studies, opt for treatment with curative intent. Validated first-line treatment options include radical prostatectomy and radiation therapy, via either interstitial seed implants or external-beam radiation (EBRT). Radical prostatectomy is the surgical gold standard curative treatment and confers a reduction in mortality versus expectant management. Surgical techniques have evolved considerably during the past several decades, and robotic-assisted laparoscopic prostatectomy (RALP) has been rapidly adopted in the USA. Radiation therapy for localized prostate cancer leads to equivalent oncologic outcomes as compared with radical prostatectomy. Interstitial seed implants and EBRT appear clinically equivalent. Modality-specific toxicity profile and logistics should be incorporated into the decision-making process of the individual patient. Owing to an increased probability of biochemical, clinical, and distant failure, treatment of locally advanced, nonmetastatic prostate cancer necessitates aggressive management. Results from randomized studies have established the value of dose-escalated radiotherapy alone in the unimodality setting versus standard-dose irradiation in combination with neoadjuvant and concurrent hormones. The timing and optimal duration of hormone therapy in the era of dose escalation remain investigational. Adjuvant radiation therapy improves clinical outcome (versus salvage radiation) for pT3 prostate cancer or positive surgical margins.
1
Bin S. Teh, MD 2 Angel I. Blanco, MD 3 Arnold C. Paulino, MD Email: Email: Email:
[email protected] [email protected] [email protected]
4
E. Brian Butler, MD Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_2 © Springer-Verlag Berlin Heidelberg 2011
568
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Epidemiology and Etiology Epidemiology data and risk factors of prostate cancer are presented in Table 19.1. Screening of prostate cancer in general population with serum prostatespecific antigen (PSA) is commonly practiced in the USA; however, such recommendation is controversial according to the conflict results of two largescale randomized clinical trials (Table 19.1). Table 19.1 Epidemiology data, risk factors, and screening for of prostate cancer Type
Description
Epidemiology
Prostate cancer is the most commonly diagnosed cancer in US men In 2010, an estimated 217,730 new cases will be diagnosed Incidence rates exhibit wide geographical variation, with an 80-fold difference between China and North America
Risk factors
Risk factors for prostate cancer are multiple More established factors: increased life expectancy, rou tine adoption of PSA, ethnicity, and family history Potential but less established factors: genetic and hor monal factors, obesity, dietary habits, exercise, prostatic inflammation, and infection
Screening for prostate cancer
PSA screening has had a significant impact on prostate cancer incidence and mortality Incidence of prostate cancer in USA rose substantially from the 1980s to 2001, with subsequent decline The percentage of low-risk disease has increased, and the age-adjusted death rate from prostate cancer has declined PSA screening in general population is controversial: The ERSPC trial demonstrated a 20% reduction in prostate cancer deaths with screening, while the North America PLCO study showed low overall mortality from prostate cancer, with or without screening
PSA: prostate-specific antigen; ERSPC: European Randomized Study of Screening for Prostate Cancer; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Sources: Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostatecancer mortality in a randomized European study. N Engl J Med 360:1320 –1328; Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310 –1319
Chapter 19 Prostate Cancer
569
Anatomy The morphological and anatomical structures of prostate, as well as its relationship with surrounding structures are detailed in Table 19.2 and Figures 19.1 and 19.2. Table 19.2 Anatomy of the prostate Aspect
Description
Structure (Figure 19.1)
Morphologically, the prostate comprises peripheral, central, and transitional zones ~75% of cancers originate in the peripheral zone Prostate is divided into 5 lobes: 2 lateral, 1 posterior, 1 median, and 1 anterior lobe
Anatomic relationship (Figure 19.2)
Shares important anatomic relationships with the Rectum posteriorly Seminal vesicles superoposteriorly Neurovascular bundles laterally Bladder anterosuperiorly Surrounds the urethra between the bladder neck and the genitourinary membrane Traversed by the ejaculatory ducts
570
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Figure 19.1 Anatomy of the prostate (~75% of all adenocarcinomas of the prostate occur in the peripheral zone). Diagram courtesy of Baylor College of Medicine. Used with permission
Figure 19.2 a–d a Coronal, b sagittal, c superior, and d inferior axial 3-Tesla MRI images obtained using torso coil, illustrating relevant prostate anatomic relationships. The yellow lines illustrate the levels of the selected coronal and axial slices. Note the 3D anatomic relationships of the prostate, bladder, rectum, seminal vesicles, and obturator internus muscles
Chapter 19 Prostate Cancer
571
Pathology Adenocarcinoma is the most common histological subtype of prostate cancer. Histological evaluation provides important prognostic information in prostate cancer. The current scoring system for adenocarcinoma developed by Gleason et al was last revised in a 2005 International Society of Urological Pathology Consensus Statement. The Gleason score is based on the degree of loss of the normal glandular tissue architectures. The classic Gleason scoring diagram shows five basic tissue patterns that are technically referred to as tumor grades. The subjective microscopic determination of this loss of normal glandular structure caused by the cancer is abstractly represented by a grade, a number ranging from 1 to 5, with 5 being the worst grade possible (Figure 19.3, Table 19.3).
1
2
3
4
5
Figure 19.3 The Gleason score is derived by adding the sums of the two most common patterns of cancer observed, each assigned a grade from 1 to 5
572
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.3 Determination of Gleason Score Type
Description
Primary gleason grade
The Primary Gleason grade (ranges from 1–5) has to be greater than 50% of the total pattern seen (i.e. the pattern of the majority of the cancer observed)
Secondary Gleason grade
The Secondary Gleason grade (ranges from 1–5) has to be less than 50%, but at least 5%, of the pattern of the total cancer observed
Gleason score
The sum of the primary and secondary Gleason grades is the Gleason score (ranges from 2 to 10)
Other histologic subtypes of prostate cancer include urethral duct carcinoma, transitional cell carcinoma, ductal adenocarcinoma, neuroendocrine carcinoma, carcinosarcoma, sarcomatoid carcinoma, endometrial carcinoma, and sarcomas.
Routes of Spread Local extension, regional (lymphatic), and distant (hematogenous) metastases are the three major routes of spread in prostate cancer (Table 19.4). Table 19.4 Routes of spread in prostate cancer Route
Description
Local extension
Local extension mainly involves direct extracapsular extension of prostate cancer or involvement of seminal vesicles The probability of local extension can be estimated by serum PSA and Gleason score A number of predictive models exist to estimate the probabilities of local extension, such as Partin’s Table and the Roach Formulas: ECE (%) = 3/2 × PSA + 10× (Gleason-3) Seminal vesicle involvement (%) = PSA + 10× (Gleason-6) The presence of local extension affects treatment strategy, and in case of EBRT, the treatment portal
Chapter 19 Prostate Cancer
573
Table 19.4 (continued) Route
Description
Regional lymph node metastasis
Lymph node metastasis is a common mode of spread in prostate cancer The probability of regional metastasis can be estimated by a number of predictive models Using the Roach formula, such probability can be calculated as: LN metastasis (%) = 2/3 PSA + 10× (Gleason-6) Lymph node metastasis, even regional, are staged as stage IV in prostate cancer
Distant metastasis
The most common route of hematogenous metastasis is through Batson’s venous plexus to the vertebral body of the lumbar spine Metastasis to other organs may occur but unlikely be the first incidence of distant metastasis
ECE: extracapsular extension; SV: seminal vesicles; LN: lymph node; EBRT: externalbeam radiation therapy Source: Roach M, Marquez C, Yuo HS et al (1994) Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33 –37
Lymph Node Metastasis The primary lymphatic vessels from the prostate gland drain into the regional lymph nodes of the true pelvis (Figure 19.4). Regional and distant lymph node groups observed in prostate cancer metastases are listed in Table 19.5.
Figure 19.4 Lymph node anatomy in the pelvis. The diagram outlines the major nodal chains seen in the pelvis. Reprinted with permission from Magnetic Resonance Imaging Clinics of N America (2004)
574
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.5 Regional and distant lymph node groups in prostate cancer metastases Lymph nodes
Subclassification of lymph nodes
Internal iliac (hypogastric) nodes Regional lymph Obturator nodes Presacral nodes (within true pelvis, + Perivesical nodes N disease) External iliac nodes Distant lymph nodes (beyond true pelvis, M1A disease)
Deep and superficial inguinal nodes Common iliac nodes Retroperitoneal (aortocaval) nodes Supraclavicular, cervical, and scalene nodes
Diagnosis, Staging, and Prognosis Clinical Presentation Although most men diagnosed because of screening PSA are asymptomatic at the time of diagnosis, advanced tumors may invade adjacent organs, regional pelvic lymph nodes, or present with osseous metastases. Such cases may present with bladder outlet obstructive symptoms, hematuria, hematospermia, erectile dysfunction, hematochezia, changes in bowel function, and/ or bone pain. The presence of such symptoms, as well as baseline assessment of urinary (including the International Prostate Symptom Score [IPSS]), rectal, and erectile function, and medical comorbidities should be documented in a focused history.
Diagnosis and Staging Tables 19.6 and 19.7, and Figure 19.5 illustrate the diagnostic procedure of prostate cancer, including suggested examinations and tests.
Chapter 19 Prostate Cancer
575
Table 19.6 Diagnostic procedures used in the diagnosis of prostate cancer Type
Description
Serum PSA
PSA screening leads to the majority of prostate cancer diagnoses Although sensitive, PSA is not specific, and false positives can result in cases of infection, benign prostatic hypertrophy, recent DRE, recent ejaculation, and other non-neoplastic conditions PSA has been shown to increase as a function of age in healthy individuals, prompting age- and race-specific reference ranges, although the appropriateness of race-specific levels is controversial The positive predictive value of PSA ≥4 ng/ml (a typical clinical threshold) ranges from 31 to 54%. Specificity increases when patient age and DRE status are considered Additional laboratory values, including free PSA (percentage of protein-unbound PSA, associated with prostate cancer for ratios <0.2), PSA density (expressed as the ratio of serum PSA to prostate volume), and PSA velocity (or rise in PSA level as a function of time, with 0.75 mg/ml/year suggestive of prostate cancer), are often utilized Persistent elevation in PSA and the presence of palpable prostatic nodules, alone or in combination, warrant consideration of transrectal ultrasound-guided (TRUS) needle biopsy
Physical examinations
The physical exam should include a thorough digital rectal exam (DRE), noting baseline rectal tone, the presence of hemorrhoids or anorectal masses, and with specific focus on the prostate glands, including its size and consistency, presence of nodules, involvement of the lateral sulci and/or seminal vesicles DRE forms the cornerstone for staging, although it is insensitive for assessment of extracapsular extension DRE is insensitive for assessment of extracapsular extension
TRUS-guided needle biopsy
This procedure represents the gold standard method for prostate cancer diagnosis, and typically consists of at least 6 cores Since the procedure can miss 20 –30% of clinically significant cancer, a larger number of cores may be considered, particularly in patients with larger prostate volumes; the TRUS biopsy protocol recommended at present by the NCCN entails an extended biopsy with a ten cores The length of each core specimen, and the length of tumor within each malignant sample, should be documented Additional diagnostic techniques are under investigation; among these, 3D prostate mapping biopsy appears promising and may improve the staging accuracy of standard core biopsy
576
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.7 Imaging studies used in the diagnosis and staging of prostate cancer Study type
Description
Imaging
An assortment of imaging technologies, including 2D, 3D, and Doppler ultrasound, CT, and MRI, has been extensively evaluated in an attempt to improve staging accuracy, but are not considered replacements for DRE Among these tools, TRUS and MRI permit optimal visualization of prostate anatomy relative to CT Surface and endorectal MRI coils can yield complementary information, with the latter providing fine resolution of the prostatic structures and the former information on the adjacent organs and regional lymph nodes T2-weighted sequences allow visualization of the zonal anatomy, vas deferens and seminal vesicles, neurovascular bundles, and penile bulb MRI allows detection of seminal vesicle invasion and extraprostatic disease, although MRI staging is made difficult by postbiopsy hemorrhage Anatomic T2-weighted MRI imaging is a sensitive diagnostic and technique whose specificity and diagnostic accuracy can be enhanced by magnetic resonance spectroscopy (MRS) and/or dynamic contrast-enhanced techniques (DCE-MRI)
Chapter 19 Prostate Cancer
577
Prostate Cancer Suspected (e.g., elevated PSA on screening test)
Complete History and Physical Including DRE
Transrectal Ultrasound Guided Prostate Biopsy
If life expectancy is greater than 5 years or symptomatic: Recommend Treatment
If life expectancy is less than or equal to 5 years and asymptomatic: No Further Treatment
Risk Classification Based on PSA, DRE, and Gleason Score
Work-ups Dependent on Risk Classification
Bone Scan 1. T1-T2 and PSA greater than 20ng/ml 2. Gleason score greater than or equal to 8 3. T3/T4 disease 4. Symptomatic
Abdominal Pelvic CT/MRI 1. T3/T4 disease 2. T1-T2 and nomogram probability of lymph node Involvement greater than 20%
Multidisciplinary Treatment Based on Risk Classification Figure 19.5 Proposed algorithm for diagnosis and staging of prostate cancer. A bone scan is recommended if PSA >20, or in symptomatic patients with PSA of 10–20, and not recommended if PSA <10. A CT scan of the abdomen and pelvis is recommended for patients with high-risk disease
578
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Tumor, Node, and Metastasis Staging Diagnosis and clinical staging depends on findings from history and physical examination, imaging, and lab tests. Pathological staging depends on findings during surgical resection and pathological examination, in addition to those required in clinical staging. The 7th edn. of the tumor, node, and metastasis (TNM) staging system of American Joint Committee on Cancer (AJCC) is presented in Tables 19.8 and 19.9. Table 19.8 AJCC TNM classification of adenocarcinoma of the prostate Stage
Description
Primary tumor (T) TX
Primary tumor cannot be assessed
T0
No evidence of primary tumor
T1a
Tumor incidental histologic finding in 5% or less of tissue resected
T1b
Tumor incidental histologic finding in more than 5% of tissue resected
T1c
Tumor identified by needle biopsy (e.g., because of elevated PSA)
T2a/pT2a
Unilateral, one-half of one side or less
T2b/pT2b
Unilateral, involving more than one-half of side but not both sides
T2c/pT2c
Tumor involves both lobes (i.e., bilateral involvement)
T3a/pT3a
Extraprostatic extension or microscopic invasion of bladder neck
T3b/pT3b
Tumor invades seminal vesicle(s)
T4/pT4
Tumor is fixed or (pathologically) invades adjacent structures other than seminal vesicles (such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall)
Regional lymph nodes (N) NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
Regional lymph node metastasis
Chapter 19 Prostate Cancer
579
Table 19.8 (continued) Stage
Description
Distant metastasis (M) MX
Distant metastasis cannot be assessed
M0
No distant metastasis
M1a
Distant metastasis to non-regional lymph nodes
M1b
Distant metastasis to skeletal system
M1a
Distant metastasis to additional sites with or without skeletal metastasis
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer (AJCC), cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
Table 19.9 AJCC stage grouping of adenocarcinoma of the prostate Group
I
T
N
M
PSA
Gleason score
T1a–c
0
0
<10
≤6
T2a
0
0
<10
≤6
T1–2a
0
0
–
–
T1a–c
0
0
<20
7
T1a–c
0
0
10 –20
≤6
T2a
0
0
<20
<7
T2b
0
0
–
–
T2c
0
0
Any
Any
T1–2
0
0
≥20
Any
T1–2
0
0
Any
≥8
III
T3a–b
0
0
Any
Any
IV
T4
N1
M1
Any
Any
IIA
IIB
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer (AJCC), cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
580
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Prognoses Beyond Gleason score, pretreatment serum PSA, and stage at diagnosis, additional pathologic factors include percent positive biopsy cores, PSA density and velocity, length of core involvement by tumor, and presence of perineural invasion also portend prognostic significance. Since the clinical behavior of prostate cancer might range from indolent to highly aggressive, prognostic assessment is important for predicting outcome and treatment selection. A number of prognostic schemes have been developed. The multitiered clinical grouping system developed by the National Comprehensive Cancer Network (NCCN) is summarized, along with suggested treatment recommendations, in Table 19.10.
Table 19.10 NCCN Prostate Cancer Risk Classification and suggested treatment strategies Risk group
Criteria
Treatment options
Very low
T1a, Gleason ≤6, PSA <10 <3 Positive biopsy cores and <50% cancer per core, and PSA density <0.15 ng/ml
Active surveillance using PSA and DRE, if expected survival <20 years
Low
T1-T2a, Gleason ≤6, and PSA <10
Active surveillance using PSA and DRE if expected survival <10 years; using PSA, DRE, and repeat biopsy if expected survival ≥10 years, or Definitive therapy using IG-IMRT, brachytherapy, or radical prostatectomy (RP)
Intermediate
T2b-T2c, Gleason 7, or PSA 10 –20
IG-IMRT with or without shortterm ADT with or without brachytherapy boost or RP
High
T3a, Gleason 8–10, or PSA >20
IG-IMRT and long-term ADT or radical prostatectomy plus PLND with or without adjuvant RT
Chapter 19 Prostate Cancer
581
Table 19.10 (continued) Risk group
Criteria
Treatment options
Locally advanced: very high
T3b–T4
IG-IMRT plus long-term ADT or radical prostatectomy plus PLND with our without adjuvant RT or ADT
Locally advanced: LN
N1
ADT or IG-IMRT and longterm ADT
Locally advanced: DM
M1
ADT
PSA: prostate-specific antigen (nanograms per milliliter); DRE: digital rectal examination; IG-IMRT: image-guided intensity-modulated radiation therapy; PLND: pelvic lymph node dissection; ADT: androgen depravation therapy; LN: lymph node involvement; DM: distant metastasis Source: NCCN clinical practice guidelines in oncology: prostate cancer v.1.2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Cited 21 June 2010
Treatment Principles and Practice Localized prostate cancer can be treated with surgery, radiation therapy, or the combination of both. In addition, hormonal therapy plays a major role in the treatment of locally advanced disease. For selected patients with very low- or low-risk diseases, active surveillance may be a valid option.
Treatment of Localized Prostate Cancer A risk-adapted schematic defining standard treatment algorithms for localized prostate cancer is listed in Table 19.10. In summary, accepted treatment options include surveillance versus active treatment with radiotherapeutic, surgical, and systemic modalities selected as a function of disease stage, side effect profile, and patient comorbidities (Table 19.11).
582
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.11 Treatment modalities used in prostate cancer Type
Description
Active surveillance
Indications
Indicated but controversial in patients with very low-risk disease (if life expectancy <20 years) or low-risk disease (if life expectancy <10 years) Populations studies suggested that only a small proportion of prostate cancer patients choose active surveillance
Facts/issues
Guidelines for active surveillance include regular PSA, DRE, and/or repeat needle biopsy Definitive treatment recommended if clinical (PSA, exam) or pathologic (higher Gleason score, increased number of positive biopsy cores) disease progression is documented Advantages of active surveillance include avoidance of unnecessary treatment and potential side effects Potential disadvantages of tumor progression and potential need for more aggressive and potentially toxic treatment, increased anxiety, and the requirement of multiple evaluations and periodic biopsies
Radical prostatectomy (RP)a
Indications
Indicated and a common treatment for patients with clinically localized prostate cancer, with life expectancy exceeds 10 years RP is considered as the standard surgical treatment
Facts/issues
The only local treatment that reduces mortality (RR = 0.56), local progression (RR = 0.33), and metastasis (RR = 0.6) over observation The procedure has evolved from perineal to retropubic, retropubic nerve sparing, laparoscopic, and robot assisted approaches Potential side effects include intra-operative bleeding, urinary incontinence, and erectile dysfunction Overall prostate-cancer-specific mortality of 12% (range of 5–38%) at 15 years after surgery
External-beam radiation therapy (EBRT)
Indications
As monotherapy for low-risk and selected intermediaterisk patients In concurrent with ADT for intermediate-, high-, and very high-risk patients Adjuvant postprostatectomy treatment for high-risk patients Palliative treatment to primary or metastatic foci
Chapter 19 Prostate Cancer
583
Table 19.11 (continued) Type
Description
External-beam radiation therapy (EBRT)
Facts/issues
Intensity-modulated radiation therapy (IMRT) represents the current standard of care for prostate EBRT Similar results in disease control relative to prostatectomy and seed implant if dose of EBRT >72 Gy
Interstitial brachytherapy Indications and contraindications
Generally well applicable modality for curative treatment of localized prostate cancer Selection criteria from the ABS and contraindications are detailed in Table 19.10
Facts/issues
Highly conformal dosimetry Moderate invasiveness, outpatient nature Minimal number of treatment visits (i.e., typically volume study and implant dates) ABS guidelines for monotherapy or as boost following EBRT are summarized in Table 19.12
Androgen ablation
Indications
Short-term ADT in intermediate-risk prostate cancer Long-term and adjuvant ADT in high to very high-risk prostate cancer Mainstay treatment for palliative therapy in metastatic disease Unproven role as a component of salvage therapy, al though it is utilized empirically in selected high-risk patients
Medications/ procedures
Orchiectomy or LHRH agonists (e.g., leuprolide, goserelin) block 90 –95% of testosterone Anti-androgen (e.g., flutamide, bicalutamide, cyproterone acetate) TAB utilizes orchiectomy or LHRH agonist plus anti-androgen for complete testosterone blockade Estrogen as a second-line hormonal therapy
RR: relative risk; ADT: androgen-deprivation therapy; TAB: total androgen blockade; LHRH: luteinizing hormone-releasing hormone a Sources: Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984; Stephenson AJ, Kattan MW, Eastham JA et al (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300430 –5
584
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
The treatment algorithm of prostate cancer based on the NCCN risk classification is illustrated in Figure 19.6. Diagnosis of Prostate Cancer
Risk Classification of Prostate Cancer
Low Risk T1-2a, G≤6, or PSA<10
Interm. Risk T2b-c, G=7, or PSA 10-20
High Risk T3a, G=8-10, or PSA>20
IG-MRT +/Brachytherapy Boost
IG-MRT +/Brachytherapy Boost
Very High Risk T3b-T4, N0, M0
Opt to Active Surveillance?
No
IG-IMRT
+/-
+/-
Yes
Definitive Treatment?
No
OR Brachytherapy
Short-term ADT (4-6 months)
Long-term ADT (2-3 years)
Radiation Therapy
Radiation Therapy
Radiation Therapy
OR
Radical Prostatectomy
OR
OR
Radical Prostatectomy
Palliative ADT
Radical Prostatectomy +PLND +/Adjuvant Radiation Therapy Surgical Therapy
Active Follow-Up Figure 19.6 Proposed treatment algorithm for adenocarcinoma of the prostate
Chapter 19 Prostate Cancer
585
It should be noted that no randomized trial exists comparing modern radiation with prostatectomy techniques, and that oncologic outcomes for localized prostate cancer appear similar when appropriate (≥72 Gy) radiation doses are employed (Table 19.12) (Source: Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat Oncol Biol Phys 58:25 –33). Table 19.12 American Brachytherapy Society selection criteria for permanent prostate brachytherapy Treatment type/ contraindication
Criteria
Monotherapy
Clinical stage T1–T2a, Gleason sum 2–6, and PSA <10 ng/ml
EBRT boost
Clinical stage T2b–T2c, Gleason sum 8–10, or PSA >20 ng/ml
EBRT boost (other)
Perineural Invasion Multiple positive biopsies Bilateral positive biopsies, or MRI evidence of capsular penetration
Monotherapy or boost plus neoadjuvant androgen suppression
Initial prostate volume >60 ml, with response
Disease related
Prior pelvic radiation therapy Prominent median lobe Gland volume >60 ml Seminal vesicle invasion
Non-disease related
Medical inoperability History of multiple pelvic surgeries IPSS score >15 Pubic arch interference Large TURP defect
Source: Nag S, Beyer D, Friedland J et al (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789 –799
586
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Dose Escalation and Treatment Outcome of External-Beam Radiation Therapy External-beam radiation therapy (EBRT) is one of the most important definitive treatment modality for localized prostate cancer of all stages. Intensitymodulated radiation therapy (IMRT) represents the current standard of care for prostate EBRT. Details of target volume delineation and selection, as well as dose and delivery are detailed in the “Radiation Therapy Technology Section.” Following initial single-institution reports of improved efficacy and therapeutic ratio by Hanks et al, dose-escalation strategies have become an important focus of prostate cancer research endeavors. Importantly, the maturing three-dimensional (3D)-conformal and emerging IMRT studies collectively suggest improvements in biochemical control and reduced toxicity rates as compared with 2D approaches. Clinical evidence for dose escalation in EBRT is presented in Table 19.13 (for nonrandomized studies) and Table 19.14 (for randomized clinical trials). With respect to biochemical control, dose escalation has shown improved outcomes on several phase III studies listed above; however, likely owing to patient heterogeneity, inadequate power, or different definitions of PSA relapse, the results have been inconsistent when analyzed according to risk groups. Table 19.13 Clinical evidences support dose escalation in EBRT for prostate cancer: non-randomized studies Studies
Description
Hanks et al (1998)a
Retrospective of 232 patients with prostate cancer treated using 3D-CRT for outcome of radiation dose escalation A dose response was observed for patients with pretreatment PSA >10 ng/ml, based on 5-year bNED results 5-year bNED rates of 35% at 70 Gy, and 75% at 76 Gy (p = 0.0049) if PSA ranged from 10 to 19.9 ng/ml No dose response was observed for patients with pretreatment PSA <10 ng/ml Dose response was observed for FC-LENT grade 2 and grades 3,4 GI sequelae, and for LENT grade 2 GU sequelae The improvement in 5-year bNED rates for patients with PSA levels >10 ng/ml suggested a benefit of radiation dose escalation
Chapter 19 Prostate Cancer
587
Table 19.13 (continued) Studies
Description
RTOG 9406 dose level Vb
Phase I/II study for radiation dose escalation in the treatment of stage T1 and T2 prostate adenocarcinoma 225 patients were treated to 78 Gy to the prostate alone (if probability of seminal vesicles [SV] involvement <15%) or 78 Gy to prostate and 54 Gy to SV (if SV involvement probability ≥15%) The frequency of grade 3 or worse late effects was compared with a similar group of patients treated in 2 other RTOG studies Acute toxicity at dose of 78 Gy was low: grade 3 acute effects in 4% of patients treated to prostate only, and 2% of patients treated to both prostate and SV. No Grade 4 or 5 acute toxicity was reported
bNED: biochemical no evidence of disease a Source: Hanks GE, Hanlon AL, Schultheiss TE et al (1998) Dose escalation with 3D conformal treatment: 5-year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41:501–510 b Source: Michalski JM, Winter K, Purdy JA et al (2005) Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V. Int J Radiat Oncol Biol Phys 62:706 –713 Table 19.14 Clinical evidences support dose escalation in EBRT for prostate cancer: randomized trials Randomized trial
Description
Dearnaley et ala
Randomized clinical trial compared 3D-CRT versus conventional RT to 64 Gy 225 patients were randomized The primary endpoint was the development of late radiation complications (>3 months after treatment) Reduced grade 1–2 late radiation proctitis in patients received 3D-CRT as compared with conventional techniques No difference in disease control was observed
Koper et al (Dutch Randomized Trial)b
Randomized clinical trial reported anorectal morbidity with the use of 3D-CRT versus conventional RT to 66 Gy 266 patients with T1–4N0M0 prostate carcinoma treated with same planning, treatment, and portal imaging procedure However, patients in the conventional treatment arm were treated with rectangular, open fields, whereas conformal radiotherapy was performed with conformally shaped fields A reduction in GI toxicity was observed after 3D-CRT (32 and 19%, p = 0.02), mostly due to the reduced grade 2 rectum/sigmoid and anal toxicity from 3D-CRT No difference in urological toxicity was observed 7
588
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.14 (continued) Randomized trial
Description
MD Andersonc
Randomized clinical trial compared 78 versus 70 Gy of EBRT using 3D-CRT 301 patients with stage T1b to T3 prostate cancer were randomized A significant 8-year biochemical DFS improvement in patients randomized to receive 78 Gy of radiation (78 versus 59%, p = 0.004) The largest benefit among patients with pretreatment PSA >10 ng/ml No significant difference in GI or GU toxicity was observed
Dutch multicenter randomized triald
Randomized trial compared 78 versus 68 Gy using 3DCRT for prostate cancer 669 patients with T1b–T4 diseases were enrolled Primary end point was freedom from failure (FFF), defined by the ASTRO definition. Other end points were freedom from clinical failure (FFCF), overall survival (OS), and toxicity With a follow-up of 51 months, 5-year FFF was significantly better after 78 Gy 3D-CRT (64 versus 54%) No significant differences in FFCF or OS were observed No difference in late GU or GI toxicity
PROG/ACR 95-09e
Randomized trial compared 70.2 Gray equivalents (GyE; conventional) or 79.2 GyE (high) proton radiation in earlystage prostate cancer 393 patients with T1b–T2b and PSA ≤ 5 ng/ml were randomly assigned to either arm, without androgen suppression therapy End points included local failure (LF), biochemical failure (BF), and OS High-dose radiation therapy reduced LF, with a HR of 0.57 The 10-year ASTRO BF rates were 32.4 versus 16.7%, favored high-dose RT (p < 0.0001) This difference was due largely to differences in low- and probably intermediate-risk disease There was a strong trend in the same direction for the intermediate-risk patients (n = 144; 37% of total; 42.1 versus 30.4%, p = 0.06) 11 versus 6% of patients subsequently required ADT for recurrence after conventional- versus high-dose RT (p = 0.047) There remains no difference in OS (78.4 versus 83.4%; p = 0.41) and toxicity rates (1–3% of grades 3–4) between the 2 arms
Chapter 19 Prostate Cancer
589
Table 19.14 (continued) RT: radiation therapy; DFS: disease-free survival; ADT: androgen deprivation therapy; HR: hazard ratio; PROG: Proton Radiation Oncology Group; ACR: American College of Radiology; ASTRO: American Society of Therapeutic Radiology Oncology a Source: Dearnaley DP, Khoo VS, Norman AR et al (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 353:267–272 b Source: Koper PC, Stroom JC, van Putten WL et al (1999) Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 43:727–734 c Source: Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74 d Source: Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990 –1996 e Source: Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal RT in early-stage adenocarcinoma of the prostate: long-term results from PROG/ACR 95 –09. J Clin Oncol 28:1106 –1111
Hormonal Therapy for Locally Advanced Disease Androgen-deprivation therapy (ADT), consisting of a combination of luteinizing-hormone-releasing hormone (LHRH) suppression and an antiandrogen, has been evaluated as an adjunct to standard-dose EBRT as an alternative strategy to improve outcomes in patients with intermediate- and high-risk prostate cancer. The supportive trials, although heterogeneous in their patient selection criteria and radiation treatment volumes, generally demonstrate statistically and clinically significant improvements in local control and disease-free survival (DFS), with inconsistent improvements in overall survival (Tables 19.15 and 19.16). Evidence in support of androgen suppression is most mature in patients with high-risk disease. Beginning in the 1980s, research organizations in the USA (including the Radiation Therapy Oncology Group [RTOG]) and Europe launched a series of trials for which mature follow-up data are now available, and which have systematically evaluated the efficacy, timing, and duration of androgen suppression therapy (Table 19.16). Proposed algorithms for the treatment of intermediate- and high-risk prostate cancers based on the above-listed level I evidence are presented in Figures 19.7 and 19.8. Given the long natural history of prostate cancer, recent studies have examined the incidence of long-term toxicities after combined androgen suppression and EBRT (Table 19.17).
590
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.15 Clinical evidence on combined EBRT with hormonal therapy for intermediate-risk prostate cancer Randomized trial
Description
D’Amico et al (intermediate risk)a
Phase III clinical trial to compare RT with or without 6 months of ADT 80% of 206 randomized patients had intermediate-risk prostate cancer Conformal radiation comprised 70.35 Gy in 36 fractions prescribed to the prostate and seminal vesicles with a cone-down boost to the prostate Initial results at a median follow-up of 4.5 years revealed statistical improvements in prostate cancer-specific survival, survival free of salvage androgen deprivation, and OS rates Updated results after a median follow-up of 7.6 years showed that all-cause mortality was significantly greater in the RT alone arm (HR 1.8, p = 0.01) Subgroup analyses suggest that the significant difference was primarily in patients with no or minimal comorbid illness
TROG 96.01 of (Australia)b
Randomized clinical trial studies the optimal duration of short-course hormonal therapy A 3-arm study compared prostate-only radiation to 66 Gy, versus 3 or 6 months of androgen deprivation before and during radiation for intermediate-risk patients Results revealed a significant improvement in prostate cancer-specific mortality with 6 (HR = 0.56) but not 3 (HR: 0.95) months of STAD
DFS: disease-free survival; OS: overall survival; TROG: Trans-Tasman Radiation Oncology Group (Australia); STAD: short-term androgen deprivation a Sources: D’Amico AV et al (2008) Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA 299:289 –295; D’Amico AV et al (2004) Six-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:82182–82187 b Source: Denham JW et al (2008) Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomized controlled trial. Lancet Oncol 9:1058 –1068
Chapter 19 Prostate Cancer
591
Table 19.16 Clinical evidence on combined EBRT with hormonal therapy for high-risk prostate cancer Randomized trial
Description
RTOG 85-31a
Randomized trial of 977 patients to adjuvant goserelin versus observation Eligible patients had advanced tumor characteristics (cT3, N+, or pathologic penetration through the capsule to the resection margin or SV involvement) Goserelin was administered indefinitely or until disease progression RT portals included treatment of the regional lymphatics to an initial 44 –46 Gy (except in node-negative postoperative cases) followed by a prostate boost to 65–70 Gy 10-year updated results demonstrated significant im provements in: local failure (23 versus 38%), disease-specific mortality (16 versus 22%), DM (24 versus 39%) NED survival (37 versus 23%), and OS (49 versus 29%), fa voring the use of adjuvant goserelin
RTOG 86-10b
Randomized clinical trial evaluated the cytoreductive and potentiating effect of androgen suppression Randomizing patients to neoadjuvant and concurrent goserelin and flutamide for 2 months prior and 2 months during RT versus observation Enrolled patients had “bulky” primary tumors (≥5 × 5 cm), with or without pelvic lymph node involvement RT target volumes and doses were similar to RTOG 85–31, also including the regional lymphatics to an initial 44 –46 Gy, followed by a prostate boost to 65–70 Gy Updated results at 10 years demonstrated significant im provements DM (35 versus 47%), disease-specific mortality (23 versus 36%), DFS (11 versus 3%), and biochemical failure (65 versus 80%) A nonsignificant trend toward improved OS with also observed No significant impact on the risk of fatal cardiac events was seen
EORTCc
Phase III study (103) compared EBRT with long-term (con current and adjuvant) androgen suppression EBRT initially targeted the prostate and pelvic nodes to 50 Gy, with a subsequent prostate-only boost to an additional 20 Gy Hormonal therapy consisted of monthly goserelin admin istration for 3 years, beginning on the first day of EBRT and 1 month of cyproterone acetate With a median follow-up of 66 months, clinically and statisti cally relevant improvements in DFS (40 versus 74%), DSS (79 versus 94%), and OS (62 versus 78%) rates were observed 7
592
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.16 (continued) Randomized trial
Description
RTOG 92-02d
Randomized trial studied the optimal duration of androgen suppression therapy EBRT was directed to the prostate and pelvic nodes (44 –50 Gy), followed by a prostate boost to 65–70 Gy All patients received 4 months of goserelin and flutamide, 2 months before and after RT (the experimental arm of 86 –10) Patients were randomization to no further treatment versus 24 months of goserelin 10-year updated results demonstrated significant improvements for long- versus short-term androgen suppression for multiple endpoints DFS (13 versus 23%), DSS (84 versus 89%), local progression (22 versus 12%), DM (23versus 15%), and biochemical failure (68 versus 52%) favored long-term androgen suppression OS was not improved, except for the subgroup of patients with Gleason 8–10 tumors
SV: seminal vesicle; DM: distant metastases; DFS: disease-free survival; DSS: diseasespecific survival; OS: overall survival a Sources: Pilepich MV et al (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013 –1021; Pilepich MV et al (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285 –1290 b Sources: Pilepich MV et al (2001) Phase III radiation therapy oncology group (RTOG) trial 8610 of androgen deprivation adjuvant to definitive RT in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243 –12252; Roach M 3rd et al (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26:585 –591 c Source: Bolla M et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360:103 –106 d Sources: Hanks GE et al (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the RTOG protocol 92-02. J Clin Oncol 21:3972–3978; Horwitz EM et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92–02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26:24972–504.
Chapter 19 Prostate Cancer
593
Ongoing studies will help define the role of androgen suppression in intermediate-risk disease in the setting of dose escalation.
Definitive Treatment Radiation Therapy Intermediate Risk Prostate Cancer T-Classification T2b,N0,M0 T2c,N0,M0 Gleason Score 7 PSA 10-20ng/mL
Image-guided IMRT (≥ 78 Gy / 43 Fractions) Or EBRT+Brachytherapy (EBRT:40-50 Gy)
Chemotherapy
Follow-Up Recommended: History/Physical Exam Annual DRE Serum PSA (Every 6-12 months for 5 years, then annually)
Neoadj. and Concurrent ADT (Total 4-6 months)
If radical prostatectomy and lymph node dissection were performed with adverse features (positive margin, extracapsular or seminal vesicle extension, detectable PSA), adjuvant radiation therapy should be considered For patients with <10-year expected survival time, active surveillance with PSA (every 6 months) and DRE (annually) can also be considered Clinical target volume may encompass pelvic lymph node regions in intermediate-risk cases (if risk >15%) If EBRT plus brachytherapy is used, boost dose of brachytherapy boost is 100–110 Gy
Figure 19.7 Proposed treatment algorithm of definitive treatment of intermediate-risk prostate cancer with external-beam radiation therapy (EBRT) and hormonal therapy
594
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Definitive Treatment Radiation Therapy High Risk Prostate Cancer T-Classification T3,N0,M0 T4,N0,M0 Gleason Score 8-10 PSA >20 ng/mL
Image-guided IMRT (≥ 78 Gy / 43 Fractions) Or EBRT+Brachytherapy (EBRT: 40-50 Gy)
Chemotherapy Neoadj. ADT (2 months) Concurrent ADT (2 months) Adjuvant ADT (2-3 years)
Follow-Up Recommended: History/Physical Exam Annual DRE Serum PSA (Every 6-12 months for 5 years, then annually)
A number of medications and combinations can be considered for androgen deprivation treatment (ADT) or total androgen blockade For locally advanced (T3b–4) prostate cancer, ADT alone is a valid option of treatment If radical prostatectomy and lymph node dissection were performed with adverse features (positive margin, extracapsular or seminal vesicle extension, detectable PSA), adjuvant radiation therapy should be considered Clinical target volume can encompass pelvic lymph node regions in high-risk cases EBRT plus brachytherapy can be used in selected patients but high-risk patients are usually poor candidates for permanent implant
Figure 19.8 Proposed treatment algorithm of definitive treatment of high-risk prostate cancer with external-beam radiation therapy (EBRT) and hormonal therapy
Treatment Outcome After Low-Dose Rate Brachytherapy Modern series continue to demonstrate excellent outcomes for radioactive seed implantation, either as monotherapy for low-risk cases or selected highrisk patients, or as boost treatment in conjunction with external beam therapy
Chapter 19 Prostate Cancer
595
Table 19.17 Studies examined long-term toxicities of androgen suppression treatment used with EBRT Study
Results
RTOG dataset analysisa
Long-term pelvic toxicity does not appreciably worsen with the addition of androgen suppression On the contrary, patients treated with EBRT and shortterm suppression had a statistically significant lower probability of ≥ grade 3 GI, GU, and other toxicities as compared with RT Patients treated with long-term suppression and EBRT had a statistically significant lower probability of ≥ grade 3 GU toxicity as compared with RT alone
RTOG 92-02b
Analysis for the potential for cardiovascular toxicity after hormonal treatment for prostate cancer Demonstrated no increased cardiovascular mortality from 24 versus 4 months of adjuvant goserelin
Harvard phase III trialc
Postrandomization analysis of the Harvard phase III trial Indicated that the benefit of androgen deprivation was restricted to those men with none/mild versus moderate/ severe comorbidities
a
Source: Lawton CA et al (2008) Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86 -10, and 92-02. Int J Radiat Oncol Biol Phys 70:437–441 b Source: Efstathiou JA et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54: 816 –823 c Source: Nguyen PL et al (2009) Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys 77:1046–1052
for high-risk disease (Table 19.18). Outcomes are related to implant quality and biological effective dose (BED).
596
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.18 Representative series describing modern outcomes following radioactive seed implantation for prostate cancer Author
Patients (n)
Risk group
Stonea
1078
Isotope(s)
Endpoint (years)
Biochemical control (%)
Intermediate Yes and high
125 103
5
All: 80%
Sylvester 223
All
Yes
125 103
I/
Pd
15
Low risk: 88% Int risk: 80% High risk: 68%
Taira
Low and Interme- No diate
125 103
Pd
12
Low risk: 97% Intermediate risk - 96%
5
V100 ≥ 90%: 100 V100 < 90%: 94%
8
Low risk: 82% Intermediate risk: 70% High risk: 48%
Zelefsky
462
562
Zelefskyb 2693
All
All
EBRT?
No
No
I/
I/
125
Pd
I
125 103
I/
Pd
EBRT: external-beam radiation therapy a Excellent outcomes seen in intermediate and high-risk patients treated with a combination of androgen deprivation, EBRT, and seed implantation, particularly if BED >220 Gy b As demonstrated in a recent multi-institutional study of 2,693 men with T1–2 prostate cancer, D 90 ≥ 130 Gy emerged as a highly significant predictor of 8-year PSA relapsefree survival (93 versus 76%, p < 0.001)
Adjuvant Radiation Therapy While prostatectomy provides good control rates for patients with organconfined disease, failure rates for patients with cancer extension beyond the capsule are substantial, particularly in cases of high Gleason grade and positive margins. Published level I evidence indicates a strong benefit for upfront postoperative EBRT of patients with pathologic high-risk disease (pT3N0 and/or positive margins) (Table 19.19).
Chapter 19 Prostate Cancer
597
Table 19.19 Clinical evidence for adjuvant radiation therapy for postoperative EBRT with pathologic high-risk disease
a
Trial
Description
SWOG 8794a
Randomized 425 patients with T3N0M0 prostate cancer to 60 –64 Gy in 30 –32 fractions versus observation The primary study endpoint was metastasis-free survival (MFS) Updated results with median follow-up exceeding 12 years demonstrated a significant improvement in MFS (10-year estimate 71 versus 61%, HR: 0.71) OS was improved with adjuvant RT (59 versus 48%, HR: 0.72), particularly noteworthy given that a third of the patients in the observation group received salvage RT Subset analysis was unable to identify a subset of patients that should not receive RT
EORTC 22911b
Randomized 1,005 patients with pT3 disease or positive surgical margins to observation versus 60 Gy Initial results presented with median follow-up of 5 years demonstrated a significant improvement in biochemical PFS and locoregional failure, with immediate versus deferred postoperative RT Updated analysis incorporating central pathology review described surgical margin positivity as the strongest predictor of prolonged biochemical DFS
ARO 96–02 (Germany)c
Phase III trial randomizing patients with pT3N0 disease and (in contrast to the prior 2 studies) an undetectable PSA level after RP to adjuvant RT (60 Gy) versus observation 5-year results demonstrated a highly significant reduction in biochemical PFS (72 versus 54%, HR: 0.53) with acceptable toxicity (0.3% incidence of ≥grade 3 toxicity)
Source: Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 181:956 –962 b Sources: Bolla M et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578; Van der Kwast TH et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178 –4186 c Source: Wiegel T et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96 -02/AUO AP 09/95. J Clin Oncol 27:2924 –2930
598
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
The potential utility of hormonal treatment in the adjuvant setting has been addressed in RTOG 9601, a phase III randomized trial comparing prostate bed to 68.4 Gy in 36 fractions with 2 years of bicalutamide versus placebo. Results of this study are pending.
Metastatic Prostate Cancer (T1–4, N0–1, M1) Advanced prostate cancers include those with distant metastases or nonregional lymph node metastases. Treatment of stages IVb and IVc patients usually requires ADT and palliative radiation therapy for symptomatic foci.
Treatment of Recurrent Prostate Cancer An estimated 20 –40% of prostate cancer patients will experience an increasing PSA level within 10 years of definitive local treatment. Diagnostic evaluation seeks to distinguish local recurrence versus systemic metastases, and may include physical examination, laboratory evaluation, computed tomography (CT) and/or magnetic resonance imaging (MRI) scans, MRI spectroscopy, and/or ProstaScint scanning. No phase III trials have addressed the efficacy and toxicity of salvage radiation therapy and, therefore, treatment decisions are typically made based on: Patient’s performance status and comorbidities Postoperative PSA level Pathologic Gleason grade, extent of disease Margin status Salvage RT appears less efficacious than adjuvant treatment is (Figure 19.8). A retrospective multicenter analysis of a cohort of 501 patients who underwent postprostatectomy salvage radiotherapy demonstrated a 4-year progression-free probability of 45%, which was significantly predicted by Gleason score 8–10, preradiotherapy PSA level ≥2.0 ng/ml, negative surgical margins, PSA doubling time ≤10 months, and seminal vesicle invasion.
Radiation Therapy Techniques External Beam Radiation Therapy for Definitive Therapy IMRT represents the current standard of care for prostate EBRT.
Chapter 19 Prostate Cancer
599
Simulation for IMRT Modern prostate EBRT requires accurate patient setup at the time of simulation (Table 19.20). Table 19.20 Patient set up and planning for prostate cancer IMRT Aspect
Details
Patient preparation
Patients should be instructed to present with an empty rectum and comfortably full bladder Patients are positioned either supine or prone (with or without a rectal balloon depending on institutional practice) on a custom immobilization device
Planning imaging
A volumetric CT scan employing a slice thickness ≤3 mm is obtained through the volume of interest and imported into a computer for organ segmentation and treatment planning A urethrogram or, alternatively, MRI fusion, is employed to delineate the prostatic apex. MRI fusion enhances definition of the prostate-rectum interface, the prostatic apex, and neurovascular bundles. The use of a T2-weighted volumetric sequence is suggested. When MRI fusion is not available, contouring fidelity can be improved by inspection of the prostate contours on a sagittal CT image and recognition of anatomic structures (e.g., GU diaphragm)
Intra-/ interfraction changes
Given susceptibilities for organ deformation, intra- and interfraction organ motion, IMRT is typically combined with daily image guidance. A variety of methods, including ultrasound, fiducial implantation and KV imaging, KV cone-beam CT, MVCT, and intrafraction tracking using transponders are in clinical use Pelvic radiation using IG-IMRT and incorporating intraprostatic fiducial markers can reduce the volumes of rectum and bladder receiving high doses thus reduce toxicities
kV: kilovoltage; MVCT: megavoltage CT
600
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Target Delineation The optimal strategy for target delineation, especially whole-pelvic lymph nodes versus prostate-only radiation therapy, has not been determined. Two clinical trials have addressed this issue with inconclusive results (Table 19.21). Table 19.21 Clinical evidence on the optimal selection of radiation portal: whole-pelvis versus prostate-only radiation therapy Randomized trial
Description
RTOG 94-13a
A 4-arm randomized trial attempted to discern the relative merits of pelvic nodal irradiation versus prostate-only EBRT in patients with an estimated risk of lymph node involvement of 15%, and timing (adjuvant versus neoadjuvant and concurrent) of hormonal therapy The total duration of hormonal treatment was 4 months An OS difference was seen among all study groups, yet there were no significant differences in PFS or OS between neoadjuvant versus adjuvant hormones, or pelvis versus prostate-only radiation When neoadjuvant hormone therapy is used in conjunction with EBRT, pelvic nodal irradiation yields an improved PFS versus prostate-only RT Neoadjuvant hormones plus pelvic nodal RT improved OS versus adjuvant hormones plus pelvic nodal RT Late severe GU toxicities were similar in the 4 arms, though severe GI toxicities were more frequent in the neoadjuvant hormone and whole-pelvis arm
GETUG-01b
Randomized phase III trial also studied the role of pelvic and prostate versus prostate-only RT The trial stratified patients according to risk of lymph node involvement Initial results with limited follow-up of 42 months demon strated indicated no significant differences in 5-year PFS between the study groups, either in the high or low-risk strata
PFS: progression-free survival; OS: overall survival; DFS: disease-free survival; RT: radiation therapy a Sources: Roach M 3rd et al (2003) Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: RTOG 9413. J Clin Oncol 21:1904 –1911; Lawton CA et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646 –555 b Source: Pommier P et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366 –5373
Chapter 19 Prostate Cancer
601
Definitions of gross target volume (GTV), clinical target volume (CTV), and planning target volume (PTV) in IMRT in prostate-only radiation include prostate on imaging studies as GTV, with 0.5- to 1-cm margins in 3D to achieve PTV (per RTOG protocols). The CTV of seminal vesicles and pelvic lymph node regions (if select to treat) are defined in Table 19.22. The probability of involvement can be determined by stage, pretreatment PSA, PSA doubling time and/or velocity, highpercent biopsy core involvement, the presence of perineural invasion, and the Roach formulas and/or Partin tables. The commonly used Roach formulas are detailed in Table 19.4. Table 19.22 CTV of seminal vesicle and/or pelvic lymph nodes Organ
Coverage for >15%a chance of involvement
Seminal vesicle
Include the proximal 1 cm, as this volume is thought at highest risk for microscopic involvement Volume reduction to include the prostate only after 45–55.8 Gy is typically employed in such cases
Pelvic nodes
Include distal common, internal, and external iliac re gions, presacral, and obturator regions Contouring can be accomplished by outlining the corre sponding vasculatures with margin
a
Typical thresholds for inclusion of SV/pelvic nodes are set by probability of involvement exceeding 15%
Salvage Treatment
Local recurrence and slow PSA doubling times
Distant recurrences, or with short PSA doubling times
Prostatectomy, pelvic irradiation, or brachytherapy*
Chemotherapy, ADT, and/or local treatment**
* Depending on initial treatment ** Recommend clinical trial setting
Figure 19.9 Suggested salvage treatment for prostate cancer recurrence
602
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
The RTOG has recently published consensus guidelines for postprostatectomy prostate bed CTV definition (Figure 19.9). Structures of interest and lymph nodal regions (CTV) contouring recommendations are listed in Table 19.23. Table 19.23 Structures of interest and lymph nodal regions (CTV) contouring recommendations in IMRT for prostate cancer CTV
Recommendation
Structures of interest
Vesicourethral anastomosis (VUA) Anterior rectal wall Levator ani and obturator internus muscles Mesorectal fasia Posterior bladder wall Vas deferens Sacrorectogenitopubic fascia
Lymph node contouring
Add 7 mm around iliac vessels, carving out bowel, blad der, and bone Commence contouring at distal common iliac vessels at L5–S1 interspace Stop external iliac contours at top of femoral heads (boney landmark for inguinal ligament) Stop contours of obturator nodes at top of pubic symphysis Subaortic presacral lymph nodes are included in CTV
Dose and Treatment Delivery Conventional fractionation to a total dose of >72 Gy is recommended. As detailed above, dose escalation does not increase acute or late adverse effects if conformal therapy is used, but may improve biochemical failure rates.
Interstitial LDR Brachytherapy Preparation of LDR Brachytherapy Suitable candidates for LDR brachytherapy are dispositioned for treatment by using either a preplanned or intraoperative technique (Table 19.24). Radiation precautions should be carefully explained to the patient and written guidelines provided. Important discussion topics should include handling of any seeds passed in the urine, minimizing radiation exposure to small children and pregnant women, and condom use during the initial postimplant period.
Chapter 19 Prostate Cancer
603
Table 19.24 Comparison of the preplanned and intraoperative LDR implant procedures Techniques
Procedure of implant
Preplanned (Seattle) technique
Utilizes a volume study prior to the date of the procedure A transrectal ultrasound is used to capture sequential axial images of the prostate in 0.5-cm increments A planning target volume is constructed to provide dosimetric margin around the prostate volume and including the proximal 1 cm of the seminal vesicles Offline planning is performed to determine an optimal seed implantation pattern using the principle of modified uniform peripheral loading to limit the urethral dose to less than 150% of the prescription dose The required seeds (typically in combination of loose and stranded patterns) are ordered and the patient scheduled for the implant procedure
Intraoperative method
Performs the planning and implant steps in a single procedure The operative procedure involves patient positioning in the lithotomy position, with careful matching of preimplant positioning if applicable Has the advantages of improved patient convenience, decreased use of resources, potentially improved dosimetric conformality, and minimal change in patient positioning
The use of a high-resolution biplanar ultrasound is recommended Needle insertion is performed under direct TRUS guidance using a template and “stepping unit,” which allows the probe to be moved in and out using 0.5-cm increments A post-implant cystoscopy may be performed to remove potential blood clots and misplaced seed in the urethra or bladder. Fluoroscopy may also be used to assess the adequacy of seed placement
Dose and Treatment Delivery 125
I or 103Pd are the two most commonly used radioactive isotopes for prostate cancer LDR brachytherapy. The current American Brachytherapy Society (ABS) prescription recommendations considered both the revised dosimetry and longstanding clinical experience and outcomes. Isotope choice remains arbitrary (Table 19.25).
604
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Table 19.25 American Brachytherapy Society prescription guidelines for LDR prostate brachytherapy Isotopea
Energy (keV)
Half-life (days)
Monotherapy dose (Gy)
Boost dose (Gy)
125
28
59.4
145
100 –110
21
17
125
90 –100
I
103
Pd
a
The ABS does not recommend the routine use of one radionuclide over the other due to lack of conclusive clinical evidence. Source: Rivard MJ, Butler WM, Devlin PM et al (2007) American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 6:34 –37
Routine assessment of post-implant CT dosimetry (typically performed within 30 days post-implant in a consistent fashion in consideration of postimplant edema) is advocated by the ABS. Post-implant dosimetry provides prognostic information and may identify systematic technical errors. The ABS recommendations include urethral delineation and reporting of the urethral dose to 5% of the volume (UrD5), UrD30, and UrV150 (urethral volume receiving 150% of the prescription dose). The rectal wall should be delineated and RV100 and RV150–the corresponding volumes of the rectal wall receiving the threshold doses–calculated. To evaluate target coverage, the dose relative to the prescribed dose (D90) criterion is typically used, and is associated with improved outcomes in a multi-institutional multivariate analysis.
Chapter 19 Prostate Cancer
605
EBRT for Adjuvant Therapy Simulation and Target Volume Delineation The recently published RTOG consensus document represents a valuable guideline for postoperative target delineation, either in the adjuvant or salvage setting (Table 19.26). Examples of CTV delineation for positive apical margins, after biochemical failure, and extracapsular extension at the base and involvement of seminal vesicle are presented in Figures 19.10 and 19.11).
Table 19.26 Anatomical borders of postoperative CTV for prostate cancer Location
Comments
Below the superior edge of the symphysis pubis Anterior
Posterior edge of pubic
Posterior
Anterior rectal wall
Inferior
8–12 mm below vesicourethral anastomosis
Lateral
Levator ani muscles, obturator internus
May need to be concave around lateral aspects May include more if concern for apical margin. Can extend to slice above penile bulb if vesicourethral anastomosis not well visualized
Above the superior edge of the symphysis pubis Anterior
Posterior 1–2 cm of the bladder wall
Posterior
Mesorectal fascia
Superior
Level of cut end of vas deferens or 3–4 cm above top of symphysis
Lateral
Sacrorectogenitopubic fascia
Vas might retract postoperative; include seminal vesicle remnants if pathologically involved If concerned about extraprostatic disease at base, may extent to obturator internus
606
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
a
b
c
d
e
Figure 19.10 a–e Representative pelvic lymph node clinical target volume (CTV) contours from consensus CT. a Common iliac and presacral CTV lymph node volumes (L5/ S1). b External, internal, and presacral CTV lymph node volumes (S1–S3). c External and internal Iliac CTV lymph node volumes (below S3). d End of external iliac CTV lymph node volumes (at top of femoral head, boney landmark for the inguinal ligament). e Obturator CTV lymph node volumes (above the top of the pubic symphysis). Source: Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74:383–387. Used with permission
Chapter 19 Prostate Cancer
607
Figure 19.11 Examples of consensus contours for patients with apical positive margins and biochemical recurrence
Figure 19.12 Examples of consensus contours for patient with extracapsular extension at base and involvement of seminal vesicle. Source: Michalski JM, Lawton C, El Naqa I et al (2010) Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361–368. Used with permission
608
Bin S. Teh, Angel I. Blanco, Arnold C. Paulino and E. Brian Butler
Dose and Treatment Delivery Whereas the phase III randomized trials for adjuvant RT utilized 60 –64 Gy, image-guided IMRT may allow safe dose escalation and improvement in therapeutic ratio, with acceptable toxicity levels. A total dose of 65–68 Gy and 66 –70 Gy for adjuvant and salvage treatment, respectively, in conventional fractionation is recommended.
Normal Tissue Tolerance Organs at risk (OARs) in EBRT of prostate cancer, in both adjuvant and definitive settings, include rectum and bladder. Suggested DVH constraints for dose-escalated IMRT (prescribed to deliver 79.2 Gy in 44 fractions) are listed in Table 19.27, below. Table 19.27 RTOG DVH constraints for prostate cancer Organ
Dose limit to specified percentage of organ volume (Gy) 15%
25%
35%
50%
Bladder
80
75
70
65
Rectum
75
70
65
60
Source: RTOG active protocols. http://rtog.org/members/active.html. Cited 15 May 2010
Chapter 19 Prostate Cancer
609
Follow-Up Posttreatment surveillance aims to identify suitable candidates for salvage therapy, potentially preventing disease dissemination (Table 19.28). Salvage therapy is advocated for (1) postprostatectomy patient(s) with failure of PSA to fall to undetectable levels, or with detectable PSA that increases on two subsequent measurements or (2) post-RT patients with rising PSA ≥2 ng/ml above the nadir or with positive DRE. Table 19.28 Follow-up schedule and examinations Schedule
Frequency
First follow-up
4 –6 weeks after radiation therapy
Years 0–1
Every 3–4 months
Years 2–5
Every 6 months
Years 5+
Annually
Examination History and physical
Complete history and physical examination Annual DRE
Laboratory tests
PSA every 6 –12 months for 5 years then annually Other lab tests based on clinical indication only
Imaging studies
Based on clinical indication only
20
Testicular Cancer Ugur Selek1
Key Points Testicular cancer is a well-treatable and often curable cancer of mainly young and middle-aged men. Testicular cancer is roughly divided into seminoma and nonseminoma types for treatment planning due to highly radiosensitive seminomas. The cure rate of seminoma (all stages combined) exceeds 90%, and approaches 100% for early-stage diseases. The tumor, node, metastasis (TNM) staging system is used for staging for seminoma. The serum markers are important for the diagnosis and follow-up including alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (-hCG), and lactate dehydrogenase (LDH). A computed tomography (CT) scan to evaluate the retroperitoneal lymph nodes is important for staging. However, 25–30% of patients with negative scans have microscopic disease. Nonseminoma frequently requires surgical staging. Radical inguinal orchiectomy with initial high ligation of the spermatic cord is the standard procedure for diagnosis and treatment. Biopsy prior to orchiectomy is usually not recommended. Radiation or chemotherapy is the option for adjuvant therapy in stage I low-risk seminoma. High-risk stage I seminoma (tumor ≥4 cm or Rete testis invasion) and stage IIB cases (nodal disease <5 cm) are recommended radiotherapy. For more extensive diseases, i.e., stage IIC or higher, chemotherapy is the treatment choice for adjuvant therapy. Follow-up is recommended to detect second primary tumors, local or distant recurrences, and to monitor for potential long-term side effects.
1
Ugur Selek, MD () Email:
[email protected] J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_3, © Springer-Verlag Berlin Heidelberg 2011
612
Ugur Selek
Incidence and Genetics An estimated 8,480 new cases of testicular cancer will be diagnosed in the USA in 2010, and ~350 patients died from the disease. Testicular cancer is more commonly diagnosed in Caucasians. The age-adjusted testicular cancer incidence rate is ~6 per 100,000 Caucasian men annually, as compared with 1.5 and 3.8 per 100,000 in African-American and Hispanic males, respectively. A number of risk factors have been identified for testicular cancer and are listed in Table 20.1. Table 20.1 Risk factors for testicular cancer Factor
Description Age: the median age at testicular diagnosis is ~35 years Approximately 75% of cases are diagnosed between ages 20 and 44 years History of cryptorchidism: 10- to 40-times increased risk of testis cancer, and 10% of patients with germ cell tumors have a history of cryptorchidism. Abdominal testis is more likely to be seminoma, testis brought to scrotum by orchiopexy is more likely to be non-germ cell tumors (NSGCT)
Patient related
Bilateral disease: ~1–3% of testicular cancer cases are bilateral Family medical history: significant familial history increases fourfold in a male with a father who had a germ cell tumors (GCT), and ninefold with an affected brother Genetic predisposition: amplifications and deletions are observed mainly in the 12p11.2–p12.1 chromosomal regions. 12p Sequence gain is seen with invasive growth of both seminomas and NSGCTs. Chromosome 9 gain points out spermatocytic seminoma. The incidence of contralateral CIS (carcinoma in situ) in a patient with testicular carcinoma is 5% (50% of them develop carcinoma in 5 years)
Environmental
Industrial chemicals: workers in manufacturing 2-naphthylamine, benzidine, gasoline derivatives have ~fivefold increased risk
Sources: Hemminki K, Li X (2004) Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer 90(9): 1765-70. Miller FH, Whitney WS et al (1999). “Seminomas complicating undescended intraabdominal testes in patients with prior negative findings from surgical exploration.” AJR Am J Roentgenol 172(2): 425-8
Chapter 20 Testicular Cancer
613
Anatomy and Routes of Spread As the embryonic origin of testis is pertinent to the pattern of lymphatic spread, they are addressed together in Table 20.2. Table 20.2 Origin and pattern of spread of testicular cancer Origin/spread
Route(s)
Embryonic origin
The testis starts descending through the inguinal canal to the scrotal sac from the genital ridge, located near the second lumbar vertebra Testicular lymphatics accompany the vessels of the spermatic cord through the inguinal canal and into the retroperitoneum
Local spread
Local extension involves the rete testis, epididymis, or spermatic cord but rarely areas outside the tunica albuginea
Distant metastasis
Lymphatic route is the predominant way of spread of seminoma, while nonseminoma favors hematogenous spread. Retroperitoneal nodes posterior mediastinal nodes left supraclavicular nodes Iliac nodes Inguinal nodes (very rare) The right testis: drainage is along the inferior vena cava first into the inter-aortocaval region, then to the pre-aortic and para-aortic lymph nodes, with possible cross-over within the retroperitoneum The left testis: drainage is first into the nodes of preaortic and para-aortic lymph nodes around the left renal hilum and then to the inter-aortocaval nodes mostly without cross-over
Lymphatic route
The retroperitoneal lymph nodes are located anterior to the T11 to L4 vertebral bodies concentrated at the L1–L3 level Nodal spread to iliac chain is ipsilaterally but infrequent (~3%) Inguinal node spread is less than 5% without lymphatic disruption by prior surgery Scrotal skin: lymphatics drain into the inguinal and external iliac nodes regardless of the testicular lymphatics. The organization of lymphatics reasons the orchiectomies through inguinal route, which avoids possible violence of the inguinal drainage basin
614
Ugur Selek
Pathology Table 20.3 summarizes the distribution of testicular tumors. Table 20.4 details the characteristics of different histological subtypes commonly diagnosed. Table 20.3 Pathology subtypes of testicular tumors Tumor type
Incidence(%)
Germ cell tumor (GCT)
95%
Non-GCT (NGCT)
5%
Subtypes
Indicence (%)
Semimona
40%
Non-seminoma
60%
Lymphoma, rhabdomyosarcoma, melanoma or stromal tumors (Sertoli or Leydig cell tumors)
Intratubular germ cell neoplasia (IGCN) may be a precursor of all types of GCT except for spermatocytic seminoma and infantile testicular cancer. Invasive component of GCT usually accompanies adjacent IGCN, and approximately 5% of patients with unilateral GCT have IGCN in the contralateral testicle. Sources: Jacobsen GK, Henriksen OB, Vonder Maase H et al (1981) Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer 47:2660–2002; Coffin CM, Ewing S, Dehner LP et al (1985) Frequency of intratubular germ cell neoplasia with invasive testicular germ cell tumors. Histologic and immunocytochemical features. Arch Pathol Lab Med 109:555–559; Dieckmann KP, Skakkebaek NE et al (1999) Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 83:815–822
Table 20.4 Characteristics of commonly diagnosed histological subtypes of testicular cancers Pathologic subtypes
Characteristics of disease
Seminoma
Classic
85% of seminomas are of the classic variety The new Armed Forces Institute of Pathology (AFIP) classification allows for a variant containing syncytiotrophoblastic cells
Anaplastic
10–12% of cases have increase nuclear pleomorphism Tends to be more aggressive but equally radiosensitive No longer included as a separate entity by the elderly AFIP
Spermatocytic
4–6% and mostly diagnosed in advanced–age patients Very well differentiated, with excellent prognosis Low probability for distant metastasis
Chapter 20 Testicular Cancer
615
Table 20.4 (continued) Pathologic subtypes
Characteristics of disease
Non-seminoma Embryonal cell carcinoma
Accounts for 20% of germ cell tumors Known as yolk sac tumor or endodermal sinus tumor in infants
Choriocarcinoma
Less than 1% of germ cell tumors Very high β-hCG at presentation Highly malignant
Teratoma
5% of germ cell tumors Contains elements of ectoderm, endoderm, and mesoderm. Benign in infants but may metastasize in adults
Mixed
Nearly 40% contain elements of more than one type of tumor, i.e., showing more than one histologic pattern Teratocarcinoma is the most common form
Clinical Presentation Table 20.5 summarizes the key points of clinical presentation and diagnosis. Table 20.5 Clinical presentation of testicular cancer Characteristics
Presentation
Age at presentation
Between 15 and 35 years old
Pain
Rare, usually painless testicular lump: testicular swelling possibly accompanied by swelling in cases of orchitis or epididymitis
Frequent differential misdiagnoses
Epididymo-orchitis or hydrocele
Fertility
Might have abnormal semen analysis at presentation (subfertile)
616
Ugur Selek
Diagnosis, Staging, and Prognosis Figure 20.1 reviews the algorithm steps to be taken in case of a suspicious testicular mass. There is no role for trans-scrotal biopsy in the diagnosis of testicular tumors.
Seminoma Suspected
Complete History and Physical Examination
Serum Chemistry & Serum Tumor Markers (Table 20-6) α-FP β-hCG LDH
Recommended Chest X-ray Abdomen and Pelvis CT Optional Testicular Ultrasound Thorax CT (if + chest X-ray or abdominopelvic CT) FDG PET Imaging Studies
Lab Studies
Discuss Sperm Banking
Radical Inguinal Orchiectomy with high ligation of the spermatic cord
Figure 20.1 The algorithm steps to be taken in a case of a suspicious testicular mass
Fluorodeoxyglucose-positron emission tomography (FDG–PET) has no benefit over computed tomography (CT) alone except restaging for residual masses (ability to differentiate fibrotic residual mass from residual tumor) (Source: Spermon JR, De Geus-Oei LF, Kiemeney LA et al (2002) The role of 18fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int
Chapter 20 Testicular Cancer
617
89:549–556; Tsatalpas P, Beuthien-Baumann B, Kropp J et al (2002) Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 68:157–163; Hinz S, Schrader M, Kempkensteffen C et al (2008) The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol 179: 936–940; discussion 940). Table 20.6 details the characteristics of serum markers commonly used in the diagnosis and staging of testicular cancer. Table 20.6 Serum markers of testicular cancer Serum markersa
AFP
β-hCG
LDH
Half-lifeb
Characteristics
5–7 days
A glycoprotein produced in the yolk sac, liver, and gastrointestinal tract Nonseminoma, presence without underlying cause for elevation shifts patient into treatment of NSGCT False positivity seen in: smoking (≈10% elevation), pregnancy, alcohol abuse, cirrhosis, hepatitis, inflammatory bowel disease, ataxia telangiectasia, Wilson’s disease, hereditary tyrosinosis, WiskottAldrich syndrome
24–48 h
Produced in the syncytiotrophoblastic cells, both seminoma and nonseminoma Measurement of the beta subunit reduces luteinizing hormone (LH) cross-reactivity Marker after resection for seminoma used for surveillance
N/A
Elevated in both seminoma and nonseminoma Mainly used in response evaluation if increased initially
AFP: -fetoprotein; -hCG: -human chorionic gonadotropin; LDH: lactate dehydrogenase a Serum markers need to be evaluated at initial diagnosis, and during and after the treatment for response. Level for diagnosis must be drawn preoperatively due to rapid fall after orchiectomy b Prolonged half-life times implies the presence of residual disease after orchiectomy
618
Ugur Selek
Staging The first-echelon lymph nodes for seminoma is retroperitoneal (stage II). The next level lies proximally to mediastinal and supraclavicular lymph nodes (stage IIIA). Advanced disease is rare with lung (stage IIIA) and non-pulmonary (bone, liver and brain) (stage IIIC) involvement. Staging of testicular tumor aim to determine the tumor (T), node (N), metastasis (M), and serum tumor marker (S) classifications. Clinical examination (i.e., assessments indicated in the diagnostic and staging algorithm) and histologic evaluation are required for clinical staging, and histologic evaluation of the radical orchiectomy specimen is used for primary tumor (pT) classification. The modified Royal Marsden Hospital staging system was the previous staging system (Table 20.7). The American Joint Committee on Cancer (AJCC) TNM staging system (2009) is the currently recommended staging system (Tables 20.8 and 20.9). Approximately 85% of pure seminoma is localized (i.e., stage I). Table 20.7 Modified Royal Marsden Staging System for seminoma Stage
Description
I
Tumor confined to the testis
II
Infradiaphragmatic nodal involvement
IIA
Greatest dimension of involved nodes < 2 cm
IIB
Greatest dimension of involved nodes ≥2 cm but < 5 cm
IIC
Greatest dimension of involved nodes 5 cm or more but < 10 cm
IID
Greatest dimension of involved nodes ≥10 cm
III
Supraclavicular or mediastinal involvement
IV
Extranodal metastases
Source: Thomas G, Jones W, VanOosterom A et al (1990) Consensus statement on the investigation and management of testicular seminoma 1989. Prog Clin Biol Res 357:285–294
Chapter 20 Testicular Cancer
619
Table 20.8 AJCC TNM staging for seminoma Stage
Description
Primary tumor (T)a pTX
Primary tumor cannot be assessed
pT0
No evidence of primary tumor (e.g., histologic scar in testis)
pTis
Intratubular germ cell neoplasia carcinoma in situ
pT1
Tumor limited to the testis and epididymis without lymphatic/vascular invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis
pT2
Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis
pT3
Tumor invades the spermatic cord with or without vascular/lymphatic invasion
pT4
Tumor invades the scrotum with or without vascular/lymphatic invasion
Regional lymph nodes (N) clinical NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
Metastasis with a lymph node mass ≤2 cm in greatest dimension; or multiple lymph nodes ≤2 cm in greatest dimension
N2
Metastasis with a lymph node mass > 2 cm but ≤5 cm in greatest dimension; or multiple lymph nodes, any one mass > 2 cm but ≤5 cm in greatest dimension
N3
Metastasis with a lymph node mass > 5 cm in greatest dimension
Pathologic (pN) pNX
Regional lymph nodes cannot be assessed
pN0
No regional lymph node metastasis
pN1
Metastasis with a lymph node mass ≤2 cm in greatest dimension and less than or equal to five nodes positive, none > 2 cm in greatest dimension
pN2
Metastasis with a lymph node mass > 2 cm but ≤ 5 cm in greatest dimension; or more than five nodes positive, none 5 cm; or evidence of extranodal extension of tumor
pN3
Metastasis with a lymph node mass > 5 cm in greatest dimension
▶
620
Ugur Selek
Table 20.8 (continued) Stage
Description
Distant metastasis (M) M0
No distant metastasis Distant metastasis
M1
M1a: nonregional nodal or pulmonary metastasis M1b: distant metastasis other than to nonregional lymph nodes and lungs
Serum tumor markers (S)
a
SX
Marker studies not available or not performed
S0
Marker study levels within normal limits
S1
LDH less than 1.5 × Nb hCG less than 5,000 (mIU/ml) AFP less than 1,000 (ng/ml)
S2
LDH 1.5–10 × Nb or hCG 5,000–50,000 (mIU/ml) or AFP 1,000–10,000 (ng/ml)
S3
LDH more than 10 × N or hCG more than 50,000 (mIU/ml) or AFP more than 10,000 (ng/ml)
Except for pTis and pT4, the extent of primary tumor is classified by radical orchiectomy. TX may be used for other categories in the absence of radical orchiectomy b N indicates the upper limit of normal for the LDH assay Source: Seventh Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, Testis, Chapter 42, page 539-546, Springer-Verlag, New York, NY (2010)
Chapter 20 Testicular Cancer
621
Table 20.9 Stage grouping of testicular cancer Stage
Group
0
pTis, N0, M0, S0
IA
pT1, N0, M0, S0
IB
pT2–4, N0, M0, S0
IS
Any pT/Tx, N0, M0, S1–3
IIA
Any pT/Tx, N1, M0, S0–1
IIB
Any pT/Tx, N2, M0, S0–1
IIC
Any pT/Tx, N3, M0, S0–1
IIIA
Any pT/Tx, any N, M1a, S0–1
IIIA
Any pT/Tx, N1–3, M0, S2 Any pT/Tx, any N, M1a, S2
IIIC
Any pT/Tx, N1–3, M0, S3 Any pT/Tx, any N, M1a, S3 Any pT/Tx, any N, M1b, any S
Source: Seventh Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Handbook, Testis, Chapter 42, page 539-546, Springer-Verlag, New York, NY (2010)
622
Ugur Selek
Prognostic Factors The commonly reported prognostic factors for stage I seminoma and effects on disease-free survival (DFS) are listed in Table 20.10. The only prognostic factor described for stage II seminoma is the bulk of the lymphadenopathy: Local recurrence related with size could be approximately summarized as 6% for tumor (T) < 3 cm, 18% for T = 3–6 cm, 36% for T > 6 cm. Factors independently predict worse prognosis for non-seminomatous cancer include presence of liver, bone, or brain metastases: very high serum markers, primary mediastinal nonseminoma, and large number of lung metastases. Table 20.10 Prognostic factors for stage I seminoma Factor
Effects on long-term DFS (%) (+)
(−)
Post-orchiectomy elevated -hCG
87%
97%
Spermatic cord involvement
86%
98%
Lymphovascular invasion
51%
78%
Size of tumor (≥4 cm versus <4 cm)
76%
87%
Age (<34 versus >34 years old)
70%
91%
Source: Dosmann MA, Zagars GK et al (1993) Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26:381–390
Treatment Principles and Practice Treatment for testicular cancer including surgery, followed by active surveillance, radiation therapy, or chemotherapy (Table 20.11). Current standard approach for initial diagnosis is radical inguinal orchiectomy with high ligation without scrotal violation. Scrotal violation (secondary to trans-scrotal biopsy) is associated with increased local/regional recurrence and should be avoided. Seminoma is extremely radiosensitive. Radiation therapy is often used for adjuvant therapy for early-stage seminoma, and its use in non-seminoma germ cell tumors (GCT) is limited. Hence, the following discussion is focused on the treatment of seminoma.
Chapter 20 Testicular Cancer
623
Table 20.11 Adjuvant treatment modalities Treatment
Description
Radiation therapy Indications
Adjuvant therapy after orchiectomy for stages I–IIb diseases Salvage of locoregional failure after surgery or chemotherapy Palliative treatment to locoregional or distant metastatic sites
Techniques
External-beam radiation therapy to regional lymph nodes using high-energy radiation Doses range 20–30 Gy (2 Gy per fraction) depends on extent of disease
Chemotherapy Indications
As an alternative to adjuvant radiation therapy for stages I–II seminoma Adjuvant therapy for stages II–IV seminoma
Regimens
Single-agent carboplatin become an alternative to radiation therapy for adjuvant treatment for stage I seminoma A number of regimens including BEP, EP, PVB, and VIP have been used and reported for stages II–IV diseases (Table 20.13)
Surveillance Indications
An option, as potentially 80–85% of patients will not develop recurrence, and salvage by radiotherapy or chemotherapy is effective if recurs Contraindicated in tumor >6 cm (>4 cm, HR 2), elevated post-orchiectomy β-HCG, spermatic cord invasion, and noncompliance
Facts/issues
Costly and inconvenient
624
Ugur Selek
An adjuvant treatment algorithm for seminoma after radical orchiectomy is summarized in Figure 20.2a,b. Chemotherapy is standard approach for stages III and IV.
Seminoma Stage I
High Risk Factors ≥ 4 cm Rete testis invasion
High Risk
Low Risk
- Paraaortic Radiotherapy
- Surveillance - Paraaortic Radiotherapy - Single dose Carboplatin
a
Seminoma Stage II
Nonbulky Node
Bulky Node (≥ 5 cm)
Paraaortic & Ipsilateral Iliac Nodal Radiotherapy
Chemotherapy
b
Figure 20.2 a, b a Adjuvant treatment algorithm for stage I seminoma after radical orchiectomy. b Adjuvant treatment algorithm for stage II seminoma after radical orchiectomy
Chapter 20 Testicular Cancer
625
Treatment for Stages I–II Seminoma After definitive surgery, adjuvant radiation therapy, chemotherapy, or active surveillance are options for management of patients with stage I seminoma. Regional lymph node irradiation has been the most commonly used adjuvant therapy, and relapse-free survival is >95% for stage I and 80% for stage II diseases after orchiectomy and radiation. Single-agent chemotherapy and active surveillance are valid options after orchiectomy in stage I seminoma. Evidence supporting their use is listed in Table 20.12. Table 20.12 Evidence supporting the use of adjuvant chemotherapy or surveillance after surgery for early-stage seminoma Trial
Description
MRC/EORTC b
Compared 1 course of carboplatin (C) at AUC × 7a with adjuvant radiotherapy (RT) for stage I seminoma Found equivalent relapse rates after a median followup period of 4 years The results indicate that a single cycle of outpatient carboplatin is not inferior to radiotherapy Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) with 6.5 years of follow-up with documented minimum 5 years on 1,148 patients revealed relapse-free rates at 5 years as 95% (C) and 96% (RT) There was a significant difference in the rate of new GCTs (2 on C versus 15 on RT) Analysis of the available data on pathological risk factors demonstrated that larger tumors (>4 cm) had poorer RFR (HR: 3.68)
Von der Masse et alc
Retrospective review of 261 patients observed without any selection criteria The failures were mostly within 3 years, and the relapse rate was 19% (15% paraaortic, 2% pelvic, 1% inguinal, and 1% lung) Only prognostic factor for relapse free survival at 4 years was tumor size >6 cm (94 versus 64%) 11% of the patients who recurred and were salvaged had second relapse
Warde and Gaspodarowicz d
Retrospective review of 172 surveillance patients demonstrating 18% failure (age younger than 34 years was the only predictor) ▶
626
Ugur Selek
Table 20.12 (continued) Randomized trial
Description
Duchesne et ale
Retrospective study of 133 surveillance patients Relapse rate of 16% at 3 years
Warde et alf
A pooled analysis of 638 patients from the four largest surveillance studies (Princess Margaret Hospital, Danish Testicular Cancer Study Group, Royal Marsden Hospital, and Royal London Hospital) With a median follow-up of 7 years, multivariate analysis revealed tumor size (≤4 cm versus >4 cm, HR 2, DFS (87 versus 76%), and invasion of the rete testis (HR 1.7, DFS of 86 versus 77%) remained as important predictors for relapse Lymphovascular invasion was not a significant prognosticator
AUC: target area under the concentration versus time curve in mg/ml·min a Carboplatin dosing: total dose (mg) = (target AUC) × (GFR + 25) b Sources: Oliver RT, Mason MD, Von der Maase H et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366:293–300; Oliver RT, Mead GM, Fogarty PJ et al (2008) Radiotherapy versus carboplatin for stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). J Clin Oncol 26:Abstract 1 c Source:Von der Maase H, Specht L, Jacobsen GK et al (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 29A:1931–1934 d Source: Warde P, Gospodarowicz MK, Panzarella T et al (1995) Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 13:2255–2262 e Source: Duchesne GM, Stenning SP, Aass N et al (1997) Radiotherapy after chemotherapy for metastatic seminoma – a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33:829–835 f Source: Warde P, Specht L, Horwich A et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20:4448– 4452
Chapter 20 Testicular Cancer
627
Treatment for Stages II–IV Seminoma Four cycles of chemotherapy (Table 20.13) after definitive surgery is recommended for stage II (if nodal mass >5 cm) and stages III–IV seminoma. Empiric radiation of residual persistent abnormalities that is ≥3 cm is controversial (Source: Duchesne GM, Stenning SP, Aass N et al (1997) Radiotherapy after chemotherapy for metastatic seminoma – a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 33:829–835). Table 20.13 Treatment for stages II–IV seminoma
Regimens
Chemotherapeutic agents
BEP
Bleomycin plus etoposide plus cisplatin
EP
Etoposide plus cisplatin (in patients with good prognosis)
PVB
Cisplatin plus vinblastine plus bleomycin
VIP
Etoposide (VP-16) plus ifosphamide plus cisplatin (worse hematologic toxic effects)
In rare cases where chemotherapy is initiated before orchiectomy, the disappearance of testicular mass does not avoid orchiectomy (Source: Herr HW, Sheinfeld J, Puc HS et al (1997) Surgery for a post-chemotherapy residual mass in seminoma. J Urol 157:860–862).
Treatment for Non-seminomatous Testicular Cancer The non-seminomatous testicular cancers are less sensitive to radiation and chemotherapy, and spread rapidly. As radiation therapy plays a limited role, detailed discussion on the treatment of nonseminomatous testicular cancer is beyond the scope of this chapter. In general, radical orchiectomy and staging work-up is followed by observation, retroperitoneal lymph node dissection, or systemic chemotherapy.
628
Ugur Selek
Radiation Therapy Techniques Preparation and Simulation Discussion on consequences of radiation therapy, including infertility is crucial, and sperm banking should be offered if appropriate. Table 20.14 summarizes the preparation and simulation for external-beam radiation therapy for seminoma. Table 20.14 Simulation for radiation therapy for seminoma Setup
Detail
Position and immobilization
Supine with a pillow or headrest placed behind the head, arms placed by the patient’s side and legs straight, with feet stabilized with a foam wedge underneath the knees
Slice thickness of CT
5 mm
Marks
Placed on the patient’s skin laterally as well as anteriorly for alignment
Intravenous contrast
Usually not necessary but may be administered to improve soft tissue and vascular definition
Shielding
Contralateral testis is shielded with a lead clamshell device. The mean dose values to the contralateral testicle in case of para-aortic (PA) or para-aortic and IL iliac (PAI) fields (PA: 1.86 versus 0.65 cGy; PAI: 3.89 versus 1.48 cGy, without or with gonadal shielding respectively)
Source: Bieri S, Rouzaud M, Miralbell R et al (1999) Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother Oncol 50:349–353
Chapter 20 Testicular Cancer
629
Target Volumes and Doses The recommended clinical target volumes (CTVs) and doses for adjuvant radiation therapy (RT) are described in Tables 20.15 and 20.16 for stage I and II seminoma, respectively. RT field for stage II disease are hockeystick field, including the para-aortic, paracaval, common iliac, and external iliac nodal regions (Figures 20.3, 20.4, 20.5, 20.6, and 20.7) (Source: Fossa SD, Horwich A, Russell JM et al (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146). Table 20.15 Radiation therapy field for stage I seminoma Aim
Description
Conventional block margins
Elective paraaortic nodal contouring
Begin at T12–L1 interspace, finish at aortic bifurcation Contour aorta and vena cava together as vessel contour (VC)
Elective CTV
Paraaortic nodal CTV: VC plus 7 mm, excluding bones For left testis: include renal hilum in CTV
Planning target volume (PTV)
Depending on anticipated set-up accuracy, usually CTV plus 3–5 mm
Superior: T11–T12 interspace Inferior: L5–S1 interspace Lateral: transverse process For left testis: cover renal hilum
CTV: clinical target volume; PTV: planning target volume
630
Ugur Selek
Table 20.16 Radiation therapy field for stage II seminoma Aim
Conventional block margins
Para-aortic nodal contouring
CTV nCTV (Positive Nodal CTV) PTV
Description Superior: T11–T12 interspace Inferior: mid-obturator foramen Lateral: transverse process down to L5–S1 interspace, then diagonally to the lateral edge of the acetabulum, then vertically downward to the median border of the obturator foramen For left testis: cover renal hilum Begin at T12–L1 interspace, finish at obturator foramen Contour aorta, vena cava and ipsilateral iliac nodes as VC Stop iliac contours at top of femoral heads as a boney landmark for Inguinal ligament Paraaortic nodal CTV: VC plus 7 mm, excluding bones For left testis: include renal hilum in CTV Gross tumor volume plus 1 cm, excluding bones Usually 2-cm margin around the node to the block margin Depending on anticipated set-up accuracy, usually CTV (CTV plus nCTV) plus 3–5 mm
Sources: Classen J, Schmidberger H, Meisner C et al (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21:1101–1106; Dosmann MA, Zagars GK (1993) Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26:381– 390; Zagars G K, Pollack A (2001) Radiotherapy for stage II testicular seminoma. Int J Radiat Oncol Biol Phys 51:643–649
Figure 20.3 Clinic target volume (CTV) is generated by adding 7 mm to the contour of aorta and vena cava together as vessel contour (VC), with exclusion of bones
Chapter 20 Testicular Cancer
631
Figure 20.4 Elective paraaortic field for stage I seminoma (from T11–T12 interspace to L5–S1 interspace)
Figure 20.5 Paraaortic and ipsilateral inguinal field for stage II left testicular seminoma, with inclusion of the renal hilus
632
Ugur Selek
Figure 20.6 Paraaortic boost field for a 3-cm left lymphadenopathy for stage IIB left testicular seminoma to a total dose of 30 Gy covering nodal CTV
Figure 20.7 The 20-Gy dose line needs to cover T12 in sagittal view for stage I seminoma cases
Chapter 20 Testicular Cancer
633
Clinical evidence favors the omission of prophylactic radiation therapy to both the mediastinum and neck. However, supraclavicular failure in stage IIa was 0% with mediastinal radiotherapy and 20% without mediastinal radiotherapy was reported (Source: Dosmann MA, Zagars GK (1993) Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 26:381–390). Prescription of RT and dose recommendations are summarized in Tables 20.17 and 20.18. Table 20.17 Prescription of radiation therapy in the treatment of seminoma Aspect
Amount
Reason
Normalization
As low as 95%
To achieve optimal coverage in order to reduce the hourglass effect of the AP/PA beams
Ideal dose distribution
98% Isodose line
Encompassing the entire treatment area and a hot spot no greater than 10% above the prescription dose
>10 MV
Equal weighting on the AP/PA beams is optimal PA beam may be weighted slightly more than the AP beam to reduce the dose to the small bowel
Energy
634
Ugur Selek
Table 20.18 Recommended doses for radiation therapy for adjuvant treatment of seminoma with supporting clinical evidences Dose
Total (Gy)
Dose per daily fraction (Gy)
Elective (stage I)
20
2
Nodes <3 cm
26
2
Nodes 3–5 cm
30
2
MRC (EORTC 30942, MRC TE 18)a
Randomized multi-institutional clinical trial compared 30 Gy (2 Gy/day) versus 20 Gy (2 Gy/day) adjuvant radiotherapy for stage I seminoma 20-Gy arm had equivalent relapse rates and reduced morbidity (mainly fatigue)
Fossa et al (MRC)b
Randomized 478 men to receive PA versus PAI fields irradiation (30 Gy per 15 fractions) No difference in relapse-free survival was detected Slightly more pelvic recurrences in PA alone group: the risk of hemipelvic failure is ~3%; and the risk of mediastinal failure is ~2%
MRC: Medical Research Council; EORTC: European Organization for the Research and Treatment of Cancer a Source: Jones WG, Fossa SD, Mead GM et al (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on MRC Trial TE18, EORTC Trial 30942 (ISRCTN18525328). J Clin Oncol 23:1200–1208 b Source: Fossa SD, Horwich A, Russell JM et al (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17:1146 Non-bulky stage II disease has a cure rate of more than 90% with radiation alone at doses of 30 to 36 Gy (Source: Mason BR, Kearsley JH (1988) Radiotherapy for stage 2 testicular seminoma: the prognostic influence of tumor bulk. J Clin Oncol 6:1856–1862; Classen J, Souchon R, Hehr T et al (2002) Radiotherapy for early stages testicular seminoma: patterns of care study in Germany. Radiother Oncol 63:179–186)
Normal Tissue Tolerance RT doses used in the treatment of seminoma are generally low, thus usually within the tolerance of normal surrounding organs. However, the effect of fractionated radiation on fertility is substantial, as detailed in Table 20.19.
Chapter 20 Testicular Cancer
635
Table 20.19 Spermatogenesis and effects of fractionated radiation therapy to male fertility Aspect
Fact/result
Normal sperm count
Estimated to be 120 million/ml
Spermatogenesis over 67 days
21 days from stem cells to primary spermatocytes, plus 46 days to become mature spermatozoa
Radiation sensitivity to single fraction diminishes rapidly with progression along maturation pathway
Spermatogonia (~0.1–0.2 Gy) Spermatocytes (~2–3 Gy) Spermatids (~4–6 Gy) Azospermia takes approximately 60–70 days after a single dose below 2 Gy, due to damage to spermatogonia, but develops faster in case above 4 Gy, with concurrent damage to spermatids
Recovery of spermatogenesis
Dose dependent and requires a long time for recovery of spermatogonia (sperm recovery: 1–1.5 years for <1 Gy, 2–5 years for 4–6 Gy, most probably permanent azospermia for 6–8 Gy) Spermatogenesis is more sensitive to fractionated radiotherapy damage, due to long (~16 day) cell cycle of sperm stem cells Oligospermia/azospermia occurs with 0.7–0.9 Gy (frequent recovery at 1–1.5 years) Permanent azospermia likely appears with fractionated doses as low as 1.2 Gy (most likely after 2 Gy)
FSH
Stimulates Sertoli cells to make androgen-binding protein as well as inhibin, which inhibits follicle-stimulating hormone (FSH) (negative feedback) and dose of 0.75–6 Gy might cause an increase in FSH
LH
Stimulates Leydig cells to make testosterone, inducing spermatogenesis, and 0.75 Gy might increase LH levels through loss of negative feedback. Therefore testosterone levels are lower shortly after radiotherapy and will take time to return to normal (up to a year)
Endocrine dysfunction with subtle Leydig cell damage is rare after cumulative 2 Gy in fractionated therapy, but testosterone production is impaired after 14 Gy in 2 Gy per fraction Sources: Shapiro E, Kinsella TJ, Makuch RW et al (1985) Effects of fractionated irradiation of endocrine aspects of testicular function. J Clin Oncol 3:1232–1239; Petersen PM, Giwercman A, Daugaard G et al (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma in situ in the testis. J Clin Oncol 20:1537– 1543; Howell SJ, Shalet SM et al (2005) Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 34:12–17
636
Ugur Selek
Follow-Up After completion of definitive treatment, long-term follow-up to detect second primary tumors, recurrences, or late side effects is recommended (Table 20.20). Table 20.20 Follow-up schedule and examinations with treatment of seminoma Schedule
Frequency
Years 1–3
Every 3–4 months
Years 4–7
Every 6 months
Years 7+
Every 12 months
Examination History and physical
Complete history and physical examination
Imaging studies
Abdominal/pelvic CT at every visit for surveillance cases Pelvic CT alone annually for 3 years for patients sta tus post only paraaortic radiotherapy Chest X-ray at alternate visits
Laboratory tests
AFP, -hCG, LDH
Adapted from: National Comprehensive Cancer Network (NCCN). Clinical practice uidelines in oncology: Testicular Cancer v.2.2010 (http://www.nccn.org/professionals/ physician_gls/PDF/testicular.pdf) Cited on September 14, 2010.
Chapter 20 Testicular Cancer
637
Acute adverse effects during radiation therapy for seminoma are usually mild, and may include nausea/vomiting, diarrhea, fatigue, and transient decline in blood count. Late adverse effects are detailed in Table 20.21. Long-term side effects would probably diminish with decreased doses and radiation fields in comparison with previous series, with an increased risk after 15 years for cardiovascular and secondary cancer mortalities (Zagars GK, Ballo MT, Lee AK et al (2004) Mortality after cure of testicular seminoma. J Clin Oncol 22:640–647). Table 20.21 Late toxicities of radiation therapy in treatment of seminoma Adverse event
Sterilization
Occurrence Generally, seminoma treatment might cause 30–180 cGy to the contralateral testis and oligospermia (CTCAE v3, infertility/sterility, grade 2) or azospermia (CTCAE v3, infertility/sterility, grade 3) followed by recovery in 18–24 months (30 cGy for PA and hemipelvic fields, and 60 cGy for hemiscrotal treatment using a testicular clamshell) In the randomized trial (PA versus PA/dog leg), the risk of azospermia at 12 months post-RT was 10% (PA nodes) versus 30% (PA/dog leg)a
a
Peptic ulcer
Rare
Small bowel obstruction
Very rare
Chronic diarrhea
Very rare
Second malignancy
~5%, approximately 2× risk of subsequent malignancy at 10–15 yearsb
Source: Jacobsen KD, Olsen DR, Fossa K et al (1997) External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis. Int J Radiat Oncol Biol Phys 38:95–102 b Source: Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354– 1365
Section VII Gynecological Cancers
VII
21 Endometrial Cancer. . . . . . . . . . . . . . . . . . . . . . . . . 641 Keyur J. Mehta, Nitika Thawani and Subhakar Mutyala 22
Cervical Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 661 Nina A. Mayr, William Small Jr. and David K. Gaffney
23
Vulva Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 Kevin Albuquerque
24
Vaginal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725 Nitika Thawani, Subhakar Mutyala and Aaron H. Wolfson
21
Endometrial Cancer Keyur J. Mehta1, Nitika Thawani 2 and Subhakar Mutyala3
Key Points Endometrial cancer is the most common gynecologic malignancy and the 4th most common cancer in women in the United States. Risk factors of the disease include length of exposure of unopposed estrogen, and the most common presenting symptom is postmenopausal bleeding. Most (>90%) cases of endometrial cancer are adenocarcinoma. Route of spread is through local extension, lymphatic or hematogenous. Stage, depth of invasion, lymphovascular space involvement, and lymph node involvement are the most important prognostic factors. The majority of patients (>70%) are diagnosed early at stage I, leading to overall good prognosis: >80% local control and >70% overall survival. Surgery (total extrafascial hysterectomy with bilateral salpingo-oophorectomy, peritoneal cytology, and pelvic/para-aortic lymph node dissection) is the mainstay of diagnosis, pathologic staging, as well as treatment Early-stage endometrial cancer can usually be treated with surgery with or without radiation therapy. Adjuvant radiation therapy (external-beam pelvic radiation and/or vaginal cuff brachytherapy) has been shown to decrease local recurrence. Locoregionally advanced endometrial cancer is treated with a combination of surgery, radiation therapy, and chemotherapy. Chemotherapy with or without hormonal therapy has been shown to benefit locally advanced or metastatic endometrial cancer.
2 Nitika Thawani, MD Keyur J. Mehta, MD () Email:
[email protected] Email:
[email protected] 1
3
Subhakar Mutyala, MD Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_4, © Springer-Verlag Berlin Heidelberg 2011
642
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Epidemiology and Etiology There are 42,160 new diagnoses of endometrial cancer expected in the USA in 2010. It is the 4th most common cancer in women, and ranks 8th among causes of cancer death. It is the most common gynecologic malignancy. Endometrial carcinoma arises from hyperplasia of the endometrial lining, resulting from exposure to unopposed estrogens. Table 21.1 outlines the other risk factors associated with this malignancy. Table 21.1 Risk factors of endometrial cancer Risk factor
Description Age: typical patients are postmenopausal between 55 and 85 years of age; incidence rate is higher than 95 per 100,000 women 65–80 years of age Endogenous estrogen exposure: early menarche, nulliparity, infertility, late menopause, estrogen-producing ovarian tumors
Patient related
Exogenous estrogen exposure: hormonal replacement therapy, hormonal replacement therapy, tamoxifen Past medical history: hypertension, diabetes mellitus Family history: although observed, < 1% of all endometrial cancers are due to familial factors Genetic predisposition: mutations in the MLH1 or MSH2 genes that mark the defect in HNPCC (Lynch syndrome II); patients with this syndrome have a 20% risk of developing endometrial cancer before age 50, and 60% before age 60
HNPCC: hereditary non-polyposis colon cancer
Anatomy The uterus is a pelvic organ bordered by the bladder anteriorly and the rectum posteriorly, and is covered by peritoneal reflections (Figure 21.1 and Table 21.2).
Chapter 21 Endometrial Cancer
643
Figure 21.1 Anatomy of the uterus
Table 21.2 Anatomic description of the uterus Anatomy
Description
Gross
The uterus is divided into the fundus, isthmus, and the cervix The uterine wall has an outer smooth muscle layer (myometrium) and an inner layer composed of glandular epithelium (endometrium); the uterus is covered by a serosal lining Supported by 5 ligaments: broad, round, cardinal, uterosacral, and vesico-uterine
Blood supply
The uterine artery, a branch of the hypogastric artery, enters the uterus at the isthmus
Lymphatics
The myometrium drains into a rich subserosal lymphatic network and joins larger lymphatic channels before exiting the uterus The fundus drains toward the adnexa and infundibulopelvic ligaments; the middle and lower uterus drains in the base of the broad ligament toward the pelvic sidewall Nodal regions at risk: obturator, external iliac, internal iliac, common iliac, and para-aortic
644
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Pathology The majority of uterine epithelial tumors are adenocarcinomas of endometrioid subtype. The World Health Organization (WHO) recommends a classification system for other subtypes and histologic variants (Table 21.3). Table 21.3 WHO histologic classification of tumors of the uterus Tumor type
Subdivision
Epithelial
Adenocarcinoma Endometrioid adenocarcinoma (75%) Serous adenocarcinoma (5–10%) Mucinous adenocarcinoma (1–3%) Clear cell adenocarcinoma (1–5%) Mixed cell adenocarcinoma Non-adenocarcinoma Squamous cell carcinoma Transitional cell carcinoma Small cell carcinoma Undifferentiated carcinomas Smooth muscle tumors Leiomyoma Leiomyosarcoma
Mesenchymal
Mixed epithelial and mesenchymal
Smooth muscle tumor of uncertain malignant potential Endometrial stromal tumors Endometrial stromal sarcoma Endometrial stromal nodule Undifferentiated endometrial sarcoma Miscellaneous Mesenchymal tumors Mixed endometrial stromal and smooth muscle tumor Adenomatoid tumor Perivascular epithelial cell tumor
Adenofibroma Adenomyoma Adenosarcoma Carcinofibroma Carcinosarcoma (malignant mixed Müllerian tumor)
Chapter 21 Endometrial Cancer
645
Routes of Spread The pattern of spread as read on pathologic specimens lends to many of the prognosticators used to risk-stratify patients (Table 21.4). Table 21.4 Routes of spread in endometrial cancer Routes
Description
Local extension
Longitudinal growth: local extension along the endometrial surface, which may spread to the Fallopian tubes, lower uterine segment, and the cervix Radial growth: results in myometrial invasion, subsequently leading to lymphovascular space invasion and lymphatic spread More aggressive local extension leads to serosal penetration, involvement of the parametrial tissues, and direct invasion of the bladder and rectum
Regional lymph node metastasis
Nodal regions at risk: obturator, external iliac, internal iliac, common iliac, and para-aortic The fundus can drain directly to the para-aortic lymph nodes
Distant metastasis
Peritoneal seeding may occur from direct serosal penetration or from spillage through the Fallopian tubes Hematogenous spread is uncommon, but occurs usually with high-grade tumors and unfavorable histologies The most common metastatic sites include the lungs, liver, and bones
Diagnosis, Staging, and Prognosis Clinical Presentation The most common presenting symptom is vaginal bleeding. In postmenopausal patients, vaginal bleeding is unexpected and may range from spotting to heavy blood loss. Pre- or perimenopausal patients may present with menorrhagia and/or metrorrhagia. Another presenting symptom is profuse, watery discharge. Although uncommon, a routine Pap smear for cervical cancer screening may detect abnormal endometrial cells.
646
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Diagnosis The diagnosis of endometrial cancer depends on the clinical presentation, history and physical examination, including a thorough gynecologic examination, imaging studies, and laboratory tests (Figure 21.2).
Endometrial Cancer Suspected by clinical presentation
Complete History and Physical Examination
Endometrial biopsy
-
+/-
Trans-vaginal ultrasound
Non-diagnostic
+
Dilatation and curettage +/- hysteroscopy
Observe
-
Pre-operative assessment +
Figure 21.2 Diagnosis of endometrial cancer
Tumor, Node, and Metastasis/Federation of Gynecology and Obstetrics Staging Endometrial cancer staging is determined by pathologic criteria. Recent changes in the Federation of Gynecology and Obstetrics (FIGO) and the American Joint Committee on Cancer (AJCC) staging recommendations were made to coincide with prognosis and are reflected in Table 21.5.
Chapter 21 Endometrial Cancer
647
Table 21.5 FIGO and American Joint Committee on Cancer (AJCC 7th edition) TNM staging for endometrial cancer FIGO staging (2008)
AJCC 7th edn (2009) TNM staginga
Group
T
N
M
IA
T1a
0
0
Limited to the endometrium or invades less than half of the myometrium
IB
T1b
0
0
Invades half or more of the myometrium
II
T2
0
0
Invades cervical stromal tissue but does not extend beyond the uterus
IIIA
T3a
0
0
Involves serosa and/or adnexa
IIIB
T3b
0
0
Vaginal involvement or parametrial involvement
IIIC1
T1–3
1
0
Metastasis to pelvic lymph nodes
IIIC2
T1–3
2
0
Metastasis to para-aortic lymph nodes
IVA
T4
any
0
Invades bladder mucosa and/or bowel mucosa
IVB
Any
Any
1
Distant metastasis
Description
a
Changes from the AJCC 6th edition and the previous FIGO staging recommendations (1988):
No longer includes uterine sarcoma (now staged with a new staging system) Positive peritoneal cytology is no longer considered (previously was T3a/ IIIA) Involvement of the endocervical glands is not longer considered (previously was stage IIA) Stages IA and IB combined (now: IA). IC moved to IB Stage IIIC subdivided into IIIC1 and IIIC2 Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
648
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Prognostic Factors Survival is strongly influenced by the stage at diagnosis (Table 21.6). Adverse prognostic factors include: More advanced age: associated with higher chance of recurrence (age > 70 have more recurrence versus 50–70) Higher grade: associated with higher chance of recurrence (grades 2–3) Aggressive histology: clear cell adenocarcinoma, undifferentiated papillary serous carcinoma are associated with worse prognosis due to more distant failure pattern Depth of myometrial invasion (>66%) Lymphovascular space invasion Gynecologic Oncology Group Trial 99 (GOG 99; Figure 21.4) outlines the prognostic factors in directing treatment. Table 21.6 Survival rate at 5 years, based on stage classification Extent of disease at diagnosis
5-year survival rate (%)
Localized Regional Distant
96% 68% 24%
All stages
83%
Principles and Practice A total extrafascial hysterectomy with bilateral salpingo-oophorectomy, peritoneal cytology, and pelvic/para-aortic lymph node dissection remains the standard initial treatment for endometrial cancer. Traditionally done through a vertical midline incision, a laparoscopic technique has recently been used. Pathologic data has shown that certain high-risk pathologic features predict higher rates of local recurrence. Therefore, adjuvant radiation therapy is recommended for these patients. Systemic therapy is typically used in locoregionally advanced, recurrent, or metastatic disease (Table 21.7).
Treatment of Early-Stage Endometrial Cancer Surgical resection is the initial management of choice. The pathologic specimen is then examined for the risk factors listed in “Prognostic Factors” along with patient-related factors to determine a patient’s risk of locoregional recurrence. The patient may be offered adjuvant therapy based on a significant risk of recurrence (Table 21.8 and Figure 21.3).
Chapter 21 Endometrial Cancer
649
Table 21.7 Treatment modalities used in endometrial cancer Treatment
Description
Total extrafascial or laparoscopic-assisted vaginal hysterectomy with bilateral salpingo-oophorectomy (including peritoneal cytology and pelvic/para-aortic lymph node staging) Indications
Curative treatment modality, leads to surgical staging
system A vaginal hysterectomy may be used in morbidly complicated patients Facts
A minimally invasive (laparoscopic) approach has been
gaining popularity Surgical lymph node staging is controversial Only 30–40% of patients undergo nodal assessment Radiation therapy Indications
Adjuvant treatment for patients with high-risk patho-
logic features May be given as definitive therapy in inoperable cases Techniques
EBRT using conventional four fields, 3D-CRT, or IMRT Intravaginal LDR or HDR brachytherapy Rotte-Y or Heyman capsule applicators in inoperable
cases Chemo-/hormonal therapy Indications
Chemotherapeutic agents are used in locoregionally
advanced, recurrent or metastatic disease Hormonal agents used in inoperable or recurrent cases Medications
Chemotherapeutic agents: alkylating agents, cisplatin,
anthracyclinces, antimetabolites, vincas, epipodophyllotoxins, topoisomerase I inhibitor, taxanes Hormonal agents: progestins, anti-estrogens, aromatase inhibitors Targeted agents are under investigation EBRT: external-beam radiation therapy; 3D-CRT: 3-dimensional conformal radiation therapy; IMRT: intensity-modulated radiation therapy; LDR: low-dose rate; HDR: high-dose rate
650
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Table 21.8 Treatment of early-stage endometrial cancer FIGO stage
Grade I
II
III
IA
Observation
Observation or VB
VB or EBRT with or without VB
IB
VB or EBRT with or without VB
VB or EBRT with or without VB
EBRT with VB
II
EBRT with VB
EBRT with VB
EBRT with VB
In the previous FIGO staging system (1988), stage IA tumors (limited to the endometrium) could generally be observed; however, VB was considered for grade 3 EBRT may be omitted in a patient with an adequate negative lymph node dissection; alternatively, EBRT is generally recommended in patients in whom the lymph nodes were not addressed and poor prognosticators were present on pathology
VB: vaginal brachytherapy; EBRT: external-beam radiation therapy Light blue cells low-intermediate risk, olive cells intermediate-high risk, red cells high risk
Surgical resection provides invaluable pathologic data that guides treatment decisions
Pathologic factors and patient-related factors determine: Treatment recommendations must be tailored to each individual patient:
Total extrafascial hysterectomy + bilateral salpingo-oophorectomy (open or minimally invasive technique)
Low-risk
Intermediate-risk
High-risk
Observation
Vaginal brachytherapy or EBRT +/vaginal brachytherapy
EBRT + vaginal brachytherapy
Figure 21.3 Proposed algorithm for treatment of early-stage endometrial cancer
Adjuvant External Radiation Therapy Table 21.9 lists four randomized trials that evaluated adjuvant external-beam radiotherapy versus observation after a surgical resection for early-stage endometrial carcinoma. The general trend shows a local control benefit, but this does not translate into a survival difference. Of note, there are inherent differences between the studies with respect to lymph node surgical staging and treatment with vaginal brachytherapy that make concrete conclusions difficult to make.
1980
2000
2004
2009
Norwegian
PORTEC
GOG-99
MRC ASTEC and NCIC CTG EN.5
906
392
715
540
No. of patients
No
No
Yes
IB–ICb IB, G2–3; IC, G1–2 IB–IC; occult II IA–IB, G3; IC, G1–3; 30% serous papillary; clear cell; IIA
Treatment LN dissection
Eligibilitya
52%
No
No
Yes
VB
Observation
50.4 Gy per 28 fractions Observation 40–46 Gy per 20–25 fractions 6
85 (NS)
85 (NS)
86 (NS)
12 3
92 (NS)
85 (NS)
3
14
81 (NS)
4
Observation
87 (NS) 90 (NS)
2 7
40 Gy Observation 46 Gy per 23 fractions
OS (%)
Vaginal/pelvic recurrence (%)
Randomized to EBRT
G: grade; TAH/BSO: total abdominal hysterectomy/bilateral salpingo-oophorectomy; NS: not statistically significant; LN: lymph node; VB: vaginal brachytherapy a FIGO stages refer to 1988 staging system b Subset analysis of Norwegian study showed locoregional control benefited patients in the IC, grade 3 subgroup the most (5 versus 20%) Sources : Aalders J, Abeler V, Kolstad P et al (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427; Creutzberg CL, van Putten WL, Koper PC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 22:1404–1411; Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744–75; ASTEC/EN.5 Writing Committee. (2009) Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 373):137–146
Year
Study
Table 21.9 Randomized trials evaluating the role of adjuvant radiotherapy in early-stage endometrial cancer after TAH/BSO
Chapter 21 Endometrial Cancer 651
652
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
As seen in the preceding tables and algorithm, there is a mixed recommendation of treatment options for the intermediate risk group of patients. This occurs due to the various disease- and patient-related factors that help make a risk assessment. GOG 99 identifies this high-intermediate subgroup of patients, and shows that adjuvant therapy may be more beneficial in this subgroup (Figure 21.4).
Grade 2/3 histology Lymphovascular invasion Outer 1/3 myometrial invasion
Age <50
Age 50-70 Age >70
3 risk factors needed
2 risk factors needed
Only 1 risk factor needed
Figure 21.4 GOG-99 high-intermediate risk subgroup
Brachytherapy Intravaginal brachytherapy may be given alone or in combination with external-beam radiotherapy (EBRT), depending on the risk of pelvic lymph node involvement. Alternatively, it may be omitted when external pelvic irradiation is used as in the Post-Operative Radiation Therapy for Endometrial Carcinoma (PORTEC) and GOG-99 studies, while maintaining good locoregional control rates as shown in Table 21.9 (although the majority of failures in these studies occurred at the vaginal cuff). The details of vaginal brachytherapy technique and dose fractionation are discussed below.
Chapter 21 Endometrial Cancer
653
Locoregionally Advanced Endometrial Cancer Adjuvant Radiation Therapy Patients with locoregionally advanced endometrial cancer as determined by surgical pathology are recommended to undergo adjuvant pelvic irradiation. Para-aortic irradiation may be added in cases where pelvic or para-aortic lymph nodes are positive. Vaginal brachytherapy is often given in addition to EBRT, due to the high risk of vaginal cuff recurrence. Adjuvant Systemic Therapy The GOG conducted a randomized trial to evaluate the role of adjuvant systemic therapy, as seen in Table 21.10. Table 21.10 Evaluation of the role of adjuvant chemotherapy for locoregionally advanced endometrial carcinoma Trial
Description
GOG 122
Randomized 388 patients with stages III–IV endometrial carcinoma after TAH/BSO, surgical staging and <2 cm residual tumor to whole-abdominal irradiation (WAI) versus doxorubicin-cisplatin (AP) chemotherapy WAI equals 30 Gy in 20 fractions AP/PA plus boost to pelvic/para-aortic LNs to 15 Gy in 8 fractions AP equals doxorubicin and cisplatin every 3 weeks for 8 cycles 5-year stage-adjusted PFS was 38% for WAI versus 50% for AP (SS) 5-year stage-adjusted OS was 42% for WAI versus 52% for AP (SS) Recurrence after WAI was 54% (13% pelvis, 16% abdomen, 22% distant); recurrence after AP was 50% (18% pelvis, 14% abdomen, 18% distant AP had more grade 3–4 hematologic and gastrointestinal (GI) toxicity Chemotherapy improves PFS and OS as compared to WAI for stage III/IV patients after surgical resection Statistical rationale of this study is questioned as all statistically significant data is given for stage-adjusted patients
Source: Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36-44
654
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Treatment of Less Common Histologic Subtypes Certain histologic subtypes, such as carcinosarcoma and serous adenocarcinoma, have a different natural history and course of disease than the more common endometrioid adenocarcinoma subtype. The treatment course for these less common subtypes is less well defined, although some studies are available to guide our treatment decisions (Tables 21.11 and 21.12) while others are ongoing. Table 21.11 Evaluation of the role of adjuvant chemotherapy for carcinosarcoma of the uterus Trial
Description
GOG 150
Randomized 206 patients with stages I–IV carcinosarcoma of the uterus after TAH/BSO, surgical staging and <1 cm residual tumor to whole WAI versus cisplatin-ifosphamide with mesna (CIM) chemotherapy WAI equals 30 Gy in 30 fractions (BID) or 20 fractions (QD) AP/ PA plus boost to pelvic LNs to 20 Gy in 20 fractions (BID) or 19.8 Gy in 11 fractions (QD) CIM equals cisplatin and ifosphamide with mesna every 3 weeks for 3 cycles Estimated crude probability of relapse within 5 years (stage and age-adjusted) was 29% lower for the CIM group (NS) Estimated crude probability of surviving at least 5 years (stage- and age-adjusted) was 29% lower for the CIM group (p = 0.085) Recurrence after WAI was 57% (3.8% vagina, 13.3% pelvis, 27.6% abdomen, 25.7% distant); recurrence after CIM was 51% (9.9% vagina, 13.8% pelvis, 18.8% abdomen, 23.8% distant) (NS) Estimated probability of recurring within 5 years for stage I, II, III, or IV disease is 37, 46, 63, and 80%, respectively (p < 0.001) Estimated probability of surviving at least 4 years for stage I, II, III, or IV disease is 65, 45, 26, and 26%, respectively CIM had more grades 3–4 anemia and neuropathy; WAI pa tients experienced more grade 2–4 GI events Chemotherapy appears to delay the onset of recurrence as compared to WAI for patients, although it does not significantly alter the outcomes of those who recur
Source: Wolfson AH, Brady MF, Rocereto T et al (2007) A Gynecologic Oncology Group Randomized phase III Trial of whole abdominal irradiation (WAI) versus cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:166–168
Chapter 21 Endometrial Cancer
655
Table 21.12 A phase II trial of adjuvant radiation therapy and chemotherapy for uterine papillary serous carcinoma (UPSC) Trial
Description
Fields et al
30 patients with stages I–IV UPSC were treated with pelvic radiation therapy (RT) “sandwiched” between 6 cycles of paclitaxel/platinum (TP) chemotherapy after TAH/BSO Pelvic RT equals 45 Gy in 25 daily fractions with a four-field pelvic technique; a para-aortic field was added when 2 or more lymph nodes were positive; patients also received vaginal brachytherapy TP equals 3 cycles of paclitaxel and platinum (cisplatin or carboplatin) were given every 3 weeks; the final 3 cycles were also given every 3 weeks after radiation therapy Median survival for all patients was 34 months Stages I–II patients had a 3-year DFS and OS of 69 and 75%, respectively Stages III–IV patients had a 3-year DFS and OS of 54 and 52%, respectively Grades 3–4 neutropenia, thrombocytopenia, or anemia occurred in 42, 1, and 3%, respectively
Source: Fields AL, Einstein MH, Novetsky AP et al (2008) Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma. Gynecol Oncol 108:201–206
Radiation Therapy Techniques Simulation and Field Arrangements A computed tomography (CT) scan (2.50- to 5-mm cut) should be performed from the top of L4 to the bottom of the lesser trochanters of the femurs. Aides that may be used during the simulation included a Foley catheter, intravaginal cuff marker, oral, and/or intravenous contrast. Organs at risk (see Table 21.17) should be delineated. External radiation fields should encompass the vaginal cuff (or the entire uterus in inoperable cases) and regional pelvic lymph nodes. Field setup is illustrated in Figure 21.5 and Table 21.13.
Dose and Treatment Delivery The pelvis is treated with external-beam radiation therapy to 45–50 Gy in 25–28 daily fractions using 6- to 18-MV photon beams.
656
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Figure 21.5 External beam radiation field setup
Table 21.13 Treatment fields/borders used in the treatment of endometrial cancer Fields
Borders
AP/PA
Superior: top of L5 Inferior: bottom of the obturator foramina Laterally: 2 cm beyond the bony margins of the pelvic inlet
Lateral
Superior/inferior: as AP/PA fields Anterior: in front of the pubis symphysis Posterior: S2–S3
Three-Dimensional Conformal Radiation Therapy and Intensity-Modulated Radiation Therapy, and Target Volume Delineation The benefits of three-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT) radiation techniques are to spare normal tissue while treating the target volumes (Figure 21.6 and Table 21.14). Definitions of gross tumor volume (GTV), clinical target volume (CTV), planning target volume (PTV), and internal target volume (ITV) in 3D-CRT and IMRT are as follows: GTV: the entire uterus (in inoperable cases) CTV: vaginal cuff, obturator lymph nodes, and external/internal/common iliac lymph nodes PTV: CTV plus 0.5–1.0 cm or ITV plus 0.5 cm Organs at risk to be contoured are bladder, small bowel, rectum, bone marrow, and the femoral heads.
Chapter 21 Endometrial Cancer
DHV Structure Aproval line Status Bladder Bowel Femoral Head, LT PTV 45 CTV Femoral Head, RT Rectum
Plan
Course
Volu- Dose Samp- Min me Cover ling Dose Cover (cm3) (%) (Gy) (%)
Max Dose (Gy)
657
Mean Dose (Gy)
Approved A-PTV imrt # Study-kjm 366.3 100.0 100.0 8.747 49.379 35.800 Approved A-PTV imrt # Study-kjm 968.5 100.0 100.0 0.544 48.679 11.543 Approved A-PTV imrt # Study-kjm 90.1 100.0 100.0 2.972 40.921 18.473 Approved A-PTV imrt # Study-kjm 705.8 100.0 100.1 35.530 49.446 46.423 Approved A-PTV imrt # Study-kjm 499.1 100.0 100.1 35.530 49.446 46.466 Approved A-PTV imrt # Study-kjm 93.9 100.0 99.9 2.374 45.858 15.699 Approved A-PTV imrt # Study-kjm 129.5 100.0 100.0 9.648 49.446 36.305
Figure 21.6 IMRT plan for adjuvant radiotherapy for endometrial cancer. PTV (red) was prescribed to 45-Gy EBRT
Table 21.14 Intensity-modulated whole-pelvic radiation therapy in patients with gynecologic malignancies Trial
Description
Roeske et al
Compared a standard “four-field box” plan with an IMRT plan on the same patient 45 Gy in 25 fractions four-field box plan versus IMRT plan IMRT reduced the volume of bowel undergoing more than 30 Gy RT IMRT reduced the average volume of rectum and bladder irradiated at the prescription dose PTV coverage did not differ significantly
Source: Roeske JC, Lujan A, Rotmensch J et al (2000) Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiation Oncology Biol Phys 48:1613–1621
658
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Brachytherapy Intravaginal brachytherapy allows the delivery of a high dose to the vagina while minimizing dose to organs at risk. A vaginal cylinder is the most common applicator used, and the largest diameter feasible is preferable. The radiation is delivered with low-dose-rate (LDR) or high-dose-rate (HDR) radiotherapy. The LDR prescription to the surface is 50–60 Gy over 60–70 h when used alone. The prescription dose is reduced to 25–30 Gy when combined with EBRT. The HDR dose prescriptions as recommended by the American Brachytherapy Society (ABS) are shown in Tables 21.15 and 21.16. Table 21.15 Suggested doses of HDR alone for adjuvant endometrial cancer Number of HDR fractions
HDR dose/fraction (Gy)
Dose-specific point
3
7.0
0.5-cm depth
4
5.5
0.5-cm depth
5
4.7
0.5-cm depth
3
10.5
Vaginal surface
4
8.8
Vaginal surface
5
7.5
Vaginal surface
Source: Nag S, Erickson B, Parikh S et al (2000) The American Brachytherapy Society Recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiation Oncology Biol Phys 48:779–790
Table 21.16 Suggested doses of HDR to be used with 45-Gy EBRT for adjuvant endometrial cancer Number of HDR fractions
HDR dose/fraction (Gy)
Dose-specific point
2
5.5
0.5-cm depth
3
4.0
0.5-cm depth
2
8.0
Vaginal surface
3
6.0
Vaginal surface
Source: Nag S, Erickson B, Parikh S et al (2000) The American Brachytherapy Society Recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiation Oncology Biol Phys 48:779–790
Chapter 21 Endometrial Cancer
659
Normal Tissue Tolerance Organs at risk (OAR) in radiation therapy of endometrial cancer include the bladder, rectum, small intestine, and the femoral heads (Table 21.17). Table 21.17 Dose limitations of OARs in radiation therapy for pelvic malignancies OAR
Dose limitations
Bladder
V80 < 15%, V75 < 25%, V70, V65 < 50%
Rectum
V50 < 50%, V60 < 35%, V65 < 25%, V70 < 200%, V75 < 15%
Small intestine
TD5/5: 45 Gy, V45 < 10% 150 ml < 40 Gy
Femoral heads
Max < 40 Gy
Vn%: volume of tissue receiving n% of Gy Sources: Viswanathan AN, Yorke ED, Marks LB et al (2000) Radiation dose–volume effects of the urinary bladder. Int J Radiation Oncology Biol Phys 76:S116–S122 ; Michalski JM, Gay H, Jackson A (2000) Radiation dose–volume effects in radiation-induced rectal injury. Int J Radiation Oncology Biol Phys 76:S123–S129
Common acute radiation-induced adverse effects include fatigue, cystitis, loose bowel movements, and diarrhea. Late adverse effects include chronic cystitis, chronic proctitis, intractable diarrhea, small bowel obstruction, and vaginal stenosis and dryness.
660
Keyur J. Mehta, Nikita Thawani and Subhakar Mutyala
Follow-Up Patients should follow-up with their surgeon and radiation oncologist at regular intervals (Table 21.18). The patient may be given a vaginal dilator at the first follow-up visit to help prevent vaginal stenosis. Table 21.18 Follow-up schedule and examinations Schedule
Frequency
First follow-up
4 –6 weeks after radiation therapy
Years 0–2
Every 3–4 months
Years 3–5
Every 6 months
Years 5+
Annually
Examinations History and physical
Complete history and physical examination
Laboratory tests
Vaginal cuff cytology
Imaging studies
Chest X-ray (if clinically indicated) CT of the abdomen and pelvis (if clinically indicated)
22
Cervical Cancer Nina A. Mayr1, William Small Jr. 2 and David K. Gaffney3
Key Points Cervical cancer is the fifth most common cancer in women and the third leading cause of cancer death in women worldwide. Risk factors include exposure to human papilloma virus (HPV), which HPV is sexually transmitted, and smoking. Screening has reduced the incidence of invasive disease and mortality in many Western countries. Most carcinomas (80–90%) are squamous cell, 10–20% are adenocarcinoma; less common histologies include neuroendocrine carcinoma, mixed mesodermal, lymphomas, and clear cell carcinoma. Common signs and symptoms include vaginal bleeding and/or discharge, and pelvic or back pain. International Federation of Gynecology and Obstetrics (FIGO) staging is based on clinical examination findings, plain radiographs, cystoscopy, and proctoscopy. However, cross-sectional imaging and positron-emission tomography (PET) further refine disease delineation and therapy planning. Stage, lymph node involvement, and tumor size are the most important prognostic factors. Overall survival is approximately 80–90% for stage IB, 70–80% for stage II, 60% for stage III, and 15% for stage IVA disease. Lung, liver, and bones are the most common metastatic sites. Primary treatment selection is guided by FIGO stage. Stage IA1 tumors are primarily treated surgically, stages IA2-IIA with surgery or radiation therapy, and stages IIB-IVA are treated with definitive radiation and concurrent chemotherapy. Brachytherapy is integrated with external-beam radiation therapy (RT) and is an indispensable component of definitive RT. Chemotherapy concurrent with RT increases local control, reduces distant metastasis, and increases disease-free and overall survival. The role of adjuvant chemotherapy following concurrent radiation/chemotherapy remains to be determined. Concurrent chemotherapy includes weekly cisplatin during RT; 5-fluorouracil (5-FU); taxanes, also have activity.
1
Nina A. Mayr, MD () Email:
[email protected]
2
William Small Jr., MD Email:
[email protected]
3
David K. Gaffney, MD Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_5, © Springer-Verlag Berlin Heidelberg 2011
662
Nina Mayr, William Small Jr. and David K. Gaffney
Key Points (continued) Total treatment course duration of more than 8 weeks is associated with decreased survival. Post-hysterectomy RT is indicated for deep stromal invasion, bulky tumor size, and/or lymphovascular space invasion; post-hysterectomy radiation with concurrent chemotherapy is indicated for involved lymph nodes, parametria, and/ or margins. Radiation and chemotherapy are used for post-hysterectomy pelvic recurrence and to palliate metastatic disease. Outcome of recurrent cervical cancer after hysterectomy or definitive RT is extremely poor. Palliative chemotherapy regimens for recurrent of metastatic cervical cancer include cisplatin, taxenes, 5-FU, topotecan, and gemcitabine.
Epidemiology and Etiology Cervical cancer is the fifth most common cancer in women worldwide. In 2010, it is estimated that approximately 11,270 new cases will be diagnosed and 4,070 deaths occur in the USA. The incidence in the USA has declined over the past four decades, largely because of successful screening. However, the incidence remains high worldwide, with an estimated 471,000 new cases and 300,000 deaths annually. In many medically underserved countries, cervical cancer remains the most common cancer and the leading cause of death for women. Human papilloma virus (HPV) vaccines and screening have the potential to decrease the incidence of this disease on a global level. Risk factors for cervical cancer are shown in Table 22.1.
Anatomy Figure 22.1 details the anatomy of the uterus and pelvis.
Chapter 22 Cervical Cancer
663
Table 22.1 Risk factors for cervical cancer Risk factor
Description
Patient related
Life style: Early age of first sexual intercourse, high number of lifetime sexual partners, exposure to sexually transmitted diseases, and high parity reflect the correlation of HPV infection with the risk of cervical cancer in epidemiologic studies Smoking is associated with increased risk due to accumulation of carcinogens in the cervical mucus. Oral contraceptive use is controversial
Environmental
Infectious exposure: HPV infection: HPV DNA is present in >90% of cervical cancers. HPV-16 and HPV-18 are most commonly associated with squamous cell carcinoma, HPV-31, HPV-33, and HPV-35 less commonly. Very few HPV infections result in invasive cervical cancer, suggesting that other factors, e.g., host immune response, also play a role HIV-related immunosuppression: cervical cancer is an AIDSdefining neoplasm Environmental exposure: Smoking (active and passive exposure) DES exposure in utero is associated with for clear cell adenocarcinoma
HPV: human papilloma virus
Fallopian tube Ovary Fundus Parametria Bony pelvis
Lower uterine segment
Cervix Vagina
Figure 22.1 Anatomy of the cervix and uterus. Tumors of the cervix grow exophytically on the portio or expand into the endocervical region. Spread occurs superiorly along the lower uterine segment, laterally to the parametria and uterosacral ligaments toward the pelvic walls and pelvic lymphatics, posteriorly to the perirectal region, and anteriorly to the bladder. Despite the proximity of bladder and rectum, mucosal involvement of these organs is uncommon. Adapted from: Kepp R, Stemmler HJ (eds) Lehrbuch der Gynäkologie, 10th edn. Thieme, Stuttgart, 1971, p 305
664
Nina Mayr, William Small Jr. and David K. Gaffney
Pathology Squamous cell carcinomas (SCCs) occur in approximately 80% and tend to originate at the squamocolumnar junction and are frequently associated with in situ precursors, progressing from mild, moderate, and severe dysplasia, to carcinoma in situ, to invasive carcinoma. Adenocarcinoma occurs in 10–20% of cases and can arise in the high endocervical region, where diagnosis is more difficult. Most adenocarcinomas are of endocervical gland origin. While SCCs have decreased in the USA, the incidence of adenocarcinoma appears to be increasing. Clear cell carcinoma, an adenocarcinoma variant, is associated with in utero diethylstilbestrol (DES) exposure. Rare histologies include neuroendocrine carcinoma, mixed mesodermal tumors, and lymphomas.
Routes of Spread Cervical cancer spreads by way of local extension along adjacent structures, lymphatics, and distant hematogenous metastasis routes, as detailed in Table 22.2. Table 22.2 Routes of spread in cervical cancer Routes
Description
Local extension
Direct extension along the parametria, uterosacral ligaments, vesicovaginal space, and perirectal space; distally by direct extension to vagina Ovarian spread may occur in adenocarcinomas but is rare
Regional lymph node spread
Generally, stepwise progression along lymphatic echelons from pelvic to para-aortic (PA) lymph nodes to thoracic duct to left supraclavicular lymph nodes Proximal, e.g., PA node, metastases in the absence of pelvic node involvement is uncommon
Distant metastasis
Distant metastases are uncommon in the absence of extensive local or lymph node involvement Most common distant metastatic sites are lung, liver, and bone
Chapter 22 Cervical Cancer
665
Lymphatic Spread The draining lymph node (LN) regions for cervical cancer are summarized in Table 22.3 and Figure 22.2. Table 22.3 Involvement of lymph node groups (in %) by stage Lymph node group
Stage I
II
III
Pelvic LN
15%
30%
50%
Para-aortic LN
5%
20%
30%
Extra-abdominal lymphatic spread occurs from the PA LN through the cysterna chyli and thoracic duct to the left supraclavicular LN.
Figure 22.2 Lymphatic drainage pattern. Adapted from: Plentl AA, Friedman EA (1971) Lymphatic system of the female genitalia. Saunders, Philadelphia, p 83
666
Nina Mayr, William Small Jr. and David K. Gaffney
Diagnosis, Staging, and Prognosis Clinical Presentation Common symptoms of cervical cancer are presented in Table 22.4. Table 22.4 Commonly observed signs and symptoms in cervical cancer Symptoms
Description
General
Abnormal vaginal bleeding (>80%) Vaginal discharge Symptoms of pelvic organ compression or extension/ invasion
Early-disease symptoms
Abnormal vaginal bleeding Dyspareunia, pelvic pain
Late-disease symptoms
Triad: Sciatic pain (from lumbosacral plexus involvement/ compression by tumor) Lower extremity edema (from extensive pelvic lymph node involvement/lymphatic obstruction) Hydronephrosis (from ureteral obstruction) Pelvic pain, urinary, rectal symptoms (e.g., bowel and/or urinary obstruction, vesicovaginal/rectovaginal fistula)
Chapter 22 Cervical Cancer
667
Diagnosis and Pretherapy Evaluation Figure 22.3 presents a proposed algorithm for diagnosis and staging of cervical cancer. The diagnostic procedures and techniques used for cervical cancer are listed in Table 22.5.
Cervical Cancer Suspected
Complete History and Physical Examination
Physical Exam Focus: Pelvic and rectovaginal examination: - Cervical portio, os - Tumor extension to vagina, parametria - Abdominal exam - Palpation of supra - Clavicular lymph nodes
Procedures: - Colposcopy (15 x magnification) - Pap smear if no bleeding - 4 quadrant punch biopsies - Cold-knife conization if no gross lesion visible, and/or microinvasive carcinoma suspected
Radical hysterectomy vs. definite radiation/ chemotherapy
FIGO staging
Lab: - CBC/differentiel - Blood chemistries - Urinalysis
Radiology: - Chest x-ray - CT or MRI of abdomen and pelvis - and/or PET, PET/CT
Exam under anesthesia Cystoscopy, proctoscopy, ureteral stent placement as indicated
Multidisciplinary Treatment Figure 22.3 Proposed diagnosis and staging of cancer of uterine cervix
668
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.5 Diagnostic procedures in cervical cancer Studier
Description
Tissue diagnosis
Diagnosis is made by Pap smear and/or biopsy Normal Pap smear in the presence of visible abnormality does not exclude tumor Biopsy, endocervical curettage, and if negative, cold-knife conization must be performed
Lab work-up
CBC to assess hemoglobin levels in view of the commonly present significant vaginal bleeding and need for intervention CBC and differential count for screening blood counts in anticipation of chemotherapy Serum chemistries to assess renal function in view of ureteral obstruction and chemotherapy
Imaging studies
FIGO staging only admits information from physical exam, procedures, and plain radiographs for staging Chest X-ray or thoracic CT is recommended for assessment for pulmonary metastasis Cross-sectional imaging generally improves delineation of disease extent Abdominopelvic CT and MRI are equally efficacious in assessment of lymph node involvement, liver, lung, and bone metastasis MRI is better than CT is in delineation of the tumor extent within the uterus and pelvic tumor extension (parametrial, uterosacral), bladder and rectal invasion PET or PET/CT has shown higher sensitivity in staging for lymphatic or distant metastasis
CBC: complete blood count
International Federation of Gynecology and Obstetrics, and Tumor, Node, and Metastasis Staging Diagnosis and staging are based on history and physical examination, and radiologic and laboratory workup. The most commonly used International Federation of Gynecology and Obstetrics (FIGO) staging is largely based on clinical examination (tumor palpation) findings and investigative procedures, including colposcopy, examination under anesthesia, cystoscopy, and proctoscopy. FIGO staging permits only minimal radiologic information from plain radiographs, and does not incorporate information on LN involvement, which is
Chapter 22 Cervical Cancer
669
an important prognostic factor. Despite not altering stage categories, cross-sectional imaging, including computed tomography (CT) and magnetic resonance imaging (MRI) and recently positron-emission tomography (PET) or PET/CT, and invasive surgical staging provide important additional information on the extent of the locoregional nodal involvement and distant-disease status. FIGO remains the gold standard for cervical cancer staging. However, radiographic and surgical staging add prognostic information in approximately one fourth of clinical FIGO stage IB, half of IIA-IIB, two thirds of IIIA, and over 90% of IIIB patients. Upstaging to more extensive disease status or higher stage occurs in 26% of stage IB, 40% of IIA, 50% of IIB, 66% of IIIA, and 75% of IIIB tumors (Sources: Averette HE, Ford JHJ, Dudan RC et al (1994) Staging of cervical cancer. Clin Obstet Gynecol 18:215–232; Eifel PJ (1994) Problems with the clinical staging of carcinoma of the cervix. Sem in Radiat Oncol 4:1–8). FIGO staging and the corresponding TNM stages are presented in Table 22.6. Table 22.6 FIGO and TNM staging of cervical cancer FIGO
TNM
Description
–
TX
Primary tumor cannot be assessed
T0
No evidence of primary tumor
–
Tis
Carcinoma in situ (pre-invasive carcinoma)
I
T1
Cervical carcinoma confined to uterus (extension to corpus should be disregarded)a
IA
T1a
Invasive carcinoma diagnosed only by microscopy (all macroscopically visible lesions are stage IB/T1b tumors). Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of 7.0 mm or less. Vascular space involvement, venous or lymphatic, does not affect classification
IA1
T1a1
Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or less in horizontal spread
IA2
T1a2
Measured stromal invasion more than 3.0 mm and not more than 5.0 mm, with a horizontal spread 7.0 mm or less
IB
T1b
Clinically visible lesion confined to the cervix or microscopic lesion greater than IA1/IA2
IB1
T1b1
Clinically visible lesion 4.0 cm or less in greatest dimension
IB2
T1b2
Clinically visible lesion more than 4.0 cm in greatest dimension
II
T2
Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina ▶
– a
670
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.6 (continued)
a
FIGO
TNM
Description
IIA
T2a
Tumor without parametrial invasion
IIA1
T2a1
Lesion 4.0 cm or less in greatest dimension
IIA2
T2a2
Lesion more than 4.0 cm in greatest dimension
IIB
T2b
Tumor with parametrial invasion
III
T3
Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney
IIIA
T3a
Tumor involves lower third of vagina, no extension to pelvic wall
IIIB
T3b
Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney
IV
T4
Bladder and/or rectal invasion or distant spread
IVA
T4a
Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as IVA)
IVB
T4b
Distant metastasis (including peritoneal spread, involvement of supraclavicular or mediastinal lymph nodes, lung, liver, or bone)
¾
Nx
Regional lymph nodes cannot be assessed regional lymph node metastasis
¾
N0
No regional lymph node metastasis
¾
N1
Regional lymph node metastasis
¾
M0
No distant metastasis (no pathologic M0; use clinical M to complete stage group)
¾
M1
Distant metastasis (including peritoneal spread, involvement of supraclavicular or mediastinal lymph nodes, lung, liver, or bone)
FIGO staging no longer includes stage 0 (Tis) Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
Chapter 22 Cervical Cancer
671
Prognosis Cervical cancer is curable when diagnosed early, accounting for improved outcome and lesser prevalence of invasive and high-stage disease in countries with ample access to health care and cytologic screening. In more advanced disease, tumor recurs in approximately one third of patients. Outcome has significantly improved with the introduction of concurrent chemotherapy in stage IB2–IVA disease (Tables 22.10 and 22.11). Neuroendocrine carcinoma of the cervix has high propensity for distant metastasis, poor prognosis, and a spread pattern similar to that of small cell lung cancer.
Table 22.7 Prognostic factors for cervical cancer based on treatment modality Treatment type
Description
Resected tumors
Intact tumor treated with RT
Clinical stage and tumor size (diameter), LVSI Pelvic and PA lymph node involvement Hemoglobin before and during RT
Histological tumor size, depth of stromal invasion, LVSI Pelvic and PA lymph node involvement Parametrial involvement Status of surgical margins
LVSI: lymph–vascular space invasion
672
Nina Mayr, William Small Jr. and David K. Gaffney
Low hemoglobin levels – a possible surrogate of tumor oxygenation – have been associated with decreased local control and survival rates, particularly when persisting during radiation therapy (RT). Imaging and molecular markers of hypoxia have also been associated with poor outcome, suggesting that hypoxia-imparted radioresistance plays a role in cervical cancer. Tumor control and disease-free survival (DFS) by FIGO stage from representative series are presented in Table 22.8.
Table 22.8 Local tumor control and survival by stage in cervical cancer
Local Control (%)
Disease-free Survival (%)
Treatment
IA - IB1
93-95% 98%
92% 96-100%
Surgery Radiation therapy
IB2
all: 94% 4-5 cm: 90% >5 cm: 82%
all: 81–85% 4–5 cm: 86% >5 cm: 67%
Radiation therapy
IIA
94-96%
70-85%
Radiation therapy
IB2-II
87%
74%
Radiation/chemotherapy
III-IV
71%
40–50%
Radiation/chemotherapy
IVB
–
0%
Palliative therapy (chemotherapy with/without radiation)
Stage
Sources: Based on the findings of randomized clinical trials detailed in Tables 22-10 and 22-11, as well as the following reports: Gadducci A, Sartori E, Maggino T et al. The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study. Eur J Gynaecol Oncol. 2003;24:513516. Eifel PJ, Morris M, Wharton JT, et al. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994;29:9-16. Lowrey GC, Mendenhall MW, RR M. Stage IB or IIA-B carcinoma of the intact uterine cervix treated with irradiation: a multivariate analysis. Int J Radiat Oncol Biol Phys 1992;24:205-210. Perez CA, Grigsby P, Nene S, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. Cancer 1992;69:2796-2806. Komaki R, Brickner T, Hanlon A, et al. Long-term results of treatment of cervical carcinoma in the United States in 1973, 1978, and 1983: patterns of care study (PCS). Int J Radiation Oncology Biol Phys 1995;31:978-982. Barillot I HJ, Pigneux J, et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostic factors. Int J Radiation Oncology Biol Phys 1997;38:969-978.
Chapter 22 Cervical Cancer
673
Treatment Principles and Practice Primary surgical management with hysterectomy is indicated in stage IA, non-bulky IB, and early-stage IIA tumors. Primary RT results in similar outcome in these stages. For more advanced disease, RT alone (for stage IB1 tumors) and with concurrent cisplatin-based chemotherapy (for disease stages ≥ IB2) is the treatment of choice. Radical hysterectomy that has been performed in stage IIB tumors results in a greater incidence of urinary complications than does primary RT, and commonly in a need to add radiation with or without chemotherapy postoperatively because of adverse histologic findings (Tables 22.7 and 22.8). An overview of treatment modalities is given in Table 22.9. Figure 22.4 presents an overview of general treatment approach for all stages. Table 22.9 Overview of treatment modalities, techniques, and indications Modality
Description
Modified radical hysterectomy (type II)a Indication Technique
Facts
Stage IA2 without LVSI Resection of uterus, cardinal ligament at the level of the ureter, partial resection of uterosacral ligaments, 1–2 cm of vaginal cuff Pelvic LN dissection; PA LN sampling can be considered Risk of nodal involvement is 5% for stage IA2 disease Survival >95% after surgical therapy Has the advantage of preserving ovarian function in selected younger patients (with low risk of ovarian metastasis) Avoidance of rare late radiation therapy morbidities
Radical hysterectomy (Meigs III)a Indications
Technique
Facts
Stage IA2 with LVSI, IB1 Non-bulky IB2-IIA Resection of uterus, cardinal ligaments at the pelvic wall, uterosacral ligaments at the posterior pelvic insertion, upper third to upper half of vagina Pelvic LN dissection and PA LN sampling Survival 80–90% after radical hysterectomy 54% of patients with stage IB1 and 84% of stage IB2 disease require post-hysterectomy RT ▶
674
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.9 (continued) Modality Radiation therapy
Indications
RT technique
Description a
Definitive treatment for stage I-IIA (resectable) disease with same efficacy as surgery Definitive treatment (with concurrent chemotherapy) for stage IIB–IVA Recommended with concurrent chemotherapy in bulky >5 cm- to 6-cm stage IB2-IIA, because of common need of post-hysterectomy RT and increased complication risk with combined surgery/RT Postoperative pelvic radiation is well-established for involved LN, involved parametria or involved surgical margins EBRT to pelvis ± PA LN irradiation Integrated with brachytherapy (BT) Radiation therapy should be completed within 7 weeks
Chemotherapyb
Chemotherapy
Chemotherapy drugs
a
As part of definitive treatment (concurrent with external beam RT [EBRT]) for locally advanced cervical cancer Stage IB1: concurrent chemotherapy not validated Adjuvant chemotherapy (following concurrent radiation/ chemotherapy) may reduce the overall recurrence rate and is currently under investigation Commonly used for palliation for local, regional or systemic disease Weekly cisplatin at 40 mg/m2 during 5 weeks of pelvic EBRT with or without chemotherapy during BT is the current standard of care 3-weekly cisplatin/5-FU is also validated by level I evidence (Tables 22.10 and 22.11) Meta-analysis results indicate no particular benefit to cisplatin as compared with other types of chemotherapy 5-FU alone is not recommended as a concurrent regimen with radiation
Source: Landoni F, Maneo A, Colombo A et al (1997) Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. Lancet 350:535–540 b Sources: Dueñas-González A, Zarba J, Alcedo J et al (2009) A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 27:18; Gaffney DK, Du Bois A, Narayan K et al (2007) Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 68:485–490; Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and metaanalysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–5812; Lanciano R, Calkins A, Bundy BN et al (2005) Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 23:8289–8295
Chapter 22 Cervical Cancer
675
Diagnosis of Cervical Cancer
Clinical/Radiological Staging of Cervical Cancer
Stage IA-B1
Stage IB2-IIA
LN + (by imaging)
RH pelv LN dissection ± PA LN samplinga)
or
ERBT + BT
Stage IIB-IVA
consider: Retroperitoneal LN dissection/debulking
RH pelv LN dissection ± PA LN sampling*
ERBT + BT concurrent chemotherapy
or ERBT + BT concurrent chemothrapy
High-risk features LVSI, depth, invasion, size b)
High-risk features Margins, LN, parametria c)
Post-op RT
Post-op RT concurrent CT
Active Follow-Up Figure 22.4 A proposed algorithm for the treatment of cervical cancer (all stages) RH: radical hysterectomy: a) see Table 22.9; b) see. 22.5; c) see. 22.6
Treatment of Stage I–IIA (Resectable) Cervical Cancer Radical hysterectomy and primary RT result in equivalent tumor control and survival in stage IA–IIA disease. One trial randomizing stage IB patients to radical hysterectomy versus RT yielded no difference in disease-free (74%), overall-survival (83%), and local-recurrence (26 versus 25%) rates, but demonstrated a higher toxicity rate with surgery (28 versus 12%, p = 0.0004) (Table 22.9).
676
Nina Mayr, William Small Jr. and David K. Gaffney
Adjuvant Therapy Two randomized trials have defined the utility of adjuvant radiation, and adjuvant radiation with concurrent chemotherapy after hysterectomy. Figures 22.5 and 22.6 summarize level I evidence and rationale for postoperative RT and postoperative combined RT/chemotherapy, based on highrisk histologic features. Eligibility criteria LVSI Positive Positive Positive Negative
Stromal Invasion Deep 1⁄3 Middle 1⁄3 Superficial 1⁄3 Deep or Middle 1⁄3
Tumor Size Any ≥ 2 cm ≥ 5 cm ≥ 4 cm
RANDOMIZATION
ARM 1
ARM 2
Pelvic RT 46 Gy 23 Fractions 50.4 Gy 28 Fractions
Observation n=140
n=137 RESULTS 1. 46% reduction in risk of recurrence favoring RT arm: hazard ratio (HR) was 0.54 (90% confidence interval [CI] was 0.35–0.81, p = 0.007) 2. Difference in overall survival was not significant (p = 0.074) 3. RT particularly beneficial in adenosquamous or adenocarcinoma: 9% recurrence with RT versus 44% recurrence without RT
Figure 22.5 Schema of GOG protocol 92: Clinical stage IB patients with lymphovascular space involvement (LVSI), large clinical tumor diameter, and more than a third of stromal invasion were randomized to post-hysterectomy pelvic RT versus no further treatment. Recurrence rate was improved, but overall survival was not significantly different. Sources: Sedlis A, Bundy BN, Rotman MZ et al (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73:177–183; Rotman M, Sedlis A, Piedmonte MR et al (2006) A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys 65:169–176
Chapter 22 Cervical Cancer
677
Postoperative pelvic radiation has been well established for involved LNs, parametria, or positive margins. The intergroup Gynecologic Oncology Group (GOG) Trial 109 evaluated whether the addition of concurrent chemotherapy is of benefit (Figure 22.6). Stage IA2, IB, or IIA patients treated with a radical hysterectomy and pelvic RT, were randomized to 4 cycles of cisplatin/5-FU versus RT without chemotherapy. Overall survival was significantly improved. Post hoc analysis showed particular benefit for larger tumor sizes and/or multiple involved LNs (Source: Peters WA III, Liu PY, Barrett RJ II et al (2000) Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18:1606–1613). Clinical Stage IA2, IB, IIA with any of the following: 1. postive lymphnodes 2. positive parametria 3. positive margins
RANDOMIZATION
ARM 1 Pelvic RT 49.3 Gy 29 Fractions n=116
ARM 2 Same RT Cisplatin/5 FU 96 hr infusion every 3 weeks x 4 n=127
RESULTS 1. HR for overall survival was 1.96 (p = 0.007), favoring RT/concurrent chemotherapy 2. Overall survival at 4 years was 71% with RT and 81% with RT and chemotherapy. Only 60% of patients received all 4 chemotherapy cycles
Figure 22.6 Schema of GOG protocol 109
678
Nina Mayr, William Small Jr. and David K. Gaffney
The decision pathway for adjuvant therapy after hysterectomy for cancer of the cervix is shown in Figure 22.7.
Diagnosis of Cervical Cancer
GOG 92 Eligibility requirements: 2 of 3: - LVSI - Tumor > 4 cm - >1/3 stromal invasion
Clinical Stage IA2-IIA
Radical Hysterectomy
Meets GOG 92 eligibility
No
Positive margins?
Yes
Pelvic RT 45-50.4 Gy
Yes
Chemo RT (cisplatin based, 45-50.4 Gy ± 2 cycles out back chemo) plus vaginal apex brachytherapy
Positive LNs or parametria?
Yes
Chemo RT (cisplatin based, 45-50.4 Gy ± 2 cycles out back chemo)
Active Follow-Up
Figure 22.7 Decision pathway for adjuvant therapy after hysterectomy for cancer of the cervix
Treatment of Stage IIB–IVA Cervical Cancer Radiation therapy with concurrent chemotherapy is the standard of care for stage IB2–IVA cervical cancer. Table 22.10 summarizes the level I evidence for the benefit from 5 randomized trials evaluating radiation with concurrent
Chapter 22 Cervical Cancer
679
cisplatin-based chemotherapy versus radiation alone. The trial of the National Cancer Institute of Canada (NCIC) was the only negative study (Tables 22.10 and 22.11).
Table 22.10 Level I evidence for radiation and concurrent chemotherapy in advanced cervical cancer Trial
GOG 85
FIGO stage
IIB–IVA
Number Comparison Followof up patients
368
HR
Increase in survival (%) 10%
PF versus HU
8.7 years
0.7
RTOG 9001
IB 388 (>5 cm)–IVA
PF versus none
43 months
0.59 15%
GOG 120
IIB–IVA IIB–IVA
526 526
P versus HU PFHU versus HU
35 months 35 months
0.61 18% 0.58 18%
GOG 123
IB2 (>4 cm)
369
P versus none
36 months
0.54
9%
NCI/Canada
IB 253 (>5 cm)–IVA
P versus none
64 months
0.91
3%
Meta-analysis
IB–IVA
Chemotherapy versus none
62 months
0.78 ¾%
3,452
HR: hazard ratio, P: cisplatin, F: 5-fluorouracil, HU: hydroxyurea Source: Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26:5802–5812
Table 22.11 details the radiation techniques, the dose, type, and schedule of chemotherapy, and the outcome data in the 5 randomized trials. After the publication of the NCI clinical alert, radiation therapy with concurrent chemotherapy promptly became the standard of care for stage IIB– IVA cervical cancer.
680
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.11 Radiation and concurrent chemotherapy: details of treatment regimens and results of five randomized trials Trial
Description Randomized PF versus HU (1986–1990) Eligibility: IIB–IVA, negative LN based on surgical staging
GOG 85, SWOG 8695a
RT: stage IIB: 40.8/1.7 Gy/day EBRT; stage II–IVA: 51 Gy/1.7 Gy/ day. 40 Gy (Point A) LDR BT, total Point A: 80–81 Gy; parametrial boost to 55–60 Gy CT: HU 80 mg/kg 2 x per week versus P 50 mg/m2, days 1 , 21; F 100 mg/m2/day × 4 days Outcome: significant changes in 5-year PSF 57% with PF versus 47%; OS 62% with PF versus 50%; less hematologic toxicity with PF no change in 3-year late complication rate Conclusion: P-based regimen superior to HU Randomized PF/pelvic RT versus pelvic plus PA RT (1990–1997) Eligibility: IB–IIA (>5 cm), IIB–IVA, negative LN by surgical staging or lymphangiogram RT: 45 Gy/1.8 Gy/day, ≥40 Gy LDR BT, total Point A: ≥85 Gy; parametrial boost to 55–60 Gy
RTOG 9001b
CT: P 75 mg/m2, 5FU 1,000 mg/m2 × 4 days × 3 cycles (#3 during BT) every 3 weeks Outcome: significant change in 8-year DFS, 61% with PF versus 46%; OS 67 versus 41%; reduction of locoregional failure 85 versus 35%; distant failure, 20 versus 35%; no change in PA failure without PA RT; no change in complication rates Conclusion: concurrent chemotherapy superior to pelvic/PA RT Randomized weekly P versus P F HU versus HU (1992–1997) Eligibility: IIB–IVA, negative LN by surgical staging RT: stage IIB: 40.8/1.7 Gy/day EBRT; stage II–IVA: 51 Gy/1.7 Gy/ day. 40 Gy (Point A) LDR BT, total Point A: 80–81 Gy; parametrial boost to 55–60 Gy
GOG 120c
CT: weekly P 40 mg/m2 versus P 50 mg/m2, F 1,000 mg/m2 × 4 days × 2 cycles during EBRT, HU 2 mg/kg 2 × per week versus HU 3 g 2 × per week Outcome: significant change in 3-year OS, 65% in P-based arms versus 47%; significant change in pelvic recurrence (20 versus 30%); less acute toxicity for weekly P Conclusion: P-based arms superior to HU, weekly P less toxic
Chapter 22 Cervical Cancer
681
Table 22.11 (continued) Trial
Description Randomized concurrent weekly P versus RT alone followed by extrafascial hysterectomy (1992–1997) Eligibility: IB2 (>4 cm), negative LN by CT, lymphangiogram, or surgical staging RT: EBRT: 45 Gy/1.8 Gy/day; LDR BT, total Point A: 75 Gy
GOG 123d
CT: weekly P 40 mg/m2 × up to 6 cycles during EBRT or last dose during BT Outcome: significant change in 3-year PFS, 79% with P versus 67%; OS 83 versus 74%; pelvic control 91 versus 79%, complete pathologic response 52 versus 41% Conclusion: weekly P superior to RT alone in bulky stage IB2 Randomized (1991–1996) Eligibility: IB,IIA (>5 cm or histologically + LN), IIB–IVA
NCI/Canadae
RT: EBRT: 45 Gy/1.8 Gy/day, BT (LDR or HDR) equivalent Point A dose of 35 Gy(LDR), total Point A: 80 Gy; RT to be completed within 7 weeks CT: weekly P 50 mg/m2 × 5 cycles during EBRT Outcome: no change in 5-year PSF and OS, 62 versus 58% Conclusion: no benefit of concurrent weekly P. Possible reasons: shorter treatment duration, only imaging-based staging, more anemia in the chemotherapy arm, smaller sample size
P: cisplatin, F: 5-fluorouracil, HU: hydroxyurea, PFS: progression-free survival, DFS: disease-free survival, OS: overall survival a Source: Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB– IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–1348 b Sources: Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143; Eifel PJ, Winter K, Morris M et al (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J Clint Once 22:972–880 c Source: Rose PG, Ali S, Watkins E et al (2007) Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:2804–2810 d Source: Keys HM, Bundy BN, Stehman FB et al (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161 e Source: Pearcey R, Brundage M, Drouin P et al (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972
682
Nina Mayr, William Small Jr. and David K. Gaffney
The management of patients with cancer of the cervix treated definitely with radiation and chemotherapy is shown in Figure 22.8.
Diagnosis of cervical cancer
Figure 22.8 Treatment for stage IIB–IVA cervical cancer
Clinical staging and imaging
Consider retroperitoneal LN dissection or surgical staging
45 Gy with cisplatin-based chemo LDR or HDR BT Point A/ tumor should receive 80-85 Gy LDR equivalent
Active Follow-Up PET/CT preferred at 3 months then clinical follow-up
Para-aortic Radiation Prophylactic radiation of the para-aortic nodes remains controversial. It decreases para-aortic recurrences, without proven survival benefit. Para-aortic radiation can be considered in patients with a risk of subclinical para-aortic node involvement. This may include patients with common iliac and/or extensive pelvic-node metastases in the absence of surgical para-aortic LN staging.
Treatment of Recurrent or Metastatic Cervical Cancer Locoregional Recurrence Post-hysterectomy recurrence is treated with individualized EBRT and brachytherapy with largely interstitial and concurrent cisplatin-based chemotherapy should be considered. In favorable patients with central small recurrences, survival rates of more than 60% are achievable with salvage radiation therapy. For patients with recurrent cancer after radiation therapy, repeat radiation has been employed in rare instances. However, pelvic exenteration is the
Chapter 22 Cervical Cancer
683
mainstay of salvage therapy in selected patients with central failures. Favorable prognostic factors for survival after salvage RT include no previous chemotherapy or radiation therapy; a long, disease-free interval; and no preceding use of cisplatin-based therapy. Improvements in surgical technique used in pelvic exenteration have reduced the morbidity and mortality. Patients with central recurrence alone have the most favorable survival rates; those with pelvic sidewall disease experience poor outcomes. Metastatic Disease Survival of patients with metastatic disease remains poor, with a median of 3–9 months. Poor prognostic factors for response of metastatic cervical cancer are black race (odds ratio [OR] = 0.49), poor performance status (OR = 0.60), pelvic site of recurrence (OR = 0.58), previous radiosensitizer use (OR = 0.52), and first recurrence within 1 year (OR = 0.61). Cisplatin has an overall response rate of 38%: 50% for untreated and 17% for previously treated patients. A combination of cisplatin and topotecan improved response rate, and improved median overall survival to 9.4 months from 6.5 months with cisplatin alone, but did not improve overall survival rate. Combination of cisplatin and bevacizumab resulted in progression-free intervals of 6 months or longer in 25% of patients with metastatic cervical cancer.
RT Techniques Definitive RT Definitive RT for cervical cancer requires the integration of two elements, EBRT (with pelvic and parametrial and nodal boosts if appropriate) and BT. Treatment must be individualized, based on the patient’s initial tumor extent, normal tissue anatomy, and tumor-response characteristics during therapy. EBRT EBRT fields encompass the primary tumor in the cervix/uterus, local tumor extension (parametria/uterosacral ligaments, vagina), draining regional lymphatics, and known areas of LN involvement. Simulation, Target Volume Delineation and Field Arrangement Three-dimensional image-guided planning is highly recommended to improve the delineation of target structures and exclusion of normal tissues, including
684
Nina Mayr, William Small Jr. and David K. Gaffney
bowel, bladder, and bone marrow. Intravenous contrast for CT can be helpful in the differentiation of regional LNs from vessels, and delineation of the bladder. Oral contrast given 1–1.5 h before simulation improves differentiation of bowel from LNs, vascular structures, and tumor. CT allows delineation of the uterus, but it does not differentiate tumor from normal uterus. With MRI, the gross tumor extent within the uterus, parametria, and the parametrial tumor extent can be delineated. MRI is otherwise equivalent to CT in the delineation of LNs and normal structures. Placement of a gold seed marker into the cervix or into the most distal visible or palpable vaginal tumor extent is recommended. Rigid vaginal markers, rectal markers, or rectally administered bowel contrast are not recommended, and may cause upward displacement of the cervix, or rectal distension and cervical displacement. If such displaced anatomy is used for target delineation, geographical miss of tumor can occur during actual treatment. Guidelines for target delineation, clinical target volume (CTV), and planning target volume (PTV) design currently used in Radiation Therapy Oncology Group (RTOG) and GOG protocols are summarized in Table 22.12. The sum of the primary tumor PTV and nodal PTV results in a confluent final PTV (Figure 22.9). Because of viabilities in the aortic bifurcation, 40% Table 22.12 Target volume for definitive radiation therapy using CT-based planning Target
Primary cervical tumor
Description GTV: entire uterus and tumor extensions to parametria, uterosacral ligaments and vagina based on imaging and implanted markers (from palpation/inspection) CTV: additional 0.7-cm- to 1-cm margin. 3-cm margin distal to the cervix or lowest vaginal tumor extent PTV: + 0.5-cm to 1-cm margin (to account for setup variability) GTV: grossly involved LN
Regional lymphatics
CTV: grossly involved LN plus 1-cm margin. Normal-appearing obturator, external, and common iliac LNs; in stage IIIA and distal-half vaginal extension, also inguinal LN; postsurgical clips and postoperative seromas. Add 0.7-cm margin, 1–2 cm anterior to S1–S3 PTV: + 0.5-cm to 1-cm margin (to account for setup variability)
Sources: Small W Jr, Mundt AJ. RTOG Gynecologic Pelvic Atlas (http://www.rtog.org/ atlases/contour.html); Small W Jr, Mell LK, Anderson P et al (2008) Consensus guidelines for the delineation of the clinical target volume for intensity modulated pelvic radiotherapy in the postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 71:428–434; Lim K, Small W, Portelance L et al (2010) Consensus guidelines for delineating of clinical target volume for intensity-modulated pelvic radiotherapy for definitive treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2010 May 14 [Epub ahead of print]
Chapter 22 Cervical Cancer
685
of common iliac LNs are reported to be located above the L4–L5 interspace. Therefore, the upper border of the EBRT field should be individualized. If higher-level common iliac LNs are involved, an increase of the upper margin for one to three vertebral bodies should be considered to include lowerlevel para-aortic LNs.
Figure 22.9 a–c MRI-based target delineation of tumor (outlined in red), uterus (outlined in dark blue), parametria (outlined in green and orange), bladder, and rectum according to consensus guidelines of the Gyn IMRT Consortium. a Axial view. b sagittal view; the dotted line indicates the plane of the axial image. c CT-based delineation of external and common iliac vessels and LN CTV. Figure 22.9a and 22.9b reprinted with permission from Lim K, Small W, Portelance L et al Consensus guidelines for delineating of clinical target volume for intensity-modulated pelvic radiotherapy for definitive treatment of cervical cancer Int J Radiat Oncol Biol Phys 2010 May 14 [Epub ahead of print]
To design parametrial boost fields, the isodose distribution from the BT (Figure 22.10) must be taken into account to prevent overlap of dose from the BT and external-beam contributions. Such overlap, caused by a standard, 4-cm midline block, has been shown to result in higher risk of late ureteral complications.
Figure 22.10 a, b CT-fusion for parametrial boost planning. a Coronal: Projection of BT ring applicator (green) and contours of uterus (blue), (bladder (yellow), involved pelvic lymph node GTV (solid red) and PTV (red line). b AP DRR: Projection of the BT prescription dose distribution is used to design right parametrial boost PTV
686
Nina Mayr, William Small Jr. and David K. Gaffney
Contouring of normal structures includes the rectum (up to the rectosigmoid junction), bowel (including large bowel above the rectum) and intraperitoneal contents (small bowel and mesentery) within 5 cm above the upper border of the target volume, the bladder, and femoral heads. If three-dimensional (3D) imaging is not available, field design should be guided by bony landmarks only (Table 22.13). Table 22.13 Fluoroscopy-based fields for radiation therapy in EBRT of cervical cancer Field
Borders
AP/PA
Superior: L4/L5 interspace Inferior: 3 cm below the lowest tumor extent (determined by gold seed or contrast tampon) or bottom of obturator foramen Lateral: 2 cm lateral to the pelvic brim and including any surgical clips with 1- to 1.5-cm margin
Lateral
Superior: same as in AP/PA Inferior: same as in AP/PA Anterior: 1 cm anterior to the pubic symphysis Posterior: at least anterior half of the sacrum
Dose and Treatment Delivery EBRT prescription dose to the PTV ranges from 45 to 50.4 Gy in 1.8-Gy factions. After BT, parametrial boosts are delivered, ranging from 5.4 to 14.4 Gy, to result in a total parametrial dose (including initial pelvic fields and parametrial fields) of 50 Gy for small stage IB tumors, 55 Gy for tumors with moderate parametrial involvement, and 60 Gy for bulky parametrial involvement. For grossly involved pelvic or para-aortic LNs, doses up to 60 Gy (including whole-pelvic EBRT) should be delivered via 3D conformal or intensity-modulated RT (IMRT) techniques (Figure 22.11). The inclusion of BT dose contributions into the parametrial boost dose prescription has been variable, and has ranged from total parametrial doses of 50.4–54 Gy (not including BT contribution to Point B) to 55–60 Gy (including the BT contribution).
Chapter 22 Cervical Cancer
687
Figure 22.11 Comparison between four-field 3D conformal RT and seven-field IMRT, showing dose reduction in region of small bowel (arrows)
IMRT IMRT (Figure 22.11) is being studied in the treatment of cervical cancer and has been shown to decrease bowel and bladder doses in pelvic RT, to reduce acute grade 3 or higher gastrointestinal toxicity, bone marrow dose, and hematologic toxicity. However, IMRT is more vulnerable to inter- and intrafractional organ motion, and meticulous attention has to be paid to allow sufficient PTV margins and/or to control organ motion to prevent geographic tumor miss. The RTOG has studied IMRT in postoperative pelvic radiation and demonstrated successful inter-institutional implementation. Standardization of target volume definitions for IMRT in intact cervical cancer are in development. (Source: Lim K, Small W, Portelance L et al (2010) Consensus guidelines for delineating of clinical target volume for intensity-modulated pelvic radiotherapy for definitive treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2010 May 14 [Epub ahead of print]
688
Nina Mayr, William Small Jr. and David K. Gaffney
BT BT is a critical component of definitive RT for cervical cancer, and its use is critical to achieve tumor control and improve survival. BT provides the ultimate conformal therapy for cervical cancer, and it enables the delivery of high doses of 85 Gy or more to the paracervical regions, which are needed for tumor control and cannot be delivered with EBRT alone. BT can be delivered in an intracavitary or interstitial fashion. The two main forms of BT are a high-dose rate (HDR) and a low-dose rate (LDR) BT (Table 22.14; Figure 22.12). Intracavitary BT generally utilizes an intra-uterTable 22.14 Patterns of care in BT for cervical cancer Evaluation
Type of BT HDR
Advantage
Outpatient delivery No need for bed Radiobiologic rest advantages of Less radiation low dose rate: personnel exposublethal damsure age repair Better individual- Longer track reization of source cord position and do Only 1–2 procesimetry dures needed Improved displacement of normal tissues
Disadvantage
Large dose fractions, narrower therapeutic ratio (- sublethal damage repair) Labor intensive dosimetry planning process High impact of errors
Practice pattern 14 in USA (%)a a
LDR
Interstitial
Advantage in tumors that cannot be encompassed in intracavitary dose distribution
Need for inpatient facility Prolonged best May result in rest, risk for vehigher complicanous thrombosis tion rates Regulatory issues, Highly operator maintenance of dependent sealed sources Personnel exposure 78
8
Source: Erickson B, Eifel P, Moughan J et al (2005) Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996–1999): a patterns of care study. Int J Radiat Oncol Biol Phys 63:1083–1092
Chapter 22 Cervical Cancer
689
ine tandem and ovoid applicators in LDR, and tandem and ovoid or ring applicators in HDR. HDR BT utilizes a source that delivers a dose rate of >12 Gy/h and generally is performed on an outpatient basis over several treatment fractions. LDR delivers <2 Gy/h and is delivered on an inpatient basis. Pulsed-dose rate (PDR) generates pulses of radiation therapy, with the aim to mimic the radiobiologic properties of LDR therapy and is generally performed on an inpatient basis (hourly). Interstitial BT uses interstitial needles inserted through the perineum into the tumor target tissue, frequently with the use of a perineal template. This can be combined with intracaviatry radiation. Interstitial BT should be utilized when intracavitary radiation therapy cannot deliver adequate doses to
Figure 22.12 a–e AP a and lateral b simulation films of LDR Fletcher-Delclos tandem and ovoid BT applicators and of HDR ring and tandem applicators (c and d, respectively). Imaging-compatible HDR ring and tandem applicators (e) allow CT–MRI fusion for more accurate delineation of the uterus and pelvic organs. The intra-uterine portion of the tandem shows dark signal on MRI, while the more distal portion of the and the rectal retractor are visible as bright contrast on the CT
690
Nina Mayr, William Small Jr. and David K. Gaffney
the target tissue; it provides a more favorable dose distribution regarding the relative dose to tumor and organs at risk. Typical indications for interstitial brachytherapy include obliteration of the cervical os, narrow fornices, tumor extension into the lower vagina, or lateral parametrial infiltrations. Local control rates of 100, >90, and 75% have been reported for stages I, II–III, and IV cervical cancer, respectively (Source: Demanes JD, Rodriguez RR, Bendre DD et al (1999) High dose rate transperineal interstitial brachytherapy for cervical cancer: high pelvic control and low complication rates. Int J Radiat Oncol Biol Phys 45:105–112). BT Dose Specification and Prescription Traditional cervical BT has been prescribed to Point A or equivalent paracervical points, with calculation of doses to Point B and organs at risk, including point doses representing bladder, rectum, and vaginal mucosa. For LDR BT, a Point A dose of 40 Gy in one or two BT applications, resulting in a total Point A dose of at least 85 Gy (from EBRT and BT contributions), has been well accepted as the minimum dose, resulting in improved tumor control. Close integration with the external-beam course is critical. For HDR BT, dose schedules are highly variable. When delivered in an HDR schedule, nominal doses result in significantly greater normal tissue effects. Dose schedules that are consistent with the biological effect of established LDR schedules are derived with the linear-quadratic (LQ) model defining the biologically effective dose (BED) as a function of the total dose (D) and dose per fraction (d) and ratio (/) according to: BED = D × [1+d/(/)], using an / ratio of 10 for the tumor BED (Gy10) and 3 for the normal tissue BED (Gy3). Prescription points and calculation points for target and normal tissue are listed in Table 22.15. The doses in Table 22.13 refer to the total of EBRT and BT doses converted to the low-dose rate equivalent dose for 2-Gy fractions. BT dose schedules are influenced by variabilities in fraction size, total doses, and external-beam dose. No one “correct” or “best” dose/fractionation schedule has been established. Most commonly used fractionation schedules and general guidelines are presented in Table 22.16.
Significance Paracervical point, where ureters cross uterine vessels Problems: Point A is applicator dependent and may not represent tumor involvement Similar to Point A, (commonly used instead of Point A in HDR)
Represents the location of the obturator LN (used by some for parametrial boost prescription)
Represents the location of the pelvic wall (not commonly used)
Description
AP film: 2 cm superior, 2 cm lateral to external cervical os or cervical end of the tandem (following the long axis long axis of the tandem) Lateral film: along tandem
AP film: 2 cm superior, 2 cm lateral to external cervical os Lateral film: 2 cm superior to ovoids on lateral film
AP film: 2 cm superior to the cervical os, 5 cm lateral of the long axis of the pelvis (independent from the direction of the endocervical canal) Lateral film: along tandem
AP film: 2 cm superior to the cervical os, 6 cm lateral of the long axis of the pelvis (independent from the direction of the endocervical canal) Lateral film: along tandem
AP film: at the mid-level of the ovoid sources or most distal tandem source; at center ICRU bladder point for organ at risk Lateral film: 0.5 cm posterior to the vaginal wall (packing or rectal retractor)
Dose point
A
M
B
C
Rectal
Table 22.15 Dose prescription points for BT in cervical cancer
<70 Gy
▼
Usually receives 15–20% of the Point A or M dose
Usually receives 15–20% of the Point A or M dose
85–90 Gy (early stage I: 80 Gy)
85–90 Gy (early stage I: 80 Gy)
Dose goal (EBRT plus BT)
Chapter 22 Cervical Cancer 691
Bladder
<75 Gy
Dose goal (EBRT plus BT)
ICRU: International Commission on Radiological Units and Measurements Sources: Petereit DG, Pearcey R (1999) Literature analysis of high-dose-rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 43:359–366; Mai J, Erickson B, Rownd J et al (2001) Comparison of four different dose specification methods for high-dose-rate intracavitary radiation for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 51:1131–1141
<100–120 Gy (LDR) Vaginal mucosal dose limiting point 140–160% of Point A dose (HDR)
ICRU rectal point for organ at risk
AP film: at center of the Foley balloon (filled with 7 ml contrast), level of the vaginal sources Lateral film: at posterior surface of balloon
AP film: at the lateral edge of the ovoids at the 9:00 o’clock position on the right Vaginal surface and 3:00 o’clock on the left on the AP Lateral film: center of ovoids
Significance
Description
Dose point
Table 22.15 (continued)
692 Nina Mayr, William Small Jr. and David K. Gaffney
Chapter 22 Cervical Cancer
693
Table 22.16 HDR BT dose recommendations Stage
Early
Advanced
External-beam dose (Gy)
HDR fractions (n)
HDR dose per fraction (Gy)
20
6
7.5
20
7
6.5
20
8
6
45
5
6
45
6
5.3–5.5
45
5
6.5
45
6
5.8
50.4
4
7
50.4
5
6
50.4
6
5.3
Adapted from: Petereit DG et al (1999) High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence – the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 45:1267–1274; Nag S, Chao C, Erickson BA et al (2002) The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52: 33–48
Normal Tissue Tolerance The addition of BT to EBRT for cervical cancer increases the risk of normal tissue toxicity. It is critical that the dose to organs at risk including rectum, bladder, and vagina are respected. It is recommended that normal tissue doses be calculated. Currently, the most widely accepted system includes the normal tissue dose points, based on International Commission on Radiation Units (ICRU) Report 38. Guidelines for normal tissue point dose limits are presented in Table 22.17. Doses include contributions from both EBRT and BT. Doses for HDR are presented in LDR equivalent doses (for 2-Gy fractions) and in BED. If the rectal dose exceeds 100 Gy3 and/or the bladder dose 120 Gy3, adjustments in applicator placement may have to be made and/or the dose/fractionation schedules adjusted to a higher number of fractions, with a lesser dose for each fraction to reduce normal tissue dose effects.
694
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.17 Recommendations for normal tissue dose limits Organ
BT LDR (Gy)
HDR LQED2 Gy (Gy)a
HDR BED (Gy3)
Rectum
<75
<75
<100
Bladder
<80
<80
<120
Vaginal mucosal surface
135
140–160% of Point A
<140
a
The nominal HDR dose has been converted to the low-dose rate equivalent dose at 2-Gy faction using the LQ formula). The BED is given as Gy3 in column “HDR BED” Sources: Petereit DG, Pearcey R (1999) Literature analysis of high-dose-rate brachytherapy fractionation schedules in the treatment of cervical cancer: is there an optimal fractionation schedule? Int J Radiat Oncol Biol Phys 43:359–366; Nag S, Chao C, Erickson BA et al (2002) The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52: 33–48; Mai J, Erickson B, Rownd J et al (2001) Comparison of four different dose specification methods for high-dose-rate intracavitary radiation for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 51:1131–1141
Timing of BT and Overall Treatment Time The overall treatment course should be completed within 8 weeks, because protraction of therapy decreases survival. A decrease in survival rate by 0.5– 1% for each additional day has been estimated. The timing of BT is critical. There is no rationale to wait 1–2 weeks after EBRT completion to begin BT. The timing of BT should be individualized, as illustrated in Figure 22.13. Optimal timing depends on regression speed of the tumor and the development of adverse anatomical normal tissue changes.
Tumor Volume (%) Degree of adverse anatomical change (%)
100
Optimal timing to begin brachytherapy
50
fast
slow inte rme diat e
0 EBRT Week # 1 2 3 4 5 Dose level (Gy) 9-10 18-20 27-30 36-40 45-50
6
7
External Beam Radiation Therapy Course
Volume Volume within BT dose larger than BT distribution dose distribution
Integration of EBRT and Brachytherapy
Figure 22.13 Optimized timing for BT. Balance between tumor regression (red curves) and onset of adverse anatomic tissue changes (black curves) influence BT start in fast (••••••), intermediately (), and slowly (- - -) regressing tumors
Chapter 22 Cervical Cancer
695
Tumor shrinkage during EBRT incrementally improves the geometry of the tumor for BT and allows the tumor to be encompassed by the BT isodose distribution (light-gray shaded area in Figure 22.13). Simultaneously, as the tumor volume gradually reduces, the normal cervical/vaginal anatomy also deteriorates from the development of fibrosis and stenosis of the vagina and cervix, which can impair optimal applicator placement and BT dose distribution. The point of optimal tumor shrinkage and least adverse anatomical change is the best time to begin BT. Timing and approach have to be in tailored to the dynamics of tumor response (fast, intermediate, and slow; Figure 22.13) and normal tissue characteristics of individual patients. Interval assessment of the tumor during RT by clinical examination and/or imaging is critical in making this determination. Once BT has started, all fractions should be completed within a 10- to 14day interval for LDR, or with once-weekly HDR fractions during pelvic EBRT, and twice weekly (>72 h apart) fractions once the pelvic EBRT has been completed. Parametrial boosts should start in the interval between BT procedures as soon as pelvic EBRT and the first BT procedure are completed. Image-Guided BT Image-guided BT may further improve precision and quality of treatment, as compared with conventional plain film based BT planning. Commonly used imaging techniques include ultrasound, CT, and MRI (Table 22.18). A recent American Brachytherapy Society (ABS) survey showed that ultrasound, CT, and MRI are used routinely for applicator placement in 56, 70, and 2% of cases, respectively, and that contouring of bladder and rectum is commonly performed (Source: Viswanathan AN, Erickson BA (2010) Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 76:104–109). Adjuvant (Postoperative) RT The same general principles as for definitive pelvic EBRT apply for postoperative pelvic-RT planning. Because of the removal of uterus and adnexae, more small bowel is excepted to be located within the pelvis. Prone positioning and the use of IMRT to more effectively exclude bowel from the treatment field should be considered. The LN target is identical to that of definitive EBRT. The postoperative CTV in the central pelvis includes the vaginal and paravaginal tissues, with the obturator muscle as the lateral margin, and at least 3 cm of vagina, as defined by the RTOG protocol 0418 and the RTOG Gynecologic Pelvic Atlas (http://www.rtog.org/atlases/contour.html).
696
Nina Mayr, William Small Jr. and David K. Gaffney
Table 22.18 Imaging techniques used in imaging-guided BT for cervical cancer Technique
Description
Ultrasounda
Interactive use of intraoperative ultrasound during the applicator placement allows real-time adjustment of the applicators Enables successful applicator placement in difficult cases, including retroverted uterus, cervical stenosis, or large uterine fibroids Reduces malplacements and uterine perforations to essentially none Likely reduces bowel and bladder complications
CT scana
CT after applicator placement detects essentially all uterine perforations, thus further improving the therapeutic ratio With traditional metallic (non-imaging compatible) applicators the tandem, ovoids, or ring, boundaries of the uterus, rectum, and bladder can usually be visualized
MRIb
MRI (using imaging-compatible BT applicators) allows significantly improved soft tissue delineation (Figure 22.13) MRI can delineate the actual tumor extent within the uterus and parametria and enables the transition from point dose prescription to image-guided, volume-based BT prescription Utilizing the GEC ESTRO guidelines for BT dose prescription based on GTV, high-risk-CTV and intermediate risk–CTV may improve tumor control and reduce complications
a
Source: Shin KH, Kim TH, Cho JK et al (2006) CT-guided intracavitary radiotherapy for cervical cancer: Comparison of conventional point A plan with clinical target volume-based three-dimensional plan using dose-volume parameters Int J Radiat Oncol Biol Phys 64:197–204 b Sources: Pötter R, Haie-Meder, Van Limbergen C et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78:67–77; Pötter R, Dimopoulos J, George P et al (2007) Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 83:148–155
Postoperative pelvic doses range from 45 to 50.4 Gy. Postoperative vaginal-cuff BT is controversial, but can be considered in patients with bulky central disease, or those with close or involved surgical margins.
Follow-Up Active follow-up after treatment of cervical cancer is recommended (Table 22.19). Most recurrences present within 2 years, and failures after 5 years are exceedingly uncommon.
Chapter 22 Cervical Cancer
697
Table 22.19 Follow-up schedule and examinations Schedule
Frequency
First follow-up after RT
4–6 weeks; if residual tumor, continue monthly monitoring
Years 0–2
Every 3 months
Years 3–5
Every 6 months
Years 5+
Annually
Examinations History and physical
Complete history and physical examination including pelvic examination Pap smear
Laboratory tests
If clinically indicated
Imaging
Chest X-ray yearly MRI at 1 month or PET/CT at 3 months after treatment may be predictive for outcome Other imaging studies based on clinical indication
Sources: Kidd EA Siegel BA, Dehdashti F et al (2007) The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110:1738–1744; Mayr NA, Wang JZ, Lo SS et al (2010) Translating response during therapy into ultimate treatment outcome: a personalized 4-dimensional MRI tumor volumetric regression approach in cervical cancer. Int J Radiat Oncol Biol Phys 76:719–727
Treatment Toxicity Short-term (acute) and late side effects, their causes, risk factors, and management are listed in Tables 22.20 and 22.21. Most acute side effects are controllable with supportive care. The frequency of late complications requiring hospitalization or surgical interventions ranges from 5 to 14%. Bowel complications are seen in less than 5%. Most complications occur within the first 5 years; however, a low risk of urinary complications persists over a 25year period (Source: Eifel PJ, Levenback C, Wharton TJ et al (1995) Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 32:1289–1300; Lanciano RM, Martz D, Montana GS et al (1992) Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A patterns of care study. Cancer 69:2124–2130).
Urinary frequency, burning Pelvic EBRT, BT Hematuria Pelvic EBRT, BT
Gastrointestinal
Genitourinary
Hematologic
Chemotherapy, PA EBRT RT and chemotherapy (especially 5-FU) RT and chemotherapy Pelvic EBRT, BT
Nausea, vomiting, gastric irritation Diarrhea, cramping Dehydration Rectal/peri-rectal irritation and bleeding
Chemotherapy and RT (dose to bone marrow) Chemotherapy, RT, bleeding from tumor Chemotherapy and RT
Chemotherapy, RT
Fatigue Anorexia
Constitutional
Neutropenia, thrombopenia Anemia Infectious complications
Cause
Side effect
System
Table 22.20 Short-term (acute) side effects of therapy for cervical cancer
Treatment break for abs. neutrophil count <500,000, platelet count <50,000; colony stimulating factors neutropenic precautions Transfusions, oral iron supplement Treatment break, hospitalization, antibiotic coverage, colony stimulating factors
Antispasmodics, urinary tract analgesics; urine culture to exclude urinary tract infection Monitor hemoglobin, bladder irrigation; in severe cases, laser fulguration, electrocoagulation
Antiemetics: for 3–4 days after each cisplatin, before each PA RT fraction; proton pump inhibitors Low-fiber/-residue diet, antidiarrheals; in severe cases, stop RT, monitor electrolytes, paregoric, tincture of opium; stool culture/ treatment for Clostridium difficile IV fluid/electrolyte replacement, IV/oral anti-emetics Topical and/or rectal steroids; steroid suppositories, pain control
Mild exercise, rest as needed Nutritional supplements
Management
698 Nina Mayr, William Small Jr. and David K. Gaffney
Cause BT insertion BT delivery, prolonged bed rest (LDR) Chemotherapy
Side effect
Bleeding, perforation, infection, anesthesia complications Venous thrombosis, pulmonary embolism
Cisplatin, 5-FU allergy (extremely rare)
System
Procedural
Allergic
Table 22.20 (continued)
Acute management of anaphylaxis
Intra-operative ultrasound, perioperative antibiotics for intra-uterine procedures Thrombosis prophylaxis (anticoagulants, SCDs)
Management
Chapter 22 Cervical Cancer 699
EBRT, BT Risk factors: postmenopausal, elderly age ERBT Risk factors: osteoporosis, elderly age
Hematuria Vesicovaginal fistula Ureteral stricture
Vaginal atrophy, dryness, stenosis Dyspareunia
Femoral fractures Sacral fractures mostly asymptomatic
Genitourinary
Vaginal stenosis
Bone
Intramedullary rod, hip replacement Conservative therapy, pain control, treatment of osteoporosis
Topical vaginal estrogen, vaginal dilators Vaginal lubricants, estrogen
Intravesial therapy, laser, cauterization of bleeding vessels Urinary diversion Ureteral stent, urinary diversion, percutaneous nephrostomy
RT, BT Risk factors: high bladder BT dose, large fraction, bladder invasion ERRT, BT, radical hysterectomy Risk factors: straight midline block for parametrial boost
Gastrointestinal
Management Low-fiber diet, long-term oral antidiarrheals Conservative management (bowel rest, nasogastric suction) For acute abdomen, bowel resection with anastomosis or bowel diversion colostomy Steroid enemas, cauterization or laser of bleeding vessel(s), supportive care pain control, transfusions Bowel diversion, colostomy
Cause, risk factor EBRT, BT, hysterectomy Risk factors: trans-peritoneal LN dissection, prior pelvic surgeries, adhesions, pelvic inflammatory disease; weight <54 kg, smoking, large EBRT volumes, low-energy beams, large fractions EBRT, BT Risk factors: high rectal-point BT dose, large BT fractions
Side effect
Small bowel Persistent diarrhea Bowel obstruction, Bowel perforation, fistula Rectum Chronic rectal bleeding, ulceration Rectal stricture, rectovaginal fistula
System/situation
Table 22.21 Long-term (chronic) side effects of therapy for cervical cancer
700 Nina Mayr, William Small Jr. and David K. Gaffney
Compression stockings, sequential compression device
ERBT Risk factors: LN involvement, LN dissection EBRT RT, chemotherapy
Lower extremity edema
Ovarian failure (menopause)
Sarcomas, leukemias , others
Lymphatic
Endocrine
Second cancers
Disease=specific tumor therapy
Hormonal replacement therapy
Management
Cause, risk factor
Side effect
System/situation
Table 22.21 (continued)
Chapter 22 Cervical Cancer 701
23
Vulva Cancer Kevin Albuquerque1
Key Points Carcinoma of the vulva is a relatively uncommon malignancy. Eighty to 90% of primary vulvar tumors are squamous carcinomas. Tumors of the vestibular glands (Bartholin’s glands) often are adenocarcinomas or adenocystic carcinomas, but 30–50% of tumors have squamous histology. Symptoms can be subtle in very early lesions, but generally with advanced disease, vulvar cancer–specific symptoms, such as pruritus, pain, spotting or bleeding, and discharge, may be evident. Progression of disease occurs in a stepwise locoregional fashion (locally to adjacent organs), while lymphatic spread is to inguinofemoral nodes (superficial and deep). Lymph node involvement increases with tumor size and depth of stromal invasion. Distant metastases are uncommon but may occur to bone and lung. Clinical diagnosis is based on history, physical examination, and biopsy confirmation, with laboratory and imaging studies playing an ancillary role. Lymph node involvement at diagnosis is the most important prognostic factor for overall survival. Tumor and treatment related factors determine local failure. Preservation of function, as well as anatomy, is paramount in the decision-making process for the treatment of vulvar cancer. Except for diseases with very limited volume and extent that can be treated with surgical excision only, the majority of cases require multidisciplinary management with limited surgery and radiation therapy (RT). Surgery has become less extensive, with (radical being >1 cm) wide local excision (WLE) preferred over total vulvectomy and the exploration of sentinel lymph node biopsy (SLNB) as a replacement for groin node dissection (GND) with its attending morbidities. Adjuvant RT is added selectively to reduce morbidities of combined treatments. Indications for RT to primary tumor and nodal beds should be determined separately, based on pathological prognostic features of each. RT (with concurrent chemotherapy) plays a major role in locoregionally advanced disease or lesions with extension to the midline structures. This is combined with inguinal dissection and function-preserving completion surgery. 1
Kevin Albuquerque, MD, MS, FRCS () Email:
[email protected] J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_6, © Springer-Verlag Berlin Heidelberg 2011
704
Kevin Albuquerque
Epidemiology and Etiology Vulva cancer accounts for about 4% of cancers of the female reproductive organs and 0.6% of all cancers in women in the USA. The Surveillance, Epidemiology and End Results (SEER) Program estimated that in 2009, about 3,580 cases of vulva cancer would be diagnosed in the USA, and about 900 of those women would die of this cancer. Predisposing factors are shown in Table 23.1. Table 23.1 Risk factors of vulva cancer Factor
Description Age: generally advanced age (median age at diagnosis is 70). Diagnosis at younger age is associated with HPV and VIN Lifestyle: cigarette smoking
Patient related
Past medical history: previous or vaginal cancer; previous HPV infection 16, 18, 31; HIV infection; previous cervical or vaginal cancer; hypertension; chronic granulomatous and dystrophic vulvar lesion; women exposed to immunosuppression therapy Preinvasive lesions: VIN, 2–5% progress; Bowen’s disease; Paget’s disease, erythroplasia
HPV: human papilloma virus, VIN: vulvar intraepithelial neoplasia
Anatomy The parts of the vulva are as shown in Figure 23.1, viz., the mons pubis, clitoris, labia majora and minora, and vaginal vestibule. Anteriorly, the vulva blends with the urinary meatus and posteriorly with the perineum (body) and anus. Bartholin’s glands – two small, mucous-secreting glands – are situated within the subcutaneous tissue of the posterior labia majora. The ducts of Bartholin’s glands open onto the posterolateral portion of the vestibule. The perineal body is a 3- to 4-cm band of skin that separates the vaginal vestibule from the anus and forms the posterior margin of the vulva.
Chapter 23 Vulva Cancer
705
Figure 23.1 Pattern of lymphatic spread showing parts of vulva anatomy (curved arrows show lymphatic drainage of different components of vulva, which generally occurs in stepwise fashion from inguinal to pelvic nodes)
Pathology Approximately 80–90% of primary vulvar tumors are squamous cell carcinomas (SCC). Tumors of the vestibular glands (Bartholin’s glands) often are adenocarcinomas or adenocystic carcinomas, but 30–50% of SCC have squamous histology. The remaining, less common histologies include melanoma, basaloid, neuroendocrine carcinoma (Merkel cell carcinoma), and sarcoma. Diagnosis of vulva cancer requires biopsy of the primary tumor, usually under local anesthesia.
Routes of Spread Local extension and regional (lymphatic) metastases are the two major routes of spread in vulva cancer. Distant metastasis (hematogenous) is less common (Table 23.2).
706
Kevin Albuquerque
Table 23.2 Routes of spread in vulva cancer Routes
Description
Local extension
Occurs in a stepwise progressive fashion from a distal-toproximal direction Direct involvement of a third of the lower urethra, a third of lower vagina and/or extension to the anus is first (FIGO stage II) More extensive cases: further progression proximally involves upper urethral and/or vaginal mucosa, bladder mucosa, rectal mucosa, or fixation to bony pelvic structures (FIGO stage IVA)
Regional lymph node metastasis
The overall risk of groin node metastasis ranges between 10 and 50%, and depends on the presence of one or more of the following factors: size of the primary tumor, depth of invasion, and the presence of lymphovascular space invasion Stromal invasion of <1 mm leads to nearly 0% of nodal involvement (hence, separately staged as 1A); stromal invasion of 2–5 mm of stromal invasion leads to 8–10% chance of nodal involvement Clitoris can theoretically drain directly to pelvic nodes (Figure 23.1), but this is rare without inguinofemoral involvement Overall incidence of pelvic lymph node metastasis is 5% Deep femoral node involvement without superficial inguinal node metastasis has been reported – from clitoris and Bartholin’s gland tumors ~25% clinical negative or nonsuspicious inguinal nodes are pathologically positive 65–75% clinically palpable/suspicious nodes are pathologically positive (FNA of enlarged groin lymph nodes should be performed to determine nodal involvement) Contralateral spread without ipsilateral nodal involvement occurs in <15% of cases A GOG study also found an unexpectedly high incidence of ipsilateral groin recurrences presumed due to involvement of lymph nodes deep to the cribriform fascia despite negative superficial nodes. Hence, both superficial and deep inguinal nodes need to be dissected
Distant metastasis
Hematogenous metastasis is rare However, the risk is 66% if ≥3 lymph nodes are involved
GOG: Gynecologic Oncology Group, FNA: fine-needle aspiration Source: Stehman FB, Bundy BN, Dvoretsky PM, Creasman WT (1992) Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 79:490–497
Chapter 23 Vulva Cancer
707
Diagnosis, Staging, and Prognosis Clinical Presentation Vulvar cancer-specific symptoms such as pain, spotting or bleeding, discharge, and pruritus, may be evident with visible lesions. With advanced disease, symptoms are due to invasion of adjacent organs, viz., difficulty urinating or defecating or with intercourse. Presentation with edema of the lower extremities secondary to disease in the groins is rare.
Diagnosis and Staging Figure 23.2 illustrates a diagnostic algorithm of vulva cancer, including suggested examinations and tests.
Tumor, Node, and Metastasis, and International Federation of Gynecology and Obstetrics Staging Diagnosis and clinical staging depends on findings from detailed history and physical examination, and imaging. Pathological staging depends on findings during surgical resection and pathological examination, in addition to those required in clinical staging. The 7th edition of the tumor, node, and metastasis (TNM) staging systems and groupings of the American Joint Committee on Cancer (AJCC), and the International Federation of Gynecology and Obstetrics (FIGO) and are presented in Tables 23.3 and 23.4. Two prognostic principles applied based on new knowledge: (1) size is not a significant factor for survival if the lymph nodes are negative and (2) number and size of nodal metastasis seem to be prognostic, and these have been separated in the new version of staging.
708
Kevin Albuquerque
Early stage vulva lesion
Early stage midline lesion
Well lateralized lesion
Yes
It tumor T1A(≤ 1mm thin and CLS negative
WL E alone
No
Radical WL E & bilateral groin node dissection
Unfavorable primary
Unfavorable primary
Depth > 5mm and CLS+
No
No
Margins < 8mm
>1 positive, or1 through capsule?, or macroscopic?
No Yes
Residual vulvar didease?
No
Observation Yes
Consider adjuvant radiotherapy to vulva
BGND & Simple excision (if possible) + adjuvant chemoradiation to vulva OR pre-op chemoradiation
Unfavorable primary
Observation Yes
Possible to perverse sphincters & clitoris with radical surgery?
Yes
Further excision (if anatomy preservation possible) or Adjuvant radiotherapy to vulva
Observation
Adjuvant RT to pelvic & inguinal nodes
Yes
Local excision (if possible) or radical surgery if not
Histological confirmation of vulvar cancer is essential and requires biopsy of the primary tumor, which can be performed under local anesthesia by punch or incision. Fine-needle spirate of enlarged groin lymph nodes should be done to determine nodal involvement A thorough gynecologic examination with Pap smear of the cervix is indicated to evaluate the extent of the disease and to screen for cervical cancer. Examination under anesthesia (EUA), cystoscopy, and sigmoidoscopy should be used as needed depending on the extent of the tumor (in advanced tumors) CT of the pelvis and abdomen may be indicated * consider RT if node positive and less than 5 nodes dissected; chemoRT for three or more positive nodes
Figure 23.2 A proposed algorithm for diagnosis, staging and management of early stage vulva cancer WLE: wide local extension, CLS: capillary lymphatic space, BGND: bilateral groin node dissection
Chapter 23 Vulva Cancer
709
Table 23.3 AJCC TNM and FIGO staging of vulvar cancer TNM
FIGO
Description
Primary tumor (T) TX
Primary tumor cannot be assessed
T0
No evidence of primary tumor a
Tis
Carcinoma in situ
T1a
IA
Lesions 2 cm or less in size, confined to the vulva or perineum and with stromal invasion 1.0 mm or lessb
T1b
IB
Lesions more than 2 cm in size or any size with stromal invasion more than 1.0 mm, confined to the vulva or perineum
T2c
II
Tumor of any size with extension to adjacent perineal structures (lower/distal third of urethra, lower/distal third vagina, anal involvement)
T3d
IVA
Tumor of any size with extension to any of the following: upper/ proximal two thirds of urethra, upper/proximal two thirds of vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone
Regional lymph nodes (N)e NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1a
IIIA
One lymph node metastasis each 5 mm or less
N1
b
IIIB
One lymph node metastasis 5 mm or greater
N2
a
IIIB
Three or more lymph node metastases each less than 5 mm
N2b
IIIB
Two or more lymph node metastases 5 mm or greater
N2c
IIIC
Lymph node metastasis with extracapsular spread
N3
IVA
Fixed or ulcerated regional lymph node metastasis
Distant metastasis (M) MX
Distant metastasis cannot be assessed
M0
No distant metastasis
M1 a
IVB
Distant metastasis (including pelvic lymph node metastasis)
FIGO no longer includes stage 0 (Tis) The depth of invasion is defined as the measurement of the tumor from the epithelial–stromal junction of the adjacent most superficial dermal papilla to the deepest point of invasion c FIGO used the classification T2/T3. This is defined as T2 in TNM d FIGO used the classification T4. This is defined as T3 in TNM e An effort should be made to describe the site and laterality of lymph node metastasis Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York b
710
Kevin Albuquerque
Table 23.4 Stage grouping of vulvar cancer Stage Grouping T1
T2
T3
T4
N0
IA
IB
II
IVA
N1a,b
IIIA
IIIA
IIIA
IVA
N2a,b
IIIB
IIIB
IIIB
IVA
N2c
IIIV
IIIC
IIIC
IVA
N3
IVA
IVA
IVA
IVA
M1
IVB
IVB
IVB
IVB
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
Prognosis Important prognostic factors for overall survival and local control in vulva cancer are detailed in Table 23.5. Most deaths are because of uncontrolled locoregional disease. Table 23.5 Prognostic factors for overall survival and local control in vulva cancer Prognostic factor
Description
For overall survival
Most important factor is presenting stage, particularly lymph node status Patients with 1 groin node involvement have lower risk of recurrence than have those with 2 or nodes involved Patients with unilateral groin nodal involvement have better survival than do those with bilateral disease Positive nodal status reduces survival by 40% (Table 23.6) Most deaths are because of uncontrolled locoregional disease, not distant metastasis
For local control
Positive or close surgical margins (most powerful predictor) of local vulvar recurrence: margin <8 mm 50% recurrence Lymphovascular space invasion Deep stromal invasion of >5 mm Large primary tumor size
Source: Heaps JM, Fu YS, Montz FJ et al (1990) Surgical–pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 38:309–314
Chapter 23 Vulva Cancer
711
Table 23.6 presents post-2005 trials results of overall survival. Table 23.6 Overall survival (OS) according to extend of disease (results of trials published after 2005) Extent of disease
Percent at diagnosis (%)
5-year OS (%)
Localized
65%
80–90%
Regional
30%
45–50a %
Metastatic
5%
15%
Sources: Surveillance, Epidemiology and End Results (SEER) Program stat fact sheet on vulva cancer (http://seer.cancer.gov/statfacts/html/vulva.html); Kunos C, Simpkins F, Gibbons H et al (2009) Radiation therapy compared with pelvic node resection for node-positive vulvar cancer. Obstet Gynecol 114:537–546; and other trials detailed in the next section)
Treatment Principles and Practice Modalities used for vulva cancer are descussed in Table 23.7. A proposed treatment algorithm based on the best available clinical evidence is presented in Figure 23.2. Table 23.7 Treatment modalities used in vulva cancer Treatment
Description
Vulvectomy/wide local excision plus inguinofemoral lymphadenectomy
Indications
The only curative treatment modality Radical in concept but function preserving It is used for T1 and possibly T2 disease Consider induction therapy (chemoradiation) for unresectable tumors or potentially mutilating surgery
Facts
Minimum pathological margin of 8 mm around primary tumor is essential to minimize risk of local recurrence The incision should be carried down to the inferior fascia of the urogenital diaphragm Inguinal lymph node dissection (LND), including superficial and deep nodes, is usually recommended for all cases with invasive disease of more than 1-mm depth with clinically negative groins (GOG 88 study) Contralateral LND is performed if ipsilateral positive lymph nodes are present Bilateral groins dissection (BGND) needed if central vulvar disease present or for stage 2 and above ▶
712
Kevin Albuquerque
Table 23.7 (continued) Treatment
Description
Radiation therapy
Indications
An adjuvant treatment after complete resection to primary tumor and nodal beds Preoperative or definitive treatment (with chemotherapy) Palliative treatment to primary or metastatic foci
Techniques
EBRT using 3D-CRT or IMRT Interstitial brachytherapy may have a role in extensive lesions where function preserving surgery not possible
Chemotherapy
Indications
Medications
Adjuvant treatment after surgery (with EBRT) being studied Induction or definitive treatment with concurrent EBRT for unresectable disease Mainstay treatment for palliative therapy Anal cancer protocols often used with 5-FU plus MMC
or cisplatin plus 5-FU
EBRT: external-beam radiation therapy, 5-FU: 5-flourouracil, MMC: mitomycin C
Treatment of Early-Stage (T1N0–2) Disease Treatment of early-stage vulva cancer (T1N1–2) and possibly T2 is mainly surgical with wide local excision (WLE) or radical vulvectomy and inguinofemoral lymphadenectomy, and then by adjuvant radiation if indicated. Clinical evidence for inguinofemoral lymphadenectomy over radiation is presented in Table 23.8. Complications of bilateral groin dissection (BGND) are significant and morbidity is high, with wound infection and breakdown in 20–30% and lower extremity lymphedema in 30–60% of cases. Hence, BGND should not be routinely performed. In selected cases (unifocal FIGO IB lateralized tumor without pathological nodes), unilateral lymph node dissection (LND) is associated with a <1% risk of contralateral groin node metastases in multiple observational studies, and it can avoid morbidity with careful selection. Sentinel node biopsy (SLNB) is under investigation as an alternative to inguinofemoral LND as a means of reducing morbidity of groin LND.
Chapter 23 Vulva Cancer
713
Table 23.8 Clinical trials for managing nodes in vulva cancer Randomized trial
Description
GOG 88a
Randomized trial of 121 patients with IB–III disease and nonsuspicious nodes (N0–1) treated with radical vulvectomy Patients randomized to bilateral inguinal femoral lymph node dissection or external radiation (50 Gy to 3 cm below skin surface) to the groin If pelvic lymph nodes were involved, patients received radiation to bilateral inguinal and pelvic nodes Study was closed after interim analysis of only 58 patients. Five of 27 patients (18.5%) in radiation group suffered groin failure 2-year overall survival rate favored the surgery group (90 versus 70%). Thus, radiation to groins not recommended for sub-clinical nodes Criticisms: poor radiation techniques of radiation dose prescription to a depth of 3 cm, resulting in all inguinal nodes that recurred receiving less than prescribed dose
Koh et al, Katz et al
Spiral CT–based 3-D studies demonstrated that the average depth of the femoral vessels was 6 cm but can range from 2 to 18 cmb Using proper radiation planning of techniques, a dose of 50 Gy should sterilize subclinical microscopic disease, as shown by several series and spare morbidity of BGNDb
a
Source: Stehman FB, Bundy BN, Thomas G et al (1992) Groin dissection versus groin radiation in carcinoma of the vulva: a GOG study. Int J Radiat Oncol Biol Phys 24:389–396 b Source: Koh WJ, Chiu M, Stelzer KJ et al (1993) Femoral vessel depth and the implications for groin node radiation. Int J Radiat Oncol Biol Phys 27:969–974 c Source: Katz A, Eifel PJ, Jhingran A, Levenback CF (2003) The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys 57:409–418
There is little margin for error in detecting occult-positive nodes, because groin recurrence in vulvar cancer is usually fatal; hence, this is not yet accepted as standard of care. Except for a few case series, not enough data are available – a Gynecologic Oncology Group (GOG) 173 validation study is awaiting publication, although initial results are promising. The results of a large prospective study from Europe are available (Table 23.9).
714
Kevin Albuquerque
Table 23.9 The Netherlands sentinel node biopsy (SLNB) observational study Type
Description
GROningen INternational Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V)
403 women with squamous cell vulvar cancer (tumor size <4 cm) had sentinel node detection with a combination of radioactive tracer and blue dye If SLN was detected and negative (n = 276), no further treatment was given; If SLN was detected and positive or if no SLN was detected, inguinofemoral LND was performed Median follow-up was 35 months, median time to recurrence was12 months; 3-year survival rate was 97% 259 patients with unifocal vulvar disease and a negative sentinel node resulted in 6 groin recurrences (i.e., 2.3% recurrence with negative SLNB) SLNB only patients had less short- and long-term morbidity, as compared to groin node dissection (GND) patients.
Source: Van der Zee AG, Oonk MH, De Hullu JA et al (2008) Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26:884–889
Radiation Therapy in Resectable Vulva Cancer The uses of radiation therapy (RT) in resectable vulva cancer are indicated as follows: Preoperative RT (with concurrent chemotherapy) plays a major role in locoregionally advanced disease or in lesions with extension to the midline structures. This is combined with inguinal dissection and function-preserving completion surgery. Postoperative RT to primary tumor and nodal beds is determined separately based on pathological prognostic features of each. Adjuvant RT for primary tumor is used when limited surgery has been performed for organ preservation or when high-risk pathologic features, such as large tumor (>4 cm), positive or close (<8 mm) surgical margin, lymphovascular space invasion, and depth of stromal invasion >5 mm, are present. Adjuvant RT for nodal regions is indicated in patients with two or more involved inguinal nodes, gross extracapsular extension (ECE), or gross residual nodal disease as per the GOG trial 37 (Table 23.10). Long-term results of GOG 37 results confirm benefit and demonstrate importance of a lymph node–positive ratio (Table 23.10). Number of nodes dissected will influence indication for radiation of groin and pelvis even if only one node is positive. Generally, > 5 nodes considered adequate, but there is no consensus. If contralateral groin negative on dissection in a well-lateralized lesion with a positive ipsilateral groin, the standard approach is to radiate the opposite pelvis, but some feel this can be omitted.
Chapter 23 Vulva Cancer
715
Table 23.10 Clinical trials for adjuvant lymph node irradiation Randomized trial
Description
GOG 37a
This was a randomized trial with 114 patients with positive inguinal nodes after radical vulvectomy and bilateral inguinal node dissection Patients were randomized to pelvic node dissection versus postoperative radiotherapy Radiation (45–50 Gy prescribed to mid-plane, using AP/PA fields) was delivered bilaterally to the pelvic and inguinal nodes while shielding the central vulva area Interim analysis revealed a significant survival advantage for patients receiving radiotherapy (2-year survival of 68 versus 54%) because of a lower rate of groin relapse in the radiotherapy arm (5 versus 24%) Subset analysis suggested that this survival advantage was particularly noted if clinically suspicious or if fixed, ulcerated groin nodes or 2 or more positive groin nodes were present
GOG 37b (longterm results)
GOG 37 trial with a median follow-up of 74 months 6 -year overall survival for radiation arm, 51% compared with 41%; hazard ratio of 0.61 Cancer-related death rate significantly higher for pelvic node resection, as compared with radiation (51% compared with 29%) at 6 years A ratio of more than 20% positive ipsilateral groin nodes (number positive/number resected) significantly associated with contralateral lymph node metastasis, relapse, and cancer-related death Benefits of radiation preserved in long-term follow-up
a
Source: Homesley HD, Bundy BN, Sedlis A et al (1986) Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 68:733–740 b Source: Kunos C, Simpkins F, Gibbons H et al (2009) Radiation therapy compared with pelvic node resection for node-positive vulvar cancer. Obstet Gynecol 114:537–546
Radical vulvectomy has been considered sufficient for treatment for vulvar carcinoma, and postoperative radiation can be directed only to the lymph nodes. However, results from a retrospective study suggested that the application of a midline block to protect the radiosensitive vulva resulted in a 48% central recurrence rate (versus the less than 10% reported historically). Long-term results from GOG-37 do not show this, however. The primary tumor bed should be radiated only if high-risk features present. The additional benefit of concurrent chemotherapy with postoperative radiation in patients with high-risk features for relapse is unclear and is being studied in cooperative group studies.
716
Kevin Albuquerque
Decision making regarding which treatment modalities to be used depends on location of primary in relation to midline (Figure 23.2).
Treatment of Locally Advanced Diseases (Most T2–3, N2c-3) Primary surgery is either not possible or will result in tremendous morbidity; hence, the use chemoradiation should be explored. Extended radical vulvectomy and BGND or pelvic exenteration may be required for tumors involving the rectum, vagina, or urethra. Preoperative radiation or combined chemoradiation therapy, or definitive chemoradiation, should be considered for organ preservation, to be succeeded by function-preserving limited surgery. Results of an important GOG study are summarized in Table 23.11. Table 23.11 Preoperative chemoradiation therapy for locally advanced diseases Trial
Description
GOG 101
Phase II GOG study of patients with stages III–IV (unresectable) squamous cell vulvar carcinoma All patients enrolled judged capable of tolerating chemoradiation succeeded by surgical resection and bilateral inguinofemoral LND (high performance status) Preoperative chemoradiation of 47.6 Gy (twice daily for the 1st week of 2-week cycle with a split course with an elective 2-week break, and then next 2-week cycle of chemoradiation); concurrent chemotherapy used cisplatin plus 5-FU 48.5% of patients with clinical complete response (CR), no visible vulvar cancer at the time of planned surgery, only 2.8% had residual unresectable disease 95% of N2c–N3 groin nodes rendered resectable; in only 3 patients was it not possible to preserve urinary and/or gastrointestinal continence Next GOG trial to increase radiation dose and eliminate “elective break”
Source: Moore DH, Thomas GM, Montana GS et al (1998) Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 42:79–85
Chapter 23 Vulva Cancer
717
Unresectable or Inoperable Diseases Definitive chemoradiation therapy is indicated for unresectable or medically inoperable vulvar cancers. Chemotherapy regimens similar to those used in anal canal cancer, infusional 5-FU plus cisplatin or mitomycin, have been described. High response rates have been reported, and the majority of patients achieving complete response have durable local control (Table 23.12; Figure 23.3 for an algorithm for management of advanced vulva cancer). Most of the definitive chemoradiation studies in vulvar cancer are single institutional and limited by small sample size. There is considerable toxicity associated with chemoradiation, including severe skin desquamation and hematologic toxicity, infection, lymphedema, etc. The preferred approach for patients with inoperable primary tumors or lymph nodes is preoperative chemoradiation, if a salvage operation can be performed. Chemoradiation is offered as an alternative to radical surgery in an effort to avoid colostomy and urostomy in stage IVA disease. If residual disease remains after chemoradiation, then local resection is indicated. The most recent GOG 205 trial is exploring weekly cisplatin with doses of 57.6 Gy for locally advanced vulvar cancer and results from this are awaited. Table 23.12 Comparison of surgery and primary chemoradiation (PCRT) in advanced SCC of vulva
Randomized trial
Description
University of Oklahoma
A retrospective study of 63 patients with stages III (n = 47) and IV (n = 16) SCC of vulva 30 patients received extended primary surgery (PS), and 33 unresectable tumors by vulvectomy and underwent PCRT Patients treated with PCRT were younger (61 versus 72 years; p= 0.09), had less nodal metastasis (54 versus 83%, p = 0.01), and larger tumors (6 versus 3.5 cm, p = 0.0001), as compared with patients who received PS Clinical CR rate was high at >85%, but the majority had undergone node dissection prior to PCRT Despite these differences, OS rates at 31 months were 69 and 76%, respectively, for PS and PCRT groups (p = NS); no differences were seen in PFS or recurrence rates either between the 2 groups Multivariate analysis showed age was the only significant predictor of OS or PFS
Source: Landrum LM, Skaggs V, Gould N et al (2008) Comparison of outcome measures in patients with advanced SCC of the vulva treated with surgery or PCRT. Gynecol Oncol 108:584–590
718
Kevin Albuquerque
-
+
Groin nodes
Negative on clinical examination and by diagnostic imaging
Positive by needle aspiration or excisional biopsy
Preoperative chemoradiation to vulvar primary and elective chemoradiation to bilateral groin nodes. No groin dissection.
Fixed or ulcerated nodes? No
Yes
Billateral groin node dissection Residual primary disease? No Yes
Unfavorable node features? Yes
Biopsy, if negative observe
Resect by functionally conservative excision if feasible. If not, boost to radical dose with chemoradiation - may use brachytherapy.
Chemoradiation to vulva, groins, and pelvic nodes
Chemoradiation to Ipsilateral or bilateral groin and pelvic nodes along with primary
No
Observe groins ChemoRT to primary
Resectable? Yes
If residual primary disease
No
Resect Boost residual residual nodes gross nodes after a preto a radical operative chemodose of radiation chemodose level radiation
Figure 23.3 A proposed treatment algorithm for advanced carcinoma of the vulva
Chapter 23 Vulva Cancer
719
Radiation Therapy Techniques Simulation Patients must be treated with equipment with photon energy of 6 MV for pelvic irradiation. Computed tomography (CT)-based planning is essential to obtain the depth of inguinal nodes. Delineation of the femoral lymph nodes is critical for adequate coverage of the inguinal nodes. Location of the inguinofemoral nodes is depicted in Figure 23.4. Figure 23.4 Topographic distribution of inguinal lymph node metastases in patients with carcinoma of the anus and low rectum (circles, n = 50), vulva vagina–cervix (triangles, n = 17), and urethra (squares, n = 17). The field arrangement described provided adequate coverage of 86% of all inguinal lymph nodes. Adapted from Wang, CJ, Chin, YY, Leung SW et al (1996) Topographic distribution of inguinal lymph nodes metastasis: significance in determination of treatment margin for elective inguinal lymph nodes irradiation of low pelvic tumors. Int J Radiat Oncol Biol Phys 35:133–136. (Used with permission from Elselvier)
720
Kevin Albuquerque
Patients are simulated in supine, frog-leg positions (to minimize the bolus effect from skin folds) with full bladders (to minimize the volume of small bowel in the radiation field), with custom immobilizations. Palpable lymph nodes, vulva tumor, scars, and anal verge should be outlined with sticky wire for identification on planning CT. Markers to be used to indicate extent of vaginal involvement if present. Four-field three-dimensional (3D) conformal technique may spare rectum and posterior skin as well as femurs (Figure 23.5), and avoids problems of matching fields.
Figure 23.5 Sagittal view of advanced vulvar cancer CTV (blue outline) treated by four-field conformal technique. Part of the rectum and posterior skin can be spared
Field Arrangements Field arrangement of conventional RT available for vulvar cancer treatment is detailed in Table 23.13. A wide anterior-posterior (AP) field includes the pelvic and inguinal regions, and a narrow posterior–anterior (PA) field covers only the pelvis and spares the femoral heads. The dose to inguinal regions is supplemented by separate anterior electron fields matched to the PA field to bring the dose to the inguinal nodal region to 45 Gy (Figure 23.6). A wide AP field and narrow PA field with a partial transmission block are placed in the central portion of the AP field. The desired dose at a specific depth is delivered to the inguinal nodes through the AP field.
Chapter 23 Vulva Cancer
721
Table 23.13 Field arrangement in RT for vulva cancer Field
Borders
Wide AP (Figure 23.6)
Superior: mid–sacroiliac joint to include external and internal iliac node involvement; L4–L5 to include the common iliac nodes if internal/external iliac nodes suspicious or positive Inferior: flash entire vulva or inferior margin of the tumor (whichever is lower) Lateral: 2 cm beyond the widest point of the pelvic inlet on the PA field, and greater trochanter to include inguinal lymph nodes in the AP field
Narrow PA
Superior: same as AP field Inferior: same as AP field Lateral: off femur and match supplemental electron fields
Supple electron
Anterior electron fields to the lateral inguinal region Matched with the exit PA field Energy based on CT depth of femoral vessels
Cone down
Primary tumor and involved inguinal lymph nodes plus
2- to 3-cm margin after 45 Gy to the pelvis
All fields should be irradiated on daily basis Bolus material should be used to ensure adequate dose to the superficial portions of the groin or tumor
Figure 23.6 Treatment borders demonstrating the wide anterior field (outer border) and the narrow posterior field (shaded region). The pelvis, vulva, perineum, and inguinal lymph nodes will be treated with the AP–PA technique to include lateral inguinal nodes within AP fields but not PA fields. The patient lies supine with a full bladder
722
Kevin Albuquerque
Intensity-Modulated Radiation Therapy Intensity-modulated radiation therapy (IMRT) has been demonstrated to offer an advantage over 3D-conformal radiation for vulvar cancer by improving conformality and eliminating matching problems (Figure 23.7). In addition, IMRT reduces the dose to normal structures, such as the bladder, rectum, small bowel, and femoral heads, and eliminates problems with matching between electrons and photons. Definitions of clinical target volume (CTV) and planning target volume (PTV) in 3D-CRT and IMRT are as follows: CTV: 1-cm margin around the entire vulvar region and around the bilateral external iliac, internal iliac, and inguinofemoral nodes PTV: CTV plus 1 cm The Radiation Therapy Oncology Group (RTOG) has formulated a (consensus) contouring atlas for IMRT for anal canal tumors, which includes guidelines for groin nodes. Simultaneous integrated boost (SIB) can also be delivered with IMRT. An example is shown in Figure 23.7, where clinically negative groin nodes received 45 Gy with chemotherapy (with sparing of femurs) and vulvar CTV received 53 Gy. However, long-term results for IMRT for vulva cancer are lacking.
Figure 23.7 Slice through vulvar IMRT plan showing how 45-Gy isodose line spares femoral neck, and 52.9 Gy (98% of prescribed dose) covers advanced vulvar tumor in a tight, conformal manner
Chapter 23 Vulva Cancer
723
Dose and Treatment Delivery Dose and fractionation of pre- and postoperative RT is detailed in Table 23.14. EBRT should be delivered as a continuous course at 1.8–2.0 Gy per daily fraction. Table 23.14 Radiation dose in vulva cancer treatment Setting
Scenario
Dose of RT (Gy)
Preoperative
–
45–50a
Microscopic residual Postoperative
Definitive a
50 +
Extracapsular external or N
55–60
Gross residual
65–70
Concurrent chemoradiation
60–65
Response in ~90% of cases after radiation alone can be expected
Normal Tissue Tolerance Organs at risk (OARs) in RT of vulva cancer, in both adjuvant and definitive settings, include small bowel, bladder, femoral heads, and vagina. Dose limitation is detailed in Chap. 22, Table 22.17.
Follow-Up Life-long follow-up (Table 23.15) is required for all patients with vulvar cancer treated with curative intent for early detection of tumor recurrence and second primary gynecological malignancies. In addition to recurrent vulvar cancer, there is a higher risk of cervical and anal cancer. Common radiation-induced adverse effects (acute and late) are presented in Table 23.16.
724
Kevin Albuquerque
Table 23.15 Follow-up schedule and examinations Schedule
Frequency
First follow-up
4 –6 weeks after RT
Years 0–2
Every 3–4 months
Years 3–5
Every 6 months
Years 5+
Annually
Examinations History and physical
Complete history and physical examination
Imaging studies
Chest X-ray (if clinically indicated) CT of the abdomen and pelvis (if clinically indicated)
Table 23.16 Commonly observed acute and late adverse effects after treatment Stage
Description
Acute
The most significant is the skin reaction in the vulva–perineal region and inguinal folds Moist desquamation by the 3rd–5th weeks of treatment is common; a treatment break is usually necessary Diarrhea and cystitis are other common acute side effects Acute hematologic toxicity is common and depends on the type and intensity of the chemotherapy used
Late
Common late toxicities include telangiectasia, atrophy of skin, fibrosis, dryness, and shortening/narrowing of the vagina Avascular necrosis of the femoral head has been reported Femoral neck fracture is associated with osteoporosis and smoking Groin radiation can cause lymphocyst formation, lymph edema, and infection
Other
Significant psychosexual consequences relating to sexual function and body image may occur
24
Vaginal Cancer Nitika Thawani1, Subhakar Mutyala 2 and Aaron H. Wolfson3
Key Points The vagina can be a common site of secondary involvement, either through direct extension from the cervix and vulva or by lymphatic and vascular spread. Invasive cancers most commonly present with irregular vaginal bleeding or discharge (often postcoital), followed by vaginal discharge or dysuria. Vaginal intraepithelial neoplasia (VaIN) is diagnosed on routine screening. Diagnostic workup should include a thorough examination under anesthesia, as secondary involvement from the cervix or vulva is more common than primary cancer is. Biopsy is the mainstay for diagnosis, and staging is clinical. Whole-body fluorodeoxyglucose-positron-emission tomography/computed tomography (FDG-PET/CT) scans can provide information on the nodal status, and magnetic resonance imaging (MRI) of the pelvis helps to determine the depth of invasion and assessment of extent of disease. There is a lack of prospective randomized studies of patients with vaginal cancer because of the rarity of the disease. Treatment decisions are thus based on retrospective data and individual assessment. Carcinoma in situ of the vagina and highly selected early-stage patients with tumors in the upper vagina can be treated with surgery alone (there are reported local control rates of 75–100%). In more advanced stages, radiation therapy is chosen as the standard treatment to avoid exenterative surgery, preserve anatomy and function, and to treat known or presumed lymph node metastasis. Because the etiology and epidemiology of vaginal carcinoma appears identical to those of patients with invasive cervical carcinoma, patients with advanced vaginal carcinoma are treated with radiation and cisplatin-based chemotherapy.
1
Nitika Thawani MD Email:
[email protected]
2
Subhakar Mutyala, MD () Email:
[email protected]
3
Aaron H. Wolfson, MD Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_7, © Springer-Verlag Berlin Heidelberg 2011
726
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Anatomy The vagina is a dilatable, tubular, structure averaging 8.5 cm in length, lined by nonkeratinizing, stratified, squamous epithelium, extending from the vestibule to the cervix of the uterus. It lies dorsal to the base of the bladder and the urethra, and ventral to the rectum. The vagina is a fibromuscular sheath of three layers: mucosa, muscle, and adventitia (Figure 24.1).
Figure 24.1 Vaginal anatomy
Chapter 24 Vaginal Cancer
727
Table 24.1 Risk factors for vaginal cancer Risk factor
Description Age: incidence peaks in the 6th and 7th decades. Incidence increasing in younger women secondary to the increased prevalence of human papilloma virus (HPV) infection or other sexually transmitted diseases
Patient related
Lifestyle: increased risks with 5 or more sexual partners, onset of sexual intercourse before 17 years, smoking, low socioeconomic status Past medical history: prior history of HPV infection, cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), immunosuppression, history of hysterectomy, and possibly previous pelvic irradiation Infections: HPV is recovered from 80% of the VaIN lesions and 60% of squamous cell lesions. High-risk HPV strains (HPV-16, -18, -31, and -33) frequently responsible
Environmental
Clear cell adenocarcinoma: in utero exposure to diethylstilbestrol (DES) during the first 16 weeks of pregnancy doubles the risk of development of vaginal intraepithelial neoplasia (VaIN) by enlarging the transformation zone – at increased risk for infection with HPV
Pathology Squamous cell carcinoma (SCC) represents about 80–90% of primary vaginal cancers. Vaginal intraepithelial neoplasia (VaIN) is a precursor of SCC and is graded I–III, depending on the degree of nuclear atypia and crowding, and the proportion of the epithelium involved. These tumors are most common on the upper posterior wall of the vagina. Clear cell adenocarcinoma (CCA) is associated with diethylstilbestrol (DES) exposure and has a predilection for involving the submucosa of the upper third of the vagina and the exocervix. Malignant melanomas account for 4% of all vaginal neoplasms and involve the lower third and the anterior vaginal wall most commonly. Sarcomas represent 3% of all the vaginal tumors, with different types including leiomyosarcomas, carcinosarcoma, endometrial stromal sarcoma, and angiosarcoma. Embryonal rhabdomyosarcoma/sarcoma botryoides is a rare pediatric tumor.
728
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Natural History Table 24.2 details the natural history (without treatment) of vaginal cancer. Table 24.2 Routes of spread for vaginal cancer Routes
Description
Local
The tumor may spread along the vaginal walls to involve the cervix and the vulva Anterior wall lesion may infiltrate the vesicovaginal septum and/or the urethra Posterior wall lesions may involve the rectovaginal septum and extend to the rectal mucosa Tumors in the vagina can extend the parametrium and the tissues of the paracolpos to invade the obturator fossa, cardinal ligaments, lateral pelvic walls, and the uterosacral ligaments
Regional lymph node involvement
Fine lymphatics course through the submucosa and the muscularis to coalesce into small trunks, running laterally along the walls of the vagina Upper anterior vagina drains along the cervical channels to the interiliac chain. Upper posterior wall drains into the inferior gluteal, presacral, and the anorectal nodes Distal vagina lymphatics drain into the inguinal and femoral, and from there into the external iliac nodes Mid-vagina may drain either way
Distant metastases
Incidence rates: stage I, 16%; stage IIA, 31%; stage IIB, 46%; and stage III, 62% Metastases are seen with advanced disease at presentation or with tumor recurrence after failure of primary therapy The most common sites of distant spread include the lungs, liver, and bony skeleton
Diagnosis, Staging, and Prognosis Clinical Presentation VaIN is most often asymptomatic and is usually detected by means of cytology and routine screening. Invasive cancers most commonly present with irregular vaginal bleeding (often postcoital), followed by vaginal discharge and dysuria. Pelvic pain can occur if the tumor extends beyond the vagina.
Chapter 24 Vaginal Cancer
729
Diagnostic Workup Figure 24.2 presents a proposed algorithm in the workup of the diagnosis of vaginal cancer.
Suspected Vaginal Malignancy
Complete History and Physical Examination (including detailed speculum inspection, digital speculum inspection, digital palpation, and colposcopic and cytological evaluation with biopsy)
Complete blood count
CT/MRI of the abdomen and pelvis
Liver and renal function tests
Intravenous urography
Vaginoscopy with aetic acid and Schiller‘s iodine Cystoscopy
Chest X-ray HIV (clinical suspicion)
FDG-PET
Laboratory Tests
Imaging Studies
Proctoscopy Exam under anesthesia
Secondary cancers of the vagina are more common thus complete metastatic workup is necessary Figure 24.2 A proposed algorithm for the diagnosis of cancer of the vagina
Staging Primary carcinoma of the vagina is staged clinically. The results of the biopsy/fine-needle aspiration (FNA) of the inguinal nodes may be included in the clinical staging. As per the 2010 American Joint Committee on Cancer (AJCC) system, the tumor, node, and metastasis (TNM) system corresponds to the Federation Internationale de Gynecologie et d’Obstetrique (FIGO) staging system (Tables 24.3 and 24.4).
730
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Table 24.3 TNM and FIGO classifications of malignant tumors of the vagina TNM
FIGO
Description
Primary tumor (T) Tx
Primary tumor cannot be assessed
T0
No evidence of primary tumor a
Tis
Carcinoma in situ (pre-invasive cancer)
T1
I
Tumor confined to the vagina
T2
II
Tumor invades the paravaginal tissues either microscopically (T2a) or grossly (T2b) but does not extend up to the pelvic side wall
T3
III
Tumor extends to the pelvic side wall
T4
IVA
Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis
Regional lymph nodes (N)
Nx
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
III
Pelvic or inguinal lymph node metastasis
Distant metastasis (M)
M0 M1
No distant metastasis IVB
Distant metastasis present
a
FIGO: staging no longer includes stage 0 (Tis) Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
Table 24.4 Stage grouping of malignant tumors of the vagina Stage Grouping T1
T2
T3
T4
N0
I
II
III
IVA
N1
III
III
III
IVA
M1
IVB
IVB
IVB
IVB
Source: Edge SB, Byrd DR, Compton CC et al (2009) American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York
Chapter 24 Vaginal Cancer
731
Prognosis Prognostic factors (Tables 24.5 and 24.6): Stage at the time of diagnosis is the most important prognostic factor. Advanced stages have the worst disease-specific survival and cause-specific survival rates. Location of the lesion (upper versus lower), size of the tumor (>4 cm versus <4 cm), age (older than versus younger than 60 years), and histologic type and grade (squamous versus adenocarcinomas) are all considered to be significant prognostic factors. CCA have an increased propensity for distant metastasis to the lung and supraclavicular lymph nodes, as compared with SCC. Patients with vaginal melanomas do more poorly, as compared with SCC, carrying a higher chance of distant metastases. Table 24.5 Outcome of vaginal cancer correlated with stage Trial
Stage 0 (%)
I (%)
II (%)
III (%)
IV (%)
Creasman et al (5-year relative survival)a
96%
73%
58%
36%
36%
Perez et al (10-year DFS)b
94%
75%
IIa: 55% IIb: 43%
32%
0%
Frank et al (5-year DSS)c
–
85%
78%
58%
58%
DFS: disease-free survival, DSS: disease-specific survival a Source: Creasman WT, Phillips JL, Menck HR (1998) The National Cancer Data Base report on cancer of the vagina. Cancer 83:1033–1040 b Source: Perez CA, Camel HM, Galakatos AE et al (1988) Definitive irradiation in carcinoma of the vagina: long-term evaluation of results. Int J Radiat Oncol Biol Phys 15:1283–1290 c Source: Frank SJ, Jhingran A, Levenback C et al (2005) Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138–147
732
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Table 24.6 Outcome of vaginal cancer correlated with treatment modality 5-years
Radiation alone: stages I–IVA (%)a
RT and chemotherapy: stages II–IVA (%)b
OS
58%
66%
DSS
75%
75%
Local control
81%
92%
Complication rate 10%
17%
OS: overall survival, DSS: disease-specific survival a Source: Frank SJ, Jhingran A, Levenback C et al (2005) Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138–147 b Source: Samant R, Lau B, E C et al (2007) Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 69:746–750
Treatment Treatment of VaIN General Principles Table 24.7 details various modalities for the treatment of VaIN. The natural history of VaIN has not been fully characterized, but the recommendation is to treat VaIN because it has the potential to progress to invasive carcinoma. The rate of conversion is reported to be from 9 to 28% in various series. Involvement is commonly multifocal and associated with concomitant cervical intraepithelial neoplasia (CIN) or vulvar intraepithelial neoplasia (VIN). Treatment is guided by multifocal disease, medical comorbidities, the desire to preserve sexual function, to previous treatment failures, and to rule out invasive disease.
Chapter 24 Vaginal Cancer
733
Table 24.7 Different modalities available for treatment of non-invasive carcinoma of the vagina Modality
Description
Non-radiotherapy treatment options Techniquesa
Excision, carbon dioxide ablation, and topical 5-FU chemotherapy have been used, with control rates ranging from 50 to 100%
Low-dose-rate brachytherapy (<200 cGy/h)
Techniqueb
Intracavitary vaginal cylinder with the intent of vaginal surface dose between 60 and 80 Gy. Largest possible diameter that can be comfortably accommodated by the patient should be used to improve the ratio of the mucosa to the tumor and eliminate vaginal rotation
High-dose-rate brachytherapy (>1,200 cGy/h) Techniquec
Applicators similar to low-dose rate can be used with a 10-Ci single iridium (Ir-192) source. Generally, 1–6 insertions with the dose per fraction ranging from 30 to 80 Gy can be used
a
Sources: Hoffman MS, Roberts WS, LaPolla JP et al (1991) Laser vaporization of grade 3 vaginal intraepithelial neoplasia. Am J Obstet Gynecol 165:1342–1344; Fanning J, Manahan KJ, McLean SA (1999) Loop electrosurgical excision procedure for partial upper vaginectomy. Am J Obstet Gynecol 181:1382–1385; Krebs HB (1989) Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil. Obstet Gynecol 73:657–660 b Source: Chyle V, Zagars GK, Wheeler JA et al (1996) Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 35:891–905 c Sources: MacLeod C, Fowler A, Dalrymple C et al (1997) High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina. Gynecol Oncol 65:74–77; Ogino I, Kitamura T, Okajima H et al (1998) High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia. Int J Radiat Oncol Biol Phys 40:881–887
Treatment of Invasive SCC General Principles Several surgical series have reported excellent outcomes in well-selected patients; however, surgery has a limited role, in part because of the close proximity of the bladder and rectum to the surgical site. Radiation therapy (RT) is the primary treatment modality, as noted by the Society of Gynecologic Oncologists in their practice guidelines published in 2006. RT can provide excellent tumor control rates and satisfactory functional results.
734
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Table 24.8 outlines some modalities for vaginal cancer; Table 24.9 outlines treatment strategy studies and results; Figure 24.3 presents an algorithm for treatment. Table 24.8 Different modalities available for treatment of invasive carcinoma of the vagina Type
Description
Surgery
Indications
In patients with stage I disease involving the upper posterior vagina: if the uterus is still in situ, radical hysterectomy, upper vaginectomy to achieve clearance of at least 1 cm, and pelvic lymphadenectomy may be performed, whereas if hysterectomy has been previously performed, radical upper vaginectomy and pelvic lymphadenectomy may be appropriate In young patients who require radiation therapy: pretreatment laparotomy may allow ovarian transposition, surgical staging, and resection of any bulky positive lymph nodes In patients with stage IVA disease, particularly if a rectovaginal or vesicovaginal fistula is present: Primary pelvic exenteration is a suitable treatment option for such patients, combined either with pelvic lymphadenectomy or with preoperative radiation. Bilateral groin dissection should be considered in such patients if the lower third of the vagina is involved In patients with a central recurrence after RT: Surgery will usually necessitate some type of pelvic exenteration in such patients
Radiation therapy Indication
RT is the treatment of choice for most patients with vaginal cancer, and comprises an integration of teletherapy and intracavitary/interstitial therapy
Techniques
External-beam RT (EBRT): to treat the pelvic and inguinal lymph nodes and the primary tumor Intracavitary brachytherapy (ICBT): with a vaginal cylinder applicator with low- or high-dose-rate brachytherapy. To treat superficial lesions <0.5 cm in depth from the vaginal surface Interstitial brachytherapy (ITB): to treat tumors involving >0.5 cm of depth from the vaginal surface, with a template or interstitial freehand implant
Chemotherapy Indication Drugs used
There is limited reported experience with concurrent
chemoradiation for vaginal cancer Cisplatin and 5-FU may be used as radiosensitizing
agents
Chapter 24 Vaginal Cancer
735
Table 24.9 Treatment strategy for vaginal cancer and supporting evidence
a
Trial
Description
Frank et ala
Retrospective review of 193 patients treated at a single institution between 1970 and 2000 Disease-specific survival (DSS) and pelvic disease control rates correlated with International Federation of Gynecology and Obstetrics (FIGO) stage and tumor size At 5 years, DSS rates were 85% for stage I, 78% for stage II, and 58% for stage III–IVA disease (p = 0.0013) Five-year DSS rates were 82 and 60% for patients with tumors <4 cm or >4 cm, respectively (p = 0.0001) At 5 years, pelvic disease control rates were 86% for stage I, 84% for stage II, and 71% for stage III–IVA (p = 0.027) The predominant mode of relapse after definitive radiation therapy was locoregional (68 and 83%, respectively, for patients with stages I–II or III–IVA disease) The incidence of major complications was correlated with FIGO stage; at 5 years, the rates of major complications were 4% for stage I, 9% for stage II, and 21% for stage III– IVA (p < 0.01)
Samant et alb
Retrospective review of all primary vaginal cancer patients treated with curative intent at the Ottawa Hospital Regional Cancer Centre between 1999 and 2004, using concurrent cisplatin (Cis)-platinum CRT 12 patients treated with concurrent weekly CRT Median age at diagnosis 56 years (range, 34–69 years), and the median follow-up was 50 months (range, 11–75 months) Stage distribution: 6 (50%) stage II, 4 (33%) stage III, and 2 (17%) stage IVA All patients received pelvic external-beam radiotherapy (EBRT), 45 Gy per 25 fractions concurrently with weekly intravenous Cis-platinum chemotherapy (40 mg/m2), followed by brachytherapy (BT) with a median dose of 30 Gy The 5-year overall survival, progression-free survival, and locoregional progression-free survival rates were 66, 75, and 92%, respectively Late toxicity requiring surgery occurred in 2 patients (17%)
Source: Frank SJ, Jhingran A, Levenback C et al (2005) Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138–147 b Source: Samant R, Lau B, E C et al (2007) Primary vaginal cancer treated with concurrent chemoradiation using Cis-platinum. Int J Radiat Oncol Biol Phys 69:746–750
736
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Diagnosis of Primary Vaginal Cancer
Staging and Workup
Stage I
Stage II
Stage III/IVa
Large-volume EBRT with concurrent chemotherapy
Pelvic RT
Parametria involved Yes Parametrial boost
Boost to the primary tumor
Intracavitary brachytherapy for lesions <0.5 cm
EBRT boost with 3D or IMRT
Active Follow-Up Figure 24.3 Proposed algorithm for treatment of vaginal cancer
Interstitial brachytherapy for lesions >0.5 cm
Chapter 24 Vaginal Cancer
737
RT Technique Early-Stage Disease (Stage I) Brachytherapy alone is usually adequate for superficial stage I patients, with 95–100% local control with intracavitary and interstitial techniques. External-beam RT (EBRT) can be combined for larger, more infiltrating, or poorly differentiated tumors with high risk of lymph node metastasis. Intermediate-Stage Disease (Stage II) Treatment should include EBRT to the pelvic lymph nodes, with a brachytherapy boost. A parametrial boost should be prescribed if the parametria are involved. Locally Advanced Disease (Stage III–IVa) These patients should receive EBRT to the pelvic lymph nodes, with an additional parametrial dose and a brachytherapy boost (Table 24.10). If brachytherapy is not feasible, they can be treated with a shrinking-field technique. Chemotherapy can improve outcomes in these patients, as indicated by data from some early studies. Table 24.10 Dose prescription for stages I–IVa vaginal cancer Target
Modality
Dose (Gy)
Pelvis
EBRT
40–50
Primary boost
Intracavitary (<5 mm deep) Interstitial (>5 mm deep) 3DCRT/IMRT (post-lesions)
Up to 50 (for apical) 25–30 20
Additional boost (total with pelvis dose)
Parametrial involvement Pelvic sidewall involvement
65 60
Source: Gay H (2008) Vaginal cancer. In: Lu JJ, LW Brady (eds) Radiation oncology: an evidence-based approach. Springer, Berlin Heidelberg New York
738
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Simulation and Target Volumes Computed tomography (CT) simulation with vessel contouring for lymph node localization provides precise and individualized field delineation (Source: Finlay MH, Ackerman I, Tirona RG et al (2006) Use of CT simulation for treatment of cervical cancer to assess the adequacy of lymph node coverage of conventional pelvic fields based on bony landmarks. Int J Radiat Oncol Biol Phys 64:205–209). Patient should lay supine. The frog-leg position can be utilized if treating the inguinal areas. A small radio-opaque marker or seed can be inserted at the tumor site. Bladder and rectal filling – leading to target motion – should be accounted for at the time of simulation. Full- and empty-bladder scans are options, and the vaginal contour drawn on both scans be fused to obtain internal target volume (ITV) (Source: Thawani N, Mutyala S, Lukaj A et al (2008) Bladder filling status strongly influences target volume changes in posthysterectomy patients treated with intensity-modulated radiation therapy (IMRT) for gynecologic cancers. Int J Radiat Oncol Biol Phys 72:S357). Vacuum-bag immobilization should be used for the legs. Treatment Techniques for EBRT Treatment Volumes Dose constraints are listed in Table 24.11, techniques of dose delivery in Table 24.12, and techniques for brachytherapy in Table 24.13. Table 24.11 Dose constraints for normal tissues Site Small bowel Bladder Rectum
Dose Individual bowel loops: V15 < 120 ml Entire potential space: V45 < 195 ml V45 < 35% (should be assessed in conjunction with the brachytherapy dose) V30 < 60% (should be assessed in conjunction with the brachytherapy dose)
Femoral heads
V30 < 15%
Bone marrow
Total marrow: V10 < 95%, V20 < 80%, V30 < 64%, and D75 < 24.5 Gy
Vn: volume of tissue receiving at least n Gy, D75: 75% dose Sources: RTOG protocol 0418, Marks LB, Yorke ED, Jackson A et al (2010) Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 76:S10–S19; Mutyala S, Thawani N, Vainshtein JM et al (2008) Dose constraint recommendations and a predictive nomogram of incidence of hematological toxicity for cervix cancer patients treated with concurrent cisplatin and intensity modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 72:S359–S360
Chapter 24 Vaginal Cancer
739
Gross tumor volume (GTV): tumor volume as defined by clinical exam, MRI (T2-weighted image) with contrast, and RT-planning CT ITV: tumor volume obtained after fusion of the filled- and empty-bladder scans Clinical target volume (CTV): lymph nodes including medial inguinofemoral, external and internal iliac, obturator, and presacral. For upper vaginal lesions, proximal perirectal lymph nodes at the level of the lesion should be included, as well as bilateral parametria Planning target volume (PTV): CTV plus Internal target Volume(ITV), with margin expansions for setup error per institutional protocol (usually 0.7–2 cm) Table 24.12 Techniques of dose delivery Type
Description
Conventional anteroposterior (AP) fields
Field borders
AP field Superior: L5–S1 Inferior: 3–4 cm below the vaginal marker Lateral: 1.5–2 cm of the true pelvic rim and medial half of the femoral heads PA field Lateral: block for the femoral head Inguinal lymph nodes (different techniques to avoid overdose to the femoral heads) Wide AP fields to cover inguinal regions with nar-
row post-fields with 2:1 weighting Combination of low- and high-energy photons
(4–6 MV AP, 15–18 MV PA) Equally weighted beams with a central transmis-
sion block on AP field Small AP photon or electron field ( depth measured
on CT to select energy for electrons) with matching for daily boost to inguinal nodes 3D conformal
Field borders
AP and PA fields as above Lateral fields Anterior: pubic symphysis Posterior: 1 cm into the sacrum, up to S2–S3
IMRT Inverse treatment planning to cover 95% of the Borders
PTV with at least 95% of the dose, with no hot spots above 107%, and the normal tissue dose constraints with a 7- to 9-beam field arrangements and beam energy of 12–18 MV
740
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Table 24.13 Treatment techniques for brachytherapy Type
Description
Low-dose-rate brachytherapy (<200 cGy/h) a
Techniques
Intracavitary single or multichannel cylinder of superficial lesions and interstitial implant freehand or with templatebased needles. Dose recommended is 65–80 Gy if used alone, or 30–40 Gy if used in conjunction with EBRT
Medium-dose-rate brachytherapy (200–1,200 cGy/h) Techniqueb
Applicators similar to low-dose rate, using Cs-137 source
High-dose-rate brachytherapy (>1,200 cGy/h)
Techniquec
Applicators similar to low-dose rate can be used with a 10-Ci single iridium (Ir-192) source. CT-based treatment planning with or without MRI fusion can be used Generally, 3–6 insertions with the dose per fraction ranging from 5 to 8 Gy can be used if used alone or 3–4 insertions for 5–8 Gy in conjunction with EBRT
a
Source: Chyle V, Zagars GK, Wheeler JA et al (1996) Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 35:891–905 b Source: Rutkowski T, Białas B, Rembielak A et al (2002) Efficacy and toxicity of MDR versus HDR brachytherapy for primary vaginal cancer. Neoplasma 49:197–200 c Source: Beriwal S, Heron DE, Mogus R et al (2008) High-dose-rate brachytherapy (HDRB) for primary or recurrent cancer in the vagina. Radiat Oncol 13:3–7
Side Effects of Treatment Early side effects include proctitis, cystitis, and vaginal mucositis during treatment. Late complications include vaginal ulceration, vaginal stenosis (incidence can be decreased by use of vaginal dilators, from 50 to 11%), cystitis, urethral strictures, development of fistula, and femoral-head necrosis. The incidence of late side effects is 10% with the conventional radiation techniques at 5 years, and increases to about 17% with chemotherapy.
Chapter 24 Vaginal Cancer
741
Follow-Up Suggested follow-up schedules and examinations are detailed in Table 24.14. Table 24.14 Follow-up schedule and examinations
Schedule
Frequency
First follow-up
2 weeks; vaginal dilator should be given
Years 0–2
Every 3 months
Years 3–5
Every 6 months
Years 6+
Annually
Examinations History and physical
Including a bimanual pelvic examination
Imaging
Chest x-ray
Pap smear
Annually
Treatment of Adenocarcinoma, CCA, and Melanoma The outcomes of these are poorer than SCC. The principles of treatment are similar however and may be combined with targeted therapies when available for other sites.
742
Nitika Thawani, Subhakar Mutyala and Aaron Wolfson
Chapter 24 Vaginal Cancer
743
Figure 24.4 a–e Treatment fields for a patient being treated for vaginal cancer with pelvic and inguinofemoral nodal radiation. a AP field to treat the pelvis and inguinals. b PA field to treat pelvis only and (c and d) small AP boost fields for daily boost to the inguinal areas. e Axial dose distribution in color wash with sparing of the femoral heads
Section VIII Lymphomas
VIII 25
Non-Hodgkin’s Lymphoma . . . . . . . . . . . . . . . . . 747 Joanne W. Jang and Andrea K. Ng
26 Hodgkin’s Lymphoma . . . . . . . . . . . . . . . . . . . . . . 771 Maryse Bernard and Richard W. Tsang 27
Multiple Myeloma and Plasmacytoma . . . . . . 811 Wee Joo Chng and Ivan W.K. Tham
28
Cutaneous T-Cell Lymphoma . . . . . . . . . . . . . . . 833 Ivan W.K. Tham
29 Primary Central Nervous System Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . 853 Marnee M. Spierer and Evan M. Landau
25
Non-Hodgkin’s Lymphoma Joanne W. Jang1 and Andrea K. Ng2
Key Points Non-Hodgkin’s lymphoma (NHL) is a group of malignancies comprising many different types of lymphoma, and has historically been classified a variety of ways. Current classification schemes take into account the cells of origin for NHL. The clinically relevant classification schemes divide the diseases into indolent and aggressive NHL. Although systemic symptoms (fever, night sweats, weight loss, a.k.a. B symptoms) can occur, most symptoms vary, depending on the site involved. Important prognostic factors include age, stage, number of extranodal sites, performance status, and lactate dehydrogenase (LDH) level, which have all been incorporated into the widely used International Prognostic Index. Other important prognostic factors include tumor size, pathologic subtype, β2-microglobulin concentration, the presence of B symptoms, bone marrow involvement, response to treatment, and duration of remission. Treatment of NHL depends on the clinical classification of the tumor (indolent versus aggressive) and the stage, but can include observation, chemotherapy, radiation, or a combination of chemotherapy and radiation. Radiation plays an important role in the treatment of limited-stage indolent and aggressive lymphomas, and may be of benefit for certain patients with advanced-stage aggressive NHL.
1
Joanne W. Jang, MD, PhD Email:
[email protected]
2
Andrea K. Ng, MD, MPH () Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_8, © Springer-Verlag Berlin Heidelberg 2011
748
Joanne W. Jang and Andrea K. Ng
Epidemiology and Etiology The incidence of non-Hodgkin’s lymphoma (NHL) is 19.5 per 100,000 in the United States. It was estimated that in 2010, 65,540 patients were diagnosed with NHL, and 20,210 patients died. Multiple risk factors have been determined for NHL and are delineated in Table 25.1. Table 25.1 Risk factors for NHL Factor
Description Part medical history: previous NHL, Hodgkin’s lymphoma, other lymphoproliferative or hematopoietic malignancies, basal cell or squamous cell skin cancers Family history: twofold increase in risk for those who have at least one 1st-degree relative with NHL Genetic predisposition: polymorphisms in TNF, interleukin-10 genes, various translocations associated with different NHL
Patient related
Immunosuppression: congenital autoimmune disorders (e.g. Sjögren’s syndrome, lupus, celiac disease, rheumatoid arthritis), organ transplantation Infections: HIV associated with NHL, HTLV-1 associated with adult T-cell leukemia/lymphoma, HHV-8 associated with NHL, EBV associated with Burkitt’s lymphoma, Helicobacter pylori associated with gastric B-cell lymphomas (particularly MALT lymphoma)
Environmental
Occupational: farmers, livestock workers, printers, teachers, woodworkers, dry cleaners, barbers, hairdressers
HTLV: T-cell lymphotropic virus type 1, HHV-8: human herpes virus type 8, MALT: mucosa-associated lymphoid tissue
Chapter 25 Non-Hodgkin’s Lymphoma
749
Classification The 2008 World Health Organization (WHO) classification of hematopoietic and lymphoid neoplasms takes into account morphology, immunophenotype, and genetic and clinical factors (Table 25.2). NHL is often subdivided into categories that are indicative of their clinical behaviors (Table 25.3). The most common histologic subtype is diffuse large B-cell lymphoma (DLBCL), and the second most common subtype is follicular lymphoma; these subtypes account for 25 and 20% of all NHL, respectively. Table 25.2 WHO classification of lymphoid neoplasms Category
Description
Precursor lymphoid neoplasms
Precursor B-cell lymphoblastic leukemia/lymphoma Precursor T-cell lymphoblastic leukemia/lymphoma
Mature B-cell neoplasms
Mantle cell lymphoma B-cell prolymphocytic leukemia Chronic lymphocytic leukemia/small lymphocytic lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Burkitt’s lymphoma Marginal zone lymphoma, extranodal and nodal Primary cutaneous follicle center lymphoma Lymphomatoid granulomatosis Plasmablastic lymphoma Hairy cell leukemia Lymphoplasmacytic lymphoma Waldenström’s macroglobulinemia Heavy chain diseases Plasma cell myeloma, solitary plasmacytoma of bone, extraosseous plasmactyoma Large B-cell lymphoma
Hodgkin’s lymphoma
Nodular lymphocyte predominant Classical
Mature T-cell or NK-cell neoplasms
T-cell prolymphocytic leukemia Anaplastic large cell lymphoma Cutaneous peripheral T-cell lymphoma Adult T-cell lymphoma/leukemia T-cell large granular lymphocyte leukemia NK-cell large granular lymphocyte leukemia Aggressive NK-cell leukemia
750
Joanne W. Jang and Andrea K. Ng
Table 25.3 NHL classified by clinical behavior Category
Description
Indolent
Chronic lymphocytic leukemia/small lymphocytic lymphoma Lymphoplasmacytic lymphoma Plasma cell myeloma, plasmacytoma Hairy cell leukemia Follicular lymphoma, grades I and II Marginal zone B-cell lymphoma Mantle cell lymphoma T-cell large granular lymphocyte leukemia Cutaneous peripheral T-cell lymphoma T-cell prolymphocytic leukemia NK-cell large granular lymphocyte leukemia
Aggressive
Follicular lymphoma, grade III Diffuse large B-cell lymphoma Mantle cell lymphoma Peripheral T-cell lymphoma Anaplastic large cell lymphoma
Highly aggressive
Burkitt’s lymphoma Precursor B lymphoblastic leukemia/lymphoma Adult T-cell lymphoma/leukemia Precursor T lymphoblastic leukemia/lymphoma
Chapter 25 Non-Hodgkin’s Lymphoma
751
Diagnosis, Staging, and Prognosis Clinical Presentation A thorough history and physical, including the presence of B symptoms and a complete lymph node and skin evaluation, should be the first objective, and is essential in guiding further testing. Approximately two thirds of patients present with painless lymphadenopathy. Other symptoms vary widely, depending on the histologic subtype and areas of involvement. Those symptoms are detailed in Table 25.4. Table 25.4 Common signs and symptoms of NHL Signs/Symptoms
Description
Patient history
Painless lymphadenopathy is present B symptoms include fever >38°C, weight loss >10% of body weight over 6 months, and night sweats Obstructing symptoms present in the thorax or abdomen from a nodal mass Mediastinal lymphadenopathy can cause cough, chest discomfort, and/or SVC syndrome Gastrointestinal lymphomas can cause anorexia, weight loss, nausea, vomiting, pain, early satiety, abdominal fullness, gastrointestinal bleeding, or perforation CNS involvement can result in headache, nausea, vomiting, seizures, or focal neurologic deficits
Abnormalities in common laboratory studies
Thrombocytopenia, neutropenia, and anemia are unreliable indicators of bone marrow involvement Blood urea nitrogen (BUN) and creatinine can indicate ureteral obstruction or, rarely, kidney involvement by NHL Liver chemistries (serum glutamic-oxaloacetic transaminase [SGOT], total bilirubin, alkaline phosphatase) can indicate hepatic involvement and assess liver function Elevated alkaline phosphatase in isolation can indicate skeletal involvement Hypercalcemia can occur in aggressive lymphomas
SVC syndrome: superior vena cava syndrome
752
Joanne W. Jang and Andrea K. Ng
Diagnostic and Staging Procedures Table 25.5 outlines the various methods of obtaining tissue for diagnosis. Once tissue is obtained, Figure 25.1 can be used as a demonstration of one diagnostic process for NHL. Table 25.5 Types of biopsy Type
Description
Excisional biopsy
The gold standard
Fine-needle aspiration (FNA)
Pros: quicker, less painful, easier, less expensive, does not require general anesthesia or hospital admission Cons: may lead to false negatives, does not provide histologic architecture, may provide inadequate amounts of tissue for ancillary testing, such as flow cytometry, immunohistochemistry (IHC), and molecular genetic studies
Core needle biopsy
Pros: can be either CT- or ultrasound-guided, can provide more tissue and architectural features, as compared with FNA Cons: still provides less tissue and architectural information, as compared with excisional biopsy
Tissue biopsy
Formalin fixation
Fresh material
H&E staining with thorough microscopic exmination
Flow cytometry or cytogenetics
IHC
If needed, PCR or FISH to confirm clonality, detect specific translocations or gene rearrangements
Figure 25.1 A proposed diagnostic algorithm for NHL
Chapter 25 Non-Hodgkin’s Lymphoma
753
Recommended studies for the initial evaluation of a patient suspected of having NHL are delineated in Table 25.6. Table 25.6 Recommended studies Type
Description Recommended
Laboratory studies
Complete blood count (CBC) with differential, peripheral blood smear lactate dehydrogenase (LDH), β2-microglobulin BUN, creatinine, albumin, SGOT, total bilirubin, alkaline phosphatase, calcium, uric acid Serum protein electrophoresis If indicated: viral serologies, hepatitis B, hepatitis C, HIV, HTLV-1 Recommended Bone marrow aspirate and biopsy Chest radiograph (posterior–anterior [PA] and lateral) CT of the chest, abdomen, and pelvis Optional: PET scan If clinically indicated
Radiologic studies or special procedures
MRI (bone marrow involvement) Ear, nose, and throat examination Slit-lamp examination (central nervous system, ocular lymphoma) Testicular ultrasound of contralateral testis in testicular lymphoma Gastrointestinal evaluation Skeletal evaluation Head CT or MRI Lumbar puncture and CSF analysis Mammogram Echocardiogram or multiple-gated cardiac exam
754
Joanne W. Jang and Andrea K. Ng
Clinical Staging of NHL The Ann Arbor Staging Classification is used for NHL, as detailed in Table 25.7. Table 25.7 Ann Arbor staging system Stage
Tumor location
I
Involvement of a single lymph node* or of a single extranodal organ or site (IE)
II
Involvement of 2 or more lymph node regions on the same side of the diaphragm, or localized involvement of an extranodal site or organ (IIE) and 1 or more lymph node regions on the same side of the diaphragm
III
Involvement of lymph node regions on both sides of the diaphragm, which may also be accompanied by localized involvement of an extranodal organ or site (IIIE) or spleen (IIIS) or both (IIISE)
IV
Diffuse or disseminated involvement of 1 or more distant extranodal organs with or without associated lymph node involvement
*
The spleen is considered nodal Cases are subclassified to indicate the absence (A) or presence (B) of B symptoms
Prognosis The International Prognostic Index (IPI) is a commonly used model that incorporates five different adverse factors (Table 25.8) to predict relapse-free survival (RFS) and overall survival (OS). Each adverse factor accounts for 1 point. The IPI is shown in Table 25.9. Table 25.8 Factors of the International Prognostic Index Risk factor
At risk when:
Age
>60 years
LDH
Abnormal
Performance status (ECOG)
≥2
Stage
III–IV
Number of extranodal sites
>1
Chapter 25 Non-Hodgkin’s Lymphoma
755
Table 25.9 International Prognostic Index Risk group
Risk factor
5-Year OS (%)
Low
0–1
73%
Low intermediate
2
51%
High intermediate
3
43%
High
4–5
26%
Source: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma: N Engl J Med 329:987– 984
There are multiple variants of the IPI, including age adjusted, stage adjusted, the revised IPI in the rituximab era, a follicular lymphoma IPI, and a second-line IPI. Other prognostic factors not accounted for in the IPI are listed in Table 25.10. Table 25.10 Additional prognostic factors Factor
Description
Clinical
Treatment related
Time to complete response Mid-treatment 18F-FDG-PET imaging
Relapsed or refractory disease
Response to second-line chemotherapy Duration of remission Primary refractory disease, as compared with relapsed disease
Histopathologic subtype Tumor size B symptoms β2-microglobulin concentration Number of nodal sites Bone marrow involvement
756
Joanne W. Jang and Andrea K. Ng
Treatment Principles and Practice In general, treatment for NHL depends on the behavior of the tumor (indolent versus aggressive) and the stage (stages I–II versus III–IV). A proposed treatment algorithm is presented in Figure 25.2.
Diagnosis an staging of NHL
Aggressive NHL
Indolent NHL
Limited stage (I-II)
Advanced stage (III-IV)
Limited stage (I-II)
Advanced stage (III-IV)
Involved field radiation (IFRT) to 30 GY-36 GY
Observation. Chemotherapy or radiation for symptomatic disease
Chemotherapy for3-8 cycles followedby IFRT to 30 Gy-40 Gy
Chemotherapy for 6-8 cycles followed by IFRT to bulky or partial response sites to 30 Gy-40 Gy
Figure 25.2 Treatment algorithm for NHL
Treatment of Limited-Stage Indolent NHL Only 15–30% of patients with indolent lymphomas present with limitedstage disease. Although data are limited, radiation is the primary treatment for these patients. Selected retrospective studies with at least 100 patients treated with radiation are presented in Table 25.11. Recommended treatment is involved-field or regional radiation therapy (involved nodal region plus one additional uninvolved region on each side of the involved nodes) to 30–36 Gy. This is associated with a local control rate of >90%, and a long-term freedom-from-treatment-failure rate of approximately 50%.
Chapter 25 Non-Hodgkin’s Lymphoma
757
Table 25.11 Clinical evidence of treatment of limited-stage indolent NHL Study
Description
Vaughan Hudson et al (BNLI)a
Retrospective review of 208 patients with stage I low-grade NHL treated with radiation alone 35 Gy suggested, but actual radiation doses and fields unknown 98% achieved complete remission (CR) for at least 3 months 10-year freedom from treatment failure (FFTF) was 47%; 10-year OS was 64% Age ≥50 years significantly associated with worse FFTF and OS
Petersen et al (Princess Margaret Hosp.)b
Retrospective review of 460 patients with stage I (74%) and II (26%) follicular lymphoma treated with radiation alone Involved-field radiation to a median dose of 35 Gy Median follow-up was12.5 years 10-year FFTF, 51%; 10-year OS, 62%
Mac Manus et al (Stanford Univ.)c
Retrospective review of 177 patients with stage I (41%) and II (59%) follicular lymphoma treated with radiation Involved-field (IF), extended-field or total lymphoid irradiation to 35–40 Gy. Most patients had chemotherapy afterward Median follow-up, 7.7 years 10-year FFTF was 44%; 10-year OS was 64% Age ≥60 years, extranodal involvement, stage II disease, and radiation on only 1 side of the diaphragm associated with worse FFTF and OS
Soubeyearan et al (Foundation Bergonié)d
Retrospective review of 103 patients with stage I (44%) and II (56%) follicular lymphoma treated with radiation with or without chemotherapy Involved-field (54%) or regional-field (46%) radiation from 35 to 40 Gy 70% of patients received chemotherapy Median follow-up, 8.3 years 10-year FFTF was 49%; 10-year OS was 56% Age ≥60 years and B symptoms were significantly associated with worse FFTF and OS ▶
758
Joanne W. Jang and Andrea K. Ng
Table 25.11 (continued) Study
Description
Guadagnolo et al (Harvard Univ.)e
Retrospective review of 106 patients with stage I (74%) and II (26%) grades 1–2 follicular lymphoma treated with radiation with (24%) or without chemotherapy (76%) Median follow-up, 12 years Involved-field (60%), regional-field (34%), or extended field (6%) radiation to a median dose of 36.7 Gy 10-year FFTF, 46%; 10-year OS, 75% Tumor size associated with worse FFTF; age ≥60 years associated with worse OS
BNLI: British National Lymphoma Investigation a Source: Vaughan Hudson B, Vaughan Hudson G, MacLennan KA et al (1994) Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 69:1088–1093 b Source: Petersen PM, Gospodarowicz M, Tsang R et al (2004) Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone. In: Abstract of the 2004 ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 22:S6521 c Source: Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282–1290 d Source: Soubeyearan P, Eghbali H, Bonichon F et al (1988) Localized follicular lymphomas: prognosis and survival of stages I and II in a retrospective series of 103 patients. Radiother Oncol 13: 91–98 e Source: Guadagnolo BA, Li S, Neuberg D et al (2006) Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64:928–934
Treatment of Advanced-Stage Indolent NHL The majority of patients with indolent NHL present with advanced-stage disease. Observation is recommended for select patients with asymptomatic, low-volume disease. Clinical evidence for this approach is presented in Table 25.12. In specific situations such as outlined in Table 25.13, palliative localized radiotherapy can be very effective. Lower doses to 20–30 Gy can be used in this setting. There is a growing body of literature that also supports the use of very low doses of involved-field palliative radiation to 4 Gy, with very good response rates, as delineated in Table 25.14.
Chapter 25 Non-Hodgkin’s Lymphoma
759
Table 25.12 Clinical evidences on treatment of advanced-stage indolent NHL Study
Description
Ardeshna et al (BNLI)a
309 patients with asymptomatic advanced-stage lowgrade NHL randomized to immediate chlorambucil versus delayed chlorambucil for progressive disease Localized RT to 15–20 Gy allowed Median follow-up, 16 years 10-year OS, 35% for the chlorambucil group and 34% for the observation group. Median OS, 5.9 years for the chlorambucil group and 6.7 years for the observation group (p = 0.84) In the observation group, 73% eventually received chemotherapy, with a median time to treatment of 2.6 years. At the time of publication, 13 patients were still alive without systemic treatment ; 5 had local radiation; 7 had spontaneous remissions
Portlock et al (Stanford Univ.)b
Retrospective review of 44 patients with stages III–IV lowgrade NHL that were observed until treatment became indicated, and 112 patients who participated in randomized controlled trials involving chemotherapy For the observation cohort, median time to treatment was 31 months, with 19 patients still on observation at the time of publication. Median OS, 121 months 4-year OS was 77.3% for the observation cohort and 83.2% for the treatment cohort (p = 0.6)
a
Source: Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516–522 b Source: Portlock CS, Rosenberg SA (1979) No initial therapy for stage III and IV nonHodgkin’s lymphomas of favorable histologic subtypes. Ann Intern Med 90:10–13
Table 25.13 Indications for palliative radiation in advanced-stage indolent NHL Indications Localized chemotherapy-resistant disease Prevention or treatment of symptomatic spinal cord or nerve root involvement Superior vena cava syndrome or obstructive pneumonia To reduce the risk of fracture of an involved bone Venous obstruction from a large pelvic mass Local symptomatic relief (e.g., orbit, stomach) Cosmetic
760
Joanne W. Jang and Andrea K. Ng
Table 25.14 Clinical evidence on low-dose radiation for advanced-stage indolent NHL
a
Study
Description
Haas et al (The Netherlands)a
Phase II study was of 109 patients (304 total sites) with recurrent indolent B-cell NHL. 90% of patients had follicular NHL 94% had prior systemic therapy, 28% had prior radiotherapy 27% had 4 Gy in 1 fraction; 73% had 4 Gy in 2 fractions Overall response rate of 92%: 61% achieved complete response (CR) and 31% had partial response (PR) Median time to local progression was 25 months; median time to local or distant progression was 14 months
Girinsky et al (France)b
Retrospective study of 48 patients (135 sites) with relapsed or refractory low-grade NHL treated with 4 Gy in 2 fractions 94% had prior systemic therapy Median follow-up was 4.5 years Median overall survival was 10.7 years At the 1- to 2-month follow-up, 43% achieved CR and 35% had PR; at the 3- to 4-month follow-up, 57% achieved CR and 24% had PR 2-year freedom from local progression was 56% On univariate analysis, tumor size ≥5 cm, >1 prior chemotherapy regimens, and age ≥65 years associated with worse 2-year freedom from local progression
Luthy et al (Harvard University)c
Retrospective review of 33 patients (43 sites) with advanced or recurrent indolent NHL were treated with 4 Gy in 2 fractions Median follow-up was 14 months Overall response rate of 95%: 84% achieved CR and 12% had PR Median time to local progression was 9 months and median time to any progression was 4 months Site of disease (head and neck) and size ≤4 cm associated with CR
Source: Haas RL, Poortmans P, de Jong D et al (2003) High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21:2474–2480 b Source: Girinsky T, Guillot-Vals D, Koscielny S et al (2001) A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 51:148–155 c Source: Luthy SK, Ng AK, Silver B et al (2008) Response to low-dose involved-field radiotherapy in patients with non-Hodgkin’s lymphoma. Ann Oncol 19:2043–2047
Chapter 25 Non-Hodgkin’s Lymphoma
761
If systemic therapy is indicated, alkylating agents or purine analogs are often used. Common historical chemotherapy regimens are listed in Table 25.15. More recently, the use of rituximab, an anti-CD20 monoclonal antibody, in combination with some of these regimens has been shown in randomized clinical trials to significantly improve outcome. As a result, it is now often given as a single agent or in combination with other chemotherapeutic agents. For patients with relapsed or refractory disease who require treatment, there is no standard therapy. Options for, and descriptions of, treatment are listed in Table 25.16. Table 25.15 Common chemotherapeutic regimens for indolent NHL Regimen
Combination of (drug)s
–
Fludarabine (single agent)
–
Chlorambucil (single agent)
CVP
Cyclophosphamide, vincristine, and prednisone
CHOP
Cyclophosphamide, adriamycin, vincristine, and prednisone
MCP
Mitoxantrone, chlorambucil, and prednisone
FCM
Fludarabine, cyclophosphamide, and mitoxantrone
Table 25.16 Treatment of relapsed/refractory advanced-stage indolent NHL Treatment Chemotherapy Immunotherapy
Radioimmunotherapy
Hematopoietic stem cell transplant (HCT)
Description Clinical trials of new chemotherapy agents, or different combinations of existing agents Rituximab, with or without additional chemotherapeutic agents Monoclonal antibodies are linked to radioisotopes Ibritumomab tiuxetan (Zevalin) is murine anti-CD20 conjugated to Yttrium-90 Tositumomab (Bexxar) is murine anti-CD20 conjugated to Iodine-131 Controversial, but may have a role in select patients Autologous HCT may be beneficial for some patients in complete or near-complete remission after their first chemotherapy regimen Autologous HCT may be of benefit for patients who have a CR or PR to second-line chemotherapy for relapsed disease Although treatment-related mortality is approximately 30%, myeloablative allogeneic HCT may be curative in some patients. Non-myeloablative (reduced intensity) allogeneic HCT decreases treatment-related mortality and can provide long-term progression-free survival (PFS)
762
Joanne W. Jang and Andrea K. Ng
Treatment of Limited-Stage Aggressive NHL Historically, radiation alone was the standard of care for limited-stage aggressive NHL, with 5-year recurrence free survival approaching 50%. The addition of chemotherapy improved recurrence free and overall survival, and the standard of care is now monoclonal antibody rituximab combined with cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and prednisone/prednisolone (R-CHOP) with or without radiation. Table 25.17 outlines some of the randomized trials assessing the role of radiation therapy for patients with early-stage aggressive NHL. Of note, none of the trials used R-CHOP, which is the current standard systemic therapy for B-cell marker CD-20–positive aggressive NHL.
Table 25.17 Radiation for limited-stage aggressive NHL Study
Description
Horning et al (ECOG 1484)a
352 patients with bulky stage I, IE, or II aggressive NHL randomized to CHOP for 8 cycles, succeeded by observation if achieved a CR versus CHOP for 8 cycles, followed by IFRT to 30 Gy if they achieved a CR. If PR, received IFRT to 40 Gy Powered to detect a difference in disease-free survival (DFS) but not OS 61% of patients achieved CR Median follow-up 12 years 6-year DFS was 53% for the observation arm, and 69% for the radiation arm (p = 0.04) 6-year OS was 67% for the observation arm, and 79% for the radiation arm (p = 0.23) 16% of patients in the observation arm, and 4% of patients in the radiation arm relapsed in a previously involved site (p = 0.06)
Miller et al (SWOG 8736)b
401 patients with stage I and non-bulky stage II disease to CHOP for 3 cycles, followed by IFRT to 40–55 Gy versus CHOP for 8 cycles, followed by observation 5-year PFS was 77% in the radiation arm, and 64% in the observation arm (p = 0.03) 5-year OS was 82% in the radiation arm, and 72% in the observation arm (p = 0.02) Updated results: at 7 years, there was no longer a difference in PFS and at 9 years, there was no longer a difference in OS Subanalysis revealed that patients in the radiation arm without any stage-adjusted IPI risk factors had a 5-year OS of 94%
Chapter 25 Non-Hodgkin’s Lymphoma
763
Table 25.17 (continued) Study
Description
Reyes et al (GELA LNH 93-1)c
631 patients 60 years or younger with stage I–II low-risk aggressive NHL randomized to chemotherapy with ACVBP versus CHOP for 3 cycles, followed by IFRT to 40 Gy Median follow-up was 7.7 years 5-year event-free survival (EFS) was 74% in the radiation arm, and 82% in the chemotherapy-alone arm (p < 0.001) 5-year OS was 81% in the radiation arm, and 90% in the chemotherapy-alone arm (p = 0.001) 14% of patients in the chemotherapy-alone arm relapsed (41% in an initial site, 38% in a distant site, and 21% in both), and 24% of patients in the radiation arm relapsed (23% in the radiation field, 72% outside of the radiation field, and 5% in both) ACVBP with a theoretical dose intensity of at least 150% greater than CHOP for 3 cycles
Bonnet et al (GELA 93-4)d
518 patients older than 60 years with stage I–II low-risk aggressive NHL randomized to CHOP for 4 cycles, followed by observation versus CHOP for 4 cycles, followed by IFRT to 40 Gy Median follow-up was 7 years 5-year EFS was 64% in the radiation arm, and 61% in the chemotherapy-alone arm (p = 0.6) 5-year OS was 68% in the radiation arm, and 72% in the chemotherapy-alone arm (p = 0.5) 29% of patients in the chemotherapy-alone arm relapsed (47% in an initial site, 37% at a distant site, and 16% in both) and 22% of patients in the radiation arm relapsed (21% in the radiation field, 66% outside of the radiation field, and 13% in both)
ECOG: Eastern Cooperative Oncology Group, SWOG: Southwest Oncology Group, GELA: Groupe d’Etude des Lymphomes de l’Adulte, ACVBP: Adriamycin (doxorubicin), cyclophosphamide, vindesine, bleomycin, prednisone a Source: Horning SJ, Weller E, Kim K et al (2004) Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22:3032–3038 b Source: Miller TP, Dahlberg S, Cassady JR et al (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 339:21–26. Updated results shown at the 2001 American Society of Hematology annual meeting c Source: Reyes F, Lepage E, Ganem G et al (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197–1205 d Source: Bonnet C, Fillet G, Mounier N et al (2007) CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the GELA. J Clin Oncol 25:787–792
764
Joanne W. Jang and Andrea K. Ng
In summary, involved-field radiation therapy (IFRT) reduced the risk of relapse at initial sites of disease, but this benefit in local control can only manifest as a benefit in disease-free or overall survival, with improved control of distant metastases obtained by using optimal chemotherapy. Radiation is not able to compensate for inferior or inadequate chemotherapy, except in a select group of highly favorable patients. Although current treatment regimens vary widely among institutions, they commonly include three to eight cycles of R-CHOP, succeeded by IFRT. Radiation is usually given to 30–36 Gy for initial sites of disease, especially if a complete response (CR) to chemotherapy is achieved. For patients with partial response (PR) to chemotherapy with residual fluorodeoxyglucose (FDG) avidity, doses of at least 40 Gy should be considered.
Treatment of Advanced-Stage Aggressive NHL Chemotherapy is the mainstay of treatment for patients with disseminated aggressive NHL. CHOP or CHOP-like chemotherapy regimens have resulted in 4-year disease-free state (DFS) rates of 35–45%. The addition of rituximab has increased the rates of survival by 10–15%, and a regimen of six to eight cycles of R-CHOP is now standard of care. The use of radiation is more controversial. However, some studies have shown a benefit to radiation to bulky sites of disease (Table 25.18). Many institutions will also give IFRT to sites with residual FDG avidity after completion of chemotherapy. As a result, although it is controversial, radiotherapy will be often given after chemotherapy for sites of bulky disease, or for presumed residual disease seen on positron-emission tomography (PET) scan.
Table 25.18 Radiation for advanced-stage aggressive NHL Study
Description
Avilés et al (Mexico)a
341 patients with nodal bulky (>10 cm) stage IV DLBCL who had a CR to 6 months of chemotherapy (cyclophosphamide, vincristine, epirubicin, prednisone, bleomycin) randomized to observation versus radiation to site of bulky disease Median follow-up was 10.1 years 5-year EFS was 55% for the observation arm, and 82% for the radiation arm (p < 0.001) 5-year OS was 66% for the observation arm, and 87% for the radiation arm (p < 0.01) 45% of patients in the observation arm (63% at site of bulky disease) and 18% of patients in the radiation arm (7% at site of bulky disease) relapsed (p < 0.001)
Chapter 25 Non-Hodgkin’s Lymphoma
765
Table 25.18 (continued) Study
Description
Schlembach et al (MDACC)b
Retrospective review of 59 patients with stage III–IV intermediate-grade or large-cell lymphoma, with at least PR to 6 cycles or more of CHOP-based chemotherapy, followed by IFRT to 30–50 Gy Median follow-up was 53 months 5-year local control (LC) was 89% for the radiation arm, and 52% for the observation arm (p = 0.001) 5-year freedom from progression (FFP) was 85% for the radiation arm, and 51% for the observation arm (p = 0.003) 5-year OS was 87% for the radiation arm, and 81% for the observation arm (p = 0.6) Improved LC and FFP mostly for patients with bulky (≥4 cm)
Ferreri et al (Italy)c
Retrospective review of 94 patients with stage III–IV DLBCL, 38 with bulky disease (≥10 cm), and 56 with semibulky disease (6–9 cm), in CR after chemotherapy, then treated with or without radiation 40 patients given radiation (50% with bulky disease), 54 patients observed (33% with bulky disease) Of patients that received radiation, 70% had IFRT to 30– 45 Gy, and 30% had EFRT to 30–46 Gy 5-year OS was 66% for radiation group, compared with 44% for observation group (p = 0.01). This benefit was mostly seen in patients with bulky disease Patients in the radiation arm had a statistically longer time to relapse (TTR) Patients with bulky DLBCL treated with radiation had fewer relapses at the site of bulky disease, and patients with semi-bulky DLBCL treated with radiation had fewer relapses overall, compared with patients in the observation arm
MDACC: MD Anderson Comprehensive Cancer Center a Source: Avilés A, Fernándezb R, Pérez F et al (2004) Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk Lymphoma 45:1385–1389 b Source: Schlembach PJ, Wilder RB, Tucker SL et al (2000) Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III–IV, intermediate grade and large-cell immunoblastic lymphomas. Int J Radiat Oncol Biol Phys 48:1107–1110 c Source: Ferreri AJ, Dell’Oro S, Reni M et al (2000) Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology 58:219–226
766
Joanne W. Jang and Andrea K. Ng
Radiation Therapy Techniques Traditionally, extended fields have been used to treat sites of active disease as well as treat adjacent nodal volumes that were presumed to be at high risk for spread. Table 25.19 lists and describes these fields. More recently, IFRT has been found to be adequate in many cases. An involved field includes the involved lymph nodes as well as other lymph nodes within the same lymph node region (Figure 25.3). Commonly used fields are described in Table 25.20 and Figure 25.4. Table 25.19 Extended radiation treatment fields for NHL Field
Mantle (Figure 25.4)
Modified mantle
Para-aortic
Description Used to treat the bilateral cervical, supraclavicular, submental, mediastinal, hilar, and axillary lymph nodes Simulate with arms up to pull axillary lymph nodes away from the chest wall, and with neck hyperextended to limit dose to oral cavity Extend fields to allow at least a 2-cm margin from disease Borders Lateral: beyond humeral heads, flash the axilla Inferior: 5 cm below the carina (~T10) Superior: 1 cm above mastoid tip or from the bottom of the lower lip to the external auditory meatus Blocks Larynx: usually after 18 Gy if giving radiation alone. Approximately 2 × 2 cm, with the inferior border at the bottom of C5 Lungs: start from the top of the 4th rib (or 2 cm below the clavicle), extending downward laterally to reach the chest wall by the 6th rib. Hilar margin is 1.5 cm if positive or 1.0 cm if negative for disease Wing block: tip of scapula Mouth: posterior mouth block on PA only Can block humeral heads, but need to make sure entire axilla is being irradiated Modifications to decrease the size of the mantle field can often be made, depending on the extent of disease Similar to a mantle field but may exclude the upper neck and/or the axillae Used to treat the paraaortic lymph nodes. Extend fields to allow at least a 2-cm margin from disease Borders: Superior: top of T11 Inferior: bottom of L4 Lateral: transverse processes Blocks: kidneys if possible
Chapter 25 Non-Hodgkin’s Lymphoma
767
Table 25.19 (continued) Field
Description
Inverted Y
Used to treat the bilateral iliac, inguinofemoral, and paraaortic lymph nodes, with or without splenic irradiation Shield testes in men, consider oophoropexy in women Extend fields to allow at least a 2-cm margin from disease Borders: Superior: top of T11 Inferior: 5 cm below the lesser trochanter Lateral: greater trochanter Medial: split obturator foramen Blocks: kidneys if possible
Total lymphoid irradiation (TLI)
Mantle field radiation followed by inverted-Y field radiation
Subtotal TLI (STLI)
TLI without the pelvic irradiation (mantle plus paraaortic fields)
Figure 25.3 Lymph node regions based on the Rye Classification for staging. (Adapted from the Surveillance, Epidemiology, and End Results (SEER) Web site at http://seer. cancer.gov)
768
Joanne W. Jang and Andrea K. Ng
Table 25.20 Involved-field radiation therapy (IFRT) for NHL Field
Description
Neck
Includes the ipsilateral cervical and supraclavicular lymph nodes Borders: Medial: contralateral pedicles Lateral: extends out laterally to include two thirds of the clavicle, often where coracoid process is seen Inferior: 1 cm below clavicular head Superior: 1 cm below mastoid tip
Mediastinum
Includes the mediastinum with bilateral hilar, subcarinal, and medial supraclavicular lymph nodes Extend fields to allow at least a 2-cm margin from disease Borders: Superior: C5/C6 Inferior: 5 cm below the carina Lateral: 1.5 cm margin from the hilum
Axilla
Includes the ipsilateral axillary, supraclavicular, and infraclavicular lymph nodes Extend fields to allow at least a 2-cm margin from disease Borders: Superior: C5/C6 Inferior: lower tip of the scapula, approximately the 6th rib Lateral: flash the axilla Medial: ipsilateral cervical transverse process or pedicle Blocks: lung
Abdomen
Includes the paraaortic lymph nodes Extend fields to allow at least a 2-cm margin from disease Borders: Superior: top of T11 Inferior: bottom of L4 Lateral: transverse processes Blocks: kidneys if possible
Inguinal
Includes the ipsilateral lower pelvic, inguinal, and femoral lymph nodes Extend fields to allow at least a 2-cm margin from disease Borders: Superior: middle or bottom of sacroiliac joint Inferior: 5 cm below the lesser trochanter Lateral: greater trochanter of the femur Medial: medial border or middle of the obturator foramen
Chapter 25 Non-Hodgkin’s Lymphoma
769
Figure 25.4 Mantle field for NHL radiation therapy. (Adapted from Koh ES, Tran TH, Heydarian M et al (2007) A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2:13)
Follow-Up The National Comprehensive Cancer Network (NCCN) has established guidelines for follow-up of patients with NHL (Table 25.21). Table 25.21 Follow-up schedule and recommendations Category
Description
Indolent NHL
Every 3 months for the first year, then every 3–6 months afterward
Aggressive NHL
Every 3 months for years 0–2, then every 6 months for years 2–5
Monitoring techniques
Careful history and physical Complete blood counts and serum chemistries (including LDH) Imaging study as clinically indicated
Source: NCCN clinical practice guidelines in oncology for NHL. Available at: http:// www.nccn.org/professionals/physician_gls/PDF/nhl.pdf)
770
Joanne W. Jang and Andrea K. Ng
PET scan has emerged as a useful modality for pretreatment staging, and mid- or posttreatment restaging, and to assess the response of NHL to therapy, such as for patients with DLBCL. However, some NHL are not reliably FDG avid, and the utility of PET imaging is limited, such as for many indolent NHL. For routine surveillance, the use of computed tomography (CT) or PET scan has not been validated, but is used in many institutions. Patients with NHL respond variably to treatment, and current response definitions are shown in Table 25.22. Table 25.22 Response definitions for NHL Response
Description
Complete remission (CR)
Disappearance of all evidence of disease If previously PET avid nodal disease or with palpable spleen or liver, disease is now PET negative and not palpable Regression of lymph nodes to normal size If involved prior to treatment, bone marrow biopsy shows no disease
Partial remission (PR)
Stable disease (SD)
Failure to attain CR, PR, or PD One or more previously involved sites remain FDG avid No change in size of previous lesions
Relapsed or progressive disease (PD)
New lesions or an increase of disease New lesions ≥1.5 cm or ≥50% increase in any diameter of a previously involved site ≥50% increase in size of liver or spleen at their nadir size during treatment New or recurrent bone marrow involvement
Regression of disease and no new sites ≥50% decrease in size of up to 6 largest masses One or more previously involved sites remain FDG avid No increase in the size of the liver or spleen
Source: Cheson BD, Pfistner B, Juweid ME et al (2007) The International Harmonization Project on Lymphoma: revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586
26
Hodgkin’s Lymphoma Maryse Bernard 1 and Richard W. Tsang2
Key Points An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010. Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30−. Common presentation is an asymptomatic lymph node enlargement in supradiaphragmatic areas (neck, mediastinum). Approximately 70% will have stage I or II disease. For early-stage disease, the standard approach is a combined modality with short-course chemotherapy (ABVD: Adriamycin, bleomycin, vinblastine, dacarbazine), followed by moderate-dose radiation targeting involved lymph node region(s). When subdivided into favorable and unfavorable groups, 5-year disease-free survival rates of approximately 90–95% (favorable) and 85–90% (unfavorable) are expected, respectively. The majority of patients with NLPHL present at an early stage and have excellent prognoses with radiation alone. For advanced-stage disease, chemotherapy is the main modality, and the focus recently has been on intensifying chemotherapy to improve efficacy. When a complete response has been obtained with ABVD chemotherapy or its equivalent, there is no role for consolidation radiation therapy. Overall 5-year diseasefree survival is 60–85%. High-dose therapy with autologous stem cell transplant is the salvage therapy of choice for refractory patients or for those who relapse after a short initial remission from chemotherapy. Different types of radiation fields have been used in Hodgkin’s lymphoma and involved-field radiation therapy (IFRT) is the current standard. It covers involved lymph nodes before chemotherapy and the nodal region (wholly or partially) in which the involved lymph node(s) is/are located. The radiation doses used in combined-modality protocols are well within the tolerance of normal tissues in virtually all supradiaphragmatic areas.
1
Maryse Bernard, MD Email:
[email protected]
2
Richard W. Tsang, MD () Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_9, © Springer-Verlag Berlin Heidelberg 2011
772
Maryse Bernard and Richard W. Tsang
Epidemiology and Etiology Hodgkin’s disease was initially described as an inflammatory disease (hence the term “disease”), but is clearly recognized and treated as a malignant lymphoma (hence the more accurate term Hodgkin’s lymphoma (HL) is used synonymously with Hodgkin’s disease). An estimated 8,490 new cases of HL were diagnosed (4,670 males and 3,820 females), and 1,320 deaths (740 males and 580 females) occurred in the USA in 2010. The incidence of HL has remained stable over the last two to three decades and is bimodal, with the first peak in the third decade in life, and a second, smaller peak after 50 years of age. The etiology of HL is unknown, but a limited number of factors documented to be associated with a higher risk include a positive family history, higher socioeconomic status, prior Epstein-Barr virus (EBV) infection, and human immunodeficiency virus (HIV) infection.
Pathology The three main morphologic features of HL include an effacement of the involved lymph node, with destruction of its normal architecture, an inflammatory cellular infiltrate, and the presence of malignant cells, the Reed– Sternberg (RS) cells. The various subtypes of HL (Table 26.1) have distinct morphologic, immunophenotypic, and clinical characteristics. Classical HL is considered separately from nodular lymphocyte-predominant HL (NLPHL) in the 4th edn. of the World Health Organization (WHO) classification.
Chapter 26 Hodgkin’s Lymphoma
773
Table 26.1 WHO classification (4th edn.) for HL (2008) and characteristics HL type
Characteristics
NLPHL Has unique pathology and biologic behavior, and in the early stage, a different treatment approach is warranted Accounts for <5% of HL NLPHL
Usually presents in middle-aged males, with localized peripheral lymph node involvement (cervical, axillary, and inguinal regions). It is characterized by the presence of an RS cell variant known as L & H cell or popcorn cell. These cells express Bcell markers (CD20+, CD79a+, CD45+, and J chain+), and are negative for CD15 and CD30
Classical HLa Characterized by a nodular growth pattern, presence of collagen bands, and the RS cell variant known as the lacunar cell Nodular sclerosis subtype
The most common subtype of HL, accounting for 65–70% of cases, and is the only subtype without a male predominance (male:female ratio approximately 1:1) Typically, the cervical and mediastinal areas are involved
Lymphocyte-rich subtype
Represents ~5% of HL Similar to NLPHL clinically, with localized disease at presentation involving a peripheral lymph node region Represents 10–15% of cases
Mixed-cellularity subtype
Lymphocytedepleted subtype
Commonly presenting in advanced stages, with a tendency to involve spleen, bone marrow, and a lesser tendency for mediastinal involvement Very rarely seen in primary presentation, as many of the previous cases were probably misdiagnosed, and have now been recognized as being non-Hodgkin’s lymphomas Has the worse prognosis among the HL subtypes
a
In classical HL the RS cells are positive for CD30 and CD15, while CD45 and the J chain are negative. EBV-related proteins are detected in approximately 40% of cases Source: Swerdlow SH, Campo E, Harris NL et al (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, France
774
Maryse Bernard and Richard W. Tsang
Diagnosis, Staging, and Prognosis Clinical Presentation Clinical presentations of HL are presented in Table 26.2. Table 26.2 Signs and symptoms of HL Signs/symptoms
Description
Most common presentation
Asymptomatic lymph node enlargement in supradiaphragmatic areas, typically in the neck
Stage at presentation
~70% present with stage I or II disease
Primary disease location
Systemic symptoms
Mediastinal lymph node involvement is common, occurring in 80% of cases, and when the disease is bulky, might cause symptoms (chest pain, cough, and dyspnea) ~5% of stages I–II patients present in infradiaphragmatic sites (e.g., inguinal, pelvic, or retroperitoneal lymph node regions) B symptoms of night sweats, fever, and weight loss are reported in approximately 30% of patients Other less frequent symptoms include pruritus and alcohol-induced pain localized over the involved lymph node
Diagnosis and Staging Figure 26.1 illustrates the diagnostic procedure of HL, including suggested examinations and tests.
Chapter 26 Hodgkin’s Lymphoma
775
Hodgkin Lymphoma Suspected
Complete History and Physical Examination Including history of B symptoms
Excision biopsy (preferred) or core biopsy Consider further immunohistochemical studies
Hodgkin‘s Lymphoma diagnosed
CBC Erythrocyte sedimentation rate (ESR) Lactate dehydrogenase (LDH) Bilirubin Transaminases Creatine
Lab Studies
Recommended Computed tomography of the head and neck thorax, abdomen and pelvis Optional FDG-PET/CT
Fertillity preservation strategies Pregnancy test Lung function tests (for thoracic RT or bleomycin use) Ejection fraction measurement (for anthracycline use) Counseling
Imaging Studies
In Selected Cases
Multidisciplinary Discussion and Management
Bone marrow biopsy is rarely positive, not required in a typical patient with stages I–IIA disease. It should be done if the CBC is abnormal, if there is stages III and IV disease, or if B symptoms are present Staging laparotomy is unnecessary, as clinical staging aided by prognostic factors to arrive at a risk-adapted treatment approach is the standard
Figure 26.1 Proposed algorithm for diagnosis and staging of HL
776
Maryse Bernard and Richard W. Tsang
Tumor, Node, and Metastasis Staging Evaluating the extent and distribution of disease in HL has an important therapeutic implication, specifically in defining radiation treatment volume. The standard staging classification used is the Ann Arbor Staging System, detailed in Table 26.3. This staging system is widely adopted; it is incorporated into the American Joint Committee on Cancer (AJCC) cancer staging manual (7th edn., 2009). Table 26.3 Ann Arbor Staging Classification
a
Stage
Disease involvement
I
Single lymph node region (I) One extralymphatic site (IE)
II
Two or more lymph node regions on the same side of the diaphragm (II) Extralymphatic organ or site with regional lymph node involvement on the same side of diaphragm (IIE)
III
Lymph node regions on both sides of the diaphragm (III) May have local extralymphatic extension (IIIE)
IV
Diffuse involvement of one or more extralymphatic organs or sites, with or without associated lymph node involvement; or isolated extralymphatic organ involvement with distant (nonregional) nodal involvement
A
No B symptoms
B
Presence of at least one of unexplained weight loss (>10% in 6 months prior to staging), unexplained fever >38°C, and/or recurrent night sweats
E
Extralymphatic diseasea
X
Bulky tumorb: either a single mass >10 cm, or more than a third of intrathoracic diameter for mediastinal mass
In the Ann Arbor system, an “E” lesion was originally defined as extralymphatic involvement. As Waldeyer’s ring, thymus, and spleen are considered to be lymphatic tissue, they do not constitute an E lesion. However, most clinicians consider these in the group of extranodal sites (E) because of their unique characteristics b The Cotwolds modification of the Ann Arbor Classification used the thoracic diameter defined at the level of T5–6, and also defines peripheral lymph nodes 10 cm or larger to be bulky. In clinical trials protocols, the definition of bulky disease may vary Sources: Edge SB, Byrd DR, Compton CC et al (eds) (2009) AJCC (American Joint Committee on Cancer) cancer staging manual, 7th edn. Springer, Berlin Heidelberg New York; Tsang R, Connors J, Gospodarowicz MG (2008) Specific management problems posed by the primary extranodal presentations: part I – staging and response evaluation. In: Cavalli F et al (eds) Extranodal lymphomas pathology and management, 1st edn. Informa, London
Chapter 26 Hodgkin’s Lymphoma
777
Lymph node regions described for staging purposes were defined by Kaplan et al and have been in use for over 40 years (Figure 26.2).
Waldeyer ring Cervical, supraclavicular, occipital and pre-auricular Infraclavicular Axillary and pectoral
Mediastinal
Epitrochlear and brachial
Spleen
Mesenteric
Paraaortic
Hilar
Figure 26.2 Lymph node regions. Reprinted with permission from Kaplan H, Rosenberg S (1966) The treatment of Hodgkin’s disease. Med Clin North Am 50:1591–1610, Copyright 1996, Elsevier
Iliac
Inguinal and femoral
Popliteal
Anatomical Regions for the Staging of Hodgkin‘s Disease
Prognosis Although the incidence of HL has been stable in the past two to three decades, the 5-year relative survival rates have improved significantly, from 74% in 1975–1977, to 79% in 1984–1986, and 86% in 1996–2004, likely due to the increasing success in treatments. Additional factors other than the clinical stage, which are important in selecting risk-adapted treatment, have been recognized to influence the outcome of patients with HL. For stages I and II patients, prognostic factors are listed in Table 26.4. By varying combinations of these factors, different groups will subclassify early-stage patients into favorable and unfavorable. For advanced-stage disease, an International Prognostic Score (IPS) has been used (Table 26.5).
EORTC
GHSG
NCIC
Favorable: Stages I–II without risk factors Unfavorable: Stages I–II with ≥1 risk factor(s) Favorable: Stages I–II without risk factors Unfavorable (or intermediate): Stages I–II with ≥1 risk factors (If stage IIB with bulky mass or extranodal disease: considered advanced stage) Favorable: Stages I–II without risk factors Unfavorable: Stages I–II with ≥1 risk factor(s)
Large mediastinal mass ESR ≥ 50 without B symptoms ESR ≥ 30 with B symptoms Age >50 ≥4 Nodal sites involved
Large mediastinal mass ESR ≥ 50 without B symptoms ESR ≥ 30 with B symptoms Extranodal disease ≥3 Nodal sites involved
Histology (MC, LD) ESR ≥ 50 Age ≥ 40 years ≥4 Nodal sites involved Note: Bulky mediastinal disease excluded from trial
HD6
HD7 HD8 HD10 HD11 HD13 HD14
H7 H8 H9 H10
Examples in this chapter
ESR: erythrocyte sedimentation rate; MC: mixed cellularity; LD: lymphocyte depleted; EORTC: European Organization for Research and Treatment of Cancer; GHSG: German Hodgkin’s Study Group, NCIC: National Cancer Institute of Canada Source: Specht L, Hasenclever D (2007) Prognostic factors in Hodgkin’s lymphoma. In: Hoppe R et al (eds) Hodgkin’s lymphoma, 2nd edn. Lippincott Williams & Wilkins, Philadelphia
Study group
Treatment groups
Prognostic (risk) factor
Table 26.4 Early-stage HL: prognostic factors and treatment groups
778 Maryse Bernard and Richard W. Tsang
Chapter 26 Hodgkin’s Lymphoma
779
Table 26.5 Advanced-stage HL: International Prognostic Score Risk factor
No. of risk factor
Freedom from progression at 5 years (%)
Serum albumin <40 g/l
0
84%
Hemoglobin <105 g/l
1
77%
Male gender
2
67%
Age ≥45 years
3
60%
4
51%
≥5
42%
Stage IV disease 9
White blood cell count ≥15 × 10 /l 9
Lymphocytopenia <0.6 × 10 /l Source: Hasenclever D, Diehl V, Armitage J et al (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 339:1506–1514
Treatment Principle and Practice The management of Hodgkin’s lymphoma has evolved from extended-field radiation alone as the main therapy to a combined-modality approach with chemotherapy and radiation, or chemotherapy alone. As a majority of patients will be cured, there is interest in achieving the best therapeutic ratio by minimizing late toxicity while maintaining effectiveness. Second cancers and cardiac disease are the two main late effects to be considered. General guidelines for HL treatment and commonly used chemotherapy regimens are described in Tables 26.6 and 26.7. Table 26.6 General guidelines for Hodgkin’s lymphoma treatment Extent of disease or subtype
Treatment strategy
Early stage
Standard approach is combined-modality with short-course chemotherapy, followed by moderate-dose radiation targeting involved lymph nodes region(s)
NLPHL
The majority of these patients present at an early stage and have excellent prognoses with radiation alone
Advanced stage
Chemotherapy is the main modality and the focus recently has been on intensifying chemotherapy. There is a limited role for radiation
780
Maryse Bernard and Richard W. Tsang
Table 26.7 Chemotherapy regimens used for HL Regimen
Medication
Delivery
ABVD
Adriamycin Bleomycin Vinblastine Dacarbazine
Each agent is given intravenously on days 1 and 15 (1 cycle), each cycle repeated at 28 days
Stanford V
Adriamycin Bleomycin Vinblastine Vincristine Prednisone Mechlorethamine Etoposide
Each agent is given intravenously, except for prednisone
BEACOPP
Bleomycin Etoposide Adriamycin Cyclophosphamide Oncovin (vincristine) Procarbazine Prednisone
Each agent is given intravenously, except procarbazine and prednisone
Treatment of Early Favorable Disease The current standard approach is Adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) (or equivalent) for two to three cycles, followed by involved-field radiation therapy (IFRT) at 20–30 Gy (Figure 26.3). Tables 26.8 and 26.9 list Stages I–II Favorable HL
ABVD x 2-3 cycles
3-4 weeks
Restaging optional
Options
Comments
ABVD × 2 restaging IFRT at 20 Gy
Based on GHSG HD10
Stanford V × 8 weeks + IFRT at 30 Gy
Stanford G4 trialb
ABVD × 2 cycles PET-CTa if CR, add ABVD × 2–4 cycles
If concerned with late RT toxicity
STLI (including spleen) with 35–40 Gy
If not a candidate for chemotherapy
IFRT 30 Gy a
b
Follow-Up
An integrated PET-CT or a PET with a diagnostic CT is recommended Source: Advani RH, Hoppe RT, Baer DM et al (2009) Efficacy of abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkin’s disease: mature results of the G4 trial. Blood 114: Abstract 1670
Figure 26.3 Treatment algorithm for stages I–II favorable HL
Chapter 26 Hodgkin’s Lymphoma
781
important evidence that supports evolution of practice from extended-field radiation therapy (EFRT) alone to combined-modality therapy. Studies have shown superiority of combined-modality approach over EFRT (Table 26.8). In addition, clinical evidence has demonstrated that combined-modality treatment allows a safe decrease of radiation volume, leading to IFRT (Table 26.9).
Dose of Radiation for Favorable Early-Stage HL When radiation therapy (RT) alone was used, it was common practice to prescribe a dose ranging from 40 to 44 Gy. Further experience and clinical trial results have suggested IFRT of 30–35 Gy after chemotherapy, and more recently, 20 Gy, as supported by the European Organization for Research and Treatment of Cancer (EORTC) H9-F and German Hodgkin Lymphoma Study Group (GHSG) HD10 trials (Table 26.9). The published HD10 trial examined treatment intensity of both ABVD and IFRT, in early favorable-stage HL: 20 Gy after ABVD for two courses appeared to be optimal for early favorable disease. When all four arms were compared (median follow-up of 7,5 years), no significant differences in terms of overall survival (OS), freedom from treatment failure (FFTF), and progression-free survival (PFS) were noted.
Treatment of Early Unfavorable Disease The definition of unfavorable prognosis in the early stage (Figure 26.4) is variable among groups (Figure 26.4). Most of the patients are in this category because of bulky mediastinal masses. The standard treatment is combined modality, with ABVD (or equivalent) for four to six cycles, followed by IFRT to a total of 30 Gy (Table 26.10). Two studies have addressed the question of field size (i.e., IFRT versus EFRT) and showed that EFRT is not required for a combined-modality approach (Table 26.10) (EORTC H8U and GHSG HD8). Different chemotherapy regimens have been tested, and reduction in intensity has not been successful, unless in integrated protocols with radiation such as Stanford V (Table 26.10). The most commonly used chemotherapy regimen is ABVD, initially based on results from advanced HL trials. The optimal number of cycles of chemotherapy has been studied (EORTC H8U and GHSG H9U), and for a combined-modality approach, four cycles of ABVD is the standard, although it is still common practice to give six cycles. Stanford V is also another option. The concept is to use a larger number of effective drugs, each with less cumulative dose than with ABVD or MOPP, in combination with radiation (36 Gy) for disease bulk ≥5 cm in diameter. It was first evaluated in a nonrandomized study, but the recent ECOG 2496 is a phase III study.
348
333
617
SWOG-9133a
EORTC H7-Fb
GHSG HD7c
81% 96%
3-year EFS 3-year OS 10-year EFS 10-year OS 7-year FFTF 7-year OS 5-year EFS 10-year OS
STLI (36–40 Gy) AV ×3 plus STLI
STLI (36–40 Gy) EBVP ×6 plus IFRT (36–40 Gy)
EFRT 30 Gy (IFRT 40 Gy) ABVD ×2 plus EFRT 30 Gy (IFRT 40 Gy)
STLI 36 Gy (IFRT 40 Gy) MOPP/ABV ×3 plus IFRT 36 Gy
74% 92%
67% 92%
78% 92%
EFRT alone
Treatment arms
98% 97%
88% 94%
88% 92%
94% 98%
CT + RT
<0.001 0.001
<0.001 NS
0.01 NS
<0.001 NS
p-value
AV: Adriamycin and vinblastine; EBVP: epirubicin, bleomycin, vinblastine, prednisone; MOPP/ABV: mechlorethamine, vincristine, prednisolone, procarbazine, Adriamycin, vinblastine, bleomycin; EFRT: extended-field radiotherapy, STLI: subtotal lymphoid irradiation, IFRT: involved-field radiotherapy; EFS: event-free survival, OS: overall survival, FFTF: freedom from treatment failure a Source: Press OW, LeBlanc, Lichter AS et al (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 19:4238–4244 b Source: Noordijk EM, Carde P, Dupouy N et al (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: longterm results of the European Organization for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24:3128– 3135 c Source: Engert A, Franklin J, Eich HT et al (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 Trial. J Clin Oncol 25:3495–3502 d Source: Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916–1927
EORTC/GELA H8-Fd 543
Patients (n)
Trial
Table 26.8 Randomized studies comparing radiotherapy alone (EFRT) versus combined-modality (CT + RT), for early favorable HL
782 Maryse Bernard and Richard W. Tsang
1370
619
133
Patients (n)
ABVD ×2 plus IFRT 30 Gy ABVD ×2 plus IFRT 20 Gy ABVD ×4 plus IFRT 30 Gy ABVD ×4 plus IFRT 20 Gy
EBVP ×6 plus IFRT 36 Gy EBVP ×6 plus IFRT 20 Gy EBVP ×6 (closed)
ABVD ×4 plus STLI 30 Gy (IFRT 36–40 Gy) ABVD ×4 plus IFRT 36–40 Gy
Treatment arms
98% 98% 8-year OS (NS) 94% 95% 94% 95%
8-year PFS (NS) 85% 87% 88% 90%
4-year OS (NS)
4-year EFS (p < 0.001) 87% 84% (70%)
96% 94%
12-year OS (NS)
OS (p-value)
87% 91%
12-year EFS (NS)
Outcome (p-value)
Source: Bonadonna G, Bonfante V, Viviani S et al (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835 –2841 b Source: Noordijk EM, Thomas J, Ferme C et al(2005) First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable and unfavorable early stage Hodgkin’s lymphoma. J Clin Oncol 23:Abstract 6505 c Source: Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. New Engl J med 363: 640-52
a
GHSG HD10c
EORTC/GELA H9-Fb
Milan favorable plus unfavorable patientsa
Trial
Table 26.9 Clinical evidence for the use of IFRT in combined-modality, early favorable HL
Chapter 26 Hodgkin’s Lymphoma 783
784
Maryse Bernard and Richard W. Tsang
Stages I–II Unfavorable HL
ABVD x 4–6 cycles
3–4 weeks
Options
Comments
Stanford V × 12 weeks + IFRT at 36Gy
RT to initial sites >5 cma
ABVD × 6 cycles
If concerned with RT toxicity (nonbulky disease). For stage IIB, this option is often considered
BEACOPP × 4 + IFRT at 20Gy or, ABVD x 4 + IFRT at 30 Gy
Based on GHSG HD11
Restaging optional
IFRT 30 Gy Consider 35 Gy for bulky site and/or significant residual mass >5 cm a
Follow-Up
Source: Horning SJ, Hoppe RT, Breslin S et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637
Figure 26.4 Treatment algorithm for stages I–II unfavorable HL
A more intensive regimen with cyclophosphamide, doxorubicin, vincristine, bleomycin, etoposide, procarbazine, and prednisone (BEACOPP) is addressed in EORTC H9U and GHSG HD11. Recently, the GHSG has investigated BEACOPP (in escalated doses) for two cycles plus ABVD for two cycles (HD14). Previous studies mentioned for the early unfavorable group are listed in Table 26.10.
Chemotherapy as a Single Modality for Early-Stage HL Some groups have tested chemotherapy alone for early-stage patients, favorable and unfavorable. Combined-modality treatment remains the optimal therapy to achieve the highest control rate with an initial therapy, as mentioned in the National Cancer Comprehensive Network (NCCN) guidelines (Sources: NCCN guidelines for Hodgkin’s disease/lymphoma, v. 2.2009. http://www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf; Herbst C, Rehan F, Brillant C et al (2009) Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica 95:494–500; Meyer RM, Gospodarowicz MK, Connors JM (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of
Patients (n)
1,064
995
808
1,395
Trial
GHSG HD8a
EORTC/ GELA H8Ub
EORTC/ GELA H9Uc
GHSG HD11d
ABVD ×4 plus IFRT 30 Gy ABVD ×4 plus IFRT 20 Gy BEACOPP ×4 plus IFRT 30 Gy BEACOPP ×4 plus IFRT 20 Gy
ABVD ×4 plus IFRT 30 Gy ABVD ×6 plus IFRT 30 Gy BEACOPP ×4 plus IFRT 30 Gy
MOPP/ABV ×6 plus IFRT 36–40 Gy MOPP/ABV ×4 plus IFRT 36–40 Gy MOPP/ABV ×4 plus STLI 36–40 Gy
COPP/ABVD ×2 plus EFRT 30 Gy (40 Gy to bulk) COPP/ABVD ×2 plus IFRT 30 Gy (40 Gy to bulk)
Treatment arms
Table 26.10 Clinical evidence with combined-modality, early unfavorable HL
85% 81% 87% 87%
94% 94% 95% 95%
OS 5-year
6
OS 4-year (NS)
EFS 4-year (NS)
FFTF 5-year
88% 85% 84%
84% 88% 87%
95% 96% 93%
OS 10-year (NS)
EFS 5-year (NS)
89% 94% 91%
91% 92%
OS 5-year (NS)
FFTF 5-year (NS) 86% 84%
OS (p-value)
Outcome (p-value)
Chapter 26 Hodgkin’s Lymphoma 785
OS (p-value)
COPP/ABV: cyclophosphamide, Oncovin, procarbazine, prednisone; BEACOPPesc: escalated dose of BEACOPP; NS: not significant a Source: Engert A, Schiller P, Josting A et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extendedfield radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608 b Source: Ferme C, Eghbali H, Meerwaldt JH et al (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357:1916 –1927 c Source: Noordijk EM, Thomas J, Ferme C et al (2005) First results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable and unfavorable early stage Hodgkin’s lymphoma. J Clin Oncol 23:Abstract 6505 d Source: Eich HT, Diehl V, Gorgen H et al (21010) Intensified chemotherapy and dose-reduced radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin study group HD11 trial. J Clin Oncol 28: published online ahead of print August 16, 2010
Closed
ABVD ×4 plus IFRT 30 Gy BEACOPPesc x 2 plus ABVD ×2 plus IFRT 30 Gy
Outcome (p-value)
GHSG HD14
Treatment arms
ABVD ×6 plus IFRT 36 Gy if massive mediastinal mass Stanford V for 12 weeks plus IFRT 36 Gy if ≥5 cm mass Closed or macroscopic splenic disease
Patients (n)
ECOG 2496 locally extensive stages I–II and advanced stage
Trial
Table 26.10 (continued)
786 Maryse Bernard and Richard W. Tsang
Chapter 26 Hodgkin’s Lymphoma
787
Canada Clinical Trials Group and Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642). However, chemotherapy with ABVD alone is an option, with disease control for 85–90% of patients (minimum of four cycles; often six cycles are considered if the approach is to give two further cycles beyond achieving complete response) (Sources: Canellos G, Abramson J, Fisher D et al (2010) Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 28:1611–1615; Strauss D (2009) The case for chemotherapy only for localized Hodgkin’s lymphoma. Oncologist 14:1225–1231). Using fluorodeoxyglucose/positron-emission tomography (FDG-PET) to select patients in complete remission after chemotherapy alone (or doing an interim FDG-PET scan after two cycles of chemotherapy) may provide a way to decide on eliminating radiation therapy, yet maintain an acceptable low risk of recurrence (risk-adapted therapy). These approaches are under active investigation in phase II and phase III clinical trials. Eliminating radiation in the initial therapy has been postulated to decrease second cancer and late cardiac risk. The trade-off consequences of substituting radiation with more chemotherapy, in terms of acute and late risks of therapy, should be considered for further study. At present, it is most sensible to consider chemotherapy alone when there is high risk expected for radiation late effects (e.g., young women with axillary disease in whom RT will expose significant breast tissue).
Treatment of NLPHL Most patients with NHPHL present in early stage, with disease often limited to a single peripheral site (neck, axilla, or inguinal region). The mediastinum is rarely involved. Stages I and II NLPHL have excellent prognoses after radiation alone. Retrospective data suggest that IFRT is adequate (compared with EFRT) (Tables 26.11 and 26.12). Despite high response rates, late relapse occasionally occurs at sites distant to the original regions of presentation. However, patients often respond to salvage treatment and have a good outcome.
788
Maryse Bernard and Richard W. Tsang
Table 26.11 Clinical evidence for the treatment of NLPHL Trial
Details
ETFLa
Treatment received for stages I–II NLPHL Stage I: 88% RT alone, 12% combined modality Stage II: 57% RT alone, 38% combined modality Results for stages I–II Stage I: FFTF 8 years: 85%, OS 8 years: 99% Stage II: FFTF 8 years: 71%, OS 8 years: 94%
GHSGb
Stage IA NLPHL Treatment options: EFRT, IFRT, or combined modality (CMT) Results for EFRT/IFRT/CMT EFRT: 2-year FFTF: 100%, OS: 94% IFRT: 2-year FFTF: 92%, OS: 100% CMT: 2-year FFTF: 97%, OS: 96% Results for EFRT/IFRT/CMT at 4 years: FFTF 93%
a
Source: Diehl V, Sextro M, Franklin J et al (1999) Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol 17:776 –783 b Source: Nogova L, Reineke T, Eich HT et al (2005) Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin’s Study Group (GHSG) Ann Oncol 16:1683 –1687 Table 26.12 Treatment options for NLPHL Type
Description
Standard
Comments
IFRT 30 –36 Gy alone
For stage IA, without risk factors If gross disease has been completely excised, 30 Gy is sufficient
Options: ABVD ×2–3 IFRT 30 Gy Chemotherapy alone (e.g., ABVD ×6) Observation post-excision
Considered if stage I with risk factors (bulky, B symptoms) or stage II For stages III–IV For highly selected patients with no residual bulk
Treatment of Advanced-Staged Disease Treatment of Stages III–IV Disease The current standard treatment for stages III–IV HL is anthracycline-based chemotherapy with ABVD. It has been shown to be superior to MOPP, and
Chapter 26 Hodgkin’s Lymphoma
789
other variants of MOPP-containing regimens such as alternating courses of MOPP and ABVD, or a MOPP–ABV hybrid regimen. Among other multidrug regimens tested, BEACOPP has the best results to date, although it is associated with a higher incidence of hematologic toxicity and gonadal damage, compared with ABVD. Therefore, ABVD for six to eight cycles is still the standard treatment, with the alternative approach of Stanford V being acceptable; the BEACOPP regimen holds promise of better disease control, particularly in patients with adverse prognosis, though at the expense of increased treatment toxicity. The Role of Consolidation RT When a complete response has been obtained with ABVD chemotherapy, or its equivalent, there is no role for consolidation RT (Table 26.13). Prior to the routine use of PET for response assessment, it was common practice to recommend consolidation RT for residual abnormalities detected by imaging, or for initially bulky disease. The use of RT (30–40 Gy) was common practice in the clinical trials examining different chemotherapy regimens. RT enhances local control but has little or no impact on overall survival (Table 26.13). A meta-analysis and multiple representative trials demonstrated no significant benefits of consolidative RT for disease-free survival (DFS), or OS (Table 26.13). The exception is the trial reported by Lasker et al, from India. However, the patients in this trial included stages I–II patients (58%), and two thirds were of mixed cellularity histology, different from a typical Western population. At present, after a complete response as assessed by FDG-PET scan, there is no definite need for consolidation radiation. Patients with partial response (residual abnormality present on PET) should be considered for biopsy to prove residual disease, and for eligible patients, salvage chemotherapy and autologous stem cell treatment (ASCT). Other Consolidation Therapy Three European trials (conducted by Scotland/Newcastle Group, European Intergroup, and Groupe Ouest-Est d’étude des Leucémies Aigues et autres Maladies du Sang [GOELAMS] in France) tested consolidation ASCT postchemotherapy for selected high-risk HL patients. They showed no improvement in DFS or OS (data not shown). At present, high-dose therapy with ASCT consolidation remains an investigational approach.
Tata Memorial Hospitald
EORTCc
SWOGb
179
250
ABVD ×6 ABVD ×6 plus RT Note: Patients randomized to observation versus RT after CR from chemotherapy
PR patients after CT: MOPP-ABV ×6 plus RT (30 –40 Gy)
421
Note: Patients randomized to observation versus RT after CR from chemotherapy
MOPP-ABV ×8 MOPP-ABV ×8 plus RT (24 Gy) Note: Patients randomized to observation versus RT after CR from chemotherapy
278
CMT versus CT: additional RT (same CT) CMT versus CT: RT versus additional CT
1,740 (14 trials)
Meta-analysisa
MOP-BAP ×6 MOP-BAP ×6 plus RT (20 Gy)
Treatment arms
Patients (n)
Trial Same (NS)
−8% for RT (0.045) OS 5 years (NS)
11% better for RT (0.0001) Same (NS) RFS 5 years (NS)
89% 100%
OS 8 years (0.002)
EFS 8 years (0.01) 76% 88%
87%
91% 85%
OS 5 years (NS)
79%
84% 79%
EFS 5 years (NS)
Subgroup analysis showed RT associated with longer remission duration in NS histology and bulky disease
79% 86%
OS 10 years
Tumor control 10 years
66% 74%
OS (p-value)
Outcome (p-value)
Table 26.13 Representative randomized trials of consolidation radiation therapy after chemotherapy for advanced HL
790 Maryse Bernard and Richard W. Tsang
1,449
GHSG HD12f
BEACOPP ×8 BEACOPP ×8 plus RT 30 Gy Note: 4-arm study, BEACOPP was increased dose in 4 cycles, or 8 cycles Residual disease if judged to be active by a panel were given RT (in 13% of reviewed patients)
OS 5 years (0.01*) 85% 94% 88% 78%
88% 95%
FFTF 5 years (NS)
92% (all patients) Not reported separately
OS 5 years (NS)
*Compared ABVPP ×8 versus ABVPP ×6 plus RT
74% 67% 78% 66%
EFS 5 years (NS)
Source: Loeffler M, Brosteanu D, Hasenclever D et al (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. J Clin Oncol 16:818 –829 b Source: Fabian CJ, Mansfield CM, Dahlberg S et al (1994) Low-dose involved field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Int Med 120:903 –912 c Source: Aleman BMP, Raemaekers JMM, Tirelli U et al (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. New Engl J Med 348:2396 –2406 d Source: Lasker S, Gupta S, Vimal MA et al (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 22:62–68 e Source: Fermé C, Sebban C, Hennequin C et al (2000) Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin’s disease: results of the Groupe d’études des Lymphomes de l’Adulte H89 trial. Blood 95:2246 –2252 f Source: Eich H, Gossmann A, Engert A et al (2007) A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advance stages of Hodgkin’s lymphoma – analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin’s Study Group. Int J Radiat Oncol Biol Phys 69:1187–1192
a
418
GELA H89e
MOPP/ABV ×8 ABVPP ×8 MOPP/ABV ×6 plus RT ABVPP ×6 plus RT Note: Patients with CR and PR ≥ 75% after 6 cycles of CT were randomized to 2 more cycles of CT, or STNI 30 –40 Gy
Chapter 26 Hodgkin’s Lymphoma 791
792
Maryse Bernard and Richard W. Tsang
PET for Therapy Response Assessment Posttreatment Response Evaluation After completion of therapy, computed tomography (CT) scans often reveal residual mass. Accurate assessment of the presence of residual disease is important because complete response (CR) is required for a curative outcome. PET has ability to distinguish between viable tumor and fibrosis in residual mass, with specificity of 90–95%. In fact, changes in tissue function often predate volume changes. For this reason, information provided by PET has been recently incorporated in the lymphoma guidelines for response evaluation after completion of the initial treatment program. Revised response criteria are detailed in Table 26.14. Table 26.14 Response criteria for lymphoma, based on initial International Workshop Criteria (IWC) and more recent revised response criteria with PET Outcome
IWCa
Revised IWCb,c
Complete response (CR)
No detectable disease; LN >1.5 cm must decrease to ≤1.5 cm
CR, CRu, PR, or SD by IWC and PET negative Bone marrow negative
Unconfirmed complete response (CRu)
LN >1.5 cm, SPD decrease >75% Indeterminate bone marrow
No longer exists
Partial response (PR)
SPD regressed >50%
CR, CRu, or PR by IWC and PET positive in ≥1 previously affected site
Stable disease (SD)
SPD decrease ≤50%, but not progressive disease
SD by IWC and PET positive in previously affected sites
Progressive disease (PD)/ relapse
New lesion or SPD increase >50% from nadir of any LN
PD by IWC and PET positive on the new or increased lesion if >1.5 cm
LN: lymph node; SPD: sum of products of the greatest diameters a Source: Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244 –1253 b PET is considered positive if uptake is greater than mediastinum blood pool (for lesion >2 cm) or if uptake greater than local background (for lesion < 2 cm) c Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 5:579 –586
Chapter 26 Hodgkin’s Lymphoma
793
Many studies have demonstrated that PET performed after conventional treatment is highly predictive of PFS and OS in HL. Two examples (among many) are detailed in Table 26.15. The role of PET in response assessment studies has been done after completing conventional treatment. Therefore, modifying initial treatment plan by abbreviating CT or omitting RT, based on a PET obtained before the end of the planned treatment, is still considered an experimental approach. Table 26.15 Selected studies on PET in HL (response assessment) Study
Stage
Details
Weihraucha All stages
Question: assess diagnostic and prognostic value of PET in HL patients with residual mediastinal masses after completed therapy 28 patients with a residual mediastinal mass after chemotherapy, at least 2 cm 19 patients after initial therapy and 9 patients after salvage CT Negative predictive value (PET negative and remission) at 1 year: 95% Positive predictive value (PET positive and relapse) at 1 year: 60%
GHSG HD15b
Question: assess negative predictive value of PET in advanced stage 817 patients with stage IIB (extranodal or bulky), III, or IV included Randomization between different regimen of BEACOPP-based CT 3 arms (BEACOPP ×8, BEACOPPesc ×6, BEACOPP14 ×6) 311 patients had PET to assess residual mass (≥2.5 cm) PET done after 6 –8 cycles of CT Local RT only for patients with PR and PET+ (n = 63) PFS: 96% for PET negative and 86% for PET positive NPV for PET: 94% Definition NPV: PET negative and no progression/relapse/RT for 12 months ▶
Advanced stage
794
Maryse Bernard and Richard W. Tsang
Table 26.15 (continued) Study
Picardic
Stage
Details
Early stage, bulky
Question: role of consolidation RT in patients with residual mass posttreatment that is PET negative 260 patients received VEBEP ×6, median follow-up of 40 months 160 patients had residual mass (median: 2.2 cm) with a PET negative PET done after 6 cycles of CT Randomization for those 160 patients RT 32 Gy to initial bulky site No RT Treatment failure RT: 11/80 (14%), in involved bulky site, within 18 months No RT: 2/80 (2.5%) PET accuracy to exclude relapse in patients not receiving RT: 86% PET false-negative results: 14% The study suggested that the addition of RT improved event-free survival (EFS)
VEBEP: vinblastine, etoposide, bleomycin, epirubicin, prednisone; BEACOPPesc: cyclophosphamide, doxorubicin, vincristine, bleomycin, etoposide, procarbazine, prednisone, filgrastin (G-CSF) a Source: Weihrauch M, Re D, Scheidhauer K et al (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin’s disease. Blood 98:2930 –2934 b Source: Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin’s lymphoma. Blood 112:3989 –3994 c Source: Picardi M, De Renzo A, Pane F et al (2007) Randomized comparison of consolidation radiation versus observation in bulky Hodgkin’s lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymph 48:1721–1727
Early-Interim-Response Assessment There is evidence that early PET (done after few cycles of CT) is prognostic in early- and advanced-stage HL, implying a high negative predictive value (Table 26.16). However, there is no randomized evidence that having response-adapted treatment, according to the results of early-interim PET, will result in superior outcomes.
Chapter 26 Hodgkin’s Lymphoma
795
Table 26.16 Selected studies on PET in HL (early-interim assessment) Study
Hutchingsa
Gallaminib
Stage
Details
All stages
Question: assess value of early-interim PET for PFS in HL 85 patients, planned to receive CT alone or combined-modality, according to stage, median follow-up of 3.3 years PET done after 2–3 cycles of chemotherapy (mostly ABVD) Relapse 62% for PET-positive patients (8/13) 6% for PET-negative patients (4/72) 5-year PFS: 38.5% for PET positive and 91.5% for PET negative Majority of early-stage patients early-interimPET positive remained in remission, while all advanced-stage patients early-interim-PET positive relapsed within 2 years
All stages
Question: assess prognostic role of early-interim PET and IPS in advanced-stage HL 260 patients (190 stages IIB–IVB and 70 stages IIA plus adverse prognosis factors), median follow-up of 2.2 years PET done after ABVD ×2 No treatment changes according to results of interim PET Treatment failure 86% for PET-positive patients (43/50) 5% for PET-negative patients (10/210) 2-year PFS: 12.8% for PET positive and 95% for PET negative In multivariate analysis, prognostic value of interim PET was superior to IPS ▶
The concept of response-adapted therapy is attractive. It represents a further progressive approach from making treatment decision on well-established and validated prognostic factors, mentioned in Tables 26.4 and 26.5. Response to treatment is likely an important prognostic factor, as well, for the individual patient.
796
Maryse Bernard and Richard W. Tsang
Table 26.16 (continued) Study
Terasawac
Stage
Details
Advanced stage
Question: to review the prognostic accuracy of PET in interim response assessment of patients with advanced HL or DLBCL 13 studies involving 360 advanced-stage HL met inclusion criteria Few unfavorable-risk patients (<10% with IPS >3) PET done mostly after 2 cycles of ABVD Sensitivity/specificity were calculated, based on PET results and whether they experienced treatment failure Results for HL: PET sensitivity of 81% (95% CI 0.72 –0.89) and PET specificity of 97% (95% CI of 0.94 –0.99) PET performed after few cycles of standard chemotherapy suggested that it is a reliable prognostic test to identify poor responders
IPS: International Prognostic Score a Source: Hutching M, Mikhaeel NG, Fields PA et al (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin’s lymphoma. Ann Oncol 16:1160 –1168 b Source: Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 25:3746 –3752 c Source: Terasaw T, Lau J, Bardet S et al (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 27:1906 –1914
Chapter 26 Hodgkin’s Lymphoma
797
Until mature results from ongoing trials with early-interim-PET response assessment are available for early-stage (Table 26.17) and advanced-stage HL, modification of treatment (decreasing number of CT cycles if PET−, or switching for a more aggressive protocol of PET+) should be regarded as experimental.
Table 26.17 Selected studies on PET in HL (ongoing trials in early stage) Study
Stage
Details
UK NCRI phase IIIa
Early-stages IA/IIA, not bulky
Question: assess the role of treatment modification with early-interim PET PET done after ABVD ×3 Randomization for PET-negative patients RT No RT If PET positive: 4th ABVD plus IFRT
GHSG HD16, ongoing phase III
Early-stages I–II without risk factor, such as: Extranodal ≥3 sites
Question: assess the role of treatment modification with early interim PET (performed after ABVD ×2) Randomized patients to Standard arm: 2ABVD plus IFRT Experimental arm: – If PET positive: 2 ABVD, plus IFRT 30 Gy – If PET negative: 2 ABVD no RT
Early stage Favorable group (F) Unfavorable group (U)
Question: assess the role of treatment modification with early interim PET (performed after ABVD ×2) Randomized patients to Standard arm F: 3 ABVD plus INRT 30 Gy U: 4 ABVD plus INRT 30 Gy Experimental arm: treatment adapted based on PET results UF if PET negative after 2 cycles: 2 more cycles, no RT UF if PET negative after 2 cycles: 4 more cycles, no RT F or UF if PET positive after 2 cycles: 2 BEACOPPesc plus INRT 30 Gy
EORTC H10/GELA ongoing phase III
BEACOPPesc: cyclophosphamide, doxorubicin, vincristine, bleomycin, etoposide, procarbazine, prednisone, filgrastin (G-CSF); F: favorable; UF: unfavorable a Source: Radford JA, Barrington SF, O’Doherty MJ et al (2007) Interim results of a UK NCRI randomized trial comparing involved-field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin’s lymphoma. Haematologica 92:Abstract C023
798
Maryse Bernard and Richard W. Tsang
Treatment of Refractory and Relapsed HL Definition Refractory HL progression of disease during initial therapy or within 3 months of completion of treatment Relapsed HL disease progression after a CR to primary treatment (early relapse is further defined as within 12 months of CR) Initial treatment for HL results in good tumor control, but a significant number of patients experience either a tumor refractory to therapy or subsequent relapse. Second-line therapy is usually required for: 10–15% of patients with initial localized disease 25–40% of patients with initial advanced-stage disease Prognostic factors for this group of patients are listed in Table 26.18. Patients relapsing after a first complete remission still have the opportunity of being cured with adequate salvage treatment. Different options exist depending on the first-line therapy received: Conventional chemotherapy (if initial treatment was RT alone) RT alone as salvage therapy Salvage high-dose chemotherapy (HDT) plus ASCT (Figure 26.5): standard of care if initially treated with chemotherapy. DFS rate at 5 years ranges from 35 to 55% after HDT with ASCT. Table 26.18 Prognostic factors for outcome after high-dose chemotherapy and stem cell transplantation for refractory or recurrent disease Factor
Description Interval between initial therapy and relapse
Sensitivity of the disease
Response to salvage therapy Number of failed prior regimens
Disease burden before salvage treatment
Disease stage at the time of recurrence Bulky disease at salvage Extranodal relapse
Constitutional symptoms
Presence of symptom B
Other factors
Low hemoglobin, serum albumin, low performance status
Source: Josting A, Franklin J, May M et al (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 20:221–230
Chapter 26 Hodgkin’s Lymphoma
Second-line therapy for cytoreduction (e. g. with DHAP)
Chemosensitive disease? Yes Salvage high-dose therapy (HDT) with chemotherapy (no role for TBI)
Stem cell collection
799
Figure 26.5 Typical schema for a salvage treatment regimen with HDT and ASCT. DHAP dexamethasone, cytosine arabinoside, cisplatin. Sources: Linch DC, Winfield D, Goldstone AH et al (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomized trial. Lancet 341:1051–1054; Schmitz N, Pfistner B, Sextro M et al (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomized trial. Lancet 359:2065–2071
Autologgous stem cell transplant (ASCT)
Follow-Up
Radiation Incorporated into HDT plus ASCT When HDT and ASCT is the salvage approach used, RT can still be incorporated in order to enhance disease control. Timing of radiation (pre-ASCT or post-ASCT), extent of radiation field, and dose vary among institutions. For example, Memorial Sloan Kettering Cancer Center gives pre-ASCT radiation therapy as follows: IFRT at 18 Gy, followed by total nodal irradiation (TNI) to a further 18 Gy, twice a day, within a 2-week period before ASCT If previous RT, TNI not administered DFS 50% at 6.5–10 years (Source: Yahalom J (1995) Integrating radiotherapy into bone marrow transplantation programs for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 33:525–528).
800
Maryse Bernard and Richard W. Tsang
Other institutions will consider RT post-ASCT. RT will be given if previous disease ≥5 cm, disease responding incompletely to salvage CT, or residual PET positive lesions after ASCT. RT given 2–3 months after ASCT, the volume individualized according to patient’s characteristics and previous treatment (range, 25–35 Gy), with DFS of 30–55% at 5 years.
Role of Radiation as Salvage Treatment HL tends to recur in previously involved sites, especially if it was bulky. Before the routine use of HDT and ASCT, selected patients who failed initial CT were treated with salvage RT. Radiation techniques used varied from involved field to extended field, such as mantle field or even total lymphoid irradiation (TLI). Salvage RT results (Table 26.19) cannot be compared with ASCT outcomes, but they do illustrate that judicious use of RT remains a salvage option for selected patients, especially for: Patients not eligible for ASCT because of age or comorbidities Patients with favorable clinical characteristics with long disease-free interval, predominantly nodal distribution of disease, and absence of systemic symptoms Table 26.19 Largest published experience of salvage RT, from GHSG GHSG protocols
Refractory/ recurrent patients
RT as salvage treatment (n = 100)
Response rate
5-year FFTF/OS
From 1988 to 1999 n = 4,754
n = 624 (after initial therapy)
RT median dose: 40 Gy IFRT: 37% EFRT: 63% (Mantle: 43%, inverted Y: 8%, TLI: 12%)
81% (CR 77%)
FFTF: 28% OS: 51%
Source: Josting A, Nogova L, Franklin J et al (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 23:1522–1529
Radiation Therapy Technique Different types of radiation fields used in HL are listed in Table 26.20. Dose of RT is detailed for individual subtypes in previous sections.
Chapter 26 Hodgkin’s Lymphoma
801
Table 26.20 Radiation therapy technique definitions Field
Definition
Extended field (EFRT)
Implies inclusion of multiple involved and uninvolved LN regions
Total lymphoid irradiation (TLI)
Includes all LN regions on both sides of diaphragm
Sub-total lymphoid irradiation (STLI)
Includes all LN regions on both sides of diaphragm, except pelvic LNs (iliac/inguinal/femoral LN)
Mantle
Includes all LN regions above the diaphragm: bilateral cervical/supraclavicular/submental/axillary nodes, mediastinal and bilateral hilar nodes
Inverted-Y
Includes all LN regions below the diaphragm: para-aortic, bilateral iliac/inguinal-femoral nodes, with or without spleen
Regional
Includes the involved LN region plus at least one adjacent clinically uninvolved region If extranodal: includes the involved organ plus uninvolved adjacent LN region
Involved-field (IFRT)
Includes involved nodes before chemotherapy and its entire nodal region If extranodal: includes the involved organ alone, if no LN involvement
Includes the originally involved nodes before chemotherapy. Concept recently introduced by the EORTC. Preliminary data Involved LN (INRT) available Requires FDG-PET before and after chemotherapy for RT planning, with reproducible patient positions Sources: Yahalom J, Hoppe R, Mauch P (2007) Prognostic factors in Hodgkin’s lymphoma. In: Hoppe R et al (eds) Hodgkin’s Lymphoma, 2nd edn. Lippincott Williams & Wilkins, Philadelphia; Girinski T, van der Maazen R, Specht L et al (2006) Involvednode radiotherapy (INRT) in patients with early Hodgkin’s lymphoma: concepatients and guidelines. Radiother Oncol 79:270 –277
Involved-Field RT As mentioned previously, IFRT is the most commonly used technique. It is implicit that IFRT targets an area smaller than the classical extended field. However, there was heterogeneity among experts regarding volumes and field-borders definition. Yahalom and Mauch have developed guidelines, published in 2002, for the Cancer and Leukemia Group B (CALGB).
802
Maryse Bernard and Richard W. Tsang
Table 26.21 lists the main IFRT treatment areas, and Table 26.22 details the set-up and treatment steps of RT for HL.
Table 26.21 Main IFRT treatment regions and radiation treatment coverage Region or organ
Field coverage
Supraclavicular
Unilateral or bilateral cervical/supraclavicular region
Mediastinum
Including bilateral medial supraclavicular LNs and lung hila
Axilla
Including the supraclavicular and infraclavicular LNs
Spleen
Spleen
Para-aortic LNs
Para-aortic LNs
Pelvis
Inguinal/femoral/external iliac regions
Source: Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13:79 –83
IFRT for Mediastinal Disease In HL, the mediastinum is the most frequent site of treatment for IFRT. Figure 26.6 illustrated a “modified mantle field” for mediastinal disease. A common IFRT target volume for mediastinal disease would have included bilateral cervical lymph nodes and the mediastinum, including the lung hila. Therefore, two-dimensional (2D) limits for this patient would have been: Superior border: above the lower tip of mastoid process Inferior border: 5 cm below the carina However, since the subclinical disease can usually be addressed by chemotherapy, entire nodal region coverage is superfluous, and the coverage, or this specific case in Figure 26.6, can be modified as follows: Exclude the left upper cervical lymph nodes Do not irradiate the entire right nodal region by excluding the highest right cervical nodes when disease is located in supraclavicular fossa only – Superior border: larynx level Exclude subcarinal lymph node, when disease is confined to superior mediastinum (as in this case) – Inferior border: according to prechemotherapy volume – Lung hila intentionally not targeted Rationales of such arrangement include reducing salivary gland and oral cavity toxicity, sparing the heart and lungs, and limiting the dose to breast tissue.
Chapter 26 Hodgkin’s Lymphoma
803
Table 26.22 Steps for radiation therapy planning Evaluation before RT Dental evaluation if upper neck treated (above larynx) Sperm banking if pelvic nodes treated (if fertility issue) Pulmonary function test (if clinically indicated) Position: supine Head in hyperextension if upper neck treated Head in neutral position otherwise Arms akimbo if axilla treated (option: arms up) Arms at sides otherwise Frog leg position if inguinal nodes treated Immobilization: Device may vary between institutions Mask for head and neck Body immobilization system for pelvis Planning: CT-based simulation If mediastinum treated, both lungs need to be scanned (for DVH) Pre-chemotherapy and post-chemotherapy information from CT and PET is important Option: fusion with FDG-PET (before/after CT) Intravenous contrast optional Volumes GTV: Usually not present post chemotherapy, if complete response – Some residual thickening is often noted with HL (sclerosis) CTV: In general, include prechemotherapy disease plus the whole nodal region(s) that contained the involved LN – For a mediastinal mass, post-CT transverse diameter is used – For para-aortic disease, post-CT transverse diameter is also used PTV: varies between institutions – Depends on immobilization, reproducibility, organ motion – Example: 10-mm margin, CTV to PTV Beam arrangement: often parallel opposed pair fields (anterior plus posterior field) Field can be shaped with multileaf collimation Use of intensity-modulated radiation therapy (IMRT) can be considered for more conformal therapy Respiratory gating can be an option for special cases (e.g., a wide mediastinal target) – Dose: may vary according to the clinical situation – Plan evaluation based on ICRU 50 and 62; PTV should receive a dose between 95 and 107% of prescribed dose – However, because of difference with patient separation within the field, dose homogeneity may be as high as 10% – Tolerance of organs at risk should be respected
804
Maryse Bernard and Richard W. Tsang
a
b
Norm. Volume
c Dose Volume Histogramm 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0
500
1000
1500 2000 Dose (cGy)
2500
3000
3500
ROI Statistics
Line Type ROI Both lungs Breast left Breast right CTV Heart PTV
Trial
Min.
Max.
Mean
Std. Dev.
% Outside crid
O. Final O. Final O. Final O. Final O. Final O. Final
6.5 2.0 2.6 649.8 13.4 640.8
3194.1 3103.5 3192.5 3202.5 2982.1 3205.4
778.8 94.5 276.2 3017.2 466.7 3000.5
1091.5 299.3 658.0 59.6 776.7 82.9
0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Figure 26.6 a–c Radiation treatment field for a 33-year-old woman with unfavorable stage II HL. She had presented with bulky mediastinal mass and a right supraclavicular node. Post-ABVD × 6, with CR, and minor anterior mediastinal thickening. a Digitally reconstructed radiograph (DRR), showing the IFRT field with coverage of mediastinum, bilateral supraclavicular area and inferior neck (upper limit is larynx level). The clinical target volume (CTV) is in blue, planning target volume (PTV) is in green and carina is in light blue. b Dose distribution of this same field (axial view, at the level of carina), for a prescribed dose of 3,000 cGy. The minimum target dose of 2,850 cGy is illustrated by the yellow isodose line (−5%). Right and left breast are in pink and purple, respectively. c Dose–volume histogram (DVH) for CTV, PTV, and organs at risk. Note that 20% of bilateral lungs receive a dose of over 20Gy
Chapter 26 Hodgkin’s Lymphoma
805
IFRT for Cervical Disease Typical IFRT field for cervical lymph adenopathy from HL is to treat the ipsilateral cervical/supraclavicular region with an anterior–posterior/posterior–anterior (AP/PA) beam arrangement. For lesions positioned close to critical normal organs (e.g., parotid gland), the intensity-modulated RT (IMRT) technique can be used to reduce dose to the uninvolved right parotid and limit higher-dose exposure to the oral cavity. However, the IMRT technique will increase the amount of normal tissues receiving lower doses. Figure 26.7 illustrates a case of cervical lymph nodal disease treated with IMRT. Other situations where IMRT considered in HL may include: Mediastinal mass with significant lateral extension along chest wall Recurrent disease at or near a previous irradiated area
806
Maryse Bernard and Richard W. Tsang
Figure 26.7 a–d Radiation treatment field for a 20-year-old man with favorable stage I HL, right cervical region. Initial disease was high in his neck, just below the parotid. He was treated with 3 cycles of ABVD and was planned for RT. Diagnostic CT scan showing right-neck Hodgkin’s lymphoma, axial perspective, at level of parotids gland a and hyoid bone b. Malignant lymph nodes in black and right parotid in white. c-d Dose distribution in axial perspective, at level of parotid c and hyoid bone d, for a prescribed dose of 30 Gy. CTV is in color wash blue. Right and left parotids are in red and pink, respectively. The oral cavity is in color wash light blue. Those organs at risk are contoured to limit the dose they receive
Chapter 26 Hodgkin’s Lymphoma
807
e Dose Volume Histogramm
1.0 0.9
Norm. Volume
0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0
500
1000
1500
2000
2500
3000
3500
4000
Dose (cGy) ROI Statistics
Line Type ROI CTV Oral Cavity PTV Parotid left Parotid right Spinal Cord
Trial
Min.
Max.
Mean
Std. Dev.
% Outside crid
O. Final O. Final O. Final O. Final O. Final O. Final
1856.7 208.5 449.1 22.1 341.8 882.9
3437.4 3227.8 3463.7 125.6 3182.7 1984.2
3118.3 1558.2 3062.3 65.9 1938.0 1613.8
80.9 596.8 154.8 18.5 637.2 154.6
0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Figure 26.7 e DVH for CTV, PTV, and organs at risk. With IMRT, the dose to right parotid can be reduced, with a mean of 19.38 Gy
Normal Tissue Tolerance and Side Effects Radiation doses used in combined-modality protocols are well within the tolerance of normal tissues in virtually all supradiaphragmatic areas.
808
Maryse Bernard and Richard W. Tsang
Follow-Up Response to treatment is documented 6–12 weeks after completion, with repeat imaging and clinical evaluation. The regression of disease may be slow, and a residual fibrotic mass may persist after treatment. FDG-PET/CT is used as a standard test to document CR, although thymic rebound or subclinical radiation pneumonitis may lead to abnormalities on FDG-PET after mediastinal RT if done too early (<12 weeks from RT). The yield of routine tests in asymptomatic patients is low for subsequent follow-up. Relapse of HL is usually detected because of patients presenting with symptoms, rather than by routine screening, so greater emphasis should be placed on patient education rather than on routine tests. Routine CT or PET imaging for follow-up has not been shown to be cost-effective. Table 26.23 summarizes the follow-up schedule. Table 26.23 Follow-up schedule and examinations Schedule
Frequency
Years 0–2
Every 3–4 months
Years 3–5
Every 6 months
Years 5+
Annually
Examinations History and physical
History and physical: focus on lymphatic tissues
Laboratory tests
CBC, ESR, TSH (if thyroid gland radiated)
Imaging
Chest x-ray
Annual counseling
Physical and psychological health, including physical activity, reproduction, cardiovascular fitness, and risk of second malignancy
Annual multidisciplinary care
Ensure appropriate advice and care from family physician or cardiologist regarding: cardiac risk factors and strategies to minimize risk (smoking cessation, blood pressure control, cholesterol, lipids, exercise, weight control), particularly for patients who received mediastinal RT. Consider cardiac stress test for 10-year survivors
Annual screening for second cancer
Screening for: colorectal cancers, lung cancers (particularly if patient uses tobacco) For women who had RT to breast tissue: mammography and/or MRI (at recommendation of radiologist or ACR guideline) starting 7–8 years posttreatment
Chapter 26 Hodgkin’s Lymphoma
809
Table 26.24 Commonly observed acute, subacute, and late toxicities in RT for HL Side effect type
Manifestation
Acute
Fatigue, nausea, skin reaction, esophagitis, laryngitis, and possible myelosuppression Most symptoms will be mild and always reversible
Subacute
Lhermitte’s syndrome (electric shock–like sensation from the neck, radiating down the spine, or upper extremities), which can start 2–4 months after RT and may last up to 6 –8 months Prolonged fatigue Radiation pneumonitis is uncommon, unless large volume of lung tissue is exposed For situations where V20 > 36–40%, and/or median lung dose >15 Gy, the risk of pneumonitis is approximately 5 –10%
Delayed toxicity
The most common delayed toxicity is hypothyroidism Other significant late effects of therapy include cardiac disease and primary second malignancies Second malignancies are particularly important for patients treated for limited stage at a young age, with an expected high cure rate for the HL, hence putting them at risk for the development of second cancers Overall, breast, lung, and colorectal cancers account for approximately half of the excess risk of second cancers
Commonly observed treatment induced adverse effects are listed in Table 26.24. A detailed discussion of late effects of therapy is beyond the scope of this chapter, but it is likely that with present reduction of radiation volumes and dose, the actual risk of second cancers from IFRT will be lower than what is reported in the literature thus far. For patients who are at risk, a screening program should be implemented in the follow-up schedule.
27
Multiple Myeloma and Plasmacytoma Wee Joo Chng1 and Ivan W.K. Tham2
Key Points Multiple myeloma is the second most common hematological malignancy. In almost all cases of myeloma, there is a preceding monoclonal gammopathy of undetermined significance phase. Diagnosis of multiple myeloma requires demonstration of monoclonal proteins or clonal plasma cells, with symptomatic manifestation. Mainstay of multiple myeloma treatment remains high-dose therapy with stem cell transplantation. Therefore, the first therapeutic decision point is whether the patient is a transplant candidate. Over the last decade, three novel agents, thalidomide, lenalidomide, and bortezomib have been approved by the US Food and Drug Administration (FDA) for treatment of multiple myeloma. The use of novel agents prior to transplantation and as maintenance therapy has greatly improved outcome of myeloma patients. Similarly, for non–transplant-eligible patients, the incorporation of novel agents into their treatments has greatly improved survival. Radiation therapy is useful in treating symptomatic bone disease and plasmacytomas.
1
Wee Joo Chng, MD () Email:
[email protected]
2
Ivan W.K. Tham, MD Email:
[email protected]
J. J. Lu, L. W. Brady (Eds.), Decision Making in Radiation Oncology DOI: 10.1007/978-3-642-16333-3_10, © Springer-Verlag Berlin Heidelberg 2011
812
Wee Joo Chng and Ivan W.K. Tham
Epidemiology and Etiology Multiple myeloma (MM) is a clonal plasma cell proliferative disorder. Approximately 19,900 new MM cases and 10,700 MM deaths occur in the USA annually. Almost all cases of MM are preceded by a premalignant condition called monoclonal gammopathy of undetermined significance (MGUS). MM is about two- or threefold more common in African-Americans as compared with Caucasians, with an Asian prevalence about half that of the Caucasians. There is a 1.7-fold significantly increased risk for MM in relatives of MM cases as compared with relatives of controls. In addition, compared with relatives of controls, relatives of MGUS patients were found to have a significantly increased risk of MGUS (RR = 2.8) and MM (RR = 2.9) (Table 27.1).
Table 27.1 Relative risk of MM and MGUS in first-degree relatives of patients with MM or MGUS Study
Relative risk of MM among first-degree relatives
Relative risk of MGUS among first-degree relatives
Swedish study
1.67
2.96
Mayo Clinic study
ND
2.00
Swedish study
2.90
2.80
Mayo Clinic study
ND
3.30
MM patients
MGUS patients
Sources: Landgren O, Linet MS, McMaster ML et al (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 MM patients: a population-based case-control study. Int J Cancer 118:3095–3098; Landgren O, Kristinsson SY, Goldin LR et al (2009) Risk of plasma cell and lymphoproliferative disorders among 14,621 first-degree relatives of 4,458 patients with MGUS of undetermined significance in Sweden. Blood 114:791–795; Vachon CM, Kyle RA, Therneau TM et al (2009) Increased risk of monoclonal gammopathy in first-degree relatives of patients with MM or MGUS of undetermined significance. Blood 114:785–790
MGUS MGUS is one of the most common premalignant disorders in Western countries, with a prevalence of 3.2% in the Caucasian population, 50 years of age or older. It is characterized by the presence of a monoclonal immunoglobulin (Ig) (M protein) without evidence of MM or other lymphoproliferative malignancies. MGUS patients have an average 1% annual risk of developing a lymphoproliferative malignancy. A risk stratification model for MGUS pro-
Chapter 27 Multiple Myeloma and Plasmacytoma
813
gression has been developed based on the high-risk factors as presented in Table 27.2. Table 27.2 Risk of progression from MGUS to MM Number of risk factora
Risk of progression at 20 years (%)
0
5%
1
21%
2
37%
3
58%
a
Risk factors include abnormal serum free light chain ratio, non-IgG MGUS, and an elevated serum M-protein value >15 g/l Source: Rajkumar SV, Kyle RA, Therneau TM et al (2005) Serum free light chain ratio is an independent risk factor for progression in MGUS of undetermined significance. Blood 106:812–817
Smoldering MM The probability of progression to MM or amyloidosis has been reported to be 54% at 5 years, 66% at 10 years, and 73% at 15 years of follow-up, with a median time to progression of 4.8 years. The overall risk of progression was 10% per year for the first 5 years, 3% per year for the next 5 years, and only 1% per year beyond 10 years of follow-up. A risk-stratification model based on three risk factors has been proposed (Table 27.3). Table 27.3 Risk of progression from SMM to MM Number of risk factora
Median time to progression (years)
1
10
2
5
3
2
Risk factors include bone marrow plasma cells 10%, serum M protein 3 g/dl, and serum Ig-free light chain ratio either <0.125 or >8 Source: Dispenzieri A, Kyle RA, Katzmann JA et al (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:785–789 a
814
Wee Joo Chng and Ivan W.K. Tham
Pathology MM is characterized by clonal expansion of plasma cells, which secrete monoclonal protein. The most common monoclonal protein is IgG (52%), followed by IgA (21%). IgD myeloma is rare (2%). Sixteen percent of patients have light chain–only myeloma, and only 3% have non-secretory MM. There is often an accompanying immunoparesis (91%). Four disease-initiating genetic abnormalities define the main genetic subtypes of myeloma. These include t(4;14) in 15%, t(11;14) in 15%, t(14;16) in 5%, and hyperdiploidy in 60% of cases. Solitary plasmacytomas of bone and extramedullary plasmacytomas are tumors with clonal plasma cells within or outside the bone, respectively.
Diagnosis, Staging, and Prognosis Clinical Presentation The clinical presentation of MM is summarized in Table 27.4, with the myeloma-related organ or tissue impairment listed in Table 27.5. Figure 27.1 presents a patient with a plasmacytoma.
Chapter 27 Multiple Myeloma and Plasmacytoma
815
Table 27.4 Clinical features of MM and plasmacytoma Feature
Description
MM
Bone disease
Bone pain is most common presenting symptom (58%), with X-ray changes in almost 80% of patients, with vertebral column and ribs being most common sites of disease X-rays may show lytic lesions and generalized osteoporosis Pathological fractures of vertebrae or long bones may occur Bone scan not sensitive because osteoblast activity inhibited; radiological skeletal survey more appropriate
Renal failure
Creatinine levels elevated in about 50% of patients, most commonly due to Bence–Jones proteins Multiple causes, including: Hypercalcemia Infection Dehydration Amyloid deposition Hyperuricemia Nonsteroidal anti-inflammatory drug use
Anemia
Present in 73% of patients
Others
Fatigue (32%) Weight loss (24%) Bacterial or viral infections, especially in the chest Primary amyloidosis, especially in the kidneys, leading to proteinuria and nephrotic syndrome Peripheral neuropathy Hyperviscosity syndrome, e.g., headache, visual disturbance, and loss of concentration
Solitary plasmacytoma
Bone
Typically affects axial skeleton, though any bone may be involved Pain, nerve root, or cord compression are common presenting symptoms
Extramedullary
Commonly arises from upper respiratory passages as a mass
Source: Adapted from: Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21–33
816
Wee Joo Chng and Ivan W.K. Tham
Table 27.5 Myeloma-related organ or tissue impairment (ROTI) Impairment
Criteria
Hypercalcemia
Serum calcium >0.25 mmol/l above the upper limit of normal or >2.75 mmol/l
Renal
Creatinine >173 mmol/l
Anemia
Hemoglobin 2 g/dl below the lower limit of normal or hemoglobin <10 g/dl
Bone
Lytic lesions or osteoporosis with compression fractures (MRI or CT may clarify)
Others
Symptomatic hyperviscosity, amyloidosis, and recurrent bacterial infections (> 2 episodes in 12 months)
Source: International Myeloma Working Group (2003) Criteria for the classification of MGUS, MM and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757
Figure 27.1 a, b a Plain X-ray of a patient complaining of neck ache, showing no gross lesions. b Sagittal gadolinium-enhanced T1-weighted fat suppressed MRI of the same patient demonstrating cord compression at C7–T2 levels by a plasmacytoma
Diagnosis and Staging Diagnosis of MM should be differentiated from smoldering myeloma and MGUS, according to criteria of the International Myeloma Working Group (Table 27.6). The diagnostic process for plasma cell neoplasms is summarized in Figure 27.2.
Chapter 27 Multiple Myeloma and Plasmacytoma
817
Table 27.6 Spectrum of monoclonal gammopathies Gammopathy
Criteria
MGUS
M protein in serum <30 g/l Bone marrow clonal plasma cells <10% and low level of plasma cell infiltration in a trephine biopsy (if done) No evidence of other B-cell proliferative disorders No ROTI
Asymptomatic MM
M protein in serum ≥30 g/l and/or Bone marrow clonal plasma cells ≥10% No ROTI
Symptomatic MM
M protein in serum and/or urine Bone marrow (clonal) plasma cells* or plasmacytoma ROTI present, though patient may be asymptomatic
No M protein in serum and/or urine with immunofixation Bone marrow clonal plasmacytosis ≥10% or plasmacyNon-secretory MM toma ROTI present
Solitary plasmacytoma of bone
No M protein in serum and/or urine** Single area of bone destruction due to clonal plasma cells Bone marrow not consistent with MM Normal skeletal survey (and MRI of spine and pelvis if done) No ROTI other than solitary bone lesion
Extramedullary plasmacytoma
No M protein in serum and/or urine** Extramedullary tumor of clonal plasma cells Normal bone marrow Normal skeletal survey No ROTI
*If flow cytometry is performed, most plasma cells (> 90%) will show a ‘neoplastic’ phenotype ** A small M-component may sometimes be present (serum IgG<3.5 g/dl; serum IgA <2.0 g/dl; urine monoclonal kappa or lambda <1.0g/24h) MGUS: monoclonal gammopathy of unknown significance; MM: multiple myeloma; MRI: magnetic resonance imaging; ROTI: related organ or tissue impairment Source: International Myeloma Working Group (2003) Criteria for the classification of MGUS, MM and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757
818
Wee Joo Chng and Ivan W.K. Tham
Plasma Cell Neoplasm Suspected
Complete History and Physi